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Abstract 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of 
the central nervous system, characterised by acute memory loss and 
behavioural symptoms. The AD brain is characterized by the presence of senile 
amyloid plaques associated with degenerating neurites and inflammatory 
processes. The major protein component of these amyloid deposits is the 
amyloid beta (Aβ) protein. The Aβ protein is a 40 or 42 amino acid cleavage 
product of APP (Amyloid Precursor Protein) which is produced in low levels in 
the normal ageing brain. Although senile amyloid plaques is the major 
pathological hallmark of AD brains, accumulating evidence has been presented 
to show that increased levels of soluble forms of Aβ42 correlate with the clinical 
manifestations and severity of the disease. Increased accumulation (both 
intracellular and extracellular) and toxicity of Aβ42 peptide in the brain play 
pivotal roles in neurodegeneration and loss of memory functions in the AD 
brain. Therefore reducing the toxicity of Aβ42 and increasing its clearance from 
the brain has been considered to be main targets for AD therapeutics.  
The search for a disease modifying therapy for AD has been very difficult 
with the majority of agents failing in later stages of clinical trials. The incomplete 
understanding of drug-target mechanisms and the lack of high-throughput 
screening systems for identifying selective target based drugs have been some 
of the main issues expressed for the failure of AD drugs. Yeast offer a simple 
eukaryotic model for studying pathological mechanisms and compared to other 
models there is availability of various experimental tools applicable for high 
throughput analysis of protein-protein, gene-gene and gene-protein interactions 
and associated cellular functions. It can also offer a versatile model for initial 
screening in drug development for various human diseases, including AD. 
Yeast models have been utilised for studying AD related proteins including APP 
and its processing enzymes (secretases) and tau phosphorylation.  
The broad aims of this work were to develop yeast models for studying 
toxicity of oligomeric Aβ42 peptide and investigate intracellular accumulation of 
aggregated Aβ42. Furthermore, these models were utilized for examining 
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compounds which modulate Aβ42 structure/toxicity or promote its clearance 
from cells.  
Extracellular treatment of oligomeric Aβ42 was used for studying toxicity 
in yeast. The uptake of extracellularly added Aβ42 peptide by yeast and its 
localisation indicated that oligomeric Aβ42 mediated cell death was associated 
with binding to the plasma membrane. It was shown that oligomeric Aβ42 
inhibited the plasma membrane H+ATPase activity which may be one important 
mechanism of oligomer Aβ42 mediated cell death in yeast. Further, this yeast 
model was utilized for investigating the effects of dairy peptides on Aβ42 
oligomerization and toxicity. It was shown that suppression of Aβ42 
oligomerization lead to concomitant reduction in the toxic effects of Aβ42 in both 
yeast and neuronal cells. In addition, studies in yeast showed that the 
recombinant oligomer forming MBP-Aβ42 fusion protein (representing a more 
stable form of oligomeric Aβ42) was toxic which was further validated in 
neuronal cells. Overall, these studies established the use of yeast as a model 
for studying oligomer Aβ42 toxicity. 
Cells expressing green fluorescent protein tagged Aβ42 (GFP-Aβ42) as 
a fusion protein was used for investigating intracellular accumulation of Aβ. 
Yeast cells expressing GFP-Aβ42 showed punctate fluorescence and reduced 
levels of expression suggesting that it is sequestered into vesicles which are 
targeted for degradation. Further investigation revealed a key role for 
intracellular degradation pathways such as the autophagy in this process and 
enhancing this pathway was shown to reduce levels of GFP-Aβ42 aggregates. 
Further, findings presented in this thesis also provided a novel mechanism of 
action for a drug latrepirdine that has shown promise in AD trials. In yeast, 
latrepirdine was shown to enhance autophagy and promote the clearance of 
GFP-Aβ42. Further, preliminary data from an in vivo mouse model showed that 
latrepirdine reduced peripheral levels of injected Aβ42 and promoted uptake 
into liver, providing further evidence for a role of latrepirdine in enhancing Aβ 
clearance.  
Overall, the findings presented in this thesis have highlighted the 
application of yeast models for investigating drug mechanisms and developing 
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high-throughput methods for screening. Reducing oligomer Aβ toxicity and 
enhancing its clearance in the brain are much sought after targets for 
therapeutic interventions in AD. The use of the yeast models presented in this 
work can therefore provide a greater scope for the search of novel AD drugs. 
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1.1     Alzheimer’s disease – Background 
 
Alzheimer's disease (AD) is a progressive neurodegenerative disease of the 
central nervous system and comprises approximately 80% of all dementia 
cases in the elderly (Terry, 2006). Dementia is posing escalating societal and 
financial burdens especially with the ageing generation. In 2007, 29.8 million 
people worldwide had dementia, with this number expected to exceed 100 
million by 2050 unless a cure or prevention is found. In 2005, the total 
worldwide societal cost of dementia was estimated to be US$315.4 billion 
including US$105 billion for care for a dementia population of 29.3 million in that 
year. In Australia, AD is the second major cause of disability burden which 
exerts an immense toll on the sufferers and care givers. It is currently estimated 
that approximately 250,000 people are suffering from dementia in Australia and 
the figure is predicted to almost quadruple by 2050 (Brookmeyer et al., 2007; 
Ziegler-Graham et al., 2008). The cost of AD is predicted to increase from about 
1% of GDP (gross domestic product) to more than 3% of GDP in the coming 
decades (Access Economics 2003) representing a major burden to the health 
care system. 
 
1.2     Prevalence of AD 
 
AD is the major cause of dementia worldwide with vascular dementia and 
other neurodegenerative diseases such as Pick‟s disease, Parkinson‟s disease, 
Frontotemporal dementia and diffuse Lewy-body dementia making up the 
majority of the remaining cases (Aronson et al., 1991; Brookmeyer et al., 2007; 
Ferri et al., 2005). The incidence of AD differs depending on the diagnostic 
criteria used, the age of the population surveyed, and other factors, including 
geography and ethnicity. Although AD is recognized as a major health crisis in 
developed countries, its impact  in developing countries is expected to be much 
more severe (Brookmeyer et al., 2007; Ferri et al., 2005). Age is the major risk 
factor for sporadic AD cases with a prevalence of approximately 5% among 
those 65-69 years of age and increases with age to 40-50% among persons 95 
years of age and over. Early-onset and genetic predisposition factors leading to 
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AD (mutations in APP, PS1, PS2) are comparatively less prevalent and 
contribute to approximately 5% of the total AD cases (Hy and Keller, 2000; 
Koedam et al., 2010; Koedam et al., 2008). 
 
1.3     Clinical Manifestations and Diagnosis of the Disease 
 
AD leads to a progressive deterioration of cognitive function starting with 
loss of memory and judgement and eventually resulting in complete inability to 
independently function in basic daily activities. The preclinical stage of AD is 
inconspicuous and there are no reliable and valid symptomatic markers which 
would allow an early diagnosis before the manifestation of irreversible loss of 
memory. Clinical diagnosis of AD is more likely to be accurate only in the late 
stages of severe cognitive impairment as other dementias have common 
overlapping features. In the mild dementia stage, difficulties with declarative 
memory are usually prominent, with less profound effects on daily activities. In 
the moderate dementia stage, other cognitive domains are noticeably affected 
including disturbances of thought, perception and behaviour. The patient is 
completely dependent on the care-giver during the late stage of illness. 
However, following clinical diagnosis of AD, life expectancy of the patient is 
significantly reduced (Forstl and Kurz, 1999; Reisberg et al., 1987).  
 
Identifying the disease at a clinical stage when the pathological damage is 
not too severe to prevent functional recovery, or stabilization, is a major issue of 
current research. Strategies for clinical diagnosis of AD include evaluation of a 
detailed history of the type and course of symptoms combined with a battery of 
neuropsychological assessments. In addition, imaging techniques such as 
magnetic resonance imaging (MRI), computed tomography (CT) scans and 
positron emission tomography (PET) are also currently being used in the 
differentiation of the various forms of dementia (Karow et al., 2010). Since the 
advent of these techniques, significant cognitive deficits may be detectable 
before the typical cognitive, behavioral, and social criteria of AD caused 
dementia are met (Howieson et al., 1997; Jacobs et al., 1995; Linn et al., 1995; 
Masur et al., 1994; Storandt et al., 2006; Tierney et al., 2005). However, there is 
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still a high degree of variability between these studies, and analytical techniques 
need to be standardised. One major challenge for AD diagnosis and specific 
biomarker discovery is the substantial overlap of major brain pathologies. The 
indefinite relation between the amount of Aβ and tau pathology, the large 
overlap of AD, synucleinopathies, and cerebrovascular pathologies are 
problematic when interpreting a biomarker profile in individual patients. Exact 
methods and thresholds for specific biomarkers in AD diagnosis are currently 
not well defined. Establishing a model with characterized definitions of 
diagnostic thresholds for specific biomarkers need to be incorporated. 
Additionally, the model needs to be validated and calibrated (Dubois et al., 
2007). 
 
1.4     Structural changes in the AD brain  
 
Structural changes in the brain during aging are complex and not well 
understood. Neurons maintain homeostatic control of essential brain functions, 
including gene expression, synaptic transmission, and metabolic regulation. 
During aging, there is a reduction in the complexity of dendrites and a host of 
other subtle changes within the cortex that includes alterations in receptors, loss 
of spines and myelin dystrophy, as well as alterations in synaptic transmission 
which are observed in the neurons. It is suggested that these multiple 
alterations in the brain may correspond to the age-related neuronal dysfunction 
and decline in cognitive function. However in AD, where age is the major risk 
factor, studies have demonstrated that neuronal losses in cortical and 
hippocampal regions are more severe and possibly caused by distinct 
pathological processes (Hof et al., 1997; Morrison and Hof, 2002; West et al., 
1994; West et al., 2004). 
 
The post-mortem AD brain is considerably atrophied with enlarged ventricles 
and extensive neuronal loss in the cortex and hippocampus compared to a 
normal aged brain (Figure 1). Significant neuron and synapse loss in specific 
brain regions is observed in the AD brain (Hof and Morrison, 2004; Hof et al., 
1997; West et al., 1994; West et al., 2004). Unlike in the normal aging brain, 
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neuronal loss is extensive in the neocortical and entorhinal regions of the AD 
brain, accompanied by an approximate 45% decline in neocortical synapses 
(Terry et al., 1991; Terry et al., 1981). An average neuronal cell loss of 68% in 
the CA1 region of the hippocampus region of AD patients is observed compared 
to age matched controls (West et al., 1994). Also, a significant reduction in 
spine density and decrease in overall dendritic area in AD patients was 
observed (Einstein et al., 1994; Ferrer and Gullotta, 1990; Moolman et al., 
2004).. 
 
Figure 1: Representation of post mortem brain cross-section of (A) healthy 
control and (B) AD patient. Differential characteristics are shown in the image. 
The AD brain is featured by severely enlarged ventricles and shrinkage of the 
A
B
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cerebral cortical and hippocampal regions, which are responsible for memory 
and cognitive functions. 
1.5     Pathological lesions in the AD brain 
 
Accompanying the selective damage in brain regions, distinguished 
abnormal fibrous protein deposits are observed within the brains of AD patients 
which include the extracellular senile amyloid plaques, intraneuronal 
neurofibrillary tangles (NFTs) and amyloid deposits in the walls of cerebral 
blood vessels (cerebral amyloid angiopathy) (Figure 2). Amyloid deposition and 
NFTs are also found in the neocortical, hippocampal, and entorhinal regions of 
cognitively normal elderly people, although in fewer numbers and considered to 
be largely non-pathogenic (Arriagada et al., 1992; Goldman et al., 2001; Kazee 
and Johnson, 1998; Price et al., 1991) although it could be argued that these 
individuals have the pre-clinical form of the disease and had they lived longer 
would have exhibited clinical symptoms. In AD, however, the robust number of 
plaques and NFTs is associated with dystrophic neurites and synaptic loss and 
show increased distribution in specific regions of the brain (Braak and Braak, 
1991; Price et al., 1991).  
 
1.5.1 Senile amyloid plaques 
 
The senile plaques in the AD brain consist of a central core of amyloid 
deposits surrounded by dystrophic neurites together with reactive microglia and 
astrocytes (Ma et al., 2010a; McGeer et al., 1994; Yasuhara et al., 1994). The 
amyloid core is composed of straight, unbranching fibrils of 8-10nm diameter, 
and display strong affinity to Congo red staining and resistance to proteolysis. 
These properties are representative of a predominant cross-β sheet structure of 
the polypeptide constituents of the plaque (Goedert and Spillantini, 2006). 
 
The amyloid-β-protein (Aβ) has been found to be the main protein 
component in the nucleating core of the senile plaques which is also the same 
protein originally isolated from cerebral blood vessels (Glenner and Wong, 
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1984a; Glenner and Wong, 1984b; Masters et al., 1985a; Masters et al., 
1985b). In addition to Aβ, other proteins accumulate within senile plaques, 
including apolipoprotein E (ApoE), α2-macroglobulin, interleukins, components 
of the complement system, α2-macroglobulin receptor, low-density lipoprotein 
receptor-related protein, collagenous Alzheimer amyloid component (Griffin et 
al., 1989; McGeer et al., 1989; McGeer et al., 1994; Namba et al., 1991; 
Strauss et al., 1992; Thal et al., 1997). In addition to the insoluble senile 
plaques, plaques of a more diffuse nature are also observed in the brain. In 
contrast, the diffuse plaques show no association with abnormal neurites or 
reactive glial cells and have few or no amyloid fibrils content. It is suggested 
that diffuse plaques are an early stage of plaque formation (Goedert and 
Spillantini, 2006). In AD, diffuse plaques are usually more abundant and 
widespread throughout the CNS than typical senile plaques. However, 
substantial amounts of these diffuse types of Aβ deposits are found in the limbic 
and associated cortices in many healthy older humans (Dickson, 1997).  
 
1.5.2  Neurofibrillary tangles  
 
The dystrophic neurites surrounding the amyloid core of the senile plaques 
contain paired helical filaments (PHFs) which are pairs of filaments (10nm in 
diameter) strung into a left-handed helical structure (~80nm in diameter). These 
PHFs constitute the main structural element of the neurofibrillary tangles 
(NFTs). The NFTs comprise of hyperphosphorylated tau, a protein involved in 
microtubule assembly and stabilization (Brion et al., 1985; Delacourte and 
Defossez, 1986; Ihara et al., 1986; Iqbal et al., 1986). In the human brain, six 
tau isoforms are produced from a single gene via alternative mRNA splicing 
(Goedert et al., 1989). Based on the number of microtubule-binding repeats, the 
isoforms are classified into two groups (three and four repeats: 3R, 4R 
respectively). The nature of N-terminal inserts distinguishes the three isoforms 
in each group. In tau filaments isolated from AD brains, similar levels of 3R and 
4R isoforms are expressed which are present in similar proportions to those in 
normal brains. Filamentous tau deposits are also found in a number of other 
neurodegenerative diseases, including progressive supranuclear palsy (PSP), 
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corticobasal degeneration (CBD), Pick‟s disease, argyrophilic grain disease 
(AGD), and Guam Parkinson dementia (GPD) [reviewed in (Lee et al., 2001)]. 
Hyperphosphorylation of tau leading to the disintegration of microtubules and 
abnormal accumulation of tau proteins is common to these diseases and is 
thought to be associated with toxicity (Avila, 2006). However the absence of 
beta amyloid pathology distinguishes a majority of these diseases from AD.  
 
The comparative relevance of these lesions in the pathogenesis of AD is 
controversial. It has been widely acknowledged that senile plaques are a better 
representative of AD pathology compared to NFTs (Terry et al., 1987). 
Therefore, quantification of senile plaques, rather than of NFTs, forms the basis 
of current post-mortem diagnostic criteria for AD (Khachaturian, 1985; Mirra et 
al., 1991). Although senile plaques are widespread in the AD brain, they are a 
poor indicator of cognitive decline and disease severity. Growing evidence has 
indicated that the soluble oligomeric forms of Aβ are responsible for the loss of 
memory functions in AD and a better correlate than plaques, of cognitive 
decline and disease severity (Fonte et al., 2001; Lue et al., 1999; McLean et al., 
1999). The role of Aβ in neurodegeneration and cellular dysfunction in the AD 
brain is discussed further. 
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Figure 2: AD pathological hallmarks (A) Senile plaques (SPs) indicated by 
dense cores and radially oriented dystrophic neurites in entorhinal cortex. (B) A 
typical neurofibrillary tangle in CA3. (C) Aβ protein immunohistochemistry 
demonstrates frequent plaques in posterior cingulate cortex, accompanied by 
cerebral amyloid angiopathy. (D) Immunohistochemical stains for 
hyperphosphorylated tau show aggregation in NFTs and cortical dystrophic 
neurites. Scale bars indicate 50µm. (Image courtesy: 
http://knol.google.com/k/lara/alzheimer-s-disease/Ing3X-NE/g1JpHQ).  
 
1.6     Role of Aβ in Neurodegeneration 
 
Although Aβ containing senile plaques are seen associated with dystrophic 
neurites and reactive microglia, they are poorly correlated with the clinical 
manifestations of the disease. Moreover, the quantitative correlations between 
manual microscopic counts of amyloid plaques in post-mortem brain sections 
and the severity of cognitive decline measured by neuropsychological tests are 
fraught with methodological challenges. Counting plaques in two-dimensional 
brain sections provides an inaccurate measure of Aβ load in the brain and is 
likely to miss other small and heterogeneous Aβ-assembly forms. Specific Aβ 
enzyme-linked-immunosorbent assays (ELISAs) coupled with western blotting 
and mass spectrometry analysis has enabled a more sensitive and 
comprehensive qualitative and quantitative assessment of Aβ forms in the brain. 
Using these techniques, studies have identified that levels of soluble Aβ 
correlate much better with the degree of cognitive deficits than plaque counts 
(Fonte et al., 2001; Lue et al., 1999; McLean et al., 1999). Also the fact that 
fibrillar amyloid plaques (~20–120-μm diameter) present much less Aβ surface 
area to neuronal membranes compared to small diffusible forms of Aβ, indicates 
that soluble assembly forms are better candidates for inducing neuronal 
dysfunction than plaques containing amyloid fibrils (Haass and Selkoe, 2007). 
Furthermore, „amyloid‟ structuring of proteins is thought to be a detoxification 
strategy to mask the promiscuous surface of the toxic oligomeric building blocks 
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(Carrell et al., 2008). Studies have also identified novel biological functions for 
amyloidogenic protein fibrils in bacteria, fungi and even mammals (Kelly and 
Balch, 2003).Supporting evidence from a range of studies in several 
neurodegenerative diseases including AD, Huntington‟s disease, Parkinson‟s 
disease, prion diseases and many other amyloidosis point to soluble protein 
oligomers in the brain as an indicator of cognitive decline rather than the 
insoluble fibrillar deposits (Ferreira et al., 2007; Glabe and Kayed, 2006; Popik 
et al., 1999). It is also indicated that oligomeric and fibrillar assemblies maybe 
formed via distinct mechanisms, possibly mediated by external factors (binding 
ligands including other proteins, metals, lipids etc) [reviewed in (Bharadwaj et 
al., 2009)]. 
 
1.6.1 Oligomeric forms of natural and synthetic derived Aβ  
 
Amyloid β-protein (Aβ) is a proteolytic product of its larger parent protein, the 
Amyloid precursor protein and is found in the brains and cerebrospinal fluid 
(CSF) of both healthy normal individuals and those with AD (Citron et al., 1992; 
Haass et al., 1992 ; Ida et al., 1996; Vigo-Pelfrey et al., 1993; Walsh et al., 
2000). Numerous isoforms of Aβ (Aβ1-42, Aβ4-42, Aβ1-40 and the 3-
pyroglutamate derivate of Aβ3-42 (pGluAβ3-42) constituting ~80% of total 
species) have been detected in the brains of healthy, sporadic and familial AD 
subjects. However the AD brain (both sporadic and familial cases) exhibit 
markedly increased levels of the Aβ42 isoform. Distinct regional specific 
differences are observed with the hippocampus exhibiting heavy A deposition 
compared to the cerebellum which results in memory impairment (Portelius et 
al., 2010; Portelius et al., 2009; Tekirian, 2001). Neurodegeneration in AD is 
believed to be caused by self association of the Aβ42 molecules into toxic 
isoforms due to its increased accumulation in the brain (Busciglio et al., 1992; 
Geula et al., 1998; Pike et al., 1991a, b), and studies have clearly demonstrated 
that aggregation of Aβ42 is essential for toxicity. 
 
Reports indicate soluble oligomeric Aβ as an indicator of the scale of 
cognitive deficits in AD (Cleary et al., 2005). In general, soluble oligomers are 
11 
 
defined as Aβ assemblies that are not pelleted from physiological fluids by high 
speed (>100,000g) centrifugation (Lue et al., 1999; McLean et al., 1999). 
Oligomeric assemblies have been isolated from post-mortem AD brains, and 
their presence correlated with memory loss (Cleary et al., 2005; Gong et al., 
2003). Intracellular and secreted soluble dimeric and trimeric oligomers have 
been described in cultured cells (Podlisny et al., 1995; Walsh et al., 2000). 
SDS-stable oligomers of varying sizes have also been detected in APP 
transgenic mouse brain and human brain (Enya et al., 1999; Funato et al., 
1999; Kawarabayashi et al., 2004; Lesne et al., 2006; Roher et al., 1996). Such 
natural Aβ oligomers can be resistant not only to SDS but also to the Aβ-
degrading enzymes like insulin degrading enzyme (IDE), which can only digest 
monomeric Aβ (Walsh et al., 2002a). The presence of similar SDS-stable 
dimers and trimers in the soluble fraction of human brain and in extracts of 
amyloid plaques suggest that these SDS stable low n-oligomers (dimers and 
trimers) of Aβ are the basic building blocks of insoluble amyloid deposits and 
could be the earliest mediators of neuronal dysfunction.(Lesne et al., 2006)) 
reported that a unique and novel Aβ isoform (Aβ*56: 56-kD soluble Aβ42 
assembly, dodecamer) as the key neurotoxic Aβ42 isoform responsible for 
cognitive decline in APP overexpressing Tg2576 mice, based on its stability, 
abundance and occurrence during memory decline. However, a more recent 
study (Shankar et al., 2008) identified Aβ dimers from the soluble extract of AD 
cerebral cortex tissues. This report specifically attributed Aβ dimers to the loss 
of long-term potentiation (LTP), enhanced long-term depression, reduced 
dendritic spine density in normal rodent hippocampus and memory disruption of 
a learned behaviour in normal rats. Importantly this study showed that insoluble 
amyloid plaque isolated from AD cortex did not impair LTP. However Aβ dimers 
released from the plaques following solubilisation (TBS, SDS, formic acid) 
showed neurotoxic properties similar to the soluble Aβ extracts, suggesting that 
plaque cores are largely inactive but can sequester toxic Aβ forms. Both the 
Lesne et al and Shankar et al studies identify different toxic Aβ species (dimer 
or Aβ*56), which might reflect the species differences (mouse and human 
respectively) and also the Aβ detection techniques employed. It is also 
suggested that an array of soluble oligomeric Aβ species (ranging from dimers 
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to dodecamers) may have similar neurotoxic properties associated with memory 
impairment in AD.  
 
A substantial amount of structural and functional information of Aβ comes 
from studies using Aβ produced by solid phase peptide synthesis (SPPS). 
Similar to naturally derived forms, Aβ42 solutions prepared from synthetic 
lyophilized peptides have shown to form multiple forms ranging from 
monomeric, oligomeric, fibrillar and many more other multimeric structures and 
show neurotoxic properties. A large body of literature describes many types of 
assembly forms of synthetic Aβ, including protofibrils (PFs), annular structures, 
paranuclei, Aβ-derived diffusible ligands (ADDLs), globulomers and amyloid 
fibrils [reviewed in (Bharadwaj et al., 2009)].  
 
Although synthetic Aβ has been widely used for variety of experimental 
purposes, the preparation and handling of the peptide solutions have not been 
very straightforward. In addition to the heterogeneous and variable nature of 
Aβ42 peptide, substantial compositional variation in Aβ produced by SPPS 
resulting in experimental irreproducibility has been reported (Howlett et al., 
1995; Simmons et al., 1994; Soto et al., 1995a; Soto et al., 1995b). Most 
lyophilized peptides contain salts which can complicate the initial solvation and 
preparation of peptide stock solutions. In addition, these non-peptide 
substances can alter the biophysical and biological behaviour of the peptide. 
Preparation of a homogenous Aβ solution is quintessential; but Aβ can form 
many different forms in aqueous state and the equilibrium and stability among 
these assemblies are not entirely understood. Some controversy exists as to 
the actual state of aggregate-free starting preparations. Chaotropic agents 
([DMSO]), organic acids (TFA), organic solvents (trifluoroethanol [TFE] and 
hexafluoroisopropanol [HFIP]), and sodium hydroxide (NaOH) all have been 
used to solubilise and disaggregate lyophilized Aβ peptide (Teplow, 2006). 
Causes of irreproducibility may include the aggregation state of the peptide in 
the solid state (Fezoui et al., 2000) and immediately after reconstitution. There 
are also some early studies regarding the variable behaviour of different peptide 
stocks (Brining, 1997; May et al., 1992). Currently, a range of carefully 
13 
 
optimized protocols for preparation of Aβ42 oligomers from synthetic lyophilized 
stocks are available (Stine et al., 2010; Teplow, 2006).  
 
1.6.2 Potential mechanisms of Aβ mediated toxicity 
Over the past two decades extensive work on understanding the mechanism 
of Aβ toxicity has been undertaken. Although Aβ is largely secreted from the 
cell surface, it can be present in many cellular compartments. Consequently Aβ 
has been found to be associated with disruption of several cellular functions 
including mitochondrial activity (Butterfield et al., 2001 ; Dyrks et al., 1992; 
Lustbader et al., 2004a; Palmblad et al., 2002), oxidative stress  (Butterfield et 
al., 2001 ; Martins et al., 1986), receptor mediated functions (Bhaskar et al., 
2009; Fuentealba et al., 2004; Pereira et al., 2004; Wei et al., 2002 ; Yaar et al., 
1997), disruption of Ca2+ homeostasis (Hartmann et al., 1994; Mattson et al., 
1993), membrane depolarization and disorder (Müller et al., 2001; Verdier et al., 
2004) and microglial activation (Giulian et al., 1996). Some of the well known 
mechanisms of Aβ induced toxicity will be discussed here. 
 
1.6.2.1 Mitochondrial dysfunction 
 
The central nervous system (CNS) has a high metabolic rate, as it 
consumes about 20% of oxygen inspired, even though it accounts for only 2% 
of the body weight (Silver and Erecinska, 1998). This large metabolic demand is 
because neurons are highly differentiated cells that need huge amounts of 
adenosine tri-phosphate (ATP) for maintenance of ionic gradients across the 
cell membranes and for neurotransmission. Since most neuronal ATP is 
generated by oxidative metabolism, neurons critically depend on mitochondrial 
function and oxygen supply (Ames, 2000; Erecinska et al., 2004). Conversely, 
neuronal function and survival are very sensitive to mitochondrial dysfunction 
(Fiskum et al., 1999; Nicholls and Budd, 2000).  
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Growing evidence indicates that mitochondrial dysfunction may be an 
important factor in AD pathogenesis. The AD brain is featured by altered 
glucose metabolism, mitochondrial activity and morphology (Baloyannis et al., 
2004; Bubber et al., 2005; Duara et al., 1986; Haxby et al., 1986), and an 
overall decrease in the number of mitochondria within vulnerable neurons (Hirai 
et al., 2001). Studies have reported an intracellular interaction between Aβ and 
ABAD (Aβ binding alcohol dehydrogenase). It was shown that Aβ accumulated 
in the mitochondria of AD brain and altered the enzyme‟s active site and 
prevented native dehydrogenase activity (Caspersen et al., 2005; Lustbader et 
al., 2004b). These studies therefore provided evidence for the presence of a 
mitochondrial pool of Aβ within the AD brain that also had the capacity to disrupt 
normal mitochondrial functionality. Other groups also provide evidence for Aβ 
accumulation in mitochondria within the brains of AD patients, rodent models, 
and neuronal cells over expressing APP (Caspersen et al., 2005; Crouch et al., 
2005; Manczak et al., 2006). There is evidence that APP and γ-secretase 
components are present in the mitochondria, indicating that Aβ could be 
generated within mitochondria (Anandatheerthavarada et al., 2003; Devi et al., 
2006; Hansson et al., 2004). Alternatively, Aβ may accumulate in the 
mitochondria due to decreased capacity to regulate Aβ levels. It has been 
shown that the human mitochondrial metallo-protease PreP (presequence 
protease) is capable of degrading Aβ (Falkevall et al., 2006; Stahl et al., 2002). 
Whether a decline in the PreP activity is related to intracellular Aβ accumulation 
or toxicity remains to be determined. 
 
Several studies have shown that direct exposure of isolated mitochondria to 
Aβ significantly impairs functionality of the mitochondrial electron transport 
chain which is essential for the cell‟s energy requirement (Casley et al., 2002; 
Crouch et al., 2005). Aβ has been shown to inhibit the COX (cyclooxygenase) 
activity in vitro supported by reports that COX activity was decreased in the AD 
brain (Chagnon et al., 1995; Mutisya et al., 1994). Aβ treatment has also been 
shown to decrease mitochondrial membrane potential and respiration rates, 
induce mitochondrial swelling, cytochrome c release, transition pore opening, 
and mitochondrial ROS output [reviewed in (Crouch et al., 2008)]. Most of the 
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Aβ related effects on mitochondria can contribute to neuronal dysfunction and 
pathology in the AD brain. Aβ induced mitochondrial dysfunction is closely 
associated with oxidative stress, which is considered a key feature in the 
pathogenesis of AD. 
 
1.6.2.2 Oxidative stress 
 
Oxidative stress has been implicated as a major cause of neurotoxicity in a 
number of neurodegenerative disorders including AD, and there is strong 
evidence linking oxidative stress to Aβ. Oxidative stress occurs when free 
radical production exceeds antioxidant defence systems, thereby leading to 
oxidative damage to cellular components. Most free radicals within a cell 
originate from reactive oxygen species (ROS) produced via the oxidative 
phosphorylation within the mitochondria. As described above the CNS 
consumes 20% of the total oxygen and therefore generates high levels of ROS. 
The brain is rich in unsaturated fatty acids and comprised mostly of post-mitotic 
tissue with limited regenerative capacity and a relatively poor antioxidant 
system (Cooper and Kristal, 1997) which makes it particularly vulnerable to 
oxidative stress. An initial report by Martins et al (Martins et al., 1986) described 
an increase in activity of enzymes from the hexose monophosphate pathways in 
post-mortem AD brain samples compared to age-matched controls, reflecting 
the increased oxidative stress in the AD brain. Several reports following have 
shown extensive oxidative damage in AD, including lipid peroxidation 
(Butterfield et al., 2002; Sayre et al., 1997), oxidized proteins (Bissette et al., 
1991; Smith et al., 1991) nucleic acid damage (Gabbita et al., 1998; Lovell et 
al., 1999) and advanced glycation end products (AGE) (Markesbery and Lovell, 
1998; Perry et al., 2003). 
  
Oxidative damage in AD may be a direct result of Aβ peptide accumulation. 
The senile amyloid plaques in the AD brain are associated with oxidative 
markers, mainly lipid peroxidation (Lovell et al., 1995; Mecocci et al., 1994). As 
discussed above, Aβ mediated oxidative stress could be a result of the inhibition 
of mitochondrial function. Alternatively, oxidative stress may involve direct 
16 
 
production of ROS by Aβ. Aβ can cause neurotoxicity by production of ROS 
(Behl et al., 1994). One of the widely known mechanisms of Aβ induced ROS is 
via interaction with metals, mainly copper (Cu) (Curtain et al., 2001; Dong et al., 
2003). Aβ-Cu generated H2O2 can result in oxidative damage of lipids and 
intracellular proteins. Aβ-metal interactions are also known to exacerbate 
aggregation and potentiate toxicity in neuronal cells, which can be rescued by 
catalase (Atwood et al., 2004; Barnham et al., 2004). Furthermore, neurons 
depleted of essential antioxidants such as glutathione are more susceptible to 
Aβ-Cu mediated toxicity (White et al., 1999). Overall, these studies indicate that 
Aβ mediated generation of free radicals is possibly involved in the neuronal cell 
death in AD. However reactive oxygen species (ROS) generation could also be 
a result of tissue injury, and it is unclear whether this is a primary or secondary 
event of Aβ mediated toxicity to cells in AD. 
 
In addition to oxidative stress and mitochondrial stress many other 
mechanisms of toxicity have been identified [review in (Harkany et al., 2000)]. 
Since Aβ has been shown to induce a variety of toxic effects in cells, it is 
unclear whether the neurodegeneration and cognitive deficits observed in AD 
are caused by disruption/loss of a particular cellular function or a collective 
contribution of several toxic outcomes. Also different isoforms of Aβ 
(predominantly fibrillar and oligomeric forms) have been shown to be toxic in 
distinct pathways (Dahlgren et al., 2002). While Aβ42 may have been shown to 
induce a variety of pathological events in the cell, it is possible that some of 
them are not associated with the disease symptoms. Also, it is argued that the 
high concentrations of Aβ peptide used in some studies may not represent the 
actual levels that may be present at any point of time in the AD brain. And most 
importantly, increased levels of soluble protein oligomers and synaptic loss in 
the AD brain have been established as the main indicators of cognitive decline 
rather than the insoluble fibrillar deposits. Therefore the role of Aβ in disrupting 
synaptic function and promoting dendrite loss has gained much interest in 
recent years. 
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1.6.2.3 Synaptic toxicity 
 
Memory impairment in AD is categorized by the loss of ability to form and 
retain new episodic memories. Cognitive impairment is often attributed to 
synaptic dysfunction and neuronal cell loss particularly in the cells 
interconnecting the hippocampal formation with the associating structures 
crucial for memory (Davies et al., 1987 ; Hyman et al., 1984). Depleted 
neurotransmitters (Hyman et al., 1984), synaptic connections (Small et al., 
2001; Whitehouse et al., 1982) and quantitative correlations of postmortem 
cytopathology with cognitive deficits indicate that synaptic loss is more robustly 
correlated than the extent of cortical gliosis (Davies et al., 1987 ). An intensively 
studied electrophysiological correlate of learning and memory is long-term 
potentiation (LTP). LTP is a long-lasting enhancement in signal transmission 
between neurons using repetitive and synchronous high frequency electrical 
stimulation. It is an important phenomena underlying synaptic plasticity. As 
memories are thought to be determined by modification of synaptic strength, 
LTP is considered as one of the major cellular mechanisms that underlies 
learning and memory (Bliss and Collingridge, 1993; Cooke and Bliss, 2006).  
 
Several reports provide evidence that naturally secreted low-n Aβ oligomers 
(Walsh et al., 2002a) and synthetically derived oligomeric Aβ42 (Lambert et al., 
1998) can inhibit the maintenance of hippocampal LTP. This effect has been 
shown by treatment of hippocampal slices (Townsend et al., 2006) or by in vivo 
microinjections in living rats (Walsh et al., 2002a), and can be specifically 
neutralized by anti-Aβ antibodies in vivo (Klyubin et al., 2005). Reports indicate 
that the induction of long term synaptic depression (LTD) affects hippocampal 
plasticity and results in decreased dendritic spine volume (Nagerl et al., 2004; 
Zhou et al., 2004). Although it is established that soluble Aβ oligomers can 
inhibit LTP in the hippocampus, the effects of Aβ on the induction of LTD are 
not well understood. Some reports show Aβ42 peptides to induce LTD in CA1 in 
vivo (Cheng et al., 2009; Kim et al., 2001b; Li et al., 2009), whereas other 
studies show no effect on LTD (Raymond et al., 2003; Wang et al., 2004).  
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The biochemical mechanism by which soluble oligomers bind to synaptic 
plasma membranes and interfere with signalling molecules that are required for 
synaptic plasticity is unclear. Aβ oligomers can interact with membranes to 
induce structural changes (Kremer et al., 2000), create ion pores (Demuro et 
al., 2005; Kremer et al., 2000), enhance membrane permeability or ion 
conductance (Kayed et al., 2004), modulate a wide array of ion channels 
(Demuro et al., 2010), and osmotic flux (Demuro et al., 2010; Mattson and 
Chan, 2003). Several studies have implicated disrupted cellular homeostasis to 
neuritic dystrophia and blockage of intra neuronal signalling essential for 
cognitive functions (De Fusco et al., 2003; Lingrel et al., 2007; Moseley et al., 
2007). The role of cation transporters has been previously reported in AD. 
Decreased Na+/K+ ATPase activity was observed in APP (Amyloid precursor 
protein) +PS1 (Presenilin 1) double transgenic mice (Dickey et al., 2005) and 
Aβ causes inhibition of Cl-, Na+/K+ ATPase in neuronal cell cultures (Bores et 
al., 1998; Mark et al., 1995; Yagyu et al., 2001). Interestingly, a recent study 
showed that neuronal electrical activity stimulated BACE (β-secretase) and 
therefore increased Aβ production, and the resulting increased levels of Aβ 
depressed synaptic transmission (Kamenetz et al., 2003). Moreover, synaptic 
activity in APP transgenic mice was correlated with the interstitial fluid Aβ 
concentrations (Cirrito et al., 2005).  
 
It is suggested that soluble Aβ oligomers may interfere with signalling 
pathways downstream of certain NMDA (N-methyl-d-aspartate), metabotropic 
glutamate (mGluR) or AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) 
receptors at synaptic plasma membranes (Snyder et al., 2005). It has also been 
shown that oligomeric Aβ can interfere indirectly with LTP through an inhibition 
of ubiquitin C-terminal hydrolase (UCH) (Gong et al., 2006). In addition to 
extracellular Aβ, studies indicate that aberrant accumulation of Aβ within 
neurons could also be involved in synaptic dysfunction. Aβ accumulation is 
most prominent in distal neurites and synapses in the brains of AD transgenic 
mice (Takahashi et al., 2002). Since accumulating Aβ42 in endosomes are 
known to reside near synapses (Cooney et al., 2002), altered function of these 
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organelles (Nixon et al, 2007) might lead to disruption of axonal transport and 
synaptic dysfunction.  
 
It has been shown that intracellular accumulation of Aβ and soluble Aβ 
oligomers can induce synaptic dysfunction and dendrite loss (Figure 3). 
However, the molecular mechanisms that underlie the loss of synapses and 
ensuing decline in memory related functions caused by Aβ are complex. 
Neurodegeneration in AD is specific to particular regions of the brain, but it is 
still not clear what makes the particular subset of neurons and their processes 
more vulnerable to the effects of Aβ toxicity.  
 
 
 
Figure 3: Aβ causes synaptic dysfunction 
Extracellular Aβ oligomers can mediate synaptic dysfunction via the 
neurotransmitter receptors (NMDA, mGluR, AMPA) on the synaptic plasma 
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membranes. Intracellular accumulation of Aβ in endosomes may disrupt axonal 
transport or affect dendrites can also be a cause of synaptic loss in AD. 
  
1.6.3 Neurotrophic effects of Aβ  
 
Although the toxic effects of Aβ peptide in mature neurons is well 
established, some early reports have demonstrated its neurotrophic effects in 
neurons. C-terminal truncated Aβ [Aβ (1-28)] peptide was shown to enhance 
survival in embryonic hippocampal cells (Whitson et al., 1989). In the same 
year, (Yankner et al., 1990) showed that the Aβ (1-40) was neurotrophic to 
undifferentiated hippocampal neurons at low concentrations and neurotoxic to 
mature neurons at higher concentrations. However, in differentiated neurons, 
Aβ (1-40) protein caused cell loss and shrinkage of dendritic processes, which 
is a widely observed phenomenon with Aβ induced neurotoxicity. Low 
concentrations of Aβ have also shown to promote neurite outgrowth (Koo et al., 
1993) and stimulate tyrosine phosphorylation /phosphatidylinositol-3-kinase 
activity (Luo et al., 1996a; Luo et al., 1996b) in neuronal cells under low serum 
conditions. Aβ also exhibits anti-apoptotic properties in serum deprived 
conditions and anti-oxidant properties [reviewed in (Atwood et al., 2003)]. 
Although largely neglected and poorly characterized, the trophic actions of Aβ 
reported in these studies may be related to the physiological role of the APP in 
neuronal development process and even AD pathology. It is even suggested 
that Aβ production may be linked to a regenerative response of the brain elicited 
in an attempt to ameliorate the degeneration and neuronal injury associated 
with AD.  
Along similar lines, recent evidences support the notion that abnormal 
activation of cell cycle events in regions susceptible to neurodegeneration in the 
AD brain (Husseman et al., 2000; Yang et al., 2003). Increased levels of cell 
cycle proteins (Cdc2, cyclin B, activated cdc25A) (Ding et al., 2000; Vincent et 
al., 2001) and mitotic signalling phosphoepitopes (p-eIF4E, p-mTOR and p-4E-
BP1. p-PKR and p-eIF2α) (Chang et al., 2002; Li et al., 2005; Li et al., 2004) 
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have been observed in the AD brain. A number of studies also show that Aβ42 
treatment (both fibrillar and oligomer) can induce neuronal cell cycle events via 
mTOR/MAP kinase cell proliferation pathways in neurons (Bhaskar et al., 2009; 
Frasca et al., 2004; Malik et al., 2008; Varvel et al., 2008; Wu et al., 2000). In 
contrast to Aβ‟s neurotrophic effects shown in previous reports, these studies 
suggest that cell cycle events induced by Aβ are associated with 
neurodegeneration and cell death. It is possible that neurons have different 
response patterns to Aβ treatment depending on their cell cycle and availability 
of neurotrophic factors, which also may explain the selective susceptibility of a 
particular subset of neuronal population to Aβ mediated toxicity in late onset 
AD.  
 
The studies on Aβ clearly indicate its pivotal role in neurodegeneration in the 
AD brain, although the exact role of Aβ in AD pathology and loss of cognitive 
functions are not completely understood. Besides the physical evidence, the 
critical role of Aβ in AD is strongly supported by the genetic risk factors 
associated with the onset of the disease.  
 
1.7     Genetic risk factors of AD 
 
There is a large amount of data about potential risk factors for AD. The 
major risk factors include age, genetics, and head injury. Many other risk factors 
have also been identified including hormonal levels, cognitive reserve 
(education and occupation), physical activity and exercise, midlife obesity, 
alcohol intake and medical conditions like stroke, diabetes, hypertension, and 
hypercholesterolaemia. However, there is insufficient overall evidence from 
epidemiological studies to support any association of lifestyle factors or medical 
conditions to the risk of AD caused dementia (Verghese et al., 2011). Age 
represents the major risk factor for AD with 4 allele of the apolipoprotein E 
gene also playing a key role (60-80% of attributed risk) (Lambert and Amouyel, 
2011) which are discussed below. 
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1.7.1 Early Onset (Familial) AD  
 
AD incidence increases exponentially with every 5 years of age, such that 
about 5% of people aged 65 have AD, whereas greater than 20% of people 
over 80 have AD (Brookmeyer et al., 2007). Based on the age at onset, the 
major types of AD are differentiated into the early-onset forms (less than 
age65), and late-onset forms (greater than age of 65). The early-onset AD 
(EOAD) have a clear family history of AD and are caused by autosomal 
dominant mutations in the genes encoding APP, presenilin-1(PSEN1), and 
presenilin-2 (PSEN2) (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington 
et al., 1995). A common feature of these EOAD mutations is change in APP 
metabolism leading to increased production or stability of the Aβ peptide 
secreted. While EOAD accounts for only a small fraction (~5%) of the total AD 
cases, it has presented a useful model for studying the fundamental aspects of 
the disorder.  
 
1.7.2 Late onset (Sporadic) AD 
 
The more common sporadic cases (late onset AD: LOAD) usually start 
manifesting symptoms after the age of 65. The 4 allele of the Apolipoprotein E 
(APOE) gene is long known to be a major genetic risk factor for the late onset 
AD cases and many studies have reported and confirmed the association of this 
allele with the disease (Farrer et al., 1997; Laws et al., 2003). In the past two 
decades several candidate genes apart from APOE have been idenified as risk 
factors for LOAD (~ 660), although with poor correlations in significantly larger 
cohorts (the Alzgene database) (Bertram et al., 2007).  
 
The major function of the apoE is to mediate the clearance of lipoproteins by 
interacting with the low-density lipoprotein (LDL) family of receptors in liver cell 
(Beisiegel et al., 1989). ApoE-containing lipoproteins initially bind to cell surface 
heparin-sulphate proteoglycans, and are subsequently transferred to the LDL 
receptor-like protein (LRP) or LDL receptor for endocytosis via clathrin coated 
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vesicles (Havel, 1998; Ji et al., 1993). Studies also suggest an important role for 
apoE in the uptake and redistribution of cholesterol within the CNS (Holtzman et 
al., 1995; Pitas et al., 1987; Roheim et al., 1979).  
 
1.7.3 The role of APOE in AD 
 
ApoE is comprised of 299 amino acids, and exists as three major isoforms 
namely: apoE ε2, apoE ε3 and apoE ε4 (Rall et al., 1982; Zannis and Breslow, 
1982). The APOE ε3 allele is present in 50–90% of people in all populations, 
whereas APOE ε4 is present in 5–35% and APOE ε2 in 1–5% of people 
(Verghese et al., 2011). Risk of AD is associated with APOE ε4. The APOE ε4 
allele is present in about 50% of patients who have late-onset disease, 
compared with 20–25% of controls (Saunders, 2000; Saunders et al., 1993). 
The presence of one copy of the APOE ε4 allele increases risk of AD by about 3 
times and two copies increases risk about 12 times. Furthermore, in patients 
with late-onset disease, the presence of APOE ε4 leads to an earlier age of 
onset compared with non-carriers (Corder et al., 1993). The APOE ε4 allele 
steadily increases risk with age, exerting its greatest effect on AD between the 
ages of 60 and 79 years, and decreasing thereafter (Farrer et al., 1997). 
Additionally, the APOE ε4 allele is associated with more rapid memory decline 
in non-demented individuals and preclinical memory impairment in 
asymptomatic middle aged individuals (Caselli et al., 2001; Deary et al., 2002; 
Flory et al., 2000). Epidemiological studies from various populations have 
confirmed the increased frequency of APOE ε4 in patients with late-onset AD 
compared with non-carriers, however the frequency varies between different 
ethnic groups (Roses, 1996). Although APOE alleles alter the onset of the 
disease, controversy exists about whether they are associated with the rate of 
progression of cognitive decline in AD after its onset (Corder et al., 1995a; 
Corder et al., 1995b). The role of APOE in the predisposition to AD is well 
established, but the association of APOE with rate of disease progression is not 
completely understood (Hone et al., 2003; Laws et al., 2003). Evidence strongly 
supports the notion that apoE plays a key role with the regulation of both 
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extracellular and intracellular Aβ clearance in the brain (Kim et al., 2009). The 
important role of apoE in Aβ clearance is discussed in a later section of this 
review (Section 1.9.1). 
 
1.7.4 Newly identified genetic risk factors 
 
Genome wide association studies (GWAS) is a high throughput genotyping 
technique for screening the whole genome for single nucleotide polymorphisms 
(SNPs). In contrast to candidate gene studies, GWAS is based on a non-
hypothesis driven genome wide analysis. Studies indicate that the GWAS 
approach can be problematic and the significance of its findings may require 
further validation (Manolio, 2010; Pearson and Manolio, 2008). Nevertheless, 
recent studies performed on GWAS of ~53000 autosomal SNPs in large 
european cohorts have reported association of CR1 gene (complement 
component 3b/4b receptor1), clusterin gene (CLU), phophatidylinositol-binding 
clathrin assembly gene (PICLAM) and bridging integrator 1 (BIN1) loci in the 
risk of AD (Corneveaux et al., 2010; Harold et al., 2009; Lambert et al., 2009; 
Seshadri et al., 2010). A more recent GWAS study has shown variants at 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP to be associated with 
AD (Hollingworth et al.). Although the newly identified genes do not represent a 
major risk factor for incidence of AD, some of them have been attributed to roles 
in lipid transport and Aβ clearance (including CLU, CR1). However, no distinct 
causative roles for these genes in AD pathology have been identified so far. 
 
Mechanisms underlying AD pathogenesis are unclear. There are several 
hypotheses, but much attention has been given to the amyloid pathway of 
neurodegeneration. The amyloid hypothesis proposes that accumulation of 
Aβ42 and subsequent toxicity as the key events responsible for 
neurodegeneration in AD (see Figure 4). Mutations in APP, PS1 and PS2 genes 
causing overproduction of Aβ leading to its accumulation in the brain is an 
important feature in the early onset AD cases. Although the causative roles of 
genes associated with sporadic AD are still unclear, APOE and the identification 
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of these new AD genetic determinants suggest that the common and late-onset 
forms of the disease are associated with a defect in Aβ peptide clearance. In 
addition, impaired degradation of Aβ by cellular pathways (autophagy, 
proteasome), by enzymes neprilysin and insulin-degrading enzyme (Iwata et al., 
2000; Miller et al., 2003) and reduced perivascular drainage (Weller et al., 1998) 
have been suggested as possible causes of Aβ accumulation in sporadic AD 
brains. Also, a recent study has shown direct evidence of decreased clearance 
of Aβ, but no increased production in the brains of sporadic AD patients 
(Mawuenyega et al., 2010). The mechanisms involved in the production and 
clearance of Aβ in the brain and their contribution to AD pathogenesis will be 
discussed further. 
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Figure 4: The sequence of genetic risk factors associated with the pathogenic 
events leading to cognitive decline and dementia in familial and sporadic cases 
of AD. 
 
 
1.8     Production of Amyloid-β protein (Aβ) 
 
Aβ is a 38-43 amino acid length peptide, formed by intramembrane 
proteolysis of the amyloid precursor protein (APP) by successive action of the β 
and γ secretases. APP metabolism and regulation of its processing are crucial 
factors involved in the pathogenesis of AD.  
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1.8.1 APP Biology  
The APP molecule is an integral transmembrane glycoprotein ubiquitously 
expressed in many tissues and concentrated in the synapses of neurons. The 
APP gene is located on chromosome 21 in humans with three major isoforms 
arising from alternative splicing known as APP695, APP751, and APP770. 
APP751 and APP770 are expressed in most tissues and contain a 56 amino 
acid Kunitz Protease Inhibitor (KPI) domain within their extracellular regions. 
The major form in neurons is the APP695 which lacks the KPI domain. Its 
primary functions are not clear, although it has been implicated as a regulator of 
synaptic function (Priller et al., 2006), neural plasticity (Turner et al., 2003) and 
iron export (Duce et al., 2010). Aβ is produced by cleavage of the APP protein 
by enzymes termed β- and γ-secretases. Three enzymes (ADAM9, ADAM10 
and ADAM17) belonging to the ADAM family (a disintegrin- and 
metalloproteinase-family enzyme) with α-secretase activity have been identified 
(Allinson et al., 2003). The β-secretase enzyme has been identified as  β-site 
APP-cleaving enzyme 1 (BACE1), and is a type I integral membrane protein 
belonging to the pepsin family of aspartyl proteases (Hussain et al., 1999; Sinha 
et al., 1999; Vassar et al., 1999). The γ-secretase enzyme has been identified 
as a complex of proteins composed of presenilin 1 or 2, (PS1 or PS2), nicastrin, 
anterior pharynx defective homolog 1 and presenilin enhancer 2 (Edbauer et al., 
2002; Francis et al., 2002; Steiner et al., 2002; Wolfe et al., 1999a; Wolfe et al., 
1999b). In addition to the four critical components, several other factors have 
been proposed as additional modulators of γ-secretase (CD147, TMP21/p23). 
Although not core components, these factors have a role in modulating γ-
secretase activity (Krishnaswamy et al., 2009; Zhang et al., 2011).  
 
1.8.2 APP processing pathways 
The processing of APP involves two competing pathways: the non-
amyloidogenic and amyloidogenic pathways (Figure 5). In the non-
amyloidogenic pathway, APP is cleaved by the α-secretase at a position located 
83 amino acids from the carboxyl (C) terminal, producing an amino (N) terminal 
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ectodomain (sAPPα) which is secreted into the extracellular medium (Kojro and 
Fahrenholz, 2005). sAPPa has an important role in neuronal plasticity/survival 
and regulates neural stem cell proliferation which is important for early CNS 
development (Furukawa et al., 1996; Ohsawa et al., 1999). The resulting C-
terminal fragment (C83) is retained in the membrane and subsequently cleaved 
by the γ-secretase, producing a short fragment termed p3 (Haass et al., 1993). 
Cleavage by the α-secretase occurs within the Aβ region, thereby precluding 
formation of Aβ.  
 
The amyloidogenic pathway is a competitive cleavage pathway for APP 
which leads to secretion of Aβ. The initial proteolysis is mediated by the β-
secretase at a position located 99 amino acids from the C terminus, resulting in 
the release of sAPPβ into the extracellular space. The 99-amino-acid C-terminal 
fragment (C99) within the membrane is subsequently cleaved (between 
residues 38 and 43) by the γ-secretase liberating the Aβ peptide, although the 
exact site can vary.  Cleavage of C99 by γ-secretase can yield Aβ40, the 
majority species, and Aβ42 (approximately 10%), the more amyloidogenic 
species, as well as releasing the intracellular domain of APP (AICD). The Aβ42 
variant is more hydrophobic and has an increased tendency to aggregate than 
Aβ40 (Jarrett et al., 1993) and is the predominant isoform found in cerebral 
plaques observed in AD brains (Younkin, 1998). Recent data has shown that 
PS/γ-secretase also mediates δ-site cleavage (Aβ46) (Zhao et al., 2004) and ε-
site cleavage (Aβ49) (Sastre et al., 2001), suggesting a sequential cleavage 
model where cleavage at the ε-site is followed by the δ-site and γ-site. The 
processing of APP by secretase activity in the generation of Aβ and other APP 
metabolites is expertly reviewed in (Zhang et al., 2011).    
 
1.8.3 APP/Presenilin mutations in EOAD 
Mutations in APP and components of PS1 and PS2 have been reported in 
EOAD cases. A common feature of these EOAD mutations is change in APP 
metabolism leading to increased production or stability of the Aβ peptide 
secreted. All APP mutations have profound effects on APP processing, resulting 
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in increased levels of the Aβ peptide (Citron et al., 1992; Eckman et al., 1997; 
Hendriks et al., 1992; Jonghe et al., 2001). The APP mutations that cluster near 
the APP γ-secretase cleavage site have been shown to shift the balance of γ-
secretase cleavage products towards the Aβ42 over Aβ40 species. One 
common mutation in the APP gene is the Swedish mutation which leads to 
increased cleavage of APP by the β-secretase (Haass et al., 1995). Some APP 
mutations, such as the Arctic (E22G), Italian (E22K), and Iowa (D23N) have 
shown to increase the aggregation of the secreted Aβ (Grabowski et al., 2001; 
Murakami et al., 2002 ; Nilsberth et al., 2001; Tagliavini et al., 1999). Reports 
have also shown loss of APP synpatotrophic functions and decreased 
interaction with PS1 as a result of EOAD APP mutations (Herl et al., 2009; 
Seeger et al., 2009). The vast majority of EOAD cases are associated with 
mutations in the PS1 gene (>180). A large number of these mutations are 
missense mutations involving substitution of a single amino acid. Others include 
small deletions, insertions or splice mutations (De Strooper, 2007). Mutations in 
the presenilins have been shown to affect APP metabolism causing increased 
production of Aβ42 (Guo et al., 1999; Jankowsky et al., 2004). Recently, a study 
has also shown that EOAD mutations in PS1 may result in impaired autophagy-
lysosomal function (Lee et al., 2010). Overall, these studies indicate that in 
addition to increased production of Aβ, EOAD mutations can also be associated 
with loss of functions of the protein which may contribute to the pathology of the 
disease. 
 
In addition to the intramembrane cleavage of APP at the cell surface by 
secretase complexes leading to secretion of Aβ, many studies also provide 
evidence for the occurrence of intracellular Aβ in the AD brains. Growing 
evidence also indicate that Aβ can accumulate intracellularly which precedes 
plaque formation and may contribute to cognitive decline in AD. The possible 
sources of intracellular Aβ have been discussed further.  
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Figure 5: Processing of APP by α-, β-, γ-secretases by non-amyloidogenic 
pathway and by amyloidogenic pathway leading to generation of Aβ peptide. 
 
1.8.4 Intracellular sites of Aβ production 
The occurrence of APP/Aβ products in intracellular compartments has been 
reported. APP has been found localized in the endoplasmic reticulum (ER), 
trans-Golgi network (Xu et al., 1995), endosomal, lysosomal (Kinoshita et al., 
2003) and mitochondrial membrane (Mizuguchi et al., 1992). Intracellular 
accumulation of Aβ has been observed in cells expressing APPSwe (familial 
APP Swedish mutation) but not wild-type APP (Martin et al., 1995). Similarly, 
duplication in the APP gene has also been associated with higher levels of 
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intracellular Aβ formation (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006). 
Sortilin-related receptor 1 (SORL1) has been found to regulate trafficking of 
APP from the plasma membrane into retromer recycling endosomes (Golde et 
al., 1992). APP and BACE1 interactions have been observed within the 
endosomes and is indicated as a possible site of Aβ generation (Kinoshita et al., 
2003). Importantly, genetic variants in SORL1 lead to increased APP trafficking 
into these Aβ-producing endosomes, which has been linked to an increased risk 
for late-onset AD (Lee et al., 2007). Also, blocking APP internalization 
significantly reduced Aβ levels, demonstrating that the internalization of APP by 
endocytosis is an important pathway for the generation of Aβ (Koo and 
Squazzo, 1994; Perez et al., 1999). Furthermore, low-density lipoprotein (LDL) 
receptor-related protein 1B (LRP1B), an LDL family member has been shown to 
bind APP holoprotein at the plasma membrane thereby preventing Aβ 
internalization and leading to decreased Aβ production and increased sAPPα 
secretion (Cam et al., 2004). In addition to the endosome system,  evidence has 
been provided in support of the notion that Aβ is generated intracellularly along 
the ER-Golgi secretory pathway (Busciglio et al., 1993). It has been shown that 
retention of APP in the ER blocks production of Aβ40 but not Aβ42, suggesting 
that Aβ42 can be produced in the ER (Lee et al., 1998; Skovronsky et al., 1998; 
Wild-Bode et al., 1997). It was further shown that Aβ40 could be produced in 
the trans-Golgi network (Lee et al., 1998; Skovronsky et al., 1998; Wild-Bode et 
al., 1997). It is notable that intracellular Aβ42 and Aβ40 can be generated at 
different sites. A number of studies also indicate that amyloidogenic processing 
of APP occurs in cholesterol- and sphingolipid-enriched membrane raft 
microdomains of intracellular organelles (Ehehalt et al., 2003; Riddell et al., 
2001; Vetrivel et al., 2005). Although intracellular synthesis of Aβ is evident, the 
organelles/transport vesicles where Aβ is generated are not fully characterized. 
A recent study showed evidence of PS1 and PS2 enriched in a compartment of 
the endoplasmic reticulum associated with mitochondria known as 
mitochondrial associated membranes (MAM) (Area-Gomez et al., 2009). This 
study indicates that presenilin components in the mitochondria may contribute 
to generation of intracellular Aβ.   
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In addition to being generated intracellularly, secreted Aβ in the extracellular 
media can be taken up by cells and internalized into intracellular pools. Binding 
to the cell surface and subsequent internalization via receptor proteins into the 
cell is thought to be an important pathway for clearance of Aβ in the brain. 
Different isoforms of Aβ have been shown to internalize via a variety of cell 
surface receptors in neurons and also in inflammatory cells (astrocytes and 
microglia). These receptors include , α7 nicotinic acetylcholine receptor 
(α7nAChR) (Nagele et al., 2002), apolipoprotein E (APOE) receptors (Zerbinatti 
et al., 2006), members of the low-density lipoprotein receptor (LDLR) family 
(Jaeger and Pietrzik, 2008), scavenger receptor for advanced glycation end 
products (RAGE) (Yan, 1996), formyl peptide receptor-like 1 (FPRL1) (Yazawa, 
2001) and NMDA (N-methyl- D-aspartate) receptors (Snyder et al., 2005). As 
Aβ can be generated intracellularly, secreted into the extracellular lumen and 
also re-internalised (Figure 6), it is not surprising that the clearance of Aβ can 
be associated with a range of mechanisms. This is discussed further below. 
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Figure 6: Intracellular accumulation of Aβ  
Aβ is secreted into extracellular media by secretase activity of APP localized in 
the plasma membrane (1). Secreted Aβ can bind to cell surface receptors (for 
example, LRP, RAGE, FPRL1, NMDA receptors and α7nAChR), and can be 
internalized (2). Aβ can be produced from APP processing within the 
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endoplasmic reticulum (ER) and Golgi system and in early endosomes (3). 
Intracellular accumulation of Aβ is seen predominantly in the multivesicular 
body and lysosomes, but also in the mitochondria, ER, Golgi and the cytosol, 
where it is known to affect proteasome function (4). 
  
1.9    Clearance mechanisms of Amyloid-β protein  
 
Defective clearance of Aβ in the brain is implicated as one of the primary 
causes of its increased accumulation and associated pathology in sporadic AD 
brains. Gene polymorphisms in APOE and some of the newly identified risk 
factors (CLU and CR1) suggest impaired Aβ clearance in sporadic AD cases. 
Direct evidence for decreased clearance of Aβ from the CNS in the brains of AD 
patients has also been provided (Mawuenyega et al., 2010). The various 
clearance mechanisms and their roles in the accumulation of Aβ in the brain will 
be discussed here. 
 
1.9.1 Effect of ApoE on Aβ clearance 
One of the major risk factors associated with LOAD is APOE. It is thought 
that the isoform specific effects of ApoE may contribute to decreased clearance 
of Aβ in the AD brain. Evidences show that ApoE alters both the transport and 
metabolism of Aβ in the brain. There is no clear evidence for isoform-specific 
effects on APP processing or production of Aβ (Biere et al., 1995; Cedazo-
Minguez and Cowburn, 2001; Cedazo-Minguez et al., 2001; Irizarry et al., 
2004). Regardless, ApoE is known to play an important role in the clearance of 
Aβ. ApoE-containing lipoprotein particles can modulate the cellular uptake and 
degradation of Aβ by receptor-mediated endocytosis (Beffert et al., 1998, 
1999a; Beffert et al., 1999b; Cole and Ard, 2000; Yamauchi et al., 2002; 
Yamauchi et al., 2000). Studies have reported that lipid-associated ApoE2 and 
ApoE3 formed SDS-stable complexes with Aβ to a much greater extent than 
ApoE4 (Aleshkov et al., 1997; LaDu et al., 1994; Yang et al., 1997). It has been 
shown that the efficiency of complex formation between lipidated ApoE and Aβ 
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follows the order of ApoE2 > ApoE3 ≫ ApoE4 (Tokuda et al., 2000). Since the 
binding efficiency of ApoE isoforms to Aβ correlates inversely with the risk of 
developing AD, it has been thought that ApoE2 and ApoE3 may enhance the 
clearance of Aβ, compared to ApoE4. 
 
Alternatively, ApoE may modulate Aβ removal from the brain to the systemic 
circulation by transport across the blood-brain-barrier. ApoE is known to play a 
very important role in mediating Aβ clearance in the periphery. Previous in vivo 
data from Prof. Martins laboratory has demonstrated that Aβ is rapidly removed 
from the plasma by the liver and kidney and the rate of its clearance is affected 
by ApoE in C57BL/6J and APOE knockout mice (Hone et al., 2003). More 
recently it was shown that APOE influences the rate at Aβ42 clearance in the 
bloodstream. Both APOε4 mice and APOE knockout mice treated with lipidated 
ApoE4 demonstrated increased retention of plasma Aβ42 compared to 
APOε2/APOE knockout rE2 and APOε3/APOE knockout rE3 mice (Sharman et 
al., 2010). ApoE3-Aβ and ApoE4-Aβ complexes were shown to be cleared out 
of the brain at a significantly faster rate than ApoE4-Aβ (Bell et al., 2007; Deane 
et al., 2008; Ito et al., 2007). However a study using mice expressing human 
ApoE3 or ApoE4 did not show any differences in the clearance of Aβ from the 
brain (Ji et al., 2001).  
 
In addition to its isoform-specific difference in the clearance of Aβ, ApoE can 
affect Aβ aggregation in vitro. One study demonstrated that all three ApoE 
isoforms promoted Aβ42 fibrillization, with the effect being more enhanced with 
the ApoE4 isoform and least with ApoE2 (Ma et al., 1994). Subsequently, others 
also found that ApoE4 was more efficient than ApoE3 at increasing Aβ40 
aggregation (Castano et al., 1995; Wisniewski et al., 1994). Overall these 
findings provide evidence for the pathogenic role of ApoE4 in the decreased 
clearance and also enhanced accumulation of Aβ in AD brain. 
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1.9.2 Aβ degrading enzymes 
Multiple enzymes within the central nervous system (CNS) also play 
important roles in Aβ clearance. Such enzymes are produced by neurons or 
microglia, and also expressed in the cerebral vasculature. Studies show that the 
reduced Aβ-degrading activity may contribute to Aβ deposition in the brain and 
in vascular system. Insulin-degrading enzyme (IDE) and neprilysin (NEP) are 
identified as the main Aβ degrading enzymes expressed in neurons and in the 
cerebral vasculature. Other enzymes which can degrade Aβ include endothelin 
converting enzymes (ECE-1,2), plasmin, matrix metalloproteinase (MMP-2, -3 
and -9) and angiotensin-converting enzyme (ACE). Reduced levels of IDE, 
NEP, plasmin, plasminogen activators (uPA and tPA) and ECE-2 enzymes in 
AD have been demonstrated, although the correlation of Aβ accumulation with 
the activities of these enzymes are still not entirely clear. Reductions in 
neprilysin, IDE and plasmin in AD have also been associated with occurrence of 
APOE e4 alleles. The roles of Aβ degrading enzymes in the development of AD 
pathology and their potential therapeutic benefits have been extensively studied 
(reviewed in (Miners et al., 2008)), however this is not of major focus in this 
review. 
 
In addition to extracellular accumulation of Aβ, numerous reports show 
evidence for intraneuronal deposition of Aβ in brains of AD patients and 
transgenic animal models (LaFerla et al., 2007 ). A study has shown that 
increased Aβ levels in membrane-associated and intracellular fractions isolated 
from the temporal neocortex of AD patients to be more closely related to AD 
symptoms than other measured Aβ species (extracellular soluble and 
extracellular insoluble) (Steinerman et al., 2008). A recent study also shows 
correlation of the presence of the APOE 4 allele with an increased 
accumulation of intraneuronal Aβ peptides in sporadic AD brains (Christensen 
et al., 2010). Intraneuronal Aβ accumulation is thought to be an early event in 
AD pathogenesis and has been reported to be critical in the synaptic 
dysfunction, cognitive decline and the formation of plaques in AD (Gouras et al., 
2000; Oddo et al., 2006). The autophagy-lysosome pathway and ubiquitin-
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proteasome system are the main intracellular degradation pathways in cells. 
Disruption of these pathways has been observed in AD brains and believed to 
play important roles in Aβ mediated neurodegeneration.  
 
1.9.3 Autophagy-Lysosome Pathway 
Autophagy is a vital cellular degradation pathway involved in degradation of 
long-lived, aggregated proteins and even whole organelles inside the cells. 
Based on the nature and delivery of substrates for degradation autophagy can 
be classified into three types: macroautophagy, microautophagy and chaperone 
mediated autophagy (CMA) (Figure 7). Macroautophagy is considered to be the 
main contributor to the overall autophagy in cells. It is mostly a non-specific 
process conserved from yeast to mammals, which is up-regulated during stress 
and nutrient starvation conditions. This process mediated through the 
mammalian target of rapamycin (mTOR) kinase and regulated through 
signalling cascades AMPactivated protein kinase (AMPK) or the class I 
phosphatidylinositol 3-kinase (PI3K)/Akt pathways (Hay and Sonenberg, 2004; 
He and Klionsky, 2009). The inhibition of mTOR initiates the formation of the 
autophagosome which sequesters the cytoplasmic material for delivery into the 
lysosome for degradation by acidic hydrolases (Klionsky and Emr, 2000). 
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Figure 7: The different types of autophagy in eukaryotes 
Macroautophagy featured by bulk degradation of cytosolic material in the 
lysosome after delivery by autophagosomes. Microautophagy is a process 
where bulk degradation by lysosome does not require intermediate vacuoles for 
delivery. Chaperone mediated autophagy is selective degradation of a cytosolic 
protein target in the lysososme by a dedicated chaperone complex. 
(Adapted from Martinet et al, 2009) 
1.9.3.1 Extensive accumulation of autophagic vacuoles in AD 
A number of reports indicate that autophagy is minimal but constitutively 
active in neurons and is essential for protein turnover and survival (Hara et al., 
2006; Komatsu et al., 2006). Autophagic vacuoles are less abundant in neurons 
of the healthy brain (Cota et al., 2006; Mizushima et al., 2008; Nixon et al., 
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2005). However in the AD brain, severe abnormalities in endocytic and 
autophagic pathway including extensive accumulation of autophagic vacuoles 
(AVs) containing APP/Aβ products and dystrophic neurites containing these 
AVs is observed (Nixon, 2007; Nixon et al., 2005). Autophagy-related pathology 
has also been increasingly documented in several other neurodegenerative 
diseases such as Parkinson‟s disease, Frontotemporal dementia and 
transmissible spongiform encephalopathy (Anglade et al., 1997; Liberski et al., 
2008; Rudnicki et al., 2008; Yue et al., 2002; Zhou et al., 1998).  
 
Severe autophagic pathology develops in mouse models of AD expressing 
familial AD forms of APP and PS1 mutations (Cataldo et al., 2004; Chishti et al., 
2001; Yang et al., 2011; Yu et al., 2005). Accumulation of autophagy substrates 
and AVs are also observed in PS1-null blastocysts and neurons of mice 
conditionally depleted of PS1 (Esselens et al., 2004; Wilson et al., 2004). A 
recent study has shown that the critical component of the Aβ-generating, γ-
secretase enzyme presenilin-1 (PS1) is required for autophagy and familial AD 
causing PS1 mutations are associated with impairments in the autophagy-
lysosome pathway. This study has identified a specific role of PS1 in the 
acidification of autolysosomes/lysosomes (Lee et al., 2010). It is suggested that 
loss of PS1 function can induce autophagy impairment alongside Aβ 
accumulation which could account for the cell death and dysfunction observed 
in AD. 
1.9.3.2 Defective lysosomal proteolysis in AD  
Many lines of evidence indicate that disruption of the lysosomal proteolytic 
clearance forms the basis for the neuronal accumulation of AVs in the AD brain. 
The AD brain is featured by AVs filled with undigested or partially digested 
substrates (Nixon et al., 2005). A similar pattern of AV accumulation and 
neuritic dystrophy is observed when lysosomal degradation is inhibited by 
deletion of cathepsins (Felbor et al., 2002; Koike et al., 2000; Koike et al., 2005) 
or by lysosomal enzyme inhibitors (Bednarski et al., 1997; Boland et al., 2008; 
Ivy et al., 1989; Takeuchi and Takeuchi, 2001; Yang et al., 2008). The abnormal 
autophagic-lysosomal pathology is comparable to that seen in particular 
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lysosomal storage disorders (LSDs), which are also associated with 
accumulation of autophagic and endosomal substrates (Nixon et al., 2008). 
Importantly, some LSDs, such as GM1 and GM2 gangliosidoses, Niemann Pick 
type C disease (NPC) and neuronal ceroid-lipofuscinosis (NCL) are associated 
with prominent nervous system degeneration (Jeyakumar et al., 2005; Walkley, 
1998, 2009). Furthermore, other similarities are also being identified between 
the cellular pathologies of AD and of certain LSDs (Chevrier et al., 2010; 
Eckhardt, 2010; Fukuda et al., 2006; Settembre et al., 2008). Some notably 
include NFTs, increased levels of the BACE-1, Aβ deposition. A recent study 
has shown that stimulating lysosomal proteolysis by deletion of an endogenous 
inhibitor of lysosomal cysteine proteases (cystatin B) in AD transgenic mice, 
diminishes accumulation of autophagy substrates, extracellular amyloid 
deposition and ameliorates learning and memory deficits (Yang et al., 2011). 
These studies establish the pathogenic significance of autophagic-lysosomal 
dysfunction in AD and specifically the importance of deficient lysosomal 
proteolysis. But, the exact contribution of autophagy to the clearance of 
intracellular Aβ is unclear.  
 
1.9.3.3 Enhancing Autophagy promotes Aβ clearance 
Modulation of autophagy to enhance clearance of protein aggregates is 
gaining interest as a therapeutic strategy in many neurodegenerative diseases 
(Rubinsztein et al., 2007). Enhancing autophagy has been suggested as a 
treatment strategy for HD (Ravikumar et al., 2004; Sarkar et al., 2007b; Williams 
et al., 2008) and α-synucleinopathies such as Dementia with Lewy Bodies 
(DLB; (Crews et al., 2010)). In mammalian AD models, activators of autophagy 
have been shown to be neuroprotective and confer cognitive benefits (Hung et 
al., 2009; Spilman et al., 2010). The best-characterised drug that enhances 
autophagy is rapamycin. Inhibition of mTOR by rapamycin has been widely 
reported to enhance clearance of aggregate-prone proteins by macro-
autophagy (Berger et al., 2006; Ravikumar et al., 2004; Sarkar and Rubinsztein, 
2008). Small molecules which activate autophagy by 1) mTOR inhibition 
(Berger et al., 2006; Ravikumar et al., 2003; Webb et al., 2003), 2) reducing 
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inositol levels (Fornai et al., 2008; Sarkar et al., 2005) or by 3) Ca2+ channel 
modulation (Zhang et al., 2007) have also shown to reduce aggregation in 
cellular models of neurodegeneration, reduce amyloid deposition and abolish 
cognitive deficits in mice models (Sarkar and Rubinsztein, 2008). Further, 
derivatives of known agents shown to have benefits in AD models, such as 
resveratrol, have been developed and shown to modulate mTOR signalling and 
facilitate autophagy and Aβ degradation (Vingtdeux et al., 2010). A recent study 
has also shown that small molecule enhancer of rapamycin (SMER28) 
decreases levels of Aβ and APP-CTF via Atg5 dependent autophagy in 
neuronal cells (Tian et al., 2011). Autophagy can also be regulated in an 
mTOR-independent manner by drugs that reduce intracellular inositol levels, 
such as lithium, valproate and carbamazepine (Sarkar and Rubinsztein, 2008). 
In addition to autophagy, the proteasome is an important pathway for 
maintenance of protein homeostasis in cells. It also has an important role in AD 
pathology. 
1.9.4 Ubiquitin-Proteasome System 
The proteasome is a large protein complex that is located in the nucleus and 
the cytoplasm and is essential for the degradation of ubiquitin tagged proteins. 
The ubiquitin-proteasome system (UPS) is essential for maintaining a constant 
balance of protein synthesis and degradation in cells and is conserved from 
archaebacteria to mammals. The UPS functions constitutively and is essential 
for the normal functioning of the cell. Protein clearance by the UPS occurs in 
two sequential steps, an ubiquitin tagging reaction catalysed by the ubiquitin 
ligase and a subsequent degradation of the tagged proteins by the proteasome 
system. Unlike autophagy the UPS substrates mostly includes proteins with 
short half-life and signalling functions inside the cell.   
 
1.9.4.1 Altered proteasomal activity in the AD brain 
Increasing evidence indicates that alterations in the UPS function may be 
involved in AD pathogenesis. Accumulation of an ubiquitin-B mutant protein 
(UBB+1) in both plaques and tangles has been observed (Mori et al., 1987; 
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Morishima-Kawashima et al., 1993; Perry et al., 1987). UBB+1 is a frameshift 
mutant of ubiquitin B gene and has been shown to block ubiquitin-dependent 
proteolysis (Lindsten et al., 2002) and mediate Aβ-induced neurotoxicity in 
neuronal cells (Song et al., 2003). Also the ubiquitin carboxy-terminal hydrolase 
L1 (UCH-L1), a deubiqutinating enzyme, is oxidized and down-regulated in the 
specific brain regions of AD cases (Castegna et al., 2002; Pasinetti, 2001). 
Recent evidence provided a positive association for genetic polymorphisms in 
an ubiquitin-like protein UBQLN1, in sporadic AD (Bertram et al., 2005). Direct 
evidence of altered proteasome activity showing a selective decrease in activity 
in specific regions of AD brain like the hippocampus has also been reported 
(Keller et al., 2000). Together, these reports suggest a possible role for 
dysfunctional UPS function in AD pathogenesis. 
 
1.9.4.2 Aβ interacts with the proteasome 
Numerous studies have reported interactions between Aβ and the 
proteasome system. Both Aβ40 and Aβ42 have shown to selectively inhibit the 
chymotrypsin-like activity of the 20S proteasome (Gregori et al., 1995; Gregori 
et al., 1997; Oh et al., 2005). Using a cell-free proteasome activity assay, 
oligomeric forms of Aβ were found to significantly decrease proteasomal activity 
in a dose-dependent manner (Tseng et al., 2008). Elevated levels of an 
ubiquitin-conjugating enzyme, E2-25K/Hip2 have been identified as a mediator 
of Aβ neurotoxicity in primary cortical neurons (Song et al., 2003). In addition, it 
has also been shown that the Aβ induced synaptic dysfunction and cognitive 
deficits can be rescued via restoring proteasomal enzymatic activity by 
increasing expression of UCH-L1 (Gong et al., 2006). Intraneuronal Aβ 
accumulation due to decreased proteasome function has been reported in the 
brains of AD transgenic models, primary neurons isolated from APP transgenic 
mice and in N2A cells treated with a proteasome inhibitor (Almeida et al., 2006; 
Oddo et al., 2006; Oh et al., 2005; Tseng et al., 2008).  
 
Evidence shows that tau can be degraded by the proteasome as inhibition 
using lactacystin in cell culture inhibits tau degradation (David et al., 2002; 
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Tseng et al., 2008). Injection of anti-Aβ antibodies into the brains of AD 
transgenic mice showed that Aβ clearance led to a significant reduction in early 
tau pathology but not late aggregated tau deposits. However concomitant 
injection of the anti-Aβ antibody with a proteasome inhibitor led to a reduction of 
Aβ deposits but no changes in tau pathology were detected (Oddo et al., 2004). 
These data indicate that the accumulation of Aβ may impair proteasome 
function thus facilitating tau accumulation.  
 
It is evident that disruption of proteasomal and autophagy-lysosomal 
functions corresponds to intracellular Aβ deposition and ensuing pathology 
including tau aggregation and memory impairments in AD. It is widely accepted 
that functions of the proteasomal and autophagic systems become 
compromised during the normal aging process contributing to benign protein 
deposition in the brain. But the exact causes of the failure of these functions in 
AD are unclear. Whether loss of specific functions in the cellular degradation 
systems leading to pathological amyloid deposition can contribute to AD is yet 
to be determined. 
 
The literature reviewed above has presented evidence of the pathogenic 
nature of Aβ in AD. The accumulation/ aggregation of Aβ and associated 
toxicity have been considered as a target for therapeutic intervention for AD and 
there is a number of therapeutics that have been developed. There has been 
considerable progress in the development of anti-amyloid therapeutics for 
clinical trials. The current strategies for drug designing and treatments 
underway in AD clinical trials for targeting Aβ production, aggregation and 
clearance in the brain are discussed further.  
 
1.10 AD therapeutics 
 
With an increasing ageing population, the need for preventative and disease 
modifying treatments for AD caused dementia is critical for the future. Current 
AD treatments target cognitive decline or failure and provide only minor benefits 
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across the array of clinical symptoms (Omerovic et al., 2007; Tariot, 2006). 
Approved AD drugs such as acetylcholine esterase (ACE) inhibitors (Aricept, 
Namenda, Exelon, etc.) and N-methyl-D-aspartate (NMDA) receptor 
antagonists (Memantine) are generally prescribed in monotherapy or in 
combination. However they are expensive and most importantly, do not prevent 
disease progression are of limited benefit to most patients (Jelic et al., 2006; 
Raschetti et al., 2007). Other drugs are used to manage mood disorder, anxiety 
and neurosis in later stages of the disease, but no treatment with a strong 
disease-modifying effect is currently available. 
 
1.10.1 Anti-amyloid therapies 
 
The main strategies that target Aβ include 1) reducing its production by 
modulating APP processing by α-, β- and γ-secretases, 2) reducing aggregation 
of Aβ and 3) enhancing clearance of Aβ by immunotherapy. 
 
1.10.1.1 Drugs to reduce Aβ production 
 
Therapeutic strategies to reduce production of Aβ include BACE1 inhibitors, 
γ-secretase inhibitors and α-secretase activators. PPAR (peroxisome 
proliferator activator receptor) agonists like rosiglitazone and pioglitazone and 
BACE1 inhibitors like CTS-21166 (Landreth et al., 2008) which reduce Aβ levels 
are currently under investigation (Mangialasche et al., 2010). A range of γ-
secretase inhibitors (semagacestat, MK-0752, BMS-708163, PF-3084014, 
begacestat), E-2012 and a subset of non-steroidal anti-inflammatory drugs 
(NSAIDs) which act as γ-secretase modulators have shown to decrease Aβ 
production (Tomita, 2009). Up-regulation of α-secretase activity and non-
amyloidogenic cleavage of APP to decrease production of Aβ and increase 
sAPPα have been shown to be neuroprotective. Many compounds have been 
shown to activate α-secretase activity (Marcade et al., 2008) and some of them 
are also currently being tested in patients with mild-to-moderate AD 
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(Mangialasche et al., 2010). Despite showing positive results in animal models, 
most drugs targeting Aβ production have failed in AD clinical trials. 
Development of drugs targeting secretases is particularly challenging because 
of the fact that these enzymes have a wide array of neuronal substrates and 
may have undesirable long term side-effects.  Of these the type I 
transmembrane protein receptor, Notch is the most pharmacologically relevant 
as it has been difficult to develop specific inhibitors/modulators of Aβ42 without 
affecting Notch signalling. Indeed, a phase 3 trial of Eli Lilly‟s γ-secretase 
inhibitor, Semagacestat in 2,600 patients, with mild-to-moderate AD, recently 
failed. In addition, cognition and the ability to complete activities of daily living 
worsened with drug treatment and increased the risk of skin cancer for the 
patients on the drug compared to those on placebo. These side effects were 
most likely related to inhibition of Notch processing. A suitable therapeutic 
window needs to be defined, through which γ-secretase activity is selectively 
modulated, thereby allowing Notch and other substrates to be normally 
processed while simultaneously reducing Aβ generation. Although results from 
the Lily‟s recent trial has placed doubts on inhibiting γ-secretase as an effective 
approach to treating AD, it does not rule out other approaches to modulating 
this target. Indeed, there is a push by major pharmaceutical companies such as 
Pfizer to develop Notch-sparing inhibitors (BioCentury; Bernstein Report on 
Biobusiness, 23/8/10). 
 
1.10.1.2 Drugs preventing Aβ aggregation 
 
Evidence for the neurotoxic activity of Aβ oligomers constitutes the scientific 
basis for the development of compounds that inhibit Aβ aggregation or 
destabilise Aβ oligomeric species. A range of compounds targeting Aβ 
aggregation have been investigated including Tramiprosate (homotaurine, 
Alzhemed; a small compound that binds preferentially to soluble Aβ and 
prevents fibrillisation) (Aisen et al., 2007; Gauthier et al., 2009), Clioquinol 
(metal chelators which reduces Aβ-metal association: PBT1 and PBT2) (Adlard 
et al., 2008; Biran et al., 2009), Scyllo-inositol (promotes dissociation of Aβ 
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aggregates) (McLaurin et al., 2006) and Epigallocatechin-3-gallate (EGCG, anti-
aggregation properties including a range of other neuroprotective functions) 
(Mandel et al., 2008). Compounds targeting Aβ aggregation have shown mixed 
results in AD clinical trials. Although promising, a major challenge in designing 
such compounds is to specifically target the toxic form of Aβ. Although soluble 
oligomers have been identified as the main toxic species, structural information 
is significantly lacking to engage target specific inhibitors. A fair amount of risk 
in modulating Aβ aggregation leading to increased toxic species in the brain 
may also be involved.  
 
Inhibitors of Aβ aggregation from natural food products or dietary intake 
have been of interest in AD therapeutics. Peptides with capacity for amyloid 
inhibition, derived from bovine dairy sources including whey, casein and 
lactoferrin, have also been reported (Bennett et al., 2009). The Colostrinin 
peptide complex (proline-rich polypeptides derived from colostrums) was shown 
to inhibit and disrupt β-sheets of amyloid proteins (Schuster et al., 2005) and 
exert several other bioactive properties (Boldogh and Kruzel, 2008; Zimecki, 
2008) that translated to proven neuroprotective bioactivity against AD 
(Bilikiewicz and Gaus, 2004). Successful in vivo neuroprotective studies with 
Colostrinin (Bilikiewicz and Gaus, 2004) suggest that other exogenous peptides, 
perhaps dietary sources, with amyloid inhibition capacity might be also be 
protective against AD. 
1.10.1.3 Immunotherapy to promote Aβ clearance 
 
Active and passive immunisations have been developed to remove soluble 
and aggregated Aβ from the CNS. In a phase 2 clinical trial of AN-1972 (anti-Aβ 
vaccine) in mild-to-moderate AD, some patients developed aseptic 
meningoencephalitis, which was attributed to cytotoxic T cells and/or 
autoimmune reactions to AN-1972 (Gilman et al., 2005). To avoid 
neuroinflammation, new vaccines that selectively target B-cell epitopes without 
stimulating T cells have been developed like CAD-106, ACI-24, UB-311, ACC-
001 and V-950 which are currently in clinical trials (Muhs et al., 2007; Wang et 
47 
 
al., 2007). Another active immunisation strategy is AFFITOPE which is based 
on short peptides mimicking parts of native Aβ42 (Schneeberger et al., 2009). 
Passive immunisation using monoclonal/polyclonal antibodies targeting Aβ have 
been shown to reduce brain amyloid load with improvement in cognitive 
functions in AD models (Wilcock and Colton, 2008). Monoclonal antibodies 
currently being tested in clinical trials include bapineuzumab (humanised anti-
Aβ monoclonal antibody), solanezumab (specific monoclonal antibody for 
soluble Aβ), PF-04360365 (humanised, modified IgG2 antibody that binds to the 
C terminus of Aβ40), GSK-933776, R-1450, and MABT-5102A (Salloway et al., 
2009). Passive immunisation may be more effective in the elderly than active 
immunotherapy, due to reduced responsiveness to vaccines. But administration 
of antibodies is time consuming and costly. Active immunotherapy is cost 
effective and may guarantee constant high antibody titres. However the risk of 
inflammation and possible adverse effects are of concern.  
 
1.10.2 Latrepirdine (DimebonTM) 
 
Several neuroprotective compounds which can enhance neurogenesis and 
reduce amyloid deposition are of current interest in many neurodegenerative 
diseases (Pieper et al., 2010). However their mode of action is largely 
uncharacterized and poorly understood. One of them is latrepirdine (2,3,4,5-
tetrahydro-2,8-dimethyl-5-[2-(6-methyl 3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole), 
which is an orally-available, small molecule previously approved in Russia as a 
non-selective antihistamine (Bachurin et al., 2001). Latrepirdine was shown to 
weakly inhibit butyrylcholinesterase and acetyl cholinesterase, block the N-
methyl-D-aspartate receptor signalling pathway, and inhibit mitochondrial 
permeability transition pore opening (Bachurin et al., 2001; Grigorev et al., 
2003; Lermontova et al., 2001). Latrepirdine has also shown neuroprotective 
effects in models for AD (Bachurin et al., 2001) and Huntington‟s disease. In the 
initial clinical study in a Russian cohort, latrepirdine showed great promise for 
improving cognition in mild-moderate AD (Doody et al., 2008). However, a 
subsequent 6 month, US-Based replication (CONNECTION) trial showed no 
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benefits of the drug for AD. The exact causes for the mixed results in the AD 
clinical trials were unclear. The lack of understanding of a specific mechanism 
of action for latrepirdine was one of the main issues expressed for its mixed 
outcomes in two different phase II AD clinical trials (Bezprozvanny, 2010; 
Editorial, 2010a, b; Jones, 2010).  
 
Interest in latrepirdine rebounded recently with the Steve McKnight paper in 
Cell pointing out the similarity of the latrepirdine scaffold to that of a new, 
neuroprotective class of drugs (Pieper et al., 2010). Subsequent studies have 
identified more neuroprotective functions for latrepirdine including enhanced 
neuronal survival (Zhang et al., 2010b), modulated Aβ secretion and 
metabolism (Steele et al., 2009) and clearance of α-synuclein protein 
aggregates (Wu et al., 2008; Yamashita et al., 2009). Some recent studies have 
also reported latrepirdine‟s cognitive enhancing properties, although the 
mechanism of action responsible for improving memory functions is still unclear 
(Giorgetti et al., 2010; Vignisse et al., 2011). Currently, a longer 12 month 
(CONCERT) trial for AD is still in progress and Phase 3 trial for Huntington‟s 
disease is also underway. 
 
1.10.3 Current challenges in AD therapeutics 
 
The search for a disease modifying therapy for AD has been very difficult. 
Some of the challenges that need to be addressed are 1) the heterogeneous 
nature of the disease (both pathology and epidemiology), 2) lack of a reliable 
diagnostic test for early detection and intervention, 3) drug delivery and ageing 
factors which may influence response to treatment, 4) linear and target driven 
reductionist approach in drug discovery 5) lack of high-throughput drug 
screening systems, 6) incomplete understanding of the drug-target mechanism 
and 7) AD drugs are targeted at a stage when brain is irreparably damaged and 
therefore effective treatment is unlikely. 
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The use of disease models ranging from in vitro non-cell based systems to 
transgenic animals form the basis for drug discovery and evaluation and 
elucidating disease mechanisms in AD. The use of animal models and the 
significance of alternative model systems in studying disease mechanisms and 
drug targets have been discussed further.  
 
1.10.4 Disease models for AD 
 
The majority of transgenic AD animal models represent overexpression of 
an EOAD associated mutation or particular fragments of human APP, to 
develop AD like pathology. Hence they are of immense value to gain knowledge 
about the mechanisms underlying AD pathology. AD animal models that provide 
information on Aβ deposition and memory impairment are most popular in drug 
testing as these attributes are considered relevant to AD pathogenesis. Apart 
from single, double and triple transgenic mice (Duyckaerts et al., 2008), other 
animal models used in AD research are hamsters (Hartig et al., 2007), rabbits 
(Woodruff-Pak et al., 2007), guinea pigs (Arjona et al., 2002), non-human 
primates (Kulstad et al., 2005), fruit flies (Ganguly et al., 2008), zebrafish 
(Newman et al., 2010) and worms (Link, 1995). A difficulty with any model is its 
relevance to AD and therefore extrapolation is indispensable, even in animal 
models (Duff and Suleman, 2004; Duyckaerts et al., 2008). Animal models are 
also very expensive, require rigorous maintenance and time-consuming, with 
years being required to reproduce an ageing process. In addition, animal 
models are unsuitable for high throughput screening techniques. Therefore, use 
of simpler model systems like yeast, worms, flies and zebrafish for studying 
disease mechanisms and map drug targets are more attractive. Yeasts are 
simple eukaryotic cells and provide a greater advantage comparing other model 
systems mainly due to its powerful genomic and proteomic screening methods 
and availability of a range of tools for molecular level analysis. The potential 
applications of yeast cell systems and models in AD research will be discussed 
further.     
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1.11 Yeast Models  
Yeast is a unicellular eukaryotic organism and is widely known for its 
applications in molecular and cellular biology studies. Yeast growth and division 
can be controlled efficiently by adjusting environmental conditions. Moreover 
yeast species including baker‟s yeast Saccharomyces cerevisiae and fission 
yeast Schizosaccharomyces pombe are genetically tractable and greatly 
amenable to modifications such as gene disruption, mutations or gene-dosage 
effects. Because of these advantageous features, yeast cells have been the 
model organism of choice in both fundamental and applied medical research. 
For example, cell division cycle proteins (CDKs) were first identified in yeast 
cells (Nurse et al., 1998). Molecular pathways and essential proteins involved in 
autophagy were first identified and modelled in yeast cells (Klionsky, 2010). 
Also the cellular target of rapamycin (mTOR pathway inhibitor) was first 
discovered in yeast (Heitman et al., 1991). 
 
1.11.1   Yeast genes and human disease 
Yeast has been successfully used as a model for human diseases and 
particularly neurodegenerative disorders characterized by protein misfolding 
and aggregation (Braun et al., 2010; Winderickx et al., 2008). Comparison of 
the yeast and human genomes has revealed that 31% of genes involved in 
human disease have functional homologs in yeast and nearly 50% of human 
genes implicated in heritable diseases have yeast homologs (Foury, 1997; 
Hartwell, 2004a; Hartwell, 2004b; Koutnikova et al., 1997). In addition to 
similarity in gene sequences, yeast cells demonstrate similarity in various cell 
signalling and metabolic pathways. Studies have shown evidence of 
morphological markers of apoptotic and necrotic cell death in yeast (Madeo et 
al., 1997; Madeo et al., 1999). Yeast cells have also shown to demonstrate 
pathological markers associated with human neurodegenerative diseases such 
as oxidative stress, mitochondrial dysfunction and endoplasmic reticulum (ER) 
stress with expression of human proteins or exogenous treatment with toxic 
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agents (Eisenberg et al., 2007; Haynes et al., 2004). Intriguingly, ageing (both 
chronological and replicative ageing) also show similar markers in yeast cells.  
Despite the evolutionary distance, the molecular pathways involved in cell 
death are highly conserved in yeast and humans (Braun et al., 2010). For 
example, regulators of cell death in yeast may include apoptosis-inducing factor 
(Aif1p), metacaspase (Yca1p), Ndi1p (homolog of AIF homologous 
mitochondrion-associated inducer of death; AMID), Bir1p (homolog of the 
inhibitor of apoptosis (IAP) family), Nuc1p (homolog of endonuclease G, 
EndoG), Bax inhibitor (BI-1), Nma111p (homolog of HtrA2/Omi), and Cpr3p 
(homolog of cyclophilin D) (Aerts et al., 2009; Buttner et al., 2007; Eisenberg et 
al., 2007; Madeo et al., 2009). It is to be noted that even though these cell death 
pathways are similar between yeast and humans, replication in mammalian cell 
models is essential for validation.  
 
1.11.2    Yeast as an experimental tool for AD research 
One of the most attractive advantages of yeast compared to other models is 
the availability of various experimental tools applicable for high throughput 
analysis of protein-protein, gene-gene and gene-protein interactions and 
associated cellular functions. Such tools offer an unbiased approach for 
studying the pathological functions of human disease proteins and establish 
models for drug screening. Some of the notable tools may include the classical 
yeast two/three-hybrid system for studying protein-protein interactions for a 
range of eukaryotic proteins (Ito et al., 2001), the Saccharomyces Genome 
Deletion Project (SGD) (Winzeler, 1999) which is a unique collection of knock-
out strains covering 96% of the yeast genome and provides a unique tool for the 
functional analysis of the yeast genome (Giaever, 2002), Synthetic Genetic 
Array analysis (SGA) which is a high-throughput technique for exploring lethal 
or growth inhibitory genetic interactions (Tong et al., 2001) and large-scale 
protein localization analysis using green fluorescent protein (GFP) tags inserted 
individually at the C terminus of 6029 yeast ORFs covering 75% of the total 
proteome (Huh et al., 2003). These tools present a variety of applications in AD 
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research including studying drug targets/mechanisms and functional analysis of 
pathological AD related proteins.  
A range of yeast models for studying AD related proteins have been 
developed to date (Table 1). Yeast models have been utilized for exploring APP 
processing, secretase activities, Aβ oligomerization/toxicity and tau 
phosphorylation (Figure 8). Yeast offers numerous advantages compared to 
mammalian models with its relatively less complex and well characterized 
biology.  But, yeast also has natural limitations: they are unicellular and not 
functionally linked to other cells.  Although they are primitive compared to 
neurons as they lack structures like synapses, axons and dendrites and related 
functions, yeast models continue to be a very valuable initial tool for 
investigating cellular mechanisms involved in AD (Bharadwaj et al., 2010) which 
can then be further validated in model systems. 
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Alzheimer’s Disease Pathology 
 
Yeast Model 
Amyloid Precursor Protein (APP) 
processing 
Expression of human APP (Le Brocque et al., 
1998; Zhang et al., 1994; Zhang et al., 1997) 
γ-secretase Functional expression of human APP with 
engineered γ-secretase complex (Edbauer et al., 
2004; Edbauer et al., 2003; Futai et al., 2009; 
Yagishita et al., 2008) 
β-secretase Expression of human β-secretase in yeast (Luthi 
et al., 2003; Middendorp et al., 2004) 
C99 Processing of C99 Fragment (Sparvero et al., 
2007) 
In vivo Aβ Oligomerization 
 
Two hybrid system (Aβ linked to LexA DNA 
binding domain and B42 transactivation domain 
(Hughes et al., 1996) 
Expression of Aβ/GFP fusion protein (Caine et al., 
2007a) 
Expression of Aβ/Sup35p fusion protein 
(Bagriantsev and Liebman, 2006; von der Haar et 
al., 2007) 
Extracellular Aβ Toxicity Toxicity of oligomeric and fibrillar Aβ (Bharadwaj 
et al., 2008) 
tau phosphorylation Expression of human tau-3R and tau-4R isoforms, 
clinical mutant tau-P301L (Vandebroek et al., 
2006; Vandebroek et al., 2005) 
Table 1: Yeast models developed for studying AD pathology 
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Figure 8: Diagrammatic representation of engineered yeast models developed 
for studying downstream pathological events in AD 
(A) Cells transfected with human APP to study endogenous α-secretase activity 
(B) Growth assay developed to monitor human β-secretase activity and screen 
for inhibitors, (C) Reconstitution of γ-secretase components using β-gal assay, 
(D) Aβ tagged to GFP to monitor localization and oligomerization, (E) Aβ42 
tagged to Sup35p protein to study oligomerization, (F) Endogenous 
phosphorylation of human tau, (G) Extracellular toxicity of oligomeric and fibrillar 
Aβ42. (Adapted from Bharadwaj et al., 2009) 
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1.12 Hypothesis and Objectives:  
  AD is a very heterogeneous and a multifactorial ageing disorder of the 
nervous system. Accumulation and toxicity of the Aβ protein are key mediators 
of neurodegeneration in AD and a major target of interest in developing 
effective treatments. As described above yeast have a number of 
characteristics that allows investigation of AD related proteins that have key 
roles in AD pathogenesis and can enable the development of cell based 
screening techniques for novel drug discovery  and identification of essential 
gene functions for Aβ clearance and protection against toxicity. This project 
mainly focuses on establishing and validating a yeast model of Aβ oligomer 
mediated toxicity and intracellular accumulation. Using these yeast models the 
project will address the following hypotheses: 
 
 Oligomeric Aβ42 alters viability and proliferation of yeast cells. 
 Whey derived peptides inhibit Aβ oligomer formation and associated 
toxicity. 
 Recombinant MBP-Aβ42 fusion protein forms oligomers and is toxic 
 The ubiquitin-proteasome and autophagy-lysosome intracellular 
degradation pathways have a role in reducing intracellular Aβ 
aggregates in yeast 
 Enhancing autophagy in yeast reduces levels of intracellular Aβ 
aggregates 
 Latrepirdine enhances autophagy and reduces the levels of 
intracellular Aβ aggregates in yeast. 
 Latrepirdine promotes A42 clearance in vivo. 
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The aims of the project are as follows: 
 
1.) Study Aβ42 toxicity and growth effects 
a.) Determine toxicity and uptake of Aβ42 and a modified Aβ42 (19:34) 
peptide in yeast cells. 
b.) Investigate the effect of dairy derived peptides on Aβ42 
oligomerization and toxicity 
c.) Determine structural characteristics and toxicity of MBP-Aβ fusion 
proteins 
d.) Determine if Aβ42 can promote proliferation of yeast within the 
stationary phase of cell growth and whether this can be blocked by 
inhibition of mTOR by rapamycin. 
 
2.) Study intracellular accumulation and degradation of Aβ42 
a.) Establish a yeast model for intracellular Aβ accumulation using GFP-
Aβ42 and GFP-Aβ42 (19:34) expressing yeast. 
b.) Study cellular degradation pathways involved in clearance of GFP-
Aβ42 inside the yeast cell using autophagy and proteasomal activity 
deficient mutants.   
c.) Determine if activation of autophagy by rapamycin promotes 
clearance of intracellular GFP-Aβ42 in yeast.   
d.) Determine if latrepirdine can stimulate autophagy and promote GFP-
Aβ42 clearance 
e.) Determine if latrepirdine influences A clearance in vivo 
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Chapter 2 
Materials and Methods 
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2.1       Materials: 
2.1.1 Yeast strains: 
Strain Genotype  Source 
Candida glabrata Candida glabrata ATCC 90030 Ass. Prof. Ian Macreadie, 
RMIT University 
Saccharomyces 
cerevisiae (Kvy55) 
MATα leu2 ura3 trp1 lys2 his3 
suc2- Δ9 
Dr. Kuninori Suzuki, 
Tokyo Institute of 
Technology (Kirisako et 
al., 2000) 
Saccharomyces 
cerevisiae 
(Kvy55:atg8Δ) 
MATα leu2 ura3 trp1 lys2 his3 
suc2- Δ9 Δapg8::HIS3 
Dr. Kuninori Suzuki, 
Tokyo Institute of 
Technology (Kirisako et 
al., 2000) 
Saccharomyces 
cerevisiae 
(BY4743) 
MATa/MATα his3Δ1/his3Δ1 
leu2Δ0/leu2Δ0 LYS2/lys2Δ0 
met15Δ0/MET15 
ura3Δ0/ura3Δ0 
Dr. Gabriel Perrone 
University of New South 
Wales 
 
Saccharomyces 
cerevisiae 
(BY4743:pep4Δ) 
MATα his3Δ1/his3Δ1 
leu2Δ0/leu2Δ0 LYS2/lys2Δ0 
met15Δ0/MET15 
ura3Δ0/ura3Δ0 pep4Δ/pep4Δ 
Dr. Gabriel Perrone 
University of New South 
Wales 
 
Saccharomyces 
cerevisiae 
(BY4743:cvt1Δ) 
MATα his3Δ1/his3Δ1 
leu2Δ0/leu2Δ0 LYS2/lys2Δ0 
met15Δ0/MET15 
ura3Δ0/ura3Δ0 cvt1Δ/cvt1Δ 
Dr. Gabriel Perrone 
University of New South 
Wales 
 
Saccharomyces 
cerevisiae 
(Wcg4a) 
MATa ura3 his3-11,15 leu2-
3,112 
Dr. Ben Distel, University 
of Amsterdam 
(Heinemeyer et al., 1993) 
Saccharomyces 
cerevisiae 
(Wcg4a:pre1Δ) 
MATa ura3 his3-11,15 leu2-
3,112 pre1-1 
Dr. Ben Distel, University 
of Amsterdam 
(Heinemeyer et al., 1993) 
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Saccharomyces 
cerevisiae 
(Wcg4a:pre1-2Δ) 
MATa ura3 his3-11,15 leu2-
3,112 pre1-1pre2-1 
Dr. Ben Distel, University 
of Amsterdam 
(Heinemeyer et al., 1993) 
 
2.1.2 Yeast media: 
1) Rich media (YEPD) contains 1% yeast extract, 2% peptone and 2% glucose 
in distilled water 
2) Minimal media (YNB+2% glucose) contains 0.67% yeast nitrogen base 
(YNB) with 0.5% ammonium sulphate and 2% glucose in distilled water 
3) Synthetic complete media (YNB complete) contains minimal media (YNB+2% 
glucose) supplemented with 20mg/L each of uracil, tryptophan, adenine, 
histidine and 30mg/L of leucine in distilled water.   
4) Selective media (YNB+2% glucose, -selective amino acid) contains synthetic 
complete media with the selected amino acid omitted from the mixture for 
selective growth. 
5.) Starvation media (YNB+ different carbon sources) contains 0.67% yeast 
nitrogen base with 0.5% ammonium sulphate and 2% maltose or 2% glycerol or 
2% ethanol or 0.1% glucose in distilled water. 
6.) Nitrogen starvation media (YNB -N) contains 0.67% yeast nitrogen base 
without ammonium sulphate, and 2% glucose in distilled water 
For solid media, 1.7% bacto-agar was added to the liquid media composition. 
 
2.1.3 Bacterial strains and media: 
For plasmid amplification, E. coli DH5α strain (fhuA2 Δ (argF-lacZ) U169 
phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17) was 
used. For production of MBP-Aβ fusion proteins, BL21 (DE3) F- ompT hsdSB 
(rB-, mB-) gal dcm (DE3) strain was used. Bacterial strains were grown in YT 
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media [0.8% bacto-tryptone, 0.5% yeast extract, 0.5% sodium chloride] plus 
50µg/ml ampicillin. 
For solid media, 1.7% agar was added to the liquid media composition. 
Yeast extract, peptone, yeast nitrogen base (YNB), bacto-tryptone and bacto-
agar were purchased from Difco or MP Biomedical. Amino acids were obtained 
from Sigma-Aldrich.  
 
2.1.4 Plasmids: 
Expression Plasmid vector Selective 
marker 
Reference 
GFP p416 URA3 (Caine et al., 2007a) 
GFP-N terminal 
fusion Aβ42 
p416 URA3 (Caine et al., 2007a) 
GFP-N terminal 
fusion Aβ42 
(F19S:L34P) 
p416 URA3 Constructed by Sonia 
Sankovich, CSIRO 
GFP-N terminal 
fusion Atg8p with 
endogenous Atg8 
promoter 
pRS306 URA3 Prof. Daniel Klionsky, 
University of Michigan 
(Suzuki et al., 2001) 
MBP-5ala pMALc2 AmpR (Caine et al., 2007b) 
MBP-N terminal 
fusion Aβ42 
pMALc2 AmpR (Caine et al., 2007b) 
MBP-N terminal 
fusion Aβ16 
pMALc2 AmpR (Caine et al., 2011) 
 
62 
 
2.1.5 Mammalian cell culture reagents: 
The human M17 neuroblastoma cell line was kindly provided by Dr. Kim 
Wark (CSIRO, Material Sciences and Engineering, VIC, Australia). SH-SY5Y 
human neuroblastoma cells and other cell culture reagents including Opti-MEM 
(minimum Eagle's medium), Dulbecco‟s MEM, neurobasal media, FCS (Foetal 
calf serum), horse serum, non-essential amino acids, penicillin, streptomycin, 
sodium pyruvate, trypsin were purchased from Gibco, Life Technologies (USA). 
Primary mouse cortical neuronal cultures were kindly provided by Dr. Giuseppe 
Ciccotosto (University of Melbourne). Primary cultures were prepared under 
sterile conditions as described previously (Barnham et al., 2003; Ciccotosto et 
al., 2004) and approved by the local institutional animal ethics committee. 
Briefly, embryonic, day 14, BL6J mouse cortices were removed, dissected free 
of meninges, and dissociated in 0.025% (w/v) trypsin in phosphate buffer. The 
dissociated cells were triturated using a filter-plugged fine pipette tip, pelleted, 
resuspended in plating medium (DMEM, 10% FCS, 5% horse serum). 
2.1.6 Reagents: 
Synthetic human Aβ42 was purchased from the W. M. Keck Laboratory 
(Yale University, New Haven, CT). Aβ42 with substitutions at positions [F19S] 
and [L34P] [Aβ42 (19:34)] was purchased from Biomatik Corporation 
(Wilmington, USA).  
Mouse monoclonal antibody WO2, raised against amino acid residues 5-8 of 
N-terminal Aβ sequence (Cherny et al., 1999) was kindly provided by Prof. Colin 
Masters (University of Melbourne, VIC, Australia). Rabbit polyclonal antibody 
raised against GFP was purchased from Abcam. Horseradish peroxidase (HRP) 
conjugated anti-mouse and anti-rabbit antibodies were purchased from Abcam. 
Gold-conjugated anti-mouse antibody (Ultrasmall Gold) was purchased from 
Aurion (ProSciTech).  
QuikChange II Site Directed Mutagenesis Kit was purchased from 
Stratagene. All restriction enzymes and T4 ligase were purchased from New 
England Biolabs (Beverley, MA).  All were used according to the manufacturer‟s 
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instructions.  DNA fragment purification was by QIAquick Gel Extraction Kit and 
DNA preparations by QIAprep Spin Miniprep Kit, both from Qiagen (Germany).  
DNA sequencing was carried out by Micromon Sequencing Facility (Monash 
University).  
Oligonucleotide primers (for GFP cDNA), GFP-L (5' - 3') 
(TCACTGGTGTTGTCCCAATTT) and GFP-R (5' - 3') (CGT 
AAGTAGCATCACCTTCACCT) were purchased from GeneWorks, Australia. 
CellSure cDNA kit was purchased from Bioline, Australia. KAPA SYBR® FAST 
universal qPCR 2X mix was kindly supplied by Dr. Mark Brown (Edith Cowan 
University, WA, Australia).  
FM 4-64 stain [N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino) phenyl) 
hexatrienyl) pyridinium dibromide, (Cat no. T-3166)] and Fluorescein 5-
isothiocyanate (FITC, Cat no. F1907) were purchased from Molecular Probes, 
Invitrogen. α-naphthyl phosphate disodium salt (Cat no. N7255) and D-sorbitol 
(S1876) were purchased from Sigma. Rapamycin (MW: 914.17, Sigma, Cat no. 
R0395) was a generous gift from Mr. Jay Steer (University of Western Australia, 
WA, Australia). Latrepirdine (Dimebolin dihydrochloride MW: 392.37) was 
purchased from Biotrend AG, Zurich. MTT reagent [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] was purchased from Sigma (M5655). CytoTox 
96® Cytotoxicity assay kit (G1780) and CellTiter 96® AQueous Cell 
Proliferation assay (G3582) kits were purchased from Promega (NSW, 
Australia).  
2.1.7 Miscellaneous consumables:  
Nupage Novex 4-12% Bis-Tris gels, lithium dodecyl sulfate (LDS) sample 
buffer (40% glycerol 4% LDS, 0.025% phenol red, 0.025% serva blue G250, 
2mM EDTA disodium, pH 7.6), MES running buffer (50mM Tris base, 50mM 3–
(N–Morpholino)propanesulfonic acid, 1mM EDTA, 0.01% SDS at pH 7.3), iBlot 
western transfer kit were purchased from Invitrogen. Micro BCA protein assay 
kit and 0.2µm filters dialysis cassette with a 2kDa cut-off were purchased from 
Thermo scientific. 96 well microtitre plates were purchased from NuncBrand 
products. 10 kDa MWCO spin column and 0.2µm filters were purchased from 
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Pall Corporation (Australia). Gas permeable membrane was purchased from 
Diversified Biotech Inc. Uranyl acetate, LR Whiteresin and nickel grids (200 
mesh) were purchased from ProSciTech. HRP-reactive Enhanced 
Chemiluminiscence reagent (ECL), Pharmacia S200 columns was purchased 
from GE Healthcare. Complete protease inhibitor cocktail was purchased from 
Roche. 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), dimethyl sulfoxide (DMSO), 
polyoxyethylene (20) sorbitan monolaurate (Tween-20), ampicillin, 
glutaraldehyde, formaldehyde, adenosine triphosphate (ATP), ammonium 
sulphate, glucose, maltose, ethanol, 1,4-piperazinediethanesulfonic acid 
(PIPES), Magnesium chloride (MgCl2), Calcium chloride (CaCl2), potassium 
chloride (KCl), ovalbumin, disodium hydrogen phosphate (Na2HPO4), potassium 
dihydrogen phosphate (KH2PO4). sulphuric acid (H2S04), hydrochloric acid 
(HCl), methanol, isopropanol, ethylene diamine tetraacetic acid (EDTA), acetic 
acid (Ch3COOH), magnesium sulphate (MgSO4), 2-(N-
morpholino)ethanesulfonic acid (MES). isopropyl b-D-thiogalactopyranoside 
(IPTG), ammonium molybdate ((NH4)6Mo7O24), sodum Nitrate (NaN3), tris-
(hydroxyl methyl)-methyamine (Tris), bovine serum albumin (BSA), sodium 
chloride (NaCl), phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate 
(Na3VO4), ascorbate were purchased from Sigma. Sodium Dodecyl sulphate 
(SDS) and Coomassie G-250 were purchased from Bio-Rad (Irvine, USA). 
Glycerol was purchased from ICN biomedicals. Cholesterol, triolein, oleate 
cholesterol, egg yolk phosphatidylcholine were purchased from Sigma. Human 
recombinant ApoE4 was purchased from Invitrogen. 
2.2            Methods: 
2.2.1 Protein detection and analysis: 
2.2.1.1 Coomassie staining  
Proteins samples containing LDS sample buffer were loaded and 
electrophoretically resolved on 4-12% Bis-Tris gels at 100V in MES buffer. The 
gels were then stained with Coomassie staining solution (0.2% Coomassie G-
250, 7.5% Acetic Acid and 50% methanol) for 2-3h. Following the staining 
solution was removed and the gels were immersed in destaining solution (20% 
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methanol, 10% acetic acid) till clear bands appeared. The gels were scanned 
on a VersaDoc 4000MP imaging system. 
 
2.2.1.2 Western Immunoblotting Analysis 
Proteins samples containing LDS sample buffer were loaded and 
electrophoretically resolved on 4-12% Bis-Tris gels at 100V in MES buffer. The 
proteins were transferred from the polyacrylamide gel to a nitrocellulose 
membrane using iBlot dry transfer method. Membranes were blocked in 5% 
skim milk in TBS solution (50mM Tris, 150mM NaCl, pH 7.4) for 1h. Primary 
antibody was diluted in TBST solution (0.5% skim milk, 0.05% Tween in TBS) at 
concentrations of (1/3000 for WO2 and 1/5000 for anti-GFP). Incubation (2h at 
RT) was followed by three washes with TBST. HRP conjugated secondary 
antibody (anti-mouse or anti-rabbit) was diluted by 1/5000 in TBST solution and 
incubated with membranes for 1h. After washing with TBST followed by TBS, 
membranes were incubated for 2 min with ECL reagent. The membranes were 
then developed on films which were scanned using a Bio-Rad GS800TM 
calibrated densitometer. The immunoreactive bands were later quantified using 
Quantity One 1-D analysis software (version 4.6.8). 
 
2.2.1.3 Determination of protein concentration: 
The Micro BCA Pierce protein assay kit was used to estimate the total 
protein concentration in all samples indicated. 100µl of blanks (respective lysis 
or suspension buffer) including standards and diluted samples (1/500) were 
added to a 96 well microtitre plate. Freshly prepared colorimetric reagents were 
added (100µl) to each sample and incubated for 30 min at 60°C. Following 
incubation the absorption at 595nm was measured using the FLUOstar 
OPTIMA multi-detection microplate reader. The protein concentrations in the 
samples were determined by reference to the bovine serum albumin (BSA) 
standard curve. 
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2.2.2 Preparation and characterisation of dairy SPE products 
The dairy peptide products were kindly provided by Louise Bennet (CSIRO, 
Food Sciences Australia, Victoria, Australia). Dairy protein hydrolysate was 
prepared from bovine whey protein isolate (Murray Goulburn, Natrapro WPI, 
MG Nutritionals, Brunswick, Australia) by dispersing at 10% total protein (w/w) 
in 10mM tri-ethanolamine (Sigma, USA), 10% EtOH, and maintaining at pH 7.4 
throughout processing. The enzymes: Glutaminase (Daiwa Kasei K.K., Shiga, 
Japan), Corolase PN-L (AB Enzymes GmbH, Darmstadt, Germany), Alcalase 
(2.4L, Novozymes, Bagsvaerd, Denmark) and Flavourzyme (1000L, 
Novozymes), were introduced in sequence, each at a final concentration of 
0.5% (w/w) and incubated sequentially at 50°C for 1h.  Finally, Trypsin 
(Novozymes, 0.5%, w/w) was added and incubated at 37°C for 17h before 
heating at 90°C for 30 min to inactivate all enzymes.  The molecular size 
fraction <8 kDa was recovered by dialysis using regenerated cellulose 
membrane (6-8 kDa molecular weight cut-off, Spectrum Laboratories, Inc., 
Dominguez, CA) before further processing by ion exchange (IEX) 
chromatography, using 2 columns (4.6 x 10 cm) connected in series. Column 1 
was packed with cation exchange resin (SP Sepharose Big Beads, GE 
Healthcare, Uppsala, Sweden) and Column 2 was packed with anion exchange 
resin (Q Sepharose Big Beads, GE Healthcare).  Batches of dialysate (400ml) 
were loaded onto the pair of IEX columns with 400ml of eluant containing non-
binding peptides recovered. In this case, the IEX-binding fractions were not 
recovered.  Eluates were freeze dried and stored at -20°C.  A single batch of 
the total hydrolysate was used for the reported studies. 
 
The product (containing 12.2% nitrogen) was sub-fractionated using C18 
solid phase cartridges (Strata-X 33µm Polymeric Reverse Phase cartridges 
(500mg/6ml, Phenomenex, California, USA). After washing with methanol and 
re-equilibrating with water, sample (100mg/ml total solids in water, 5.0ml) was 
loaded and non-binding solids eluted in a further 5.0ml of water (designated 
Load+Void sample). Bound fractions were sequentially eluted with 5.0ml of 40% 
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and 100% acetonitrile respectively (Ajax Fine Chem, NSW, Australia) and 
designated SPE40, and SPE100 respectively. In some cases the bound fraction 
was eluted entirely into 100% acetonitrile (SPE-total product). The ratio of solid 
eluted by 40% to 100% acetonitrile was approximately 19:1.  Products were 
dried by evaporation under vacuum and stored at -20°C.   
 
Amino acid analysis of the SPE-total product was conducted in duplicate 
using the High Sensitivity Waters AccQTag Ultra (Milford, MA, USA) chemistry. 
Results were expressed in mole percent of detectable amino acids. Tryptophan 
was not detectable by this method.  SPE products were analysed (5mg/ml, 20µl 
injection) by reverse phase HPLC (Jupiter 5µ C18 300Å, 250 x 4.6 -
Phenomenex, USA) under gradient elution (mobile phase A (0.1% TFA in water, 
Sigma) and B (0.1% TFA in 95% acetonitrile), using a Waters Alliance HPLC 
with a flow rate of 1.0 ml/min and photo-diode array detector set at 220nm. The 
gradient was programmed for 2 to 50% B over 54 mins, then 100% B for 4 mins 
before re-equilibration to starting conditions.  The equivalence of batches of 
SPE40, SPE100 and SPE-total prepared for these studies, was routinely 
verified by HPLC profiling. 
 
2.2.3 Expression and purification of MBP-Aβ fusion proteins 
The cloning, expression and purification of recombinant MBP-Aβ fusion 
proteins was done as previously described (Caine et al., 2007b). Bacterial 
transformants were grown in 2X YT + 50 mg/ml ampicillin + 0.2% glucose at 
37°C until the OD600 reached 0.8. For induction of recombinant protein 
expression, IPTG was added to a level of 0.3mM. Following overnight growth at 
30oC, the cells were harvested by centrifugation, weighed and resuspended in 
cold lysis buffer (50mM Tris pH 7.5, lysozyme 0.05mg/ml, Complete Protease 
Inhibitor) for 30 min. This solution was then sonicated and the crude protein 
extract was collected by centrifugation and purified by affinity chromatography 
using an amylose column (10mm X 10mm). All chromatography procedures 
were performed at 4°C. The MBP fusion proteins were eluted in 50mM Tris pH 
7.5 buffer containing 10mM maltose.  After elution, the eluted peak was 
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concentrated using 10 kDa MWCO spin column, sterile filtered using 0.2μM 
filters and stored at 4°C. The eluted protein was checked for purity and stability 
by SDS-PAGE and Western blotting using 4-12% NuPage gels in a MES 
buffering system and coomassie staining as described in Section 2.2.1. Gel 
filtration was performed on a superdex S200 (Pharmacia S200) column in 
50mM Tris pH 8.0 at 0.5ml/min.  Absorbance was monitored at 280nm. 
 
2.2.4 Aβ peptide preparations and treatment in cells 
2.2.4.1 Preparation of Aβ peptides: 
Solutions of Aβ peptides were prepared according to the method of 
(Bharadwaj et al., 2008) with some modifications. 0.5mg Aβ peptide was 
dissolved in 500µl HFIP solution and incubated overnight at RT. The Aβ 
dissolved HFIP solution was aliquoted into 5 tubes each containing 0.1mg Aβ 
peptide. The HFIP was then evaporated by vacuum and the tubes containing 
the peptide films were stored in the -80 freezer. Aβ peptide solutions were 
prepared fresh prior to use. The 0.1mg peptide film in the tube was dissolved in 
200µl sterile double-distilled water. The solution was vortexed and sonicated on 
ice for 5 min followed by centrifugation for 10 min at 14000xg. The supernatant 
was incubated at RT overnight which was used for the toxicity experiments. The 
concentration of the Aβ solution was approximately 0.5mg/ml (~110µM). The 
exact concentration was determined by measuring absorbance at 214nm. The 
final concentration was calculated using the formula Aβ (M) = Abs214 x dilution 
factor (DF) / 75887. All solvents used for the preparation of Aβ solutions were 
filtered using 0.2µm filters and the entire procedure was performed in laminar 
air flow hoods. Both Aβ42 and Aβ42 (19:34) peptide solutions were prepared as 
described above. 
 
2.2.4.2 Fluorescein isothiocyanate (FITC) labelling of Aβ peptides: 
FITC labelling of Aβ peptide was done as described by manufacturer‟s 
(Invitrogen, Molecular probes) instructions with slight modifications. FITC 
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dissolved in DMSO (10mg/ml) was mixed with premade Aβ solution [0.5mg/ml 
(~110µM)] at 1:10 (wt/wt) dye: protein ratio. The mixture was incubated at 4˚C 
on a rotator for 2h. The labelled peptide solution was dialyzed in sterile double-
distilled water at 4˚C for 2h using a dialysis cassette with a 2kDa cut-off to 
remove unlabelled FITC molecules. Following dialysis, the solution was 
centrifuged for 10 min at 14000g and the supernatant was used for 
experiments. Aβ42 and Aβ42 (19:34) were FITC labelled as described above.  
 
2.2.4.3 Aβ treatment in Yeast cells: colony count viability assay: 
Yeast cells (Candida glabrata) were stored on YEPD agar plates at 4ºC. A 
single yeast colony from stock agar plates was inoculated in 5ml 
YNB+2%glucose and incubated with shaking at 30ºC overnight. The overnight 
culture was resuspended in fresh YNB+2%glucose to an initial cell density (OD 
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking and 
grown up to exponential phase (OD 1.5-2). These cultures were diluted to 
~5X103 yeast cells/ml in sterile, pure water. Cells were then aliquoted into 96-
well microtitre plates for peptide treatments. Vehicle or peptide preparations 
were added to the diluted cell suspension to required concentrations.  The final 
volume in each well was made up to 125μl. The microtitre plate was then sealed 
with a gas permeable membrane and incubated at 30°C constantly shaken at 
150rpm for time periods as indicated. Cell survival was determined by plating 
aliquots of the cell suspensions onto YEPD agar plates to measure the number 
of colony-forming units (CFU) after incubation at 30°C for 2 days. Cell viability 
following Aβ treatment was calculated from the CFU count and represented as 
percent change from vehicle treated. 
 
2.2.4.4 Aβ treatment in M17 Neuroblastoma cells: MTT viability 
assay: 
The human M17 neuroblastoma cell line was maintained in Opti-MEM 
medium supplemented with 10% FCS (Foetal calf serum), 0.1mM non-essential 
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amino acids, 50 IU/ml penicillin, 50mg/ml streptomycin, and 1mM sodium 
pyruvate, in 5% CO2 at 37˚C. Cells were seeded in 96-well tissue culture plates 
at 104 cells per well and incubated for 20h. Cells maintained in serum free Opti-
MEM media were incubated with freshly prepared Aβ solutions for 48h at 37˚C. 
Cell viability was determined using MTT toxicity assays (Robert et al., 2009). 
Following Aβ treatment, cells were re-suspended in 100μl fresh Opti-MEM 
media containing 5mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] for a 24h incubation at 37˚C. Plates were 
centrifuged, the supernatant was removed and 100μl of 0.1M HCl in isopropanol 
was added to each well to dissolve the MTT crystals. The absorbance was 
measured at 560nm using the FLUOstar OPTIMA multi-detection microplate 
reader. Cell viability following Aβ treatment was calculated from the absorption 
values at 560nm and represented as percent change from vehicle treated. 
 
2.2.4.5 Aβ treatment in SH-SY5Y human neuroblastoma cells: LDH 
and MTS viability assays 
The SH-SY5Y human neuroblastoma cell line was maintained in DMEM 
medium supplemented with 10% FCS (Foetal calf serum), 50 IU/ml penicillin, 
50mg/ml streptomycin in 5% CO2 at 37˚C as described in (Zhang et al., 2009). 
For Aβ42 toxicity experiments, cells were plated in 96-well tissue culture plates 
at a density of 104 cells/well in DMEM media containing 1% FCS for 20h. 
Oligomeric Aβ42 (10µM) co-incubated for 20h with SPE products (0.001-0.1 
mg/ml) was added to the cells and incubated for 72h at 37°C.  Lactate 
dehydrogenase (LDH) released into the media as a result of Aβ42 toxicity, was 
measured in cell supernatants using the CytoTox 96R Cytotoxicity assay as per 
manufacturer‟s (Promega) instructions. The cells were then incubated (4h at 
37C) with fresh DMEM medium containing 1% (v/v) MTS reagent and viability 
was measured as per manufacturer‟s (Promega) instructions.  The fluorescence 
(LDH) or colorimetric (MTS) measurements were determined using a Fluostar 
Optima plate reader (BMG Labtech, Victoria, Australia), and results corrected 
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for reagent controls. The data were reported as the percentage standardized 
change compared with sample-free controls, after correction for reagent blanks. 
 
2.2.4.6 MBP-Aβ fusion protein treatment in primary cortical neurons: 
CCK-8 assay  
The mouse primary cortical cell cultures were prepared and maintained in an 
incubator set at 37 °C with 5% CO2 as described before in Section 2.1.5. The 
cells were allowed to mature for 6 days in culture before commencing treatment 
using freshly prepared neurobasal medium plus B27 supplements minus 
antioxidants.  For the treatment of neuronal cultures, freshly prepared soluble 
MBP-Aβ and MBP stock solutions were diluted to 30µM in neurobasal medium 
and added to neuronal cells for up to 4 days in vitro.  Cell viability was 
quantitated using the CCK-8 assay kit according to the manufacturer‟s 
instructions (Dojindo, Maryland, USA).  Briefly, the medium was replaced with 
fresh neurobasal medium supplemented with B27 lacking antioxidants, and 10 
% v/v CCK-8 was added to each well and incubated for 3h at 37°C in a 5% CO2 
incubator. Plates were gently shaken, and a 150µl aliquot from each well was 
transferred to separate wells of a 96-well plate. The colour change of each well 
was determined by measuring the absorbance at 450nm using a FLUOstar 
Omega (BMG LABTECH, Germany) microplate reader and background 
readings of CCK-8 incubated in cell-free medium were subtracted from each 
value before calculations.  The data were normalized and calculated as a 
percentage of untreated vehicle control values.   
 
2.2.5 Localization analysis of Aβ peptide treated yeast cells: 
2.2.5.1 Preparation of cell extracts from Aβ treated yeast cells 
Uptake of Aβ was determined by Aβ immunoblotting analysis of soluble and 
insoluble membrane protein extracts of yeast cells treated with Aβ peptides. 
Exponentially-growing yeast cells (Candida glabrata) in YNB+2%glucose were 
treated with Aβ peptide (5µM) for 3, 6, or 20h. Following treatment, the cells 
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were washed in 1XPBST (1XPBS+0.05% tween) and resuspended in 1XPBS 
containing 1Xcomplete protease inhibitor cocktail (PI). For cell lysis, the mixture 
was vortexed with 0.5-0.6mm diameter glass beads for 4 min with intermittent 
cooling on ice and centrifuged at 14000g for 15 min. The supernatant contained 
the soluble cytosolic protein fraction. The pellet was washed in 1XPBST and 
resuspended in lysis buffer (1% SDS/2M urea/200mM Na2CO3) + 1XPI. The 
mixture was incubated at 50°C for 20-30 min followed by centrifugation at 
14000xg for 15 min. The supernatant contained the insoluble membrane 
associated protein fraction (Caine et al., 2007a). The protein extracts were 
analysed by Aβ western immunoblotting as described above. 
 
2.2.5.2 Fluorescent Light Microscopy:   
For studying the localization of Aβ, yeast cells were treated with FITC 
labelled Aβ peptides (5µM) for 6h, washed in 1XPBST (1XPBS+0.05% tween) 
and resuspended in 1XPBS. A total of 4-5µl of the suspension was loaded on a 
microscopic slide for imaging using oil immersion at 100X magnification. Cells 
were analysed by fluorescent microscopy using wide field optics in Olympus 
BX51 Upright Microscope. Fluorescent and bright field images were taken using 
Olympus DP71 digital camera. For a better resolution and co-localization 
analysis, yeast cells treated with FITC-Aβ42 peptide were observed using Leica 
TCS NT upright confocal microscope (Dr. Judy Callaghan, Monash Micro 
Imaging). Yeast cells were treated with FITC labelled Aβ42 (5µM) for 6h, 
washed in 1XPBST (1XPBS+0.05% tween) and resuspended in 1XPBS. The 
cells were then incubated with lipophilic membrane stain FM4-64 (1µM) for 
20min at RT, followed by further washing in 1x PBST and  resuspended in 1X 
PBS. A total of 4-5µL of the suspension was loaded on microscopic slide for 
imaging using oil immersion at 100X magnification. Images were taken with 
different fluorescent filters (red and green channels) using Olympus DP71 
digital camera. Image and overlay analysis was done using Leica LASAF 
imaging software. 
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2.2.5.3 Transmission electron microscopy of yeast cells: 
Aβ42 peptide treated yeast cells (6h) were prepared for imaging by 
transmission electron microscopy according to the protocol described by 
(Wright, 2000). The method involved fixation, cell wall permeabilization, ethanol 
dehydration, embedding in LR White resin, sectioning, labelling and imaging.  
Pre-fixation: The cells were incubated in 1X fixative (0.2M PIPES, pH 6.8, 
0.2M sorbitol, 2mM MgCl2, 2mM CaCl2, 0.5% glutaraldehyde, 4% 
formaldehyde) at RT for 5 min. The cells were washed in water and 
resuspended in 1X fixative and incubated for 30 min at 4°C. The fixative was 
removed by centrifugation and cells were resuspended in water and incubated 
for 10 min. To permeabilize the cell wall, the yeast cell suspension was 
incubated in 1% sodium metaperiodate for 15 min at RT. The cells were then 
washed in water and resuspended in 50 mM ammonium chloride for 15 min at 
room temperature for quenching of free aldehydes. Dehydration was done by 
incubating the cells in a graded ethanol series (25, 50, 75, 95, and 100% 
ethanol).  
Embedding: The dehydrated yeast cell suspensions were embedded in LR 
White resin. The ethanol dehydrated yeast pellet was suspended in 2:1 
ethanol:resin and incubated in a glass vial for 1h. The resin was replaced twice 
with 1:1 ethanol:resin  and incubated overnight. Following incubation the 
ethanol:resin mixture was removed and replaced twice with 100% resin and 
incubated for 1h. The resin was then filled into a gelatine capsule. 
Thin-Sectioning: The capsules were incubated in a temperature block at 
45°C for hardening. Thin sections of 80-120nm were prepared using an ultra-
microtome with diamond knife (Jacinta White, CSIRO, Material Sciences 
Engineering, Clayton, Australia). The thin sections were then overlayed onto 
nickel grids. 
Aβ Immunolabeling: The nickel grids were blocked in TBSTOem (140mM 
NaCl, 3mM KCl, 0.05% Tween-20, 2% ovalbumin, 8mM Na2HPO4 and1.5mM 
KH2PO4) for 15-30 min. The grids were removed from blocking buffer and 
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excess liquid was removed using a piece of torn filter paper. Following the grids 
were then incubated with the primary antibody (WO2, 1/1000 dilution in 
TBSTOem) for 2h. Following three washes with TBSTem (140mM NaCl, 3mM 
KCl, 0.05% Tween-20, 8mM Na2HPO4 and1.5mM KH2PO4) the grids were 
blocked in TBSTOem for 15-30 min. Later the grids were incubated for 1h with 
gold conjugated secondary antiserum (anti-mouse, 1/2000 dilution in 
TBSTOem). The grids are washed in TBSTem three times. Following the grids 
were submerged in 2% glutaraldehyde in TBS and incubated for 1h. The grids 
are then washed in three times in TBSTem, two times in TBS and in distilled 
water. The grids are then air dried and stored in a grid box. 
Imaging of yeast sections using transmission electron microscope: 
The grids were stained with 2% uranyl acetate for 5–15 min and washed in 
water. The grids were then stained with reynolds‟ lead citrate for 5 min at RT 
following another wash step. Grids were examined in a Tecnai 12 transmission 
electron microscope operating at 120 keV, and images were obtained using a 
Soft Imaging Systems MegaView III CCD camera. 
 
2.2.6 Preparation of crude yeast plasma membrane fractions:   
The isolation of yeast plasma membrane fractions was performed as 
described by (Monk et al., 1991 ). Untreated cells were washed twice with 
distilled water and resuspended in homogenization medium (2.5mM EDTA, 
1mM phenylmethylsulfonyl fluoride (PMSF), and 50mM Tris, pH 7.5) with 0.5-
0.6µm diameter glass beads. The mixture was then vortexed for 4 min with 
intermittent cooling on ice and centrifuged.  Immediately after cell disruption, the 
homogenate was adjusted to pH 7.25 with 2M Tris. After two centrifugations at 
5000g for 10 min to remove cellular debris and unbroken cells, a crude 
membrane fraction was pelleted from the supernatant by centrifugation at 
30000g for 1h. The crude plasma membrane fraction was pelleted from the 
supernatant by centrifugation at 76000g for 1 h. The crude membranes were 
washed and suspended in plasma membrane suspension buffer (20% glycerol, 
1mM EDTA, 1mM PMSF and 10mM Tris, pH 7.0). The crude plasma 
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membranes were snap-frozen in liquid nitrogen and transferred to -70˚C for 
storage. 
 
2.2.7 Delipidation of yeast plasma membrane fractions and sample 
preparation for mass spectrometric analysis:  
Crude plasma membrane fractions from cells treated with 5μM Aβ42 and 
Aβ42 (19:34) were prepared as described above. Delipidation of Aβ-treated 
yeast membrane fractions was done according to (Mirza et al., 2007). The 
crude plasma membrane fractions were incubated in 0.75ml of chloroform on a 
shaker at room temperature for 1h. To this, 0.75ml of methanol water (1:1 
vol/vol) was added, and the mixture was vortexed for 10 min. The mixture was 
centrifuged at 2000g for 1 min, and the chloroform layer was discarded. Another 
1ml of chloroform was added to the mixture and sonicated in a bath sonicator 
for 30 min. The mixture was then centrifuged at 14000g for 5 min. The 
chloroform layer was discarded. To the aqueous layer 1ml acetone was added 
and incubated at 4°C for 1h. The protein was recovered by centrifugation at 
10000g for 15 min. The protein precipitate was dissolved in 70% acetonitrile, 
0.1% TFA and analysed in an Agilent Q-TOF 6510 mass spectrometer (Bio21, 
University of Melbourne, VIC, Australia). 
 
2.2.8 Plasma membrane ATPase assays:  
Yeast plasma membrane ATPase assays were performed by the 
colorimetric measurement of free phosphate released by ATP hydrolysis in 
microtiter plates (Monk et al., 1991 ). The basic ATPase assay medium 
contained 15mM MgSO4 and 15mM ATP in 50mM MES-Tris buffer at pH 6.0 
but also included 0.2mM ammonium molybdate, and 5mM NaN3 to eliminate 
nonspecific phosphatase, and mitochondrial ATPase activities. The crude 
plasma membrane fractions were incubated with different concentrations of 
freshly prepared Aβ peptide solutions for 15-20 min, prior to addition of ATPase 
assay medium. The final reaction mixture was incubated for 1h at RT, and the 
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reaction was stopped by addition of 100μl of a stop developing reagent 
containing 1% SDS, 100mM ammonium molybdate, 0.6M H2S04, and 0.8% 
ascorbate. After a 10 min of incubation at RT, the absorbance at 630nm was 
determined. Activity was measured by subtracting the absorbance at 630nm of 
the same set of sample treated with ATPase inhibitor vanadate (Na3VO4). The 
amount of phosphate (Pi) liberated was estimated by reference to a linear 
standard curve containing 0-100nM of H3PO4 in the reaction mixture. The 
values were represented as percent activity of the vehicle treated. 
 
2.2.9 Protein structure analysis 
2.2.9.1 Dynamic light scattering of MBP and MBP-Aβ fusion proteins 
Dynamic light scattering (DLS) analysis of MBP and MBP-Aβ solutions was 
done by Dr. Jo Caine (CSIRO, Parkville, Australia) as described in (Caine et al., 
2011). DLS was completed using Dyna Pro Nano Star plate reader at laser 
wavelength 830nm.  Both MBP and MBP-Aβ42 (~0.8mg/ml) was set up in 
triplicates in a Greiner 384-well low volume glass bottom plate (approx 20 µl 
working volume). Forty individual 5 second DLS collections per well were taken 
at 25ºC. The hydrodynamic radius, Rh, was estimated from translation diffusion 
coefficient by the Stokes–Einstein relationship. For comparison the radius of 
gyration, Rg, was calculated as follows. For MBP protein the MOLREP program 
(Vagin and Teplyakov, 1997) was used with the crystal structure [PDB: 4MBP] 
(Quiocho et al., 1997)) and Rg was adjusted by a scaling factor of ρ=Rg/Rh=0.77 
(Wilkins et al., 1999) for globular protein structures like MBP. For MBP-Aβ 
fusion proteins with unknown structures the empirical relationships established 
by (Wilkins et al., 1999) Rh=0.475 N
0.29 nm for native proteins and Rh=0.221 
N0.57 nm for highly denatured proteins, where N  is a number of protein 
residues, were used. The average radii, Rav, of the MBP-Aβ fusion proteins 
were also estimated from volumes occupied by the protein molecules: V = D M 
10-3, where D=1.43 (nm3/Da) is the mean density of proteins (Quillin and 
Matthews, 2000), M,  the molecular weight in Dalton and V, the volume of the 
protein in nm3. 
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2.2.9.2 Circular Dichroism Spectroscopy 
Aβ42 peptide solutions were prepared as described in Section 2.2.4.1. Aβ42 
peptide solutions (0.05mg/ml; 11µM), pre-incubated with different 
concentrations of SPE40 and SPE100 preparations (Section 2.2.2) (final 
concentrations: 005, 0.05 & 0.25 mg/ml in de-ionised water) were analysed by 
Jasco J-810 CD Spectropolarimeter (JASCO Inc., Easton, MD, USA). The 
mean residue ellipticities of samples were recorded across the far UV range 
(190-260 nm), using a 0.1cm path-length quartz cuvette, at room temperature, 
monitoring at 0.1 nm intervals. The acquisition parameters were 100 nm/min 
with 1 sec response times, 1.0 nm bandwidth, and 0.1 nm data pitch, and data 
sets were averaged over 3 scans. Spectra of SPE products alone at appropriate 
concentrations were subtracted from respective profiles of Aβ42+SPE product, 
but were otherwise unsmoothed. The instrument was calibrated with de-ionised 
water. The spectra were analysed and generated using the Jasco‟s Spectra 
Manager TM.  
2.2.9.3 Fourier Transform Infra-Red Spectroscopy 
Fourier transform infrared (FTIR) spectroscopic analysis of Aβ42+SPE 
fractions were done by Rabia Sarroukh (Université Libre de Bruxelles, Belgium). 
Aβ42 peptide solutions were prepared as described in Section 2.2.4.1. Aβ42 
peptide solutions (0.05mg/ml; 11µM) were pre-incubated with different 
concentrations of SPE40 and SPE100 preparations (Section 2.2.2) (final 
concentrations: .001,  0.005, 0.01, 0.05 & 0.1 mg/ml mg/ml in de-ionised water). 
Following, IR spectra of the solutions were recorded using a Equinox 55 
infrared spectrophotometer (Bruker Optics, Ettlingen, Germany) placed in a 
thermoregulated room (21°C) and equipped with a liquid N2-refrigerated 
mercury-cadmium-telluride detector. Fourier self-deconvolution was applied to 
increase the resolution of spectra in the amide I region, which is that most 
sensitive to protein secondary structure. The FTIR data were preprocessed as 
described in (Goormaghtigh et al., 1999).  Briefly, the water vapor contribution 
was subtracted with 1956-1935 cm-1 as the reference peak, and then the spectra 
were baseline-corrected and normalized for equal area between 1700-1500 
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cm−1. The spectra were finally smoothed at a final resolution of 4 cm−1 by 
apodization of their Fourier transform using a Gaussian peak shape (full width 
at half height of 13.33 cm-1) and self-deconvolution was carried out using a 
Lorentzian peak shape (full width at half height of 20 cm-1). The resolution 
enhancement factor was therefore 1.5. Extraction of spectral data was 
conducted using in-house software generated with Matlab (Mathworks Inc. 
Natick, MA, USA). 
 
2.2.9.4 Transmission Electron Microscopy 
Aβ42 peptide pre-incubated with SPE fractions (Section 2.2.2) and 
MBP/MBP-Aβ fusion protein were analysed by transmission electron 
microscopy (TEM).  The samples were diluted to a final concentration of 
0.01mg/ml with de-ionised, filtered (0.2 µm) water before applying to carbon-
coated 400-mesh copper grids, which had been glow discharged in nitrogen. 
After 1 min adsorption time excess sample was wicked off with filter paper and 
the sample stained with 2–3 drops of 2% aqueous uranyl acetate. The grids 
were air-dried and examined in a Tecnai 12 Transmission Electron Microscope 
(FEI, Eindhoeven, The Netherlands) operating at 120 KV. Micrographs are 
recorded using a Megaview III CCD camera running under AnalySiS imaging 
software (Olympus Australia, Mt Waverley, Australia). 
 
2.2.10 Inducing stationary phase in yeast  
Yeast cells were stored on YEPD agar plates at 4ºC. A single yeast colony 
from stock agar plates (Candida glabrata or Saccharomyces cerevisiae 
BY4743) was inoculated in 5ml YNB+2%glucose or YNB+2%glucose (-trp) 
respectively and incubated with shaking at 30ºC overnight. For inducing 
stationary phase, the overnight culture was washed in sterile water and 
resuspended in YNB+ different carbon sources including 2% maltose or 2% 
glycerol or 2% ethanol or 0.1% glucose media at a starting dilution of 0.2 optical 
density (OD) at 600nm and incubated for 7h at 30°C. For normal growth the 
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overnight culture was incubated in YNB+2%glucose or YNB+2%glucose (-trp) 
for Candida glabrata or Saccharomyces cerevisiae BY4743 respectively. The 
growth was determined every hour for 7h by measuring the OD at 600nm. 
Flow cytometric analysis of yeast cells (Candida glabrata) was done in 
Beckman Coulter EPIC flow cytometer. The size distribution of actively growing 
cells (exponential phase) in YNB+2%glucose and starved cells (stationary 
phase) in YNB+2%maltose were studied by forward scatter (FSC) analysis 
(Tzur et al., 2011). Data was analysed using CellQuest analysis software. To 
determine budding, the cells were analysed by light microscopy. 
 
2.2.11 Aβ treatment of stationary phase yeast cells 
The stationary phase yeast cells were treated with Aβ42 peptide similar to 
treatment in exponential phase cells described above (Section 2.2.2.3). Cell 
proliferation was determined by plating aliquots of the cell suspensions onto 
YEPD agar plates to measure the number of colony-forming units (CFU) after 
incubation at 30°C for 2 days. Cell proliferation following Aβ treatment was 
calculated from the CFU count and represented as percent change from vehicle 
treated. 
2.2.12 Construction of GFP-Aβ42 (19:34) mutant in p416 plasmid  
The yeast shuttle plasmid, p416.GPD (Mumberg et al., 1995) was used to 
express GFP, GFP-Aβ42 and the mutant GFP-Aβ42 (19:34) in yeast. It is a 
centromeric plasmid stably maintained at one or two copies per cell, and has 
the strong constitutive GPD promoter to direct heterologous gene expression 
throughout the yeast life cycle. Standard molecular biology techniques were 
used for the construction of recombinant plasmids. Briefly, a GFP coding 
fragment was isolated from pAS1N (Prescott et al., 1997) and inserted into 
p416.GPD. The GFP-Aβ42 fragment was obtained from pAS1N.GFP-Aβ42 from 
the previous work (Caine et al., 2007a). 
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The GFP-Aβ42 (19:34) mutant was constructed in p416 (Figure 1) by Sonia 
Sankovich, CSIRO. To create the GFP-Aβ42 (19:34) mutant, site-directed 
mutagenesis was carried out on a sub-fragment cloned into pBluescript to avoid 
spurious changes in coding sequences. The changes effected were F19S, 
L34P, with numbering referring to Aβ amino acid residue number.  Sequencing 
was carried out to confirm that the required changes had been effected and that 
no additional mutations were introduced into the Aβ coding sequence.  Mutated 
fragments were subsequently cloned back into p416.GPD. 
 
Figure 1: The p416 is a shuttle vector with low copy number. It has the 
ampicillin resistance selectable marker (AmpR) and uracil synthesis selectable 
marker (URA3) genes. (Adapted from www.atcc.org) 
 
2.2.13 Yeast Transformation: 
Yeast cells were transformed with p416 (GFP/GFP-Aβ expressing) and 
pRS306 (GFP-Atg8p expressing) using electroporation. A single colony of the 
untransformed yeast strain was inoculated in 5ml YEPD media and incubated at 
30ºC overnight with shaking. The overnight culture was transferred into fresh 
YEPD media and grown until mid-exponential phase (OD at 600nm, 1). Cells 
were washed in ice-cold sterile water two times and then in 1M sorbitol. The 
cells were then resuspended in 1M sorbitol. A 50µl aliquot of the yeast 
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suspension was mixed with ~5µg plasmid DNA in a pre-chilled electroporation 
cuvette (0.2cm) and pulsed once at V=1.5kV, 25µF, 200Ohms. A 1M sorbitol 
(500µL) was added to the yeast suspension and plated out on selective media 
agar plates (YNB+2%glucose –ura for p416 and pRS306 expression). The 
plates were then incubated at 30ºC for 5-6 days. Yeast colonies from the 
transformant plates were then re-streaked onto fresh selective media agar 
plates (YNB+2%glucose –ura) and stored at 4ºC after formation of yeast 
colonies. 
 
2.2.14 cDNA synthesis and Real Time PCR: 
Starting culture (OD 0.2) of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) 
expressing yeast cells (KVY55) were grown in selective YNB+2%glucose (-ura) 
media till exponential phase (OD 0.6). Untransformed cells (KVY55) grown in 
YEPD media were also collected (OD 0.6). Total cell number and viability was 
measured by Vi-CELL XR cell counter. The cDNA from the frozen pellets (~1-3 
X 106 cells) was synthesized using CellSure cDNA kit (Bioline). A 1uL aliquot of 
the cDNA template was mixed with KAPA SYBR® FAST universal qPCR 2X 
mix, primers for GFP (L, R: 5µM final) and DNase free water to a final volume of 
15µl. The samples were run on the iQ5 real-time PCR detection system. Using 
the LinRegPCR (version 2009) software the threshold Ct values and the mean 
PCR efficiencies were calculated. GFP transcript levels/106 cells was calculated 
by using the comparative Ct method with slight modifications, The transcript 
levels were expressed as levels/106 cell = 106 * (relative 2-(∆Ct) value/total 
number of cells) (Schmittgen and Livak, 2008).   
 
2.2.15 Agarose gel electrophoresis: 
The PCR products (from rtPCR reaction described above, Section 2.2.14) 
were analysed by agarose gel electrophoresis and observed under UV 
transillumination. Agarose (1.5%) was prepared in 1 x TAE (0.04M Tris-acetate, 
0.001M EDTA, pH 8.3) by boiling in a microwave. The dissolved agarose was 
cooled to ~60°C and then poured into a gel tray to set, with combs positioned to 
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produce sample wells. Set gels were placed in tanks (Bio-Rad), which were 
then filled with 1XTAE buffer. Ethidium bromide (stock solution 10mg/ml) was 
added to give a final concentration of 1 μg/mL in the cooled gel before pouring. 
Sample loading dye was added to samples and loaded into the wells. Gels were 
run at 70 Volts for 45 minutes to an hour, then visualised under UV light in the 
Bio-Rad Gel DocTM UV transilluminator system. 
  
2.2.16 Analysis of GFP fluorescence by microscopic imaging: 
GFP/GFPAβ expressing yeast cells were stored on YNB+2%glucose (-ura) 
agar plates at 4ºC. A single yeast colony from stock agar plates was inoculated 
in 5ml YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight. 
The overnight culture was resuspended in fresh YNB+2%glucose (-ura) to an 
initial cell density (OD at 600nm) of 0.2 and incubated at 30°C with shaking. 
Yeast cell suspensions were collected at different points of growth from early 
exponential phase till late log phase for microscopic analysis and GFP 
fluorescence quantification. Following washing in distilled water, a total of 4-5µL 
of the suspension was loaded on microscopic slide for imaging using oil 
immersion at 100X magnification. Images were taken using similar fluorescence 
and bright field exposure levels using Olympus DP71 digital camera. GFP 
fluorescing cells were counted relative to the total number of cells in the frame 
to determine the levels of the GFP/GFP-Aβ protein in the cell population. A 
number of 10 image frames each containing approximately 50 cells were 
quantified for each sample.   
 
2.2.17 Preparation of cell extracts from GFP/GFPAβ expressing 
yeast  
Yeast cell suspensions of GFP/GFPAβ expressing yeast were collected at 
different points of growth from early exponential phase till late log phase as 
described above. Total cell protein extracts from yeast were used for 
immunoblotting. Frozen cell pellets were resuspended in 150μl cold lysis buffer 
(50mM Tris pH 8, 1mM EDTA, 150mM NaCl, 1mM DTT, 2% SDS) with freshly 
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added 1XPI and then incubated at 70ºC for 15-20min. Following centrifugation 
at 18000g for 10min, the supernatant was collected and protein concentration of 
each sample was measured using the Micro BCA protein assay kit as described 
above (Section 2.2.1.3). A total of 50µg protein of each sample was studied by 
SDS-PAGE and western blot analysis as described previously as described 
above (Section 2.2.1.2). 
 
2.2.18 Assessing autophagy in yeast 
Autophagy was assessed by FM 4-64 staining, vacuolar alkaline 
phosphatase activity: Pho8 assay and by GFP-Atg8p transport assay as 
described below.  
2.2.18.1 FM 4-64 staining:  
Vacuolar membrane specific lipophilic dye, FM 4-64 staining in yeast was 
performed as described in (Journo et al., 2008). Saccharomyces cerevisiae 
(KVY55, and atg8Δ) yeast cells were cultured to mid exponential phase in 
YEPD media. The cells were later washed in 50mM HEPES (pH 7) twice and 
resuspended in YNB+2%glucose (complete) or YNB (-N) media containing 
1mM PMSF. Latrepirdine or rapamycin treatment was done in YNB+2%glucose 
(-trp) media. Following 6h incubation at 30ºC, the cells are washed and 
resuspended in YNB (-trp) media containing 10mM sodium citrate (pH 4.3). FM 
4-64 stain was added to the cells to a final concentration of 1µM. The solutions 
were incubated for 30min at RT. The cells were washed and resuspended in 
YNB+2%glucose (-trp) media containing 10mM sodium citrate (pH 4.3) and 
observed under the fluorescence microscope. A total of 4-5µL of the suspension 
was loaded on microscopic slide for imaging using oil immersion at 100X 
magnification. Images were taken using similar fluorescence and bright field 
exposure levels for all samples using Olympus DP71 digital camera 
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2.2.18.2 Vacuolar Alkaline phosphatase activity: Pho8 assay  
Vacuolar alkaline phosphatase activity in yeast cell lysates were measured 
as described in (Noda and Klionsky, 2008).  Saccharomyces cerevisiae 
(KVY55, atg8Δ) yeast cells were cultured to mid exponential phase in YEPD 
media. The cells were later washed in sterile water twice and resuspended in 
YNB+2%glucose (complete) media or YNB (-N) media. Latrepirdine or 
rapamycin treatment were done in YNB complete) media. Following 6h 
incubation at 30ºC, the cells are washed and re-suspended in ice-cold assay 
buffer (250mM; Tris-HCl, pH 9.0; 10mM MgSO4, and 10mM ZnSO4). The cells 
were lysed using glass beads vortexing for 3 X 2min on ice. The samples were 
centrifuged at 14000g for 5min. The supernatant was used for the assay. 
Protein concentration of each sample was measured using Micro BCA protein 
assay kit as described before (Section 2.2.1.3). A total of 100µg of cell lysate 
was incubated with 55mM α-naphthyl phosphate disodium salt for 20min at 
30ºC and diluted in the lysis buffer to a final volume of 0.5ml. The reaction was 
stopped by adding 0.5mL stop buffer (2M glycine-NaOH, pH 11). The 
fluorescence was measured at 345nm excitation and 470nm emission 
wavelengths. After correcting for blank, the activity was calculated as Units/µg 
of sample.  
2.2.18.3 GFP-Atg8p transport assay:  
The atg8Δ cells were transformed with pRS306 (GFP-Atg8p expressing) 
plasmid as described in section 2.2.9.2). For the GFP-Atg8p processing assay 
(Yen et al., 2007), yeast strains harbouring the GFP-Atg8 plasmid were grown 
to mid exponential phase in YNB+2%glucose (-ura). Cells were then treated 
with latrepirdine, rapamycin or nitrogen starved for 6h at 30ºC. Following 
incubation the samples were collected for fluorescence microscopy. Following 
washing in distilled water, a total of 4-5µl of the suspension was loaded on 
microscopic slide for imaging using oil immersion at 100X magnification. Images 
were taken using similar fluorescence and bright field exposure levels using 
Olympus DP71 digital camera. Intravacuolar GFP fluorescence in cells relative 
to the total number of cells in the frame was determined as an indicator of 
85 
 
activation of autophagy in the cell population. The intravacuolar green 
fluorescence indicates GFP-Atg8p transport to vacuole and cleavage of GFP 
into vacuole. A number of 10 image frames each containing approximately 50 
cells were quantified for each sample.   
2.2.19 Aβ clearance in APOE knockout mice: 
The Aβ peripheral clearance experiment in mice were performed by Dr 
Ian Martins, Kevin Taddei, Mike Morici and Linda Wijaya from our laboratory. 
APOE knockout mice (B6.129P2 ApoE−/−), were originally obtained from the 
Jackson Laboratory, Bar Harbor, Maine. All mice were bred and maintained at 
the Animal Resources Centre (ARC, Perth,Western Australia). Mice were 
housed 5–6 per cage in a controlled environment at 22°C on a 12h day/night 
cycle (light from 0700 to 1900 h). A standard laboratory chow diet (Rat and 
Mouse Cubes, Specialty Feeds Glen Forrest,WA, Australia) and water were 
consumed ad libitum. This study was conducted in accordance with the 
Australian code of practice for the care and use of animals for scientific 
purposes as specified by the National Health and Medical Research Council 
(NHMRC). The experimental protocols were approved by the University of 
Western Australia Animal Ethics Committee.  
 
Stock Aβ42 was prepared by dissolving the Aβ42 peptide in DMSO to a 
concentration of 1mg/ml. The stock was diluted in sterile isotonic saline solution 
(0.9% w/v NaCl) immediately before experimentation to a concentration of 20μg 
in 50μL. The ApoE4 lipid emulsions were prepared as described in (Sharman et 
al., 2010). The composition of the remnant like emulsions was triolein 
45.8%±3.2%, total cholesterol and cholesterol oleate 21.5% ± 3.2% and egg 
yolk phosphatidylcholine 32.7% ± 2.5%. The remnant like emulsion particles 
had a mean diameter of 133nm ± 17.6nm as measured by laser light scattering 
using the Malvern Instruments particle Zetasizer (Malvern Instruments, 
Worcestershire, United Kingdom). Partially lipidated human recombinant ApoE4 
(Invitrogen, Madison, WI, USA) was freeze dried, resuspended in isotonic saline 
and then lipidated by incorporation into lipid emulsion particles that were 
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prepared by sonication and purified by ultracentrifugation as described 
previously (Hone et al., 2003; Yang et al., 1999b). 
 
 
To determine the role of latrepirdine in the peripheral clearance of Aβ42 
12monthold APOE knockout mice were anaesthetized with an intraperitoneal 
injection of Ketamine/Xylazine (75/10 mg/kg). APOE knockout mice were 
injected with lipidated recombinant ApoE4 (75μg) plus Aβ42 (20μg/50μl) pre-
incubated with latrepirdine (3.5mg/kg) or vehicle (saline). Blood samples were 
taken from the retroorbital sinus using 1.0mm diameter heparinised haematocrit 
tubes at 2.5, 5 and 15 min postinjection for Aβ analysis by immunoblotting (3µl 
of plasma) as described in Section 2.2.19. Injected mice were sacrificed by 
decapitation and liver tissues were collected at similar time points (2, 5 and 
15min). Tissue samples were homogenised in TBS (pH 7.4) containing 5μg/ml 
aprotinin, 0.1mMPMSF and 5μg/ml leupeptin followed by Aβ immunoblotting 
analysis (100µg of total protein of total homogenate) as described in Section 
2.2.1.2.  
 
2.2.20     Statistical Analysis: 
Student t-tests and one-way ANOVA tests were used for statistical 
analysis and p-value analysis. All graphs were made in Microsoft ExcelTM. All 
data were represented as Data±SEM (Standard error of mean).  
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Chapter 3 
Toxicity and Cellular 
localization of Oligomeric Aβ42 
in Yeast 
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3.1     Introduction: 
 
Soluble oligomer Aβ42 is a key mediator of neuronal dysfunction and toxicity 
in the AD brain. As described in Chapter 1, Aβ can affect a wide array of 
neuronal functions and thereby may lead to neurodegeneration [reviewed in 
(Bharadwaj et al., 2009)]. Aβ42 mediated toxicity has been found to be 
associated with disruption of mitochondrial activity (Butterfield et al., 2001 ; 
Dyrks et al., 1992; Lustbader et al., 2004a; Palmblad et al., 2002), receptor-
mediated functions (Bhaskar et al., 2009; Fuentealba et al., 2004; Pereira et al., 
2004; Wei et al., 2002 ; Yaar et al., 1997), disruption of Ca2+ homeostasis 
(Hartmann et al., 1994; Mattson et al., 1993) and oxidative damage of 
membranes (Butterfield et al., 2002; Müller et al., 2001; Verdier et al., 2004).  
 
The natural occurrence of multiple structural entities of Aβ42 in the brain and 
the complexity of detecting specific isoforms in cellular compartments have 
confounded the study of oligomer Aβ-mediated toxicity in neuronal cell models. 
Although, the toxicity of exogenously-added oligomeric Aβ42 peptide compared 
to other forms has been well established in neurons, the cellular localization and 
target of oligomeric Aβ42 by which it mediates the cascade of events leading to 
cell death are unclear. A growing body of evidence indicates that membrane 
mediated cytotoxicity is an inherent property of protein oligomers including Aβ 
(Glabe, 2006; Glabe and Kayed, 2006). Since the majority of Aβ42 produced is 
secreted into the extracellular lumen, it is thought that it can have a major 
impact on neuronal functions and viability by interacting with the cell surface 
membranes (Talaga and Quere, 2002; Verdier and Penke, 2004; Verdier et al., 
2004). A recent study has also shown that increased Aβ levels in membrane-
associated and intracellular fractions isolated from the temporal neocortex of 
AD patients to be more closely related to AD symptoms than other measured 
Aβ species (extracellular soluble and extracellular insoluble) (Steinerman et al., 
2008).  
 
Aβ-mediated toxicity has been studied in other non-mammalian models 
including Caenorhabditis elegans (worm) (Link, 1995) and Drosophila 
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melanogaster (fly) (Finelli et al., 2004). However these models are largely 
based on transgenic overexpression of Aβ/APP and are complex systems 
compared to yeast cells. Moreover, yeast is a well established model organism 
for studying toxic proteins involved in neurodegenerative diseases (Bharadwaj 
et al., 2010; Braun et al., 2010; Winderickx et al., 2008). Yeast cells combine a 
high level of conservation in cellular processes with mammalian cells with 
added advantages of fast cell division, simple growth requirements and an 
abundance of experimental tools (Hughes, 2002; Mager and Winderickx, 2005; 
Simon and Bedalov, 2004).  
 
Recently, I developed a novel method for determining toxicity of different Aβ 
isoforms in yeast (Bharadwaj et al., 2008). In this study, oligomeric Aβ treatment 
was shown to be more toxic compared to fibrillar Aβ, consistent with previous 
observations in neuronal cells (Dahlgren et al., 2002; Stine et al., 2003). The 
yeast model of oligomeric Aβ toxicity (Bharadwaj et al., 2008) therefore 
represents a simple cellular model for studying Aβ toxicity and uptake. In this 
chapter, I have extended the work to compare the toxicity of oligomeric Aβ42 
and a non-oligomeric Aβ42 (19:34) peptide in yeast and neuronal cells. Further I 
have investigated the cellular localization and binding of Aβ peptide to the yeast 
plasma membrane to provide potential mechanisms of oligomer Aβ42 mediated 
toxicity in yeast cells. 
 
3.2     Aims: 
 
1.) Compare the toxicity of oligomeric Aβ42 and non-oligomeric Aβ42 (19:34) 
peptides in yeast and in M17 neuroblastoma cells. 
2.) Determine the uptake and cellular localization of oligomeric Aβ42 and non-
oligomeric Aβ42 (19:34) peptide in yeast.  
 
3.3     Materials and Methods: 
 
Aβ42 and Aβ42 (19:34) peptide solutions were prepared as described in 
Section 2.2.4.1. The peptide solutions were characterized by SDS-PAGE 
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followed by western blotting analysis. The toxicity of the peptides were tested in 
yeast (Candida glabrata) and M17 neuroblastoma cells by colony count and 
MTT assays respectively as described in Section 2.2.4.3 and Section 2.2.4.4. 
Uptake of exogenously added Aβ42 in yeast was studied by immunoblotting 
analysis (with WO2, an anti Aβ antibody) of cell extracts (soluble and 
membrane-associated) as described in Section 2.2.5.1. Sub-cellular localization 
was analysed using Leica TCS NT (upright confocal microscope) by 2 channel 
fluorescence imaging of yeast cells treated with FITC-labelled Aβ42 (green 
channel) for 6h followed by staining with lipophilic membrane stain (FM4-64, red 
channel). Yeast cells treated with Aβ42 (6h) were also analysed by 
immunoelectron microscopic analysis as described in Section 2.2.5.3. Plasma 
membrane fractions of Aβ42-treated yeast cells were delipidated and analysed 
by electrospray ionization-mass spectrometry (ESI-MS) as described in Section 
2.2.7. Aβ42 peptides were co-incubated with crude plasma membrane fractions 
and assayed for vanadate sensitive H+ATPase (ATP hydrolysing) activity as 
described in Section 2.2.8.  
 
3.4       Results: 
3.4.1 Toxicity of oligomeric and fibrillar Aβ42 peptides in yeast:    
 
In neuronal cells, fibrillar Aβ42 is less toxic compared to oligomeric Aβ42 
peptide (Dahlgren et al., 2002). In the previous work, I showed that similar to 
neuronal cells, fibrillar Aβ42 was less toxic to yeast cells (Figure 1A), whereas 
oligomeric Aβ42 treatment caused a dose-dependent loss of cell viability in 
yeast (Figure 1B). Significant cell death was observed from concentrations of 
1µM with complete loss of cell viability at higher concentrations of 30µM 
(Bharadwaj et al., 2008). 
 
Due to its heterogeneous nature and advanced aggregation state, fibrillar 
Aβ42 would be an inappropriate control to compare cellular uptake and 
localization. Instead a non-aggregating, monomeric form of Aβ would be better 
suited. Aβ42 is difficult to be maintained in a monomeric form due to its 
hydrophobic nature and tendency to aggregate under physiological conditions. 
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Besides, a control would need to be prepared under the same conditions. 
Therefore, an Aβ42 peptide modified at positions F19S and L34P [Aβ42 
(19:34)] with reduced tendency to aggregate was chosen for this work (Ahmed 
et al., 2010; Hughes et al., 1996; Luhrs et al., 2005; Wurth et al., 2002). 
  
 
Figure 1: Toxicity of oligomeric and fibrillar Aβ42 peptides in yeast (Bharadwaj 
et al, 2008) 
Toxicity of oligomeric and fibrillar Aβ peptide preparations were tested in yeast 
cells. Exponentially growing yeast cells (Candida glabrata) were treated with 
5μM oligomeric, fibrillar Aβ42 peptide or vehicle buffer alone for 20h at 30ºC 
(A). Cell viability was determined by counting the number of colonies formed 
and expressed as a percentage of vehicle treated control. Compared to vehicle 
treated cells, cell viability was significantly reduced (** p<0.01) in cells treated 
with oligomeric Aβ42. No significant loss of viability was observed with fibrillar 
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Aβ42 treatment. Dose response of oligomeric Aβ42 (0.5, 1, 5. 30 and 100µM) 
peptide in yeast (B) Compared to vehicle treated cells, cell viability was 
significantly reduced with oligomeric Aβ42 peptide in a dose dependent manner 
(* p<0.05, ** p<0.01). All data are expressed as mean ± SEM (n=4). 
 
3.4.2    Oligomerization and toxicity of Aβ42 and Aβ42 (19:34) 
peptides:    
 
Firstly, oligomer Aβ42 and non-aggregating Aβ42 (19:34) peptide were 
characterized by SDS-PAGE electrophoresis followed by coomassie staining 
and western immunoblotting analysis (Figure 2A). Aβ42 peptide was observed 
as monomers (4.5kDa) and SDS stable oligomers in the 7-17kDa range, 
indicative of low-n oligomers (dimers, trimers, tetramers) by both coomassie 
staining and Aβ immunoblotting using WO2 (Figure 2A, lanes 1, 3). However in 
Aβ42 (19:34) peptide, only monomeric species (4.5kDa) was detectable by both 
methods (Figure 2A, lanes 2, 4). Supporting the (Wurth et al., 2002) study, this 
result shows that Aβ42 (19:34) had reduced tendency to form oligomers 
compared to Aβ42.     
 
Further the toxicity of oligomeric Aβ42 and non-oligomeric Aβ42 were 
tested in yeast and M17 neuroblastoma cells. Oligomeric Aβ42 treatment 
caused a 75-90% cell death at concentrations of 5-10μM as measured by viable 
counts. However Aβ42 (19:34) treatment showed less than 5% cell death at 
similar concentrations (Figure 2B). The toxicity of Aβ peptides at similar 
concentrations was also tested in human M17 neuroblastoma cell lines by 
determining the ability of cells to reduce MTT to purple formazan after treatment 
(Mosmann, 1983) (Figure 2C). 5-10μM of oligomeric Aβ42 treatment caused 
~75-95% decrease in cell viability, whereas Aβ42 (19:34) caused only ~5% 
decline in MTT reduction (Figure 2C). Overall the results showed that Aβ42 
(19:34) had reduced tendency to form oligomers and was less toxic in yeast and 
neuronal cells compared to oligomeric Aβ42. This result supports previous 
studies indicating that oligomerization is essential for Aβ mediated toxicity in 
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cells [reviewed in (Bharadwaj et al., 2009)]. Further, the uptake and localization 
of Aβ42 and Aβ42 (19:34) peptides in yeast cells was studied. 
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Figure 2: Toxicity of Aβ42 and Aβ42 (19:34) in yeast and M17 neuroblastoma 
cells 
The Aβ42 and Aβ42 (19:34) peptides were prepared as described Section 
2.2.4.1. The peptide solutions were size fractionated by SDS-PAGE 
electrophoresis (4-12% Bis-Tris gels) (A). 100ng of Aβ42 (lane 1) and Aβ42 
(19:34) (lane 2) were analysed by immunoblotting (anti-Aβ, WO2). 5μg of Aβ42 
(lane 3) and Aβ42 (19:34) (lane 4) of the same peptide stock were analysed by 
coomassie staining. Exponentially growing yeast cells (Candida glabrata) were 
treated with Aβ42 or Aβ42 (19:34) peptide (5μM and 10μM) for 20h at 30ºC. 
Cell viability was determined by counting the number of colonies formed and 
expressed as a percentage of untreated control (B). Compared to untreated 
cells, cell viability was significantly reduced (**, p<0.01) in cells treated with 5 or 
10µM Aβ42. Treatment with Aβ42 (19:34) did not significantly alter cell viability. 
M17 neuroblastoma cells plated in Opti-MEM were treated with Aβ42 or Aβ42 
(19:34) peptide (5μM and 10μM) for 48h at 37°C. Cell viability was measured by 
MTT assay as described in Section 2.2.4.4 and expressed as a percentage of 
untreated control (C). Similar to yeast cells, Aβ42 treatment caused significant 
loss of viability at concentrations 5 and 10µM (**p<0.01), whereas treatment 
with Aβ42 (19:34) did not significantly alter cell viability in M17 neuroblastoma 
cells. All data are expressed as mean ± SEM (n=4). 
C
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3.4.3     Uptake and toxicity of Aβ42 and Aβ42 (19:34) peptides in 
yeast: 
 
The uptake of exogenously added Aβ peptides in yeast was first determined 
by fluorescent microscopy of cells treated with fluorescein isothiocyanate 
(FITC)-labelled Aβ peptides. FITC labelling of Aβ42 and Aβ42 (19:34) peptides 
was performed as described in Section 2.2.4.2. Exponentially growing yeast 
cells were treated with FITC-labelled Aβ peptides for 6h at 30°C and observed 
under the microscope. Cells treated with FITC-Aβ42 showed a strong intense 
green fluorescence around the cell surface (Figure 3A). Cells treated with FITC-
Aβ42 (19:34) also showed a similar pattern but lower intensity of fluorescence 
around the cell surface (Figure 3C). No internalization of Aβ peptide (both Aβ42 
and Aβ42 (19:34)) was observed at 6h incubation. To determine if Aβ 
internalizes with longer incubation, yeast cells were treated with FITC labelled 
Aβ for 20h. However, even with longer incubation times no intracellular 
fluorescence could be observed. This suggested that Aβ42 was largely 
associated with the cell surface. 
 
Aβ peptide uptake was also studied by western immunoblotting analysis in 
yeast cells. Soluble (cytosolic) and insoluble (membrane associated, 1% SDS 
solubilised) extracts of yeast cells treated with Aβ42 and Aβ42 (19:34) peptides 
for 3, 7 and 20h were analysed by Aβ immunoblotting (WO2). Both Aβ42 and 
Aβ42 (19:34) were detected in the insoluble extracts (lanes 5, 6, 10 and 11) and 
undetectable in the soluble extract (lanes 7, 8, 12 and 13) (Figure 3G, H and I). 
Also, cells treated with Aβ42 showed increased uptake with longer incubation 
times (7, 20h) compared to Aβ42 (19:34) treatment. At 3h, only monomeric 
Aβ42 (4.5kDa) was detectable, but with 7 and 20h incubation, Aβ42 oligomers 
(7-17kDa range and 50-200kDa range) were evident in the insoluble extract 
(Figure 3G, H, I: lanes 5 and 6). However with Aβ42 (19:34) peptide treatment, 
only monomeric forms were detectable and no significant increase in levels of 
uptake was observed (Figure 3G, H, I: lanes 10 and 11). These results 
indicated that Aβ42 had increased affinity to cell surface membrane compared 
to Aβ42 (19:34). It was notable that both the Aβ peptides were undetectable in 
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the soluble cytosolic lumen of the cell, even with longer incubation times. The 
increased uptake of Aβ with longer incubation times was evident in Aβ42 but 
not in Aβ42 (19:34) treatment. One explanation is that Aβ42 is more 
hydrophobic and prone to self-aggregation than Aβ42 (19:34) and as a result 
shows increased association with the cell surface membrane.  
 
To determine if there is a correlation of Aβ42 uptake with toxicity, cell 
viability of yeast cells treated with oligomer Aβ42 (5µM) was determined at 
different incubation times (0, 3, 7 and 20h) (Figure 3J). Compared to vehicle 
treated cells, cell viability was significantly reduced with increasing incubation 
time with 5µM Aβ42. Cell death was significant from 3h incubation with Aβ42 
(~20%) and was found to increase to ~60% at 7h and ~75% at 20h. This 
indicated that toxicity of oligomer Aβ42 was dependent on the incubation period. 
Together with the immunoblotting analysis, the result suggested a correlation of 
detection of Aβ42 oligomers with toxicity in yeast cells. With Aβ42 treatment at 
3h, only monomeric forms were detectable with a cell death of ~20%. Whereas 
at 7h and 20h, Aβ42 oligomers (7-17kDa range and 50-200kDa range) were 
detected comparing to increased cell death of up to ~60-75% (compare Figure 
3G, H, I with J). 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
Figure 3: Analysis of the uptake and toxicity of Aβ42 and Aβ42 (19:34) peptides 
in yeast cells 
Uptake of Aβ42 in yeast cells was analysed by microscopic analysis of FITC 
labelled Aβ treated yeast. Fluorescent and bright-field images of exponentially 
growing yeast cells (Candida glabrata) treated with FITC-Aβ42 (A, B) and FITC-
Aβ42 (19:34) (C, D) for 6h and 20h at 30°C are shown here. Cells treated with 
FITC-Aβ42 showed a strong intense fluorescence around the cell surface. Cells 
treated with FITC-Aβ42 (19:34) exhibited a similar pattern but lower intensity of 
fluorescence. Vehicle buffer treatment showed no fluorescence at similar 
exposure levels (E, F). Yeast cells incubated with unlabelled Aβ42 or Aβ42 
(19:34) peptides were collected for western immunoblotting analysis (WO2) at 
3h (G), 7h (H) and 20h (I). Soluble (cytosolic) proteins were isolated by glass 
bead lysis in lysis buffer and insoluble (membrane) proteins were extracted 
using 1% SDS/200mM Na2CO3/2M urea in lysis buffer. Samples (in duplicates) 
were size fractionated by SDS-PAGE electrophoresis (4-12% Bis-Tris gels) and 
analysed by Aβ immunoblotting (anti Aβ-WO2) (G, H). Lanes are- vehicle 
treated: insoluble (1, 2), soluble (3, 4), Aβ42 treated: insoluble (5, 6), soluble (7, 
8) and Aβ42 (19:34) treated insoluble (10, 11), soluble (12, 13) including 100ng 
loading standards of Aβ42 (9) and Aβ42 (19:34) (14). Both Aβ42 and Aβ42 
(19:34) were detected in the insoluble extracts and undetectable in the soluble 
extracts. Cell viability of yeast cells treated with oligomer Aβ42 (5µM) was 
determined at different incubation times (0, 3, 7 and 20h) and expressed as a 
percentage of vehicle treated control (J). Compared to vehicle treated cells, cell 
viability is significantly reduced (*, p<0.05, **, p<0.01) with increasing incubation 
time (from 3h) with 5µM Aβ42. Data are expressed as mean ± SEM (n=4). 
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3.4.4    Cellular localization of Aβ42 in yeast 
 
FITC-Aβ and western blot analysis in yeast showed that Aβ42 bound to the 
cell surface membrane and was undetectable in the soluble cytosolic lumen of 
the cell. The data suggested that Aβ42 was associated with the cell surface and 
not internalized into the cells. To further study the sub-cellular localization of 
Aβ42, cells were analysed by fluorescent imaging confocal microscopy. To 
determine whether Aβ42 associated with the plasma membrane, cells were 
treated with FITC-Aβ42 for 6h followed by staining with FM4-64 stain for 15 min 
at 30°C (Figure 4A-C). FM4-64 stain is a lipophilic styryl dye which binds to 
cellular membranes. The fluorescence of FM4-64 dye is quenched in aqueous 
state, but when inserted into membranes it fluoresces. It is ideally used for 
analysis of endocytosis and as a plasma membrane marker (Fischer-Parton et 
al., 2000). Co-localization analysis of FITC (green channel) and FM4-64 
fluorescence (red channel) showed association of FITC-Aβ42 with FM4-64 
staining (Figure 4D). To determine the levels of co-localization, a region of 
interest (ROI) across the diameter of the cell was chosen and fluorescence 
intensities was measured across the red (FM4-64) and the green (FITC-Aβ42) 
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channels (Figure 4D). Significant overlap of the red and green channels 
indicated the association of FITC-Aβ42 with FM4-64 fluorescence. Although 
FITC-Aβ42 and FM4-64 fluorescence were not completely overlapping, the 
result indicated a strong association of Aβ42 with the yeast plasma membrane. 
 
For enhanced image resolution and sensitivity of Aβ detection, yeast cells 
treated with oligomeric Aβ42 were analysed by immunoelectron microscopy 
(Mulholland and Botstein, 2002; Wright, 2000) as described in Section 2.2.5.3. 
Aβ localization was detected by WO2 (anti-Aβ) probing followed by incubation 
with gold conjugated secondary antibody. The yeast sections were then stained 
with uranyl acetate and Reynolds‟s citrate solution for imaging by electron 
microscopy. Aβ immunoreactivity was indicated by the appearance of distinct 
dark spots. Cells treated with Aβ42 showed dark spots associated with the cell 
surface, whereas no such spots were observed within the cell. The dark spots 
were mainly found populated on the cell wall and also in the outer leaflet of the 
yeast plasma membrane (Figure 4F). Vehicle treated cells showed no dark 
spots associated with the cell (Figure 4E). Overall the data from co-localization 
analysis (with plasma membrane marker FM4-64) and immunoelectron 
microscopy showed that Aβ42 binds to the yeast cell surface and supported the 
previous data where intracellular uptake of Aβ was absent in yeast (Section 
3.4.3). 
 
To provide insight into specific Aβ oligomeric forms associated with the 
yeast plasma membrane, crude fractions of yeast plasma membranes were 
isolated from cells treated with Aβ42 and Aβ42 (19:34) peptide (5µM, 6h) and 
analysed by electrospray ionization mass spectrometric analysis (ESI-MS) 
(Figure 5). Distinct species with mass/charge ratio of 4514.09, 9027.61 and 
13539.88, indicating Aβ42 monomer, dimer and trimer respectively were 
detected in the crude membrane fractions of cells treated with Aβ42 (Figure 
5A). Crude membrane fractions isolated from cells treated with Aβ42 (19:34) 
(5µM) for 6h showed no detectable levels of Aβ (Figure 5B). The peaks 
observed in the Figure 5B represent the yeast plasma membrane proteins. This 
was absent in the crude membranes isolated from Aβ42 treated cells (Figure 
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5A) because the levels of Aβ42 detected was ~10 fold higher than the yeast 
membrane proteins. Due to this, the graphs are represented in different Y-axis 
range [(relative abundance): highest point of 2X104 in figure 5B and 9.5X105 in 
figure 5A]. Overall, the result supported the earlier observations showing that 
Aβ42 has increased affinity to the plasma membrane compared to Aβ42 
(19:34). 
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Figure 4: Aβ42 associates with the yeast plasma membrane 
Cellular localization of Aβ42 in yeast was analysed by confocal and 
immunoelectron microscopic analysis of Candida glabrata cells treated with 
Aβ42. Cells were analysed by dual channel fluorescence imaging (Leica TCS 
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NT confocal microscope) after treatment with FITC labelled Aβ42 (A, green 
channel) for 6h and staining with FM4-64 stain for 15 min (B, red channel) at 
30°C. Images were recorded using Olympus DP70 camera. Image overlay (C) 
and co-localization of FITC-Aβ42 and FM4-64 staining across the region of 
interest (ROI) was done using Leica LASAF software image analysis. 
Fluorescence intensities (arbitrary units) of FITC-Aβ42 (green), FM4-64 (red) 
and overlay (orange) across the ROI is represented by the green, purple and 
orange dotted lines respectively (D). A significant association of FITC-Aβ42 with 
FM4-64 staining was observed. Cells treated with vehicle (E) or unlabelled 
Aβ42 (6h) (F) were fixed, permeabilized and prepared on gold grids for electron 
microscopic imaging. The grids were probed with WO2 (anti-Aβ) followed by 
incubation with gold conjugated anti-mouse secondary antibody. The samples 
were observed by negative staining using 2% aqueous uranyl acetate and 
Reynold‟s lead citrate and micrographs were recorded using a Megaview III 
CCD camera. Cells treated with Aβ42 showed dark circular spots around the 
cell surface, indicative of Aβ42 associating with the yeast plasma membrane (F) 
(indicated by black arrows). No distinct dark spots were observed with the 
untreated sample. Overall, the data suggested that Aβ42 localized on the yeast 
plasma membrane. However, Aβ42 was not detected in the intracellular lumen 
of yeast.  
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Figure 5: Mass spectrometric (ESI-MS) analysis of plasma membrane fractions 
of Aβ42 treated yeast cells  
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Mass spectrometric (ESI-MS) analysis of plasma membrane fractions of 
Aβ42 treated yeast cells: Plasma membrane fractions of yeast cells treated with 
Aβ42 (5µM) (A) and Aβ42 (19:34) (B) were isolated and analysed by mass 
spectrometry (ESI-MS). The crude plasma membrane (CPM) fractions from the 
cells were delipidated using chloroform/methanol/water extraction. The protein 
from the aqueous layer was recovered using acetone precipitation and air dried. 
The protein pellet was dissolved in 70% acetonitrile, 0.1% TFA and analysed in 
an Agilent QTOF 6510 mass spectrometer (mass range of 4-100kDa). Distinct 
species with mass/charge ratio of 4514.09, 9027.61 and 13539.88, indicating 
Aβ42 monomer, dimer and trimer respectively were detected in cells treated 
with oligomer Aβ42 as shown in the ESI-MS spectra here. However, no species 
representative of Aβ was identified in cells treated with Aβ42 (19:34). The 
graphs are represented in different Y-axis range (relative abundance: highest 
point of 2X104 in figure 5B and 9.5X105 in figure 5A). 
 
 
3.4.5    Effects of Aβ42 and Aβ42 (19:42) peptides on plasma 
membrane H+ATPase activity  
 
Cellular localization analysis of Aβ42 and Aβ42 (19:34) uptake in yeast 
clearly showed that exogenously added Aβ42 is localized to the cell surface, 
strongly associated with the plasma membrane. It was suggested that Aβ42 
caused cell death in yeast is possibly mediated by plasma membrane 
associated toxicity. In neuronal cells, Aβ42 is known to disrupt membrane 
associated proteins and related functions contributing to its ability to induce cell 
death. One of these targets for Aβ42 that has been suggested is the Na+/K+ 
ATPase, which is critically important for osmotic balance and cell volume 
maintenance. Decreased overall Na+/K+ ATPase enzyme activity is observed in 
the hippocampus of the APP+PS1 mice (Dickey et al., 2005). Reports have 
shown that Aβ42 can mediate disruption of cellular homeostasis via inhibition of 
Na+/K+ ATPase activity in neurons (Dickey et al., 2005; Mattson et al., 1993).  
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In yeast, the proton (H+)-transporting plasma membrane protein (H+-
ATPase) is mainly responsible for maintenance of cellular homeostasis and 
viability (Ambesi et al., 2000). It is also a member of the P2-ATPase family in 
eukaryotes and a functional homolog of the Na+/K+ ATPase. The H+-ATPase is 
the most abundant plasma membrane protein in yeast cells (Ambesi et al., 
2000) and also an important target for anti-fungal drugs implying its essential 
role in cell survival (Billack et al., 2010; Manavathu et al., 1999). 
 
To determine if oligomeric Aβ42 can damage the yeast H+-ATPase, in vitro 
plasma membrane H+-ATPase (vanadate sensitive ATP hydrolysis) activity was 
determined in crude membrane fractions incubated with Aβ peptides (Figure 6). 
ATPase activity measurement was performed as described in Section 2.2.8. 
Following Aβ pre-incubation for 15-20min, the crude membranes were tested for 
plasma membrane ATPase activity. The assay was done in presence of 
ammonium molybdate and sodium nitrate to prevent residual effects of 
nonspecific phosphatase, and mitochondrial ATPase activities. Pre incubation 
with oligomeric Aβ42 was found to cause a dose-dependent inhibition of H+-
ATPase activity of yeast plasma membranes. A ~70% and ~95% loss of 
ATPase activity was observed when 15μg of total yeast membrane suspension 
was incubated with 1 and 1.5μM of Aβ42, respectively. However, treatment with 
similar amounts of Aβ42 (19:34) did not alter the ATP hydrolysing activity. The 
result suggested that inhibition of H+-ATPase activity was mediated by 
oligomeric Aβ42 and not by non-oligomeric Aβ42 (19:34).  
 
 
 
 
 
108 
 
 
Figure 6: Oligomeric Aβ42 inhibits H+-ATPase activity in yeast plasma 
membrane fractions  
Crude plasma membranes (CPM) were prepared from exponentially growing 
yeast. The CPM fractions (15μg) was pre-incubated with different 
concentrations (0-1.5µM) of oligomeric Aβ42 or the non-aggregating Aβ42 
(19:34) peptide for 15-20 min followed by addition of ATP assay buffer 
containing 10mM ATP and reaction at RT for 45-60 min. The ATP hydrolysing 
property of the plasma membrane H+-ATPase was determined from the 
phosphate released, which was measured colorimetrically at (630nm) using 
ammonium molybdate stop buffer. Activity (%) was measured by subtracting the 
Abs (630nm) of vanadate-treated CPM fractions and normalized using 
phosphate standard curve. A significant inhibition of H+-ATPase activity was 
observed with Aβ42 pre-incubation (**, p<0.01), but not with Aβ42 (19:34). Data 
are expressed as mean ± SEM (n=4). 
 
 
 
 
 
 
 
(µM) (µM)
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3.5       Discussion: 
3.5.1 Modified Aβ42 (19:34) exhibited reduced aggregation and 
toxicity  
 
It is well established that the toxicity of Aβ is associated with its ability to 
oligomerize and aggregate. A number of mammalian models have been used to 
study mechanisms of Aβ mediated toxicity. A major advantage of using yeast 
cells for Aβ toxicity is the ability to perform the assay in water. Unlike 
mammalian cells which require osmotic and nutrient support, yeast cells can 
survive in water for several days with minimal loss of viability (Bharadwaj et al., 
2008). Since Aβ42 has an increased tendency to form heterogeneous 
aggregates in the presence of salts under physiological conditions (Stine et al., 
2003), studies of oligomer Aβ specific toxicity in mammalian cell models can be 
problematic. Using yeast cells for oligomer Aβ42 toxicity in water therefore can 
overrule the influence of the salts on Aβ aggregation. In this chapter, I have 
extended my previous finding where I showed that oligomeric Aβ was more 
toxic than fibrillar Aβ (Figure 1). The major aim of this study was to investigate 
the uptake and localization of oligomeric Aβ42 in yeast cells.  
 
Due to the heterogeneous nature of Aβ fibrillar preparations, an Aβ42 
peptide modified at positions F19S and L34P [Aβ42 (19:34)] (Wurth et al., 2002) 
with reduced tendency to aggregate was chosen as a control for oligomeric 
Aβ42 in this study. In vitro structural modelling and yeast two hybrid analysis 
indicate that positions 19 (phenylalanine) and 34 (leucine) in Aβ42 sequence 
play an important role in self interaction of the peptide monomers (Ahmed et al., 
2010; Hughes et al., 1996; Luhrs et al., 2005). Size fractionation analysis by 
SDS-PAGE showed that Aβ42 (19:34) peptide was completely monomeric, 
compared to the stable low-n oligomers (7-17kDa range) observed with 
oligomeric Aβ42 preparations (Figure 2A). In both yeast and M17 
neuroblastoma cells, oligomeric Aβ42 caused significant loss in cell viability 
(Figure 2B, C). Approximately 75% cell death was observed at concentrations 
of 5μM of Aβ42 in both yeast and M17 neuroblastoma cells, compared to less 
than 5% cell death at similar concentrations of Aβ42 (19:34). As expected, 
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these results showed that oligomeric Aβ42 was more toxic than the non-
oligomerizing Aβ42 (19:34). This data supports the previous studies in 
mammalian cells indicating that soluble oligomeric form of Aβ42 is the main 
toxic species responsible for cell death (Dahlgren et al., 2002; McLean et al., 
1999; Shankar et al., 2007; Shankar et al., 2008).  
 
3.5.2 Accumulation of Aβ42 in the yeast plasma membrane  
 
Due to its hydrophobic nature, Aβ has an inherent nature to associate with 
biological membranes. The ability to interact with membranes is therefore an 
important feature of oligomer Aβ mediated toxicity to cells. The cellular 
localization of the oligomeric Aβ42 and the non-oligomeric Aβ42 (19:34) was 
determined by fluorescence microscopy (Figure 3A-F) and Aβ immunoblotting 
of cell extracts (Figure 3G-H) showed that both Aβ peptides bound the cell 
surface. However, oligomeric Aβ42 displayed an increased binding affinity 
compared to the modified Aβ42 (19:34) (Figure 3). Also, an increased level of 
Aβ42 oligomers (7-17kDa range and 50-200kDa range) in the insoluble 
membrane fraction was evident with longer incubation periods (Figure 3G, H 
and I: lanes 5 and 6). However no increase in levels of the modified Aβ42 
(19:34) was observed with longer incubation times (Figure 3G, H and I: lanes 10 
and 11). The hydrophobic nature of Aβ42 and its ability to oligomerize may 
explain its accumulation in the insoluble membrane fraction, which was clearly 
reduced with Aβ42 (19:34) treatment. It is likely that the decreased ability of the 
Aβ42 (19:34) peptide to self associate (Hughes et al., 1996; Wurth et al., 2002) 
may contribute to its low affinity and accumulation in the cell compared to 
oligomeric Aβ42.  
 
Importantly, the progressive accumulation of Aβ and the appearance of Aβ 
oligomers (7-17kDa range and 50-200kDa range) in the insoluble membrane 
fraction showed correlation with increased loss of viability in yeast with longer 
incubation times (compare lanes 5, 6 Figure 3G-I with 3J). This observation 
supports previous reports indicating that increased binding to the plasma 
membrane can enhance the neurotoxic property of Aβ (Ciccotosto et al., 2004; 
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Crouch et al., 2008). Further, confocal microscopic analysis and 
immunoelectron microscopy clearly showed that oligomeric Aβ42 was largely 
populated on the cell surface, strongly associated with the cell wall and the 
outer leaflet of the plasma membrane of the yeast cell. The crude plasma 
membranes of Aβ42 and modified Aβ42 (19:34) peptide treated cells were 
analysed by ESI-MS (Figure 5A). Aβ42 treated cells revealed monomer and 
oligomeric forms (dimer and trimer). However, the membrane fractions isolated 
from cells treated with modified Aβ42 (19:34) showed no detectable levels of Aβ 
(Figure 5B). It is likely that Aβ42 (19:34) was stripped during the delipidation 
process of sample preparation for ESI-MS, due to its weak binding to the yeast 
cell surface membranes (cell wall and plasma membrane). This suggests that 
the modification at residues 19 and 34 of the Aβ sequence affects not only the 
self interaction of the Aβ42 (19:34) peptides, but its nature of membrane 
interaction. Furthermore the results suggested that the reduced affinity of Aβ42 
(19:34) peptide to the cell surface could be one of the reasons for its decreased 
cytotoxicity. However, it could be argued that the lack of detection of the 
modified Aβ42 (19:34) peptide in the crude plasma membrane fractions may be 
due to its vulnerability to degradation compared to Aβ42 because of its inability 
to form oligomers. 
 
The binding dynamics of Aβ42 to membranes is complex. Aβ42 has a long 
hydrophobic C-terminus which can insert into the lipid bilayer membranes of cell 
surfaces. Studies suggest that these cell surfaces can catalyse amyloid 
aggregate nucleation, perhaps in a different mechanism from that observed in 
solution state (Sethuraman and Belfort, 2005; Stefani, 2007). Cellular surfaces 
can also accelerate amyloidogeneis and possibly impact the structural integrity 
and functions of membranes (Porat et al., 2003). Aβ can bind a variety of 
cofactors on the plasma membrane including ion channels proteins, receptor 
complexes, lipid and sterol molecules which can impact its binding and also 
contribute to cellular dysfunction and death. The results presented in this 
chapter provide evidence in support of the idea that binding to the plasma 
membrane plays an important role in oligomer Aβ mediated cell death. 
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3.5.3 Inhibition of H+-ATPase in vitro activity by oligomeric Aβ42 
 
Ion motive ATPases are vital plasma membrane protein complexes 
responsible for the active transport of ions across the plasma membrane and 
maintenance of cellular homeostasis (Skou, 1982). Decreased Na+/K+ ATPase, 
Cl--ATPase activity and protein levels has been observed in APP +PS1 double 
transgenic mice (Dickey et al., 2005) and also in the AD brains (Hattori et al., 
1998). Reduced activity of the Na+/K+-ATPase and Cl--ATPase has been 
associated with elevated intracellular Ca+, Na+, swelling of neurons, increased 
vulnerability to excitotoxic stress, accumulation of reactive oxygen species 
(ROS) and apoptotic cell death in AD (Dickey et al., 2005; Mark et al., 1995). 
Moreover decreased activity of Na+/K+-ATPase proteins has been observed to 
be associated with amyloid deposition in the hippocampus of APP+PS1 mice 
(Dickey et al., 2005). In addition, reports suggest that disruption of Na+/K+ 
ATPase and Cl- ATPase activity by Aβ can result in neuronal cell death in AD 
(Bores et al., 1998; Mark et al., 1995; Yagyu et al., 2001).  
 
Aβ42 toxicity in yeast was found to be mediated by its binding to the plasma 
membrane. Oligomeric Aβ42 was toxic to cells and showed increased affinity to 
the plasma membrane compared to the modified Aβ42 (19:34) which had 
reduced binding to the plasma membrane (Section 3.4.3). Furthermore oligomer 
Aβ42 was found to inhibit the H+ATPase activity in isolated yeast plasma 
membranes whereas the modified non-oligomerizing Aβ42 (19:34) did not affect 
the activity. Approximately a 70-95% decrease in activity with 1-1.5μM of 
oligomeric Aβ42 treatment was observed compared to only a 5% decrease with 
Aβ42 (19:34) at similar concentrations (Figure 6). Collectively the data indicated 
that inhibition of the plasma membrane H+-ATPase as one of the possible 
mechanisms of oligomer Aβ42 mediated cell death. This finding was consistent 
with the data obtained from neuronal cells.  
 
Previous studies report decreased Na+/K+ ATPase and Cl--ATPase activity 
in plasma membranes isolated from Aβ42 peptide treated hippocampal cells 
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(Bores et al., 1998; Mark et al., 1995; Xiao et al., 2002). It is however difficult to 
distinctly associate the effect of Aβ42 peptide to the inhibition of the ion-motive 
ATPase activity. Aβ42 induced disruption of membrane integrity, lipid 
peroxidation and other affected cellular functions may also contribute to the 
decreased activity. It has also been shown that mRNA for the Na+/K+ ATPase 
αIII subunit is consistently down-regulated in the hippocampus ridden with 
amyloid deposition (Dickey et al., 2003). Alternative pathways involving 
interactions of Aβ with membrane proteins leading to modulation of signal 
transduction cascades can also contribute to the decreased expression of 
Na+/K+ ATPase. A study showing that Lyn, a tyrosine kinase can phosphorylate 
Na+/K+ ATPase leading to its reduced expression levels (Bozulic et al., 2004) 
further supports this idea. However, Aβ peptide treatment [both oligomer Aβ42 
and non-oligomeric Aβ42 (19:34)] was performed in isolated wild type yeast 
plasma membranes. Moreover, the assay was done in the presence of 
ammonium molybdate and sodium nitrate to prevent residual effects of 
nonspecific phosphatase, and mitochondrial ATPase activities. This suggested 
that oligomer Aβ42 specifically inhibited the ATP hydrolysing property of the 
yeast plasma membrane H+-ATPase. Overall the data from the toxicity, cellular 
localization of Aβ peptides and the isoform specific effects on the H+-ATPase 
activity suggested that inhibition of plasma membrane H+-ATPase activity can 
be one of the main causes of cell death mediated by oligomeric Aβ42 in yeast. 
 
3.6    Summary: 
The results presented in this chapter have confirmed the toxicity of 
oligomeric Aβ42 to yeast cells. In addition I have shown that oligomeric Aβ42 
binds the yeast plasma membrane where it can alter the activity of the plasma 
membrane proton pump H+ATPase. This may be one mechanism by which 
oligomeric Aβ can impact cellular homeostasis and cause cell death. Preventing 
the formation or disrupting oligomeric structures of Aβ has shown to inhibit 
toxicity (Yang et al., 1999a; Yang et al., 2005). In the next chapter, I determine 
the effects of dairy derived peptides in modulating Aβ structure and toxicity in 
yeast and neuronal cells.   
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4.1     Introduction 
 
Preventing the formation or disrupting the specific Aβ toxic oligomer 
structures that cause neuronal dysfunction in the brain has been proposed as a 
therapeutic strategy for AD (Klein, 2007; Zimecki, 2008). A wide range of 
inhibitors and modulators of Aβ42 aggregation, including peptide, protein and 
small molecular classes of natural and synthetic origin (Estrada and Soto, 2007; 
Gordon et al., 2002; Kokkoni et al., 2006) have been shown to regulate toxicity 
of Aβ42 both in vitro and in vivo (Amijee et al., 2009; Bastianetto et al., 2008; 
Dumery et al., 2001; Findeis, 2002; Nerelius et al., 2009). A major challenge in 
designing such Aβ inhibitors is to specifically target the toxic form of Aβ and 
identify potent compounds with low cytotoxicity.  
 
Inhibitors of Aβ aggregation from natural food products or dietary intake has 
been of interest in AD therapeutics. Milk proteins are well known for chaperone 
activity. The micellar structure of the bovine milk caseins represents a 
thermodynamically stable architecture that accommodates the amphiphillic 
casein proteins and colloidal calcium phosphate components of milk (Ferrandini 
et al., 2005). Two of the four proteins of the casein micelle, -casein (Cn) and 
S2 casein on isolation readily form fibrils under either reducing or non-
reducing conditions, respectively (Thorn et al., 2008; Thorn et al., 2005a) but 
this behaviour is suppressed by αS1-casein and β-casein, present in 
stoichiometric excess, in fresh milk (Thorn et al., 2008; Thorn et al., 2005a). 
Anti-fibril properties have been previously demonstrated in milk protein 
hydrolysates (Bennett et al., 2009). Anti-fibril and other bioactivities have also 
been extensively characterised in a peptide extract from ovine colostrum 
(Schuster et al., 2005) and also shown to improve learning and memory in rats 
(Popik et al., 1999). The chaperoning activity of milk proteins implicates them as 
interesting candidates for targeting Aβ oligomerization and associated toxicity.  
 
Toxicity of oligomeric Aβ42 has been recently established in a yeast cell 
model [(Bharadwaj et al., 2008), (Chapter 3)]. In addition to its high level of 
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conservation in cellular processes with mammalian cells, yeast cells present 
added advantages of simple growth requirements, fast cell division, and a 
robust nature making it a very attractive cellular model for drug screening 
(Hughes, 2002; Mager and Winderickx, 2005; Simon and Bedalov, 2004). The 
yeast model for oligomer Aβ toxicity is therefore well suited for characterizing 
the effects of Aβ structure modifying compounds. In this chapter, the dose-
dependence effects of a whey protein-derived peptide hydrolysate (SPE product 
series) on Aβ42 structure were characterized using circular dichroism, fourier 
transform infrared spectroscopy (FTIR), transmission electron microscopy 
(TEM) and by size fractionation (SDS-PAGE). To determine the effects of SPE 
mediated modulation of Aβ42 structure, the toxicity of pre-incubated SPE-Aβ42 
mixtures were studied in yeast and further validated in neuronal cell models.  
 
4.2     Aims: 
 
1.) Preparation and amino acid analysis of SPE hydrolysate fractions from 
bovine whey protein isolate 
2.) Study the effects of SPE fractions on Aβ42 secondary structure and 
oligomerization  
3.) Investigate the effects of SPE fractions on Aβ42 toxicity 
   
4.3     Materials and Methods: 
 
Preparation and amino acid analysis of SPE fractions recovered from dairy 
whey protein hydrolysate was done as described in Section 2.2.2 (Louise 
Bennett, CSIRO). Aβ42 solutions were prepared and incubated with different 
concentrations of SPE fractions. The SPE-Aβ42 mixtures were then analysed 
by circular dichroism (CD), Fourier transform infrared spectroscopy (FTIR, 
Rabia Sarroukh, Université Libre de Bruxelles, Belgium) for determining the 
secondary structure constitution as described in Section 2.2.9.2 and Section 
2.2.9.3. The mixtures were also studied by transmission electron microscopy 
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(TEM) and size fractionation (SDS-PAGE, Aβ immunoblotting) for analysis of 
Aβ oligomerization. Cellular toxicity of the pre-incubated SPE-Aβ42 solutions 
were studied in yeast by CFU (colony forming units) count and in SH-SY5Y 
human neuroblastoma cells by LDH and MTS assays as described in Section 
2.2.4.5. 
4.4      Results: 
4.4.1 Characterization of Whey Peptide SPE Product 
 
The dairy whey protein hydrolysate was fractionated by preparative SPE and 
fractions recovered in either 40% acetonitrile (SPE40) followed by 100% 
acetonitrile (SPE100) elution, or a „total‟ fraction recovered in 100% acetonitrile 
(SPE) were studied.  HPLC profiles indicated significant retention of peptides by 
the C18 SPE media and overlap between SPE40 and SPE100 peptide 
assemblages (Figure 1A). However, the SPE40 contained a relatively higher 
proportion of species eluting in the 15 to 22 min range (Figure 1A).  
 
The amino acid composition of the SPE product was compared with 
Colostrinin, which is a proline rich peptide complex derived from ovine 
colostrums, reported to exhibit many functional properties of relevance to 
bioactivity of the bovine whey SPE product (Boldogh and Kruzel, 2008; Kruzel 
et al., 2001; Zimecki, 2008). Colostrinin has also shown to inhibit Aβ oligomer 
mediated toxicity (Schuster et al., 2005), regulate levels of reactive oxygen 
species (ROS) and immunomodulatory functions (Boldogh et al., 2008; Boldogh 
and Kruzel, 2008). A significant correlation was observed between the amino 
acid contents of the two products (Pearson Product Moment correlation 
coefficient was 0.604 and P=0.013, Figure 1B). Colostrinin was significantly 
richer in mole percentage of Glu+Gln and Proline whereas SPE was relatively 
richer in the non-polar amino acids: Alanine and Leucine.   
 
Dairy derived peptides have previously shown to have anti-fibril and protein 
chaperoning properties (Bennett et al., 2009; Thorn et al., 2005b), however its 
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effects on Aβ42 structure and aggregation has not been studied before. To 
study the effects of SPE fractions on Aβ42 secondary structure and 
oligomerization, pre-incubated mixtures of Aβ42 with different concentrations of 
SPE were studied by circular dichroism, Fourier transform infrared spectroscopy 
(FTIR), transmission electron microscopy (TEM) and by size fractionation (SDS-
PAGE).  
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Figure 1: Preparation and characterization of SPE fractions from dairy whey 
protein hydrolysate  
Reverse phase HPLC profiles of sub-fractions of dairy peptide hydrolysate 
showing solid phase extraction (SPE) cartridge non-binding void plus wash 
fraction (pooled) and products eluted with 40% and 100 % acetonitrile, 
designated SPE40 and SPE100, respectively.  The ratio of SPE40 to SPE100 
present in SPE-total was approximately 19:1 and profiles have been 
standardised for mass of solids analysed. (A). Amino acid analysis of total SPE 
retentate of dairy hydrolysate was compared with ovine colostral „Colostrinin‟ 
(Georgiades, 2004). The Pearson Product Moment correlation coefficient for 
colostrinin with the SPE total was 0.604 and P=0.013 (B).  
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4.4.2 Effect of SPE on Aβ42 secondary structure  
 
Aβ42 peptide solutions (0.05 mg/ml; 11µM), pre-incubated with different 
concentrations of SPE40 and SPE100 (final concentrations: 0.005, 0.05 & 0.25 
mg/ml in de-ionised water) were analysed by CD spectrometer. The mean 
residue ellipticities of samples were recorded across the far UV range (190-260 
nm). Spectra of SPE products alone at appropriate concentrations were 
subtracted from respective profiles of Aβ42+SPE product, but were otherwise 
unsmoothed. The beta sheet content of Aβ42 in the presence of increasing 
concentrations of SPE40 and SPE100 was analysed using the CD spectra 
generated (Figure 2). The ratio of Aβ42 molarity per mg of SPE product was 
2200 down to 44, from 0.005 to 0.25 mg/ml, respectively. Inhibition of β-sheet 
development of Aβ42 (peak at 215 nm) was evident at a ratio of 44 (0.25 mg/ml) 
and not above 220 (0.05 or 0.005 mg/ml). The suppression of β-sheet was also 
accompanied by progressive apparent loss of alpha helix (190-200 nm, Figure 
2). The results showed that the SPE product was able to interfere with 
assembly of β-sheet structures in Aβ42. 
 
Modulation of Aβ42 secondary structure in the presence of increasing 
concentrations of SPE product was further studied using FTIR spectroscopy. 
FTIR characteristics of SPE product indicated that SPE did not absorb in 
designated β-sheet regions at either 1695 or 1629 cm-1. FTIR analysis also 
showed no change in SPE peptide secondary structure over the concentration 
range studied. After incubation for 20h at 30°C in the absence of the SPE 
product, Aβ42 exhibited anti-parallel β-sheet structure associated with the 
presence of oligomers as previously shown (Cerf et al., 2009). Similar to CD 
data (Figure 2), modulation of Aβ42 secondary structure by the SPE product 
was evident by FTIR spectroscopy. The SPE product induced FTIR spectral 
changes in the Amide I region (1700-1600 cm-1) reflecting its effects on the 
extent of Aβ42 self-assembly (Figure 3).  Specifically, curve fitting indicated that 
SPE-concentration-dependent structural changes occurred in the β-sheet 
(1613-1629 and 1695 cm-1) and to a lesser extent, in the α-helix and/or random 
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coil structure regions, clustering between 1620 and 1705 cm-1. Difference 
spectra produced after subtraction of SPE product at each concentration 
permitted evaluation of „pure‟ Aβ42 FTIR spectra (Figure 3A). The ratio of 
1695/1630 cm-1 allowed the ratio of anti-parallel to total β-sheet to be quantified, 
and detect the effect of SPE product specifically on formation of oligomeric 
Aβ42.  By this method, the oligomer content of Aβ42 was found to be 
significantly lowered by the SPE product in a concentration-dependent manner 
(Figure 3B). Overall, these results suggested that the SPE product 
progressively inhibited the self-assembly of Aβ42 into oligomers and reversed 
existing β-sheet structures. To further study the effect of SPE mediated β-sheet 
inhibition of Aβ, pre-incubated Aβ42+SPE mixtures were examined by TEM and 
SDS-PAGE analysis. 
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Figure 2: CD spectroscopy of Aβ42+SPE mixtures  
The absorption bands of Aβ42 peptide solutions (11 µM), pre-incubated with 
different concentrations of SPE40 and SPE100 were analysed by Jasco J-810 
CD Spectropolarimeter. The mean residue ellipticities of samples were recorded 
across the far UV range (190-260 nm), using a 0.1 cm path-length quartz 
cuvette, at room temperature, monitoring at 0.1 nm intervals. Concentration-
Aβ42
Aβ42 + SPE40
Aβ42 + SPE40
Aβ42 + SPE40
Aβ42
Aβ42 + SPE100
Aβ42 + SPE100
Aβ42 + SPE100
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dependent effects of SPE40 (A) and SPE100 (B) on Aβ42 peptide (11 M), 
following 24 hr incubation at 22ºC was determined. Spectra of SPE products 
alone at appropriate concentrations were subtracted from respective profiles of 
Aβ42+SPE product. Individual data sets (n=3) acquired were averaged over 3 
scans. At higher concentrations (0.25mg/ml) SPE fractions (40 and 100) 
reduced total beta sheet content in Aβ42 solutions, as indicated by the changes 
in the 210-230nm band region. 
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Figure 3: FTIR spectroscopy of Aβ42+SPE mixtures 
 
Infra red (IR) spectra of Aβ42 solution pre-incubated with different 
concentrations of SPE fraction (total) were measured using an Equinox 55 
infrared spectrophotometer. Spectral subtraction was applied between 4000 
and 800 cm-1 and changes mainly reflected effects of SPE-total on Aβ42 
secondary structure in the Amide I band region (1700-1600 cm-1). Fourier self-
deconvolution was applied to increase the resolution of spectra in the amide I 
region, which is that most sensitive to protein secondary structure. The FTIR 
data was preprocessed, baseline corrected and normalized for equal area 
between 1700-1500 cm−1as described in (Goormaghtigh et al., 1999). ATR-
FTIR spectra of Aβ42 incubated at 30C for 20h in the presence of (a) 0, (b) 
0.001, (c) 0.005, (d) 0.01, (e) 0.05, (f) 0.1 mg/ml of SPE-total, after subtraction 
of SPE-total controls (A). Ratio of 1695/1630 cm−1 intensities normalized to 
control Aβ42 (100%) is plotted as a function of the concentration of SPE-total 
(B).  Each spectrum represents the mean of 128 repetitions recorded at a 
resolution of 2 cm-1 and further averaged across triplicate independent sample 
preparations. Increasing concentrations of SPE reduced the relative 
absorbance intensity at 1695/1630 cm−1 band region, indicating decrease of 
anti-parallel β-sheet structures 
 
4.4.3 Effect of SPE on Aβ42 oligomerization 
 
The oligomerization of Aβ42 is initiated by a conformational change from 
random coil or α-helix into a β- sheet maximized by cross linking hydrophobic 
interactions, quite similar to prion and other amyloidogenic proteins (Lansbury 
Jr, 1996; Tycko, 2003). Previously it was shown that increasing concentrations 
of SPE showed significant inhibition of β-sheet structures in Aβ42 (Figure 2, 3). 
To study the effects of SPE induced β-sheet inhibition on Aβ42 structure and 
oligomerization, pre-incubated Aβ42-SPE100 mixtures (11µM Aβ42+0.1 mg/ml 
SPE100) were observed by transmission electron microscopy or analysed by 
Aβ immunoblotting.  
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Aβ42 alone exhibited globular oligomeric (50-60nm in diameter) and proto-
fibrillar structures (100-150nm in length, Figure 4A) as observed by TEM 
analysis. However, Aβ42 co-incubated with SPE also comprised small globular 
structures (10-20nm in diameter, Figure 4B) similar to the SPE100 control, and 
was devoid of larger oligomeric and fibrillar structures. The SPE product alone 
was characterised by small globular particles of approximately 10 nm diameter 
(Figure 4C).  It is notable, that TEM analysis showed visible aggregates (10nm 
diameter) in SPE100 fraction, whereas CD and FTIR analysis of pure SPE 
fractions contained less hydrophobic peptides and showed no detectable 
aggregation. The TEM images of Aβ42 incubated with the SPE100 reflected 
strong suppression of oligomer/protofibril development (Figure 4B) compared to 
Aβ42 only (Figure 4A).   
 
Freshly prepared Aβ42 was incubated with increasing concentrations of 
SPE100 and aliquots were collected for SDS-PAGE/Aβ immunoblotting analysis 
at 0h, 24h and 48h time points. Aβ42 showed increasing levels of higher-order 
oligomers (~50-110 kDa) with increasing incubation time (0, 24 and 48h), with 
no noticeable change in lower-order oligomers (dimer, trimer, tetramer) (Figure 
5). Higher mass oligomeric Aβ42 (~50-110 kDa range) products were 
suppressed with increasing concentrations of SPE product (Figure 5). However, 
no change was observed with the levels of low mass Aβ42 oligomer (~7-20 kDa 
range) and monomer bands.  
 
Overall, the data from secondary structure analysis (CD, FTIR), showed 
clear evidence for suppression of total β-sheet content and anti-parallel β-
sheets associated with Aβ42 oligomerization by SPE products. TEM and 
western blotting analysis further supported the data from CD and FTIR showing 
that SPE inhibited formation of Aβ oligomers. Further the toxicity of the Aβ42-
SPE mixtures were determined in yeast and validated in neuronal cells. 
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Figure 4: Electron micrographs of Aβ42+SPE mixtures     
Aβ42 solutions (11µM) pre-incubated with SPE100 (0.1 mg/ml in 10% ethanol) 
or vehicle (10% ethanol) for 20 h at 22C were applied to glow discharged 
carbon-coated 400-mesh copper grids. The excess sample is removed and the 
grids are stained with 2–3 drops of 2% aqueous uranyl acetate (Sigma). The 
grids were air-dried and examined by Tecnai 12 Transmission Electron 
Microscope operating at 120 KV. Micrographs of Aβ42 alone (A), Aβ42 pre-
incubated with SPE100 (B) and SPE100 alone (C) were recorded using a 
Megaview III CCD camera. Oligomer Aβ42 preparations showed oligomeric 
structures (50-60 nm in diameter) and proto-fibrillar structures (100-150 nm in 
length), which were undetectable in pre-incubated SPE100-Aβ42 samples and 
SPE100 samples.       
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Figure 5: SDS-PAGE western blotting analysis of Aβ42+SPE mixtures     
Aliquots from pre-incubated Aβ42 (10µM) with increasing concentrations of 
SPE100 (lanes 1-5 are 0, 0.005, 0.01, 0.05, 0.1 mg/ml) at different time points 
(0h, 24h and 48h) were analysed by western blot analysis. The samples were 
separated by electrophoresis using a 4-12% Bis-Tris gel with MES buffering 
system. The protein was transferred to nitrocellulose membrane and probed 
with WO2 antibody (anti-Aβ) and developed on films using enhanced 
chemiluminiscence (ECL). SPE100 inhibited the formation of higher Aβ 
oligomers (50-110kDa) in a dose dependent manner.   
 
 
 
 
 
 
 
1    2    3    4    5         1    2    3    4   5     1    2    3    4    5
0h 48h24h
Aβ42 (0.05mg/ml)  + 
PO147 (0.1mg/ml) 
 
PO147 (0.1mg/ml) 
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4.4.4 Modulation of Aβ42 toxicity 
 
Aβ42 oligomerization is strongly associated with toxicity to both yeast and 
neuronal cells [Chapter 3, (Bharadwaj et al., 2008)]. Compounds which inhibit 
Aβ oligomerization have shown to protect cells from toxicity (Amijee et al., 2009; 
Findeis, 2002). The previous data showed suppression of Aβ42 oligomerization 
by SPE (Figure 2-5). To correlate the reduced oligomer content with toxicity to 
cells, SPE products were tested in Aβ42 toxicity assays with both yeast and 
neuronal cells. Oligomeric Aβ42 peptide was toxic to both yeast and neuronal 
cells in a dose-dependent manner (Figure 6A) with the concentration of 10µM 
chosen for subsequent experiments.  
 
Pre-incubated Aβ42 (10µM) +SPE (0.001-0.1mg/ml) mixtures were treated 
with yeast cells for 20h followed by viability analysis using colony forming unit 
(CFU) count. A dose-dependent increase in yeast cell viability was observed 
with increasing concentrations of SPE in the Aβ42+SPE mixtures (Figure 6B). 
Protection against Aβ toxicity was evident at higher concentrations of 0.05 and 
0.1mg/ml concentrations. Aβ42 only (10µM) caused ~50% cell death compared 
to ~40% with 0.05mg/ml SPE100 and complete reversal of toxicity at 0.1mg/ml 
SPE100. Interestingly, at lower concentrations of SPE (0.001-0.01mg/ml), cell 
death was increased compared to Aβ42 only (by 10%). Yeast toxicity 
experiments indicated that SPE100 was more protective than SPE40 at 0.05 
and 0.1 mg/ml (Figure 6B) and subsequent studies with neuronal cells focussed 
on effects of SPE100.   
 
SHSY5Y cells were treated with pre-incubated Aβ42 (10µM) +SPE100 
(0.01-0.1mg/ml) mixtures for 3days followed by viability analysis by LDH and 
MTS assays as described in Section 2.2.4.5. Similar to yeast, the SPE100 
product exhibited concentration-dependent rescue of Aβ toxicity, measured by 
either decreased release of LDH or enhanced reduction of MTS reagent in cells 
(Figure 6C). A 50% loss of viability as measured by MTS assay was seen with 
Aβ42 treatment (10µM). Increased viability of ~65% with SPE concentrations of 
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0.01mg/ml was observed which further improved to ~80% with 0.1mg/ml of 
SPE100. A similar pattern of rescue was observed with LDH release in cells. 
Aβ42 only treatment induced ~35% cell death whereas the cell death decreased 
to 20-15% with SPE100 concentrations of 0.01-0.1mg/ml. Overall, the data from 
the toxicity analysis of Aβ42+SPE mixtures in yeast and neuronal cells showed 
that SPE inhibited Aβ42 induced toxicity at higher concentrations. Together with 
the effects of SPE on Aβ42 structure and oligomerization, the results indicated 
that suppression of Aβ42 oligomerization inhibited its toxicity in both yeast and 
neuronal cells.  
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Figure 6: Toxicity of Aβ42+SPE mixtures in yeast and neuronal cells    
Dose response of Aβ42 treatment on viability in yeast (by colony forming units 
count, CFU) and SHSY5Y cells (by LDH and MTS methods) (A). Dose 
response effects of Aβ42 pre-incubated with SPE100 (0.01 to 0.1 mg/ml) on 
viability of exponentially growing yeast cells incubated at 30˚C for 20h (B). Dose 
response effects of Aβ42 pre-incubated with SPE100 (0.01 to 0.1 mg/ml) on 
viability of SHSY5Y cells (C). Cell viability was determined by the ratio of colony 
numbers in the absence and presence of SPE samples, and reported by LDH 
and MTS assay methods. At higher concentrations, SPE fractions significantly 
reduced Aβ42 toxicity in yeast and SHSY-5Y cells. However, at lower 
concentrations, SPE40 and SPE100 enhanced Aβ42 toxicity in yeast but not in 
SHSY-5Y cells. Results represent the mean and SEM of triplicate 
determinations at each concentration with significance of differences to control 
(*, P<0.05; **, P<0.01; #, P<0.05; ##, P<0.01) determined by Students t test.  
 
4.5     Discussion: 
 
The self-assembly of proteins into fibrillar structures based on cross β-sheet 
„laminae‟ of amyloidogenic polypeptides represents a common folding pathway 
of many proteins (Krebs et al., 2008). Furthermore, „amyloid‟ structuring of 
proteins has been described as a detoxification strategy to mask the 
promiscuous surface of the oligomeric building block (Carrell et al., 2008). 
Studies have also identified novel biological functions for amyloidogenic protein 
fibrils in bacteria, fungi and even mammals (Kelly and Balch, 2003). Supporting 
evidence from a range of studies in several neurodegenerative disease 
including AD correlate soluble protein oligomers in the brain as the indicator of 
cognitive decline rather than insoluble fibrillar deposits (Ferreira et al., 2007; 
Glabe and Kayed, 2006; Popik et al., 1999).  
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Aβ42 fibrils are assembled from a planar „laminate‟ of up to six parallel -
sheets, stacking and elongating the fibril perpendicular to the laminate plane 
(Burkoth et al., 2000). However, formation of meta-stable oligomeric Aβ42 
represents an early competing folding pathway (Necula et al., 2007) 
characterised by anti-parallel β-sheet structure (Sarroukh et al., 2010). Widely 
differentiated behaviour in propensities for self-aggregation into oligomers and 
fibrils is observed in naturally-secreted forms of Aβ (e.g., Aβ37-42, Aβ40) and 
also in forms of Aβ generated by mutations of APP in the brain (Tomiyama et 
al., 2008) (Bharadwaj et al., 2009; Peralvarez-Marin et al., 2009).  Underlying 
these effects is the key role of primary Aβ sequence in permitting β-sheet 
organisation.  Studies have also identified key amino acids involved in Aβ 
structural morphology. For example, deletion of E22-glutamate from Aβ42 
permitted assembly of dimers and trimers but not ThT-binding fibrils (Tomiyama 
et al., 2008) whereas substitution of Phe19 to Pro19 in Aβ42, prevented ability 
to form oligomers and fibrils (Bernstein et al., 2005). Also, modification of Phe19 
to Ser19 and Leu34 to Pro34 in Aβ42 showed decreased aggregation (Wurth et 
al., 2002) and was less toxic compared to oligomeric Aβ42 in yeast and 
neuronal cells (Chapter 3). Apart from its natural tendency to self-associate via 
multiple folding pathways sequence, several environmental factors and binding 
partners can alter Aβ aggregation in the brain. Studies implicate that Aβ 
structures in the brain can be heterogeneous (Bibl et al., 2006), and associate 
with chaperone like species that may affect its morphology and regulate 
proteostasis (Voisine et al., 2010). Actually, increased chaperone levels have 
shown to be associated with longer lifespan (Tatar et al., 1997) and also protect 
cells from the toxic proteins (Balch et al., 2008; Zhou et al., 2001).   
 
Chaperones that facilitate or prevent assembly of either the β-sheet laminate 
or the intra-laminate assembly are likely to catalyse or inhibit, respectively, the 
self-assembly of Aβ42. The development of peptide-based inhibitors of Aβ42 
aggregation has focussed significantly on active domains of chaperone 
proteins. For example, transgenically-expressed human Aβ42 in C. elegans 
elicited the expression of known heat shock „chaperone‟ proteins that were 
subsequently immunoprecipitated with Aβ42 (Fonte et al., 2002) (Fonte et al., 
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2008), and which regulated the folding of Aβ42 towards less toxic pathways. 
Similarly, α1-anti-chymotrypsin (ACT), which is present in AD brain plaque, 
drives Aβ42 along either amorphous aggregation or fibril pathways, depending 
on the molar ratio (Janciauskiene et al., 1998). A peptide fragment of the 
chaperone protein α-crystallin also inhibited aggregation of Aβ42 (Raman et al., 
2005) and its toxicity to PC12 cells (Santhoshkumar and Sharma, 2004).  By 
analogy, mixture studies with different ratios of Aβ42 in the presence of Aβ40, 
show that the presence of Aβ40 can inhibit mature fibril development when 
Aβ40 approaches equimolar ratios to Aβ42, with corresponding attenuation of 
cell toxicity (Jan et al., 2008).  Also, compounds which dissociate intact cross β-
sheet structures (β-sheet „breakers‟) have been successfully designed from 
peptoid and retro-peptoid analogues of an amyloidogenic peptide such as 
amylin (Elgersma et al., 2007).  Chaperone-mediated interactions can alter the 
morphology and toxicity of amyloid proteins (Fonte et al., 2002) and supports 
that aggregation pathways can be strategically manipulated by exogeneous 
„chaperone‟ agents.  
 
In this study, the chaperoning like effects of whey derived peptide 
hydrolysate (SPE) on beta-amyloid protein (Aβ42) folding pathways and cellular 
toxicity was demonstrated.  The SPE product bioactivity described follows the 
precedent reported for proline-rich complex „Colostrinin‟ (Kruzel et al., 2001) 
and other mammalian sources of colostrum (Sokolowska et al., 2008). Peptides 
with capacity for fibril regulation, derived from bovine dairy sources including 
whey, casein and lactoferrin, have also been reported (Bennett et al., 2009). 
The colostrinin peptide complex was shown to inhibit and disrupt β-sheets of 
amyloid aggregates (Schuster et al., 2005) and exert several other bioactive 
properties  including neuroprotection in AD (Bilikiewicz and Gaus, 2004). It is 
suggested that other exogenous peptides, perhaps dietary sources, with 
aggregate inhibition capacity might be also be protective against AD and other 
amyloidogenic diseases (Balch et al., 2008; Powers et al., 2009). The SPE 
product prepared from bovine whey proteins described in this study appears to 
be of very similar but not identical composition to Colostrinin (Figure 1B), 
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probably reflecting differences in respective host materials and the processing 
method used to produce the SPE product.  
 
4.5.1 Inhibition of Aβ42 oligomerization and toxicity by SPE 
 
CD and FTIR spectroscopy were used for studying the modulation of 
secondary structure of Aβ42, with FTIR results permitting evaluation of the ratio 
of anti-parallel (oligomer) to parallel (fibril) β-sheet content (Cerf et al., 2009) 
(Sarroukh et al., 2010). FTIR monitoring of Aβ42 self-assembly in the presence 
of SPE product indicated that the Aβ42-SPE mixtures contained structures of 
net lower β-sheet content and specifically lower anti-parallel β-sheet (Figure 3). 
Analysis by TEM (Figure 4) and Western blot analysis (Figure 5) clearly showed 
that SPE inhibited Aβ42 oligomerization, supporting previous data from CD and 
FTIR studies.  The concomitantly protective effects against Aβ42 toxicity in 
yeast and neuronal cells (Figure 6B, C), were clearly evident. The pattern of 
loss of high mass oligomers of Aβ42 and associated toxicity was very similar to 
that seen in the presence of curcumin (Yang et al., 2005). Low mass ratio of 
SPE to Aβ42 showed enhanced toxicity in yeast (Figure 6B). However, the 
„promotion of toxicity‟ was not present for neuronal cell studies or detected by 
CD or FTIR studies. This observation reflects the sensitivity of the methods and 
the possibility that different Aβ isoforms might possess differentiated toxicity 
profiles in yeast compared with neuronal cells. There is a possibility that the 
„enhanced‟ toxicity observed (Figure 6B), is a result of SPE (at lower 
concentrations) induced formation of „off pathway‟ toxic soluble complexes with 
Aβ42.  
 
Overall, a positive correlation between suppression of β-sheet content and 
oligomerization by SPE fractions (Figures 2-5) and protection against Aβ42-
mediated toxicity to both yeast and neuronal cells (Figure 6) was observed. 
Collectively, these results provide important evidence that suppression of anti-
parallel β-sheet structures can prevent formation of oligomeric structures linked 
with toxicity.  The lack of toxicity of a mutant form of Aβ12-28 (Peralvarez-Marin 
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et al., 2009), in contrast to Aβ25-35 and related variants (Pike et al., 1995) , in 
spite of the presence of aggregates characterised by having β-sheet secondary 
structure, further supports these observations.   
The Aβ structure modulating properties of the dairy derived peptides (SPE 
fractions) demonstrated in this study implicate them as interesting candidates 
for identifying novel inhibitors of Aβ oligomerization and toxicity. Further 
characterization of the SPE product mixture aided by cleaner and better 
resolved preparations is necessary to isolate specific peptides which are 
responsible for anti-Aβ activity. However for future therapeutic application, it will 
be essential to determine whether these dietary peptide preparations can 
survive gut enzymatic degradation and if they will be able to cross the blood 
brain barrier.  
 
4.6    Summary: 
 
A number of molecular species have been shown to act as chaperones and 
thereby regulate the folding pathway of Aβ42. In many cases, the toxicity of 
products is differentiated from unchaperoned Aβ42, usually attenuated. Thus, 
„chaperones‟ of Aβ42 represent obvious molecules for development into 
disease-modifying therapeutics, if in vitro bioactivities can translate to protective 
effects in vivo.  These results demonstrate the important finding that 
suppression of anti-parallel β-sheet structures is specifically required for 
regulation of oligomer toxicity to cells. In addition to inhibition and disruption of 
Aβ42 oligomers, the SPE dairy peptide product may display other useful 
neuroprotective properties as shown for Colostrinin. It is unknown the extent to 
which dietary factors already play a role in chaperone-mediated modulation of 
Aβ42 toxicity in vivo, if at all, however, based on in vitro properties, it is possible 
that a wide range of adequately bio-available dietary peptides and 
phytochemicals might contribute to neuroprotection by chaperone-mediated 
activity. 
 
 
138 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5  
Oligomerization and Toxicity of 
MBP-Aβ fusion proteins 
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5.1     Introduction: 
 
A substantial amount of structural and functional information of Aβ comes 
from studies using synthetically derived Aβ produced by solid phase peptide 
synthesis (SPPS). Although synthetic Aβ has been widely used for variety of 
experimental purposes, the preparation and handling of the peptide solutions 
have not been very straightforward. In addition to its intrinsic heterogeneous 
and variable nature, substantial compositional differences and intrinsic 
impurities in Aβ produced by SPPS resulting in experimental irreproducibility 
has been reported (Dobeli et al., 1995; Howlett et al., 1995; Simmons et al., 
1994; Soto et al., 1995a; Soto et al., 1995b; Zagorski et al., 1999). In addition, 
aggregation kinetics and toxicity of synthetic Aβ have been reported to fluctuate 
between different batches and also with storage and solubilisation conditions 
(Soto et al., 1995b). 
 
 The in-vitro solubility and aggregation properties of the Aβ peptide are 
found to be dependent on the pH environment, temperature, peptide 
concentration, incubation times (Burdick et al., 1992; Stine et al., 2003), 
hydrostatic pressure (Foguel et al., 1999) and other local interacting factors 
including metals, lipids and other proteins [reviewed in (Bharadwaj et al., 2009)]. 
However, the precise molecular interaction leading to the formation of the toxic 
Aβ oligomers have not been completely understood.  Several papers report 
methods to produce Aβ oligomers from synthetic Aβ (Barghorn et al., 2005; 
Lambert et al., 1998; Lambert et al., 2001; Stine et al., 2003) but the 
preparations differ in the sizes of oligomers, and stability and even 
reproducibility can be an issue (Brining, 1997).   
 
In addition to synthetic Aβ (SPSS derived), recombinantly produced Aβ 
proteins have also been reported. Recombinantly–derived Aβ present 
significant advantages comparing SPSS synthesized Aβ mainly for the reason 
that primary structure changes are rare because of the high fidelity of the 
cellular expression systems and the physiological conditions under which these 
140 
 
operate. Moreover recombinant production is more cost effective than SPSS 
synthesis for large scale manufacture. There are several studies reporting 
methods for recombinant production of Aβ in different cellular systems (Dobeli 
et al., 1995; Hortschansky et al., 2005; Lee et al., 2005; Li et al., 2009; Luhrs et 
al., 2005; Sharpe et al., 2005; Subramanian and Shree, 2007; Walsh et al., 
2009; Wiesehan et al., 2007). However, most of the existing methods either 
yield low amounts or require enormous efforts for purification. More importantly, 
a majority of these studies have not established the toxic properties of the 
recombinantly derived Aβ. Caine et al 2007 described a novel method for 
producing Aβ as an N-terminal fusion to maltose binding protein (MBP). In this 
methods, the maltose binding protein tagged Aβ42 (MBP-Aβ42) fusion protein 
could be stably produced in large quantities, purified easily using affinity 
columns and showed properties (binding to Cu and Zn) similar to Aβ peptide 
(Caine et al., 2007b). However, the toxic properties of these MBP-Aβ fusions 
have not been determined.  
 
Toxicity of synthetically derived Aβ oligomers has been established in 
yeast cells (Bharadwaj et al., 2008). In chapter 3 it was shown that oligomeric 
Aβ was more toxic than the non-oligomerizing Aβ peptide in yeast and neuronal 
cells. In chapter 4, it was shown that inhibition of Aβ oligomerization using dairy 
derived peptides (SPE fraction) suppressed its toxicity both in yeast and 
neuronal cells. In this chapter, the MBP-Aβ fusion proteins were studied in the 
yeast model where their toxicity was demonstrated.  Furthermore the toxicity of 
the MBP-Aβ fusion proteins was also observed in neuronal cells. 
 
5.2     Aims: 
 
1.) Purification and characterization of MBP-Aβ fusion proteins 
2.) Determine the toxicity of MBP-Aβ fusion proteins in yeast and neuronal cells. 
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5.3     Materials and Methods: 
 
Purification of MBP, MBP-Aβ16 and MBP-Aβ42 fusion proteins were done as 
described in Section 2.2.3. The MBP fusion proteins were harvested in bacteria 
followed by purification via affinity chromatography using an amylose column 
and analysis by size exclusion chromatography (superdex-200 gel filtration 
column) as described in Section 2.2.3. The purified fusion proteins were 
characterized using SDS-PAGE followed by western blotting analysis and 
coomassie staining. Volume analysis of the protein gel bands was done using 
the Quantity-1D analysis software. The fusion proteins were studied using 
Transmission electron microscopy (TEM) and Dynamic light scattering (DLS) 
(Jo Caine, CSIRO) as described in Section 2.2.9. Toxicity of purified MBP, 
MBP-Aβ16 and MBP-Aβ42 fusion proteins were tested in yeast cells and 
primary mouse cortical cells by colony count and CCK-8 assays respectively as 
described in Section 2.2.4.3 and Section 2.2.4.6 respectively.  
 
5.4      Results: 
5.4.1 Purification and characterisation of MBP-Aβ42 fusion protein 
 
MBP fusion variants were expressed and purified from E. coli and 
analysed by SDS-PAGE followed by coomassie staining (Figure 1A) and 
western blot analysis using anti-Aβ (WO2) (Figure 1B) and anti-MBP (Figure 
1C). The molecular mass estimated from the SDS PAGE analysis were found to 
be to be 39.6 kDa for MBP, 42.6 kDa for MBP-Aβ16, and 45.7 kDa for MBP-
Aβ42. In addition, the proteins exhibited no breakdown products. The MBP-
Aβ42, under non-reducing conditions, demonstrated additional higher molecular 
weight bands, corresponding to sizes ~97 kDa (dimer), ~135 kDa (trimer), ~160 
kDa (tetramer), and ~235kDA (hexamer) (Figure 1B, C). Volume analysis of 
these bands showed the monomeric band to be the major species on the gel 
(~71% of the total protein) followed by tetramers, hexamers, dimers and trimers 
(~19%, 6%, 3% and 1% of total protein respectively). The shorter MBP-Aβ16 
fusion shows ~94% of the total protein in the lane made up of a monomeric 
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band at 42 kDa and a faint dimer band (~6%) (Figure 1B, C).  
 
The MBP-Aβ fusion proteins were further studied by size exclusion 
chromatography using a superdex-200 gel filtration column (performed by Jo 
Caine). The gel filtration profile of the concentrated peaks eluted from the 
amylose affinity column showed two major peaks plus a small peak for MBP-
Aβ42 (Figure 1D). The S200 profile of MBP-Aβ16 protein showed one main 
peak and a small peak (Figure 1E). Interestingly, purified peaks collected and 
left at 4oC for 1 week or more reproduced the original profile of three peaks 
when re-run on the S200 column. The results from the SDS-PAGE western 
blotting and size exclusion chromatograph showed that MBP-Aβ42 formed 
higher oligomeric structures compared to MBP-Aβ16. To further analyse their 
structure, the MBP-Aβ proteins were observed by transmission electron 
microscopy (TEM).  
 
 
A B C
1     2      3      4 1     2      3      4 1     2     3     4
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Figure 1: SDS-PAGE Western blotting and gel filtration profiles of MBP-
Aβ42 and MBP-Aβ16. 
MBP-Aβ samples (5µg) were run on a 4-12% Bis-Tris gel in a MES buffering 
system and coomassie stained (A).  For immunoblotting, MBP-Aβ samples 
(0.5µg) were run on identical gels, transferred to nitrocellulose membranes and 
probed with anti-Aβ (WO2) (B) and anti-MBP (C) antibodies and visualised 
using chemiluminescence. Lane loadings as follows: Lane 1 = molecular weight 
markers, Benchmark (A) and Precision Western C (B and C); Lane 2 = MBP; 
Lane 3 = MBP-Aβ16 and Lane 4 = MBP-Aβ42. Samples from the amylose 
affinity column were concentrated on a spin concentrator (10kDa MWCO) and 
fractionated using Superdex-200 gel filtration column equilibrated in 50mM Tris 
pH8.0 at 0.5ml/min. Absorbance was monitored at 280nm.  The plots of the 
S200 gel filtration profile show profiles of MBP-Aβ42 (D) and MBP-Aβ16 (E).   
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5.4.2 Transmission electron microscopy of MBP-Aβ fusion 
proteins 
 
Samples from the MBP-Aβ fusion proteins (MBP, MBP-Aβ16 and MBP-
Aβ42) were analysed by TEM (Figure 2). The electron micrographs showed that 
the MBP control and MBP-Aβ16 proteins had small globular structures of 5-9nm 
in diameter (Figure 2A and 2B respectively). However, MBP-Aβ42 showed large 
amorphous globular structures ranging from 11-16 nm in diameter in addition to 
globular structures of 5-9nm in the TEM (Figure 2C). However no fibrillar 
structures were seen in any of the fusion protein preparations. TEM analysis of 
the MBP-Aβ fusion proteins showed that MBP-Aβ42 formed larger amorphous 
structures compared to smaller globular structures found in MBP-Aβ16 and 
MBP solutions. The results supported the previous observations from SDS-
PAGE immunoblotting and size exclusion chromatography analysis indicating 
that MBP-Aβ42 can form higher oligomeric structures (Figure 1). To determine 
the size distributions of these oligomeric structures, the MBP-Aβ fusion proteins 
were analysed by dynamic light scattering (DLS). 
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Figure 2: Electron micrographs of MBP-Aβ solutions.  
The MBP-Aβ fusion proteins (MBP, MBP-Aβ16 and MBP-Aβ42) were applied to 
carbon coated copper grids which were glow-discharged in nitrogen. After the 
application of uranyl acetate, the grids were examined by TEM.  MBP (A) and 
MBP-Aβ16 (B) contain species mainly 5-9nm in size; whereas MBP-Aβ42 (C) 
contains species 11-16 nm in size and 5-9nm range.  
 
5.4.3 Dynamic light scattering analysis of MBP-Aβ fusion proteins 
 
The size distribution of MBP-Aβ fusion proteins (MBP and MBP-Aβ42) in 
solution were analysed by Dynamic light scattering (DLS) (performed by Jo 
Caine). DLS of MBP and MBP-Aβ42 (~0.8mg/ml) proteins were performed 
using the DynaProTM NanoStar plate reader at laser wavelength 830nm. The 
particle size of MBP and MBP-Aβ42 fusion proteins in solution were 
represented as hydrodynamic radii (Rh) and radius of gyration (Rg) which were 
calculated as described in Section 2.2.9.1. The size distributions of the particles 
were determined on the basis of modality and dispersity. Modality refers to the 
number of „peaks‟ in the size distribution and dispersity is a measure of 
heterogeneity or homogeneity of the species comprising the population. 
 
MBP was found to be a monomodal monodispersed species with an 
average hydrodynamic radius (Rh) of 2.8 ± 0.3 nm (Figure 3A).  The radius of 
gyration for MBP calculated from the available crystal structure was found to be 
Rg = 2.07 nm.  This would be converted to an Rh =Rg/0.77=2.69 nm which was 
very close to the experimental Rh value for MBP. The DLS data collected for 
MBP-Aβ42 showed that the sample was monomodal polydispersed, indicating 
the presence of different forms of MBP-Aβ42. The Rh for the most abundant 
species of MBP-Aβ42 was determined to be 8.8 ± 0.5 nm (Figure 3B) with a 
range of radii between 3-100 nm. The polydiversity of the MBP-Aβ42 peaks 
indicated that there is a range of oligomeric species present. This result 
supported the previous data from SDS-PAGE, size exclusion chromatography 
(Figure 1) and TEM analysis (Figure 2) indicating that MBP-Aβ42 forms 
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oligomers whereas the MBP alone remained largely monomeric in physiological 
aqueous solutions. 
 
 
Figure 3:  DLS measurements of MBP & MBP-Aβ42 
The dynamic light scattering plot is representative of the average of 40 
individual 5 sec DLS collections for 3 separate dilutions of the MBP (A) and 
MBP-Aβ42 (B).  The results indicate a monomodal monodisperse species in 
MBP with hydrodynamic radii of 2.8 ± 0.3 and monomodal polydisperse in MBP-
Aβ42 (B) with a hydrodynamic radii range 3–100 nm with a peak at 8.8 ± 0.5.   
A
B
Radius (nm)
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5.4.4 Toxicity of MBP-Aβ fusion proteins in yeast and neuronal 
cells: 
 
The previous data showed that MBP-Aβ42 formed oligomers whereas 
MBP alone and MBP-Aβ16 remained largely monomeric. Further, the toxicity of 
these fusion proteins were determined in yeast and subsequently validated in 
mouse primary cortical neuronal cultures. The toxic effects of the MBP-Aβ 
fusion proteins was determined using a colony forming unit (CFU) count assay 
after treatment in yeast (Bharadwaj et al., 2008). The full length MBP-Aβ42 was 
significantly toxic while MBP-Aβ16 and MBP alone were not. At a concentration 
of 22µM, MBP-Aβ42 caused 50% loss of yeast cell viability, compared to less 
than 5% cell death with MBP-Aβ16 treatment, while MBP alone was not toxic 
(Figure 4A). Untreated yeast cells were exposed to 10mM maltose/20mM 
Tris/HCl vehicle buffer alone. In addition, the MBP-Aβ42 protein mediated 
toxicity was dose dependent with 25% cell death seen at 10μM and a 3-fold 
higher 75% cell death measured at concentration of 44μM (Figure 4B). 
  
Having confirmed that the MBP-Aβ42 fusion protein was toxic in yeast, 
the toxicity of the MBP-Aβ fusion proteins was determined in mouse primary 
cortical neuronal cultures treated with 30µM of different isoforms of MBP-Aβ for 
4 days. Cell viability was determined by CCK-8 assay. The CCK-8 assay uses a 
tetrazolium dye (WST-8, 2-(2-methoxy-4-nitrophenyl)-3- (4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt) which is reduced to a yellow 
colored product (formazan) by dehydrogenases in cells. The amount of the 
formazan dye generated was determined to measure viability following 
treatment (Zhang et al., 2010a). Vehicle treated cells were exposed to 10mM 
maltose/20mM Tris/HCl buffer alone. Treating the cortical cultures with MBP-
Aβ42 caused a significant reduction (25% loss) in cell viability (Figure 4C).  In 
contrast, the MBP-Aβ16 fusion and MBP control proteins did not display any 
neurotoxicity at the same concentration tested (Figure 4C). Overall the data 
showed that MBP-Aβ42 was more toxic than MBP and MBP-Aβ16 proteins in 
both yeast and neuronal cells. 
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Figure 4: Toxicity of MBP-Aβ proteins in yeast and neuronal cells 
Yeast cells were treated with 22µM MBP, MBP-Aβ16 and MBP-Aβ42 proteins. 
Untreated cells were exposed to 10mM maltose/20mM Tris/HCl vehicle buffer 
alone.  Following treatment, cell viability was determined by counting the 
number of colonies formed (A). 22µM MBP-Aβ42 caused significant loss of 
yeast cell viability (50%, **p<0.0001) compared to less than 5% cell death with 
MBP-Aβ16 treatment, while MBP alone was not toxic. Yeast cells were treated 
with increasing concentrations of MBP-Aβ42 fusion protein (5-44µM) (B). A 
dose dependent increase in cell death was seen with MBP-Aβ42 treatment 
(**p<0.0001, *p<0.01). Primary cortical neurons were treated with 30µM MBP, 
MBP-Aβ16 and MBP-Aβ42 proteins for 4 days (C). Vehicle treated cells were 
exposed to 10mM maltose/20mM Tris/HCl buffer alone.  Following treatment, 
cell viability was determined by CCK-8 assay.  30µM MBP-Aβ42 caused 
significant loss of cell viability (25%, *p<0.01) while MBP-Aβ16 and MBP were 
not toxic. Data is presented as mean +/- SEM, n=4 per treatment group.  
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5.5      Discussion: 
 
Similar to naturally derived forms, Aβ42 prepared from synthetic lyophilized 
peptides have shown to form multiple forms ranging from monomeric, 
oligomeric, fibrillar and many more other multimeric structures and show 
neurotoxic properties. Various methods are also available to prepare oligomeric 
Aβ from synthetic Aβ peptides including filtration using low molecular weight 
cut-off filters (Bitan and Teplow, 2005), treatment of lyophilized Aβ with strong 
acids and bases to disrupt pre-formed aggregates (Stine et al., 2010; Zagorski 
et al., 1999), photo-induced crosslinking (Bitan et al., 2003), density gradient 
centrifugation (Ward et al., 2000) and size exclusion chromatography (SEC) 
(Lambert et al., 1998; Walsh et al., 1997).  
 
However, the above methods for preparing Aβ oligomers involve tedious 
purification work and high costs for pure lyophilized peptides stocks. Although 
well suited for studies involving physiological level analysis (requiring 
nanomolar concentrations), such methods for Aβ oligomer preparations are not 
suitable for larger scale purposes required for physicochemical and structural 
analysis. Therefore recombinantly produced Aβ can be beneficial for such high 
throughput screening methods. It is however essential to characterize the 
structural and functional properties of such recombinantly derived Aβ. 
Previously, (Caine et al., 2007b) described a method for producing large 
quantities of soluble MBP tagged Aβ fusion protein using a bacterial expression 
system. In this chapter, the oligomerization and the toxicity of these 
recombinantly produced MBP-Aβ fusion proteins were studied to enable further 
characterization of these fusion proteins. The structural characteristics of the 
MBP-Aβ fusion proteins were studied using a variety of techniques. Further, the 
toxicity of the MBP-Aβ fusion proteins was determined in yeast and neuronal 
cells. 
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5.5.1 Oligomerization of MBP-Aβ42 
 
The structural characteristics of MBP-Aβ fusions were studied using SDS-
PAGE, size exclusion, TEM and DLS analysis. The MBP-Aβ42 fusion protein 
was shown to form SDS stable higher molecular weight oligomeric structures 
corresponding to dimers (~97 kDa), trimers (~135 kDa) tetramers (~160 kDa), 
and hexamers (~ 235 kDa) (Figure 1). MBP-Aβ16 solutions were found to 
contain a faint band at ~97kDa which also corresponded to the small peak 
found by size exclusion (gel filtration analysis) (Figure 1). This indicated the 
presence of a possible dimer species, which formed ~6% of the total protein, as 
measured by band volume analysis (Figure 1). However, no higher molecular 
weight structures (trimers, tetramers and hexamers) could be found in MBP-
Aβ16 solutions similar to that present in MBP-Aβ42. TEM and DLS analysis 
further showed that the particle sizes present in the MBP-Aβ42 solutions were 
bigger and morphologically different compared to those in MBP and MBP-Aβ16 
proteins (Figure 2, 3). DLS analysis also showed that the size ranges of the 
particles in MBP-Aβ42 solutions are monomodal polydispersed. This showed 
that MBP-Aβ42 contained a mixture of particles derived from a single 
monomeric form, which suggested that the solutions contained a mixture of 
monomeric and oligomeric forms (Figure 3). However MBP had a monomodal 
monodispersed population indicating that the majority of the solution contained 
monomers. Overall the data indicated the presence of oligomeric forms in MBP-
Aβ42 solutions.  
 
In addition to its nature of forming oligomers, the MBP-Aβ42 fusion was 
stable. Size exclusion, TEM and DLS results indicated that this fusion protein 
does not form fibrils but small oligomers which maintain species equilibrium on 
the removal of higher oligomers. The major SDS stable oligomeric species from 
the gel electrophoresis and DLS measurements appear to be multimeric 
species up to hexamers. In the literature, the toxic state of the Aβ peptide has 
been variously ascribed to multimers ranging from dimers to dodecamers 
(Barghorn et al., 2005; Singh et al., 2002; Walsh et al., 2002a). The absence of 
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higher molecular weight (greater than hexamers) or fibrillar forms in MBP-Aβ42 
may be due to lower self-association propensity of MBP-Aβ42 compared to 
Aβ42 due the attached MBP fusion protein. Higher oligomers of the MBP-Aβ42 
are prevented from forming most likely due to steric clashes from the much 
larger globular part of the fusion protein. This has been clearly shown in the 
crystallographic study of MBP fusion with a T-cell leukemia virus type 1 gp21 
ectodomain (Kobe et al., 1999) where the 31 amino acid gp21 fusion peptide 
forms a trimer while possible higher oligomers were prevented from forming due 
to the close proximity of the globular MBP protein.  
 
5.5.2 Toxicity of MBP-Aβ42 
 
The toxicity of these different fusions was determined in yeast and also in 
neuronal cells to establish their functional nature. MBP-Aβ42 was found to be 
significantly more toxic than MBP-Aβ16 and MBP in both yeast and neuronal 
cells. Moreover MBP-Aβ42 showed a dose-dependent response on yeast 
viability (Figure 4). However, MBP-Aβ42 was found to be less toxic compared to 
Aβ42 peptide in mammalian cell lines (Hung et al., 2008) and  also in yeast 
[Chapter 3, (Bharadwaj et al., 2008)]. It is likely that the steric hindrance from 
the much larger globular part of the fusion protein (MBP) may contribute to 
reduced toxicity. The inability to form higher molecular weight structures 
(greater than hexamer) may also contribute to its reduced toxicity compared to 
Aβ42 in cells.  
 
Although it is widely accepted that soluble oligomeric forms of Aβ42 are the 
main toxic species in the AD brain, no particular Aβ species has been identified 
as the main cause of neuronal dysfunction and death. (Lesne et al., 2006) study 
implicated a unique and a novel Aβ isoform (Aβ*56: 56-kD soluble Aβ42 
assembly, dodecamer) as the key neurotoxic Aβ42 species responsible for 
cognitive decline. However, a more recent study (Shankar et al., 2008) has 
identified Aβ dimers from the soluble extract of AD cerebral cortex tissues as 
the main toxic isoform. Both Lesne et al and Shankar et al studies identify 
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different toxic Aβ species (dimer or Aβ*56), which might reflect differences in 
the Aβ detection techniques employed. Alternatively, it is also suggested that an 
array of soluble oligomeric Aβ species (ranging from dimers to dodecamers) 
may have neurotoxic properties associated with memory impairment in AD. The 
MBP-Aβ42 toxicity data shown here supports the notion that oligomer Aβ42 
mediated cell death can be a collective contribution of a variety of toxic isoforms 
and not mediated by a single isoform. Compared to Aβ42, MBP-Aβ42 solutions 
lacked higher oligomeric forms (greater than hexamers) which only reduced its 
toxicity and did not rescue it completely. The reduced toxicity of MBP-Aβ42 
solutions could therefore represent the absence of the toxic higher oligomeric 
forms. In addition, due to its MBP fusion partner, it is also quite likely that the 
oligomers formed by MBP-Aβ42 are structurally different compared to the 
natural Aβ42 oligomers which further suggests that different oligomeric 
structures of Aβ42 can be toxic. Due to its nature of maintaining species 
equilibrium, it was difficult to unequivocally attribute the toxicity to the oligomeric 
MBP-Aβ42 isoforms. Further investigation using stable cross-linking analysis of 
the MBP-Aβ42 oligomeric species can provide a better idea of the contribution 
of different isoforms to toxicity and cell death.   
 
5.6    Summary 
 
Overall the data presented here shows that MBP-Aβ42 forms oligomers 
and is a stable protein. The oligomer forming MBP-Aβ42 protein was also found 
to be toxic in yeast and neuronal cells. It is therefore a well suited model for 
structural elucidation and physicochemical studies of smaller Aβ oligomers 
(Caine et al., 2011). The MBP-Aβ42 fusion protein could also be a potential tool 
for analysing the toxicity of Aβ42.  In addition, it provides the opportunity of 
developing assays for screening potential inhibitors of Aβ oligomer induced 
toxicity.  
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Chapter 6 
Effect of Aβ42 Induced Cell 
Division in Yeast is Restricted 
to Stationary Phase  
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6.1     Introduction: 
 
There is now strong evidence to show abnormal activation of cell cycle 
events in the regions of the brain that are susceptible to neurodegeneration in 
AD (Husseman et al., 2000; Yang et al., 2003). Increased levels of cell cycle 
proteins (Ding et al., 2000; Vincent et al., 2001) and mitotic signalling 
phosphoepitopes (Chang et al., 2002; Li et al., 2005; Li et al., 2004) have also 
been observed in degenerating hippocampal neurons of AD brains.  
 
A number of studies have shown that Aβ42 treatment (both fibrillar and 
oligomer) can induce neuronal cell cycle events via mTOR/MAP kinase 
pathways in neurons (Bhaskar et al., 2009; Frasca et al., 2004; Malik et al., 
2008; Varvel et al., 2008; Wu et al., 2000) and associated toxicity via activation 
of protein kinase R (PKR) through calcium signalling and caspase 8 activation 
(Suen et al., 2003). A recent study also showed that long-term inhibition of 
mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of 
Aβ42 in the PDAPP transgenic mouse model (Spilman et al., 2010). 
 
In contrast, other studies show a significant decrease in p-mTOR and p-
p70S6K (serine/threonine kinase) levels in differentiated neuroblastoma cells 
(N2a. SH-SY5Y cells) treated with Aβ42 (Lafay-Chebassier et al., 2005; Lafay-
Chebassier et al., 2006). A recent study also showed correlation between the 
inhibition of mTOR signalling and impairment in synaptic plasticity in 
hippocampal slices from an AD mouse model and also with Aβ42 treatment (Ma 
et al., 2010b). One possible explanation for the conflicting findings observed 
with modulating mTOR signalling by Aβ42, is that neurons have different 
response patterns to Aβ42 treatment depending on their cell cycle and 
availability of neurotrophic factors. However it is unclear whether Aβ induced 
growth or toxic effects in neurons are dependent on the cell cycle. 
 
Investigating Aβ42 induced cell cycle events in neurons can be problematic 
and unreliable. One problem is that neurons of the adult brain are terminally 
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differentiated and lack the capacity to divide in vivo and in vitro, (McShea et al., 
1999). Also, re-activation of cell cycle machinery in post-mitotic neurons can 
lead to cell loss (Feddersen et al., 1992; Park et al., 2007). Moreover Aβ42 is a 
known neurotoxic protein. Therefore this poses a challenge to dissect the toxic 
and trophic properties of Aβ42 in neurons. A particular advantage of studying 
cell cycle in yeast cells compared to neurons is their robust nature. Cell cycle 
can be physiologically modulated effectively by nutrient limitations without loss 
of viability and they can survive prolonged periods in starvation, which makes it 
a very useful model for studying Aβ induced effects (Lillie and Pringle, 1980). 
Moreover, Aβ42 has been shown to be toxic in yeast cells [Chapter 3, 
(Bharadwaj et al., 2008)] which will enable differentiating the biphasic properties 
of Aβ42.  
 
In the studies presented in this chapter, I determined whether Aβ42 can 
induce cell division in yeast cells within the stationary phase of the cell cycle 
and assessed the role of mTOR signalling in this process. 
 
6.2     Aims: 
 
1) Induce entry of yeast cells into the stationary phase of cell growth by nutrient 
starvation 
2) Determine if Aβ42 can promote proliferation of cells within the stationary 
phase of cell growth and whether this can be blocked by inhibition of mTOR by 
rapamycin. 
 
6.3    Materials and Methods: 
 
Candida glabrata cells and Saccharomyces cerevisiae (BY4743) grown in 
YNB+2% glucose (no amino acids) and YNB+2%glucose (-Trp) respectively 
were used for this study. For inducing stationary phase, cell division was 
inhibited via starvation in media lacking essential nutrients (non-fermentable 
carbon source) as described in Section 2.2.10. Aβ42 peptide was prepared as 
158 
 
described in Section 2.2.4.1 and used to treat yeast cells as described in 
Section 2.2.11. Stationary phase cells were treated with Aβ42 (in the presence 
or absence of 0.2µM rapamycin). 
 
6.4       Results: 
6.4.1 Starvation induced entry of yeast cells into a stationary 
growth phase: 
 
To induce starvation, yeast cells (Candida glabrata) were incubated in 
YNB+2% or 0.1% glucose or starved in non growing media (YNB+ non-
fermentable carbon source i.e. 2% ethanol, 2% maltose, 2% Glycerol) for 6-7h 
at 30°C. Following incubation, the cell density (OD at 600nm) at different time 
points was measured. In addition, the morphology of the cells was studied by 
flow cytometry using forward scatter (FSC) analysis (Tzur et al., 2011) and light 
microscopy. These results are shown in Figure 1. An increase in cell density 
was observed in cells incubated in YNB+2%glucose compared to YNB+ other 
non-fermentable carbon sources (Figure 1A). Forward scatter analysis for cell 
volume showed that cells incubated in YNB+2% glucose showed increased cell 
volume (Figure 1B) indicative of active metabolism. Also the actively growing 
cells were distributed across a size range of 3-8μm (Figure 1C). Whereas cells 
incubated in YNB+2% maltose showed no increase in cell volume (Figure 1D) 
and were distributed over a size range of 2-4μm (Figure 1E). Microscopic 
analysis of cells incubated in YNB+2% glucose showed active budding [(Figure 
1F), indicative of cell division in yeast] (Mortimer and Johnston, 1959) whereas 
cells incubated in YNB+2% maltose showed no budding (Figure 1G). Overall 
the data showed that starvation in non-growing media induces entry into 
stationary phase in yeast. Cells in exponentially and stationary phase were 
used for subsequent experiments 
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Figure 1: Nutrient starvation inhibits cell division and induces stationary phase 
in Candida glabrata cells. Exponentially growing Candida glabrata cells in YNB+ 
2% glucose were washed and incubated in YNB containing different carbon 
sources (2% glucose, 0.1% glucose, 2% ethanol, 2% maltose or 2% glycerol). 
Cell density at 600 nm was measured at different time points (0-7 h) (A). Cells 
incubated in YNB+2% glucose and YNB+2% maltose were analysed by forward 
scatter analysis (B, D) and size distributed (C, E) using flow cytometry (FACS). 
The cells were also analysed by bright field microscopy (F, G). Cells incubated 
in YNB+2% glucose showed increasing cell density and active budding 
indicating growth, however, cells incubated in other carbon sources showed no 
increase in cell density, no budding and reduced cell size indicating entry into 
stationary phase. 
 
6.4.2 Aβ42 induced cell division in starved cells:  
To determine the effects of Aβ42 on cell growth, Candida glabrata cells in 
stationary phase and exponential phase were treated with Aβ42. Candida 
glabrata cells incubated in YNB+ 2% glucose and YNB+ 2% maltose for 7h 
were treated with vehicle or 5μM Aβ42 for 20h at 30°C. Following treatment the 
cells were spread on YEPD media plates. Images of media plates from the 
5µm 5µm
F GYNB+2%glucose YNB+2%maltose
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viable count assay are showed in Figure 2A-D. Aβ42 induced cell death in 
exponential phase cells (grown in YNB+2% glucose) is indicated by the 
decrease in the number of colonies compared the untreated (Figure 2A, B). In 
contrast, Aβ42 induced growth in stationary phase cells (incubated in YNB+2% 
maltose) is indicated by the increase in the number of colonies compared to the 
vehicle treated (Figure 2C, D).  
Quantitative analysis of Aβ42 induced cell division in stationary phase cells 
was determined by colony forming unit (CFU) count. Candida glabrata cells 
incubated in YNB+ different carbon sources (2% glucose, or 0.1% glucose, 2% 
maltose or 2% glycerol) for 7h were treated with vehicle or 5μM Aβ42 for 20h at 
30°C. Exponential phase cells (YNB+2% glucose) showed marked loss of 
viability (25-30% viable) with Aβ42 treatment, compared to vehicle (Figure 2E). 
This level of reduction is similar to that shown in Chapter 3 and as previously 
reported (Bharadwaj et al., 2008). However, treating cells in stationary phase 
(YNB+0.1% glucose, 2% maltose or 2% glycerol) with Aβ42 caused a 
significant increase in the number of colonies (200-250%) indicating an increase 
in cell division (Figure 2E).     
To determine if lower doses of Aβ42 could significantly increase cell division, 
cells in stationary or exponential growth phases were treated with vehicle or 
0.1-5µM of Aβ42. Cells were also treated with 20 and 50µM of Aβ42 to 
determine if higher levels were toxic. The results are shown in Figure 2F. A 
dose-dependent decrease in the number of colonies with Aβ42 treatment was 
observed in exponential phase cells indicating loss of viability. In stationary 
cells, a significant increase in the number of colonies was observed from 
concentrations of 100nM (~150%) up to a maximum of ~200-250% increase at 
2-5μM. However at, higher concentrations of Aβ42 (≥20μM), cell viability 
decreased in both exponential growing and stationary phase cells (Figure 2F). 
These results indicate that Aβ42 can promote proliferation only in cells that are 
in the stationary phase at doses that are otherwise toxic to exponentially 
growing cells. Overall the data above indicates that Aβ42 may induce mitotic 
cell division in Candida glabrata promoting cell proliferation. An essential 
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pathway for cell cycle progression and proliferation in eukaryotes is the mTOR 
signalling pathway (Hay and Sonenberg, 2004). To determine if this signalling 
pathway has a role in Aβ42 induced cell division stationary phase growing cells 
were treated with Aβ42 in the absence or presence of mTOR inhibitor, 
rapamycin. 
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Figure 2: Aβ42 induces cell division in stationary phase yeast cells 
Candida glabrata cells incubated in YNB+ 2% glucose and YNB+ 2% maltose 
for 7h were treated with vehicle or 5μM Aβ42 for 20h at 30°C. Following 
treatment the cells were spread on YEPD media plates. Images of yeast media 
plates showing Aβ42 caused cell death (decrease in number of colonies) in 
exponentially growing cells (YNB+2% glucose) (A, B) and cell division (increase 
in number of colonies) in stationary phase cells (YNB+2% maltose) (C, D) after 
a 20h treatment at 30°C are shown. Quantitative analysis of Aβ42 induced cell 
division in stationary phase cells was determined by colony forming unit (CFU) 
count. Exponentially growing Candida glabrata cells were incubated in YNB+ 
different carbon sources (2% glucose, or 0.1% glucose, 2% maltose or 2% 
glycerol) for 7h followed by Aβ42 (5µM) treatment for 20h. Cell viability was 
measured by the number of colonies (CFU) and expressed as percent change 
compared to untreated control (E). Aβ42 caused significant cell death in yeast 
grown in YNB+2% glucose (**p<0.001). However, a significant increase in cell 
division with Aβ42 treatment was observed in cells grown in other carbon 
sources (0.1% glucose, 2% maltose or 2% glycerol, ##p<0.001). To determine 
effects of low concentrations of Aβ42, cells incubated for 7h in YNB+2% 
glucose and YNB+2% maltose were treated with increasing concentrations of 
Aβ42 (0.05-5μM). A dose-dependent effect of Aβ42 induced loss of viability in 
cells grown in YNB+2% glucose and increased cell division in cells grown in 
YNB+2% maltose was observed (F) (*p<0.05, **p<0.001, ##p<0.001). However, 
at very high concentrations, Aβ42 was toxic in cells grown in YNB+2% maltose 
(**p<0.001). All data are represented as mean ± SEM (n=4). 
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6.4.3 Rapamycin suppressed Aβ42 induced cell division in yeast:  
Rapamycin is a macrolide which binds to FK-binding protein 12 (FKBP12) 
and inhibits the complex formation with mTORC1 thereby suppressing the 
downstream growth signalling pathway (Brown et al., 1994). It has been shown 
to inhibit G1 cell cycle progression via mTOR pathway in a variety of cell types 
including yeast at concentrations from 0.1-0.2µM (Heitman et al., 1991). To 
determine whether inhibition of mTOR signalling affects Aβ42 induced cell 
division, stationary phase yeast (Candida glabrata) cells were treated with 
increasing doses of Aβ42 (0.1-5µM) in the absence or presence of rapamycin 
(0.2µM) for 20h at 30°C followed by colony count.  
Compared to vehicle treated cells, treating cells with Aβ42 in the absence of 
rapamycin induced a dose-dependent increase in the number of colonies in 
stationary phase Candida glabrata cells (Figure 3). The number of colonies 
increased by ~125-150% on treatment with 0.1-0.5µM A reaching a maximum 
of ~200-250% increase at 2-5µM. However, in cells treated with Aβ42 in the 
presence of rapamycin, a significant decrease in the number of colonies 
compared to Aβ42 per se was observed (Figure 3). The inhibition of Aβ42 
induced cell division by rapamycin was significant at all concentrations of Aβ42 
tested (0.1-5µM). At lower concentrations of Aβ42 (0.1-0.5 µM) co-incubated 
with rapamycin, the number of colonies decreased to 80-90% compared to 
~125-150% with Aβ42 per se. However this decrease in cell number [Aβ42 (0.1-
0.5μM) +0.2μM rapamycin] was not significant compared to the untreated 
control (Figure 3). Overall rapamycin suppressed Aβ42 induced cell division in 
stationary phase yeast cells. To gain a better insight into the Aβ42 induced 
growth effect, Aβ42 peptide treatment was assessed in genetically diverse 
species Saccharomyces cerevisiae and Candida glabrata. 
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Figure 3:  Rapamycin treatment inhibited Aβ42-induced cell division in yeast 
Exponentially growing Candida glabrata cells were incubated in YNB+ 2% 
maltose for 7h to inhibit cell division and induce stationary phase. The stationary 
cells are co-incubated with rapamycin (0.2µM) and different concentrations of 
Aβ42 (0-5µM) for 20h at 30°C. Aβ42 induced cell division was determined by 
colony forming unit (CFU) count and expressed as percent change compared to 
untreated control. A dose-dependent increase in number of colonies was 
observed with Aβ42 treatment without rapamycin (##p<0.01, #p<0.05). 
However in the presence of rapamycin, a significant decrease in the number of 
colonies compared to Aβ42 alone was observed (*p<0.05, **p<0.01). All data 
are represented as mean ± SEM (n=4). 
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6.4.4 Aβ42 does not induce cell division in Saccharomyces 
cerevisiae cells 
Candida glabrata and Saccharomyces cerevisiae cells represent the main 
models in evolutionary yeast biology. Candida glabrata cells shows 
considerable genomic diversity in growth signalling pathways compared to 
Saccharomyces cerevisiae (Bowman et al., 1992; Walsh et al., 2002b). 
Although the gene expression patterns in Candida glabrata and Saccharomyces 
cerevisiae are highly conserved, significant diversity is observed in the 
signalling and regulatory networks (Lelandais et al., 2008). Therefore, to gain 
insight into the mechanism of Aβ42 induced cell division, stationary phase 
Candida glabrata and Saccharomyces cerevisiae cells were treated with Aβ42 
peptide.  
Candida glabrata cells were initially used for studying Aβ42 induced growth 
effects mainly for its faster growth rates compared to Saccharomyces cerevisiae 
(Lelandais et al., 2008). Aβ42 induced growth effects were studied in stationary 
phase Saccharomyces cerevisiae and Candida glabrata cells. Similar to 
Candida glabrata, Saccharomyces cerevisiae cells (BY4743) were subjected to 
starvation in YNB+2% maltose (Figure 4A) to induce stationary phase. 
Saccharomyces cerevisiae cells (BY4743) showed increased cell density with 
time in YNB+2% glucose (-Trp), however no increase was seen in YNB+2% 
maltose for both cell types indicating entry into stationary phase. As expected, 
Saccharomyces cerevisiae cells (BY4743) showed a slower growth rate 
compared to Candida glabrata in normal media (Figure 4A). 
 
Next, Aβ42 induced growth effect was also tested in Saccharomyces 
cerevisiae yeast cells alongside Candida glabrata (Figure 4B). Stationary phase 
induced Candida glabrata and Saccharomyces cerevisiae (BY4743) cells were 
treated with increasing concentrations of Aβ42 (0.5-5µM) (Figure 4B) for 20h at 
30°C. As seen before in Section 6.4.2 and 6.4.3, a dose dependent increase in 
the number of colonies was observed with Aβ42 treatment in Candida glabrata 
cells. A maximum of ~150-200% increase in colonies at 2-5µM Aβ42 was 
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observed. No increase in the number of colonies was seen at lower Aβ42 
concentrations (0.5 and 1µM) in Saccharomyces cerevisiae cells. Interestingly, 
at higher Aβ42 concentrations (2-5µM), a significant decrease in the number of 
colonies in Saccharomyces cerevisiae cells was observed indicating cell death 
(by ~20-25%, Figure 4B). The results showed that stationary phase 
Saccharomyces cerevisiae cells were unresponsive to Aβ42 induced growth 
effects. The effect of Aβ42 to induce cell division with longer incubation times 
was then assessed considering the slower growth rate of Saccharomyces 
cerevisiae compared to Candida glabrata cells. 
 
To determine growth effects at longer incubation times, Aβ42 (2µM) was 
incubated with stationary phase Candida glabrata and Saccharomyces 
cerevisiae cells for 12, 24 and 36h followed by colony count analysis (Figure 
5A, B). Aβ42 treatment induced a significant increase in the number of colonies 
(~200%) at 12-24h incubation in Candida glabrata. However, the number of 
colonies started to decline (~150%) with longer incubations (36h) (Figure 5A). 
No change in number of colonies was observed in Saccharomyces cerevisiae 
cells treated with Aβ42 for 12h. Indeed, at 24 and 36h incubation times Aβ42 
treatment caused a significant decrease in the number of colonies (~20-25%), 
indicating cell death (Figure 5B). 
 
Overall the results showed that Aβ42-induced growth effects were absent in 
Saccharomyces cerevisiae cells. As previously discussed, Candida glabrata 
and Saccharomyces cerevisiae have considerable differences in genomic 
structure and cellular make-up (Bowman et al., 1992; Walsh et al., 2002b), 
which is the most likely factor responsible for the differential effects of Aβ42.  
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Figure 4: Concentration dependent Aβ42 growth effects in Candida glabrata 
and Saccharomyces cerevisiae.   
Candida glabrata and Saccharomyces cerevisiae (BY4743) cells grown in 
YNB+ 2% glucose and YNB+ 2% glucose (-Trp) respectively were washed and 
incubated in fresh growth media [YNB+ 2% glucose or YNB+ 2% glucose (-Trp)] 
or in YNB+ 2% maltose to induce stationary phase. Cell density at 600 nm was 
measured at different time points (0-7h) (A). Similar to Figure 1, Candida 
glabrata cells showed increased cell density in YNB+ 2% glucose and no 
growth in YNB+ 2% maltose. Similarly, Saccharomyces cerevisiae (BY4743) 
cells showed growth in YNB+ 2% glucose (-Trp), but absent in YNB+ 2% 
maltose. Wild type Candida glabrata cells and Saccharomyces cerevisiae 
(BY4743) were grown in YNB+2% glucose and YNB+2% glucose (-Trp) 
respectively followed by starvation in YNB+2% maltose for 7 h. The starved 
cells were then treated with different concentrations of Aβ42 (0-5μM) for 20h at 
30°C. Colony forming units (CFU) were counted and expressed as percent 
change compared to untreated control (B). A dose-dependent increase in 
number of colonies was observed in Candida glabrata with Aβ42 treatment 
(##p<0.01). No change in number of colonies was seen in Saccharomyces 
cerevisiae cells (BY4743) at lower Aβ42 concentrations (0.5-1µM). At higher 
concentrations (2-5µM), Aβ42 showed a significant decrease in number of 
colonies in Saccharomyces cerevisiae cells (BY4743) (*p<0.05). 
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Figure 5: Time dependent Aβ42 growth effects in Candida glabrata and 
Saccharomyces cerevisiae.  
Candida glabrata and Saccharomyces cerevisiae (BY4743) cells grown in 
YNB+ 2% glucose and YNB+ 2% glucose (-Trp) respectively were washed and 
incubated in fresh growth media [YNB+ 2% glucose or YNB+ 2% glucose (-Trp)] 
or in YNB+ 2% maltose to induce stationary phase. Aβ42 (2µM)-induced growth 
effect at different incubation time points (12h, 36h and 48h) was also measured 
in starved Candida glabrata cells (A) and Saccharomyces cerevisiae (BY4743) 
cells (B). Aβ42 treatment induced a significant increase in the number of 
colonies from 12h incubation in Candida glabrata (**p<0.01). But, no change in 
the number of colonies was observed in Saccharomyces cerevisiae cells 
(BY4743) at 12h incubation with Aβ42. However, at 24h and 36h incubation 
times, Aβ42 showed significant decrease in the number of colonies in 
Saccharomyces cerevisiae cells (BY4743) (*p<0.05). All data are represented 
as mean ± SEM (n=4). 
 
6.5       Discussion 
6.5.1 Aβ42 mediated growth or toxicity is dependent on cell cycle 
stage  
The neurotoxic property of Aβ42 is thought to play a key role in mediating 
neurodegeneration in AD. In contrast to its toxic nature, Aβ42 can also possess 
mitogenic properties and has shown to enhance cell survival in neurons (Luo et 
al., 1996a; Whitson et al., 1989). However, the relationship between the 
mitogenic properties of Aβ and AD pathology is poorly understood. It is 
hypothesized that the biphasic nature of Aβ-induced toxic or proliferative effects 
may depend on the cell cycle.  
In this chapter, the effects of Aβ42 within different cell cycles (exponential 
and stationary phase) of yeast growth were determined. Yeast cells were 
starved in non-growth media to induce stationary phase (G0) or incubated in 
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normal media to maintain exponential growth phase (Figure 1) prior to Aβ42 
treatment. In exponentially growing yeast cells, Aβ42 caused a dose-dependent 
loss of viability as previously observed [Chapter 3, (Bharadwaj et al., 2008). 
However in the stationary phase cells, low concentrations of Aβ42 (0.1-5µM) 
induced cell division up to a maximum of ~250%, but at higher concentrations 
(≥20µM) the cell viability decreased, indicating toxicity (Figure 2). The results 
showed that Aβ42 can promote proliferation only in cells that are in the 
stationary phase and induce cell death in exponentially growing cells (Figure 2). 
The Aβ-induced growth and toxic effects within different cell cycles in yeast is 
comparable to the initial report showing that Aβ can enhance survival in freshly 
plated undifferentiated hippocampal cells (Yankner et al., 1990), but toxic in 
aged differentiated cultures. Studies showing Aβ42 mediated cell death in 
neurons expressing particular cell cycle-related elements (cyclin dependent 
kinases, Cdk4/6, Cdk5) (Giovanni et al., 1999; Liu et al., 2004), and in G1 cell 
cycle stage (Simakova and Arispe, 2007) further supported the notion that Aβ42 
mediated toxicity or growth is dependent on the cell cycle. The data presented 
here also indicated that Aβ42 induced growth effect happens at a much lower 
concentration range (0.1-5µM) compared to its toxicity which is significant only 
at higher concentrations (>5µM).  
It was also evident from the data that induction of stationary phase in yeast 
increased resistance to Aβ42 toxicity. At concentrations of 5-20µM, Aβ42 
treatment caused 50-75% cell death in exponential phase cells whereas at the 
same concentrations Aβ42 induced cell proliferation in stationary phase cells 
(~200%). Toxicity of Aβ42 in stationary phase cells was observed only at 
concentrations as high as 50µM. Induction of stationary phase in yeast is 
featured by enormous cellular transformation including development of a thick 
cell wall, sharp decline in metabolic rates, increased lipid, glycogen and 
trehalose storage, resistance to a variety of toxic insults, stimulated catabolic 
pathways like autophagy and repression of high energy consumers like ion 
channel proteins and proton pumps (Herman, 2002; Werner-Washburne et al., 
1993). The rate of protein synthesis falls ~300 fold in stationary phase cells and 
only a low level of protein synthesis (less than 10%) essential for stationary 
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phase survival is maintained (Paz and Choder, 2001; Werner-Washburne et al., 
1996). It is therefore possible that one or many of these featured changes in the 
cell may contribute to the increased resistance to Aβ42 toxicity. Of particular 
interest are the ion channel proteins and cell surface receptors expressed or 
repressed during the stationary phase, since Aβ42 was found to be largely 
localized in the yeast plasma membrane and inhibited the activity of the proton 
pump H+ATPase (Chapter 3). Whether repression of H+ATPase expression 
during stationary phase is directly associated with decreased Aβ42 toxicity 
remains to be determined. 
Collectively the data raises a wide range of possibilities on the nature of 
Aβ42 interaction with the cell and the potential receptor coupled pathways that 
maybe associated with the distinct effects observed in this chapter. The Aβ42-
induced growth effect is observed within a physiological concentration range 
(starting from 100nM) compared to its toxicity (>5µM), suggesting that Aβ42-
mediated cell division involves a high-affinity receptor. Since Aβ42-induced 
effects are dependent on the cell cycle stage, a broad array of proteins and 
receptors associated with metabolism, stress, transcription factors and 
intracellular growth signalling pathways are potential candidates involved with 
the response to Aβ treatment.  
 
6.5.2 Inhibition of mTOR signalling suppressed Aβ42 induced 
growth effects 
The cell cycle is a tightly regulated process with several checkpoints that 
ensure normal development when appropriate nutritional and trophic signals are 
present. Neurons of the adult brain are terminally differentiated and do not show 
mitotic cell division. Also, differentiated neurons lack the capacity to divide in 
vivo and in vitro, possibly due to lack of components necessary to complete the 
cell division process (McShea et al., 1999). However in AD, studies show 
increased levels of cell cycle related proteins and abnormal entry into mitosis in 
areas vulnerable to neurodegeneration in AD (reviewed in (Bonda et al., 2010; 
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Lee et al., 2009). It is suggested that in AD, the neurons may be attempting to 
initiate the early phases of mitosis (Zhu et al., 2008). Studies have shown that 
re-activation of cell cycle machinery in post mitotic neurons can lead to cell loss 
and degeneration (Feddersen et al., 1992; Park et al., 2007). It is believed that 
in AD, the incomplete transition of the neuronal cells into M phase makes them 
vulnerable to reactive oxygen species, excitotoxic stress and apoptosis (Park et 
al., 2000).  
mTOR is an eukaryotic cell signalling pathway essential for cell cycle 
progression,  and proliferation. Reports show increased levels of mTOR 
pathway components (p-eIF4E, p-mTOR and p-4E-BP1) in AD brains (Li et al., 
2005; Li et al., 2004) and it is believed that Aβ42 induced cell cycle events in 
neurons are closely associated with mTOR signalling. However studies in 
neuronal cell cultures and animal models have yielded contradictory results as 
previously discussed (Ma et al., 2010b; Pei and Hugon, 2008; Spilman et al., 
2010). In this Chapter, the role of mTOR signalling in Aβ42 mediated growth 
effects was determined. Aβ42 treatment induced a dose-dependent increase in 
cell division in stationary yeast cells (Figure 3). But when co-incubated with 
rapamycin, an mTOR inhibitor, the increase in cell division was significantly 
repressed (Figure 3). Overall the result showed that rapamycin suppressed 
Aβ42-induced cell division in stationary phase yeast cells. It suggested that 
mTOR is one pathway by which Aβ42 can stimulate growth effects in the yeast 
cell. mTOR signalling can be initiated by extracellular membrane bound sensors 
and transporters of growth factors and nutrients in eukaryotic cells. Yeast cells 
possess several nutrient-sensing systems localized in the plasma membrane 
that are associated with growth signalling. Importantly, some of the plasma 
membrane sensors include the amino acid permease Ssy1p-Ptr3p-Ssy5p family 
(SPS) and the glucose transporters Gpa2p, Snf3p and Rgt2p which are also 
members of highly conserved nutrient-transport protein families involved with 
TOR signalling (Cardenas et al., 1999; Cutler et al., 1999; Forsberg et al., 2001; 
Forsberg and Ljungdahl, 2001a, b). Immunoelectron and confocal microscopy 
analysis showed that Aβ42 was localized in the yeast plasma membrane 
(Chapter 3). It is therefore likely that Aβ42 may induce growth via interaction 
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with one or more of these transmembrane receptors involved with mTOR 
pathway.  
6.5.3 Aβ42 induced growth effect was absent in Saccharomyces 
cerevisiae 
 
Aβ42 induced growth effect was evident in stationary phase Candida 
glabrata cells and was suppressed by mTOR inhibitor, rapamycin (Figure 2, 3). 
Interestingly, the increased cell division with Aβ42 treatment was absent in 
Saccharomyces cerevisiae cells (Figure 4). No evidence of cell division was 
seen at lower Aβ42 concentrations (0.5-1µM) or even with extended periods of 
treatment (Figure 4). In fact at concentrations of 2-5µM, Aβ42 caused cell death 
(20-25%) in Saccharomyces cerevisiae cells compared to increased cell 
division (~200%) in Candida glabrata (Figure 4). It is well accepted that Candida 
glabrata cells have considerable genomic diversity compared to 
Saccharomyces cerevisiae, which is probably the most likely explanation for this 
phenomenon. It is notable that Saccharomyces cerevisiae cells showed a 
slower growth rate compared to Candida glabrata, which is a widely accepted 
phenomenon among yeast biologists.  
 
One important difference between the species is the supplements required 
for growth. Candida glabrata is a prototrophic strain, which indicates that it has 
wild-type characteristics of a naturally-occurring fungal cell capable of growth in 
media depleted of amino acids (YNB+2% glucose media without amino acids 
for Candida glabrata). However, Saccharomyces cerevisiae is an auxotrophic 
laboratory strain which needs amino acid supplements for growth (YNB +2% 
glucose+ histidine+ alanine+ uracil+ leucine for Saccharomyces cerevisiae 
BY4743). It is therefore a possibility that Candida glabrata expresses high 
affinity amino acid transporters (amino acid permeases) compared to 
Saccharomyces cerevisiae which enables it to survive in amino acid depleted 
conditions (Yadav and Bachhawat). It is likely that Aβ42 could bind to such high 
affinity amino acid transporters to induce growth in Candida glabrata. It also 
explains the absence of the Aβ42 induced growth effect in Saccharomyces 
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cerevisiae, which could be attributed to the lack or repressed expression of 
such receptors. However further investigation of other fungal species using 
mutational analysis is required to confirm this interesting notion.    
 
 
6.6 Summary: 
Aβ42 was found to induce cell division in stationary phase yeast cells, but 
was toxic in exponential phase cells at similar concentrations. The effect of 
mTOR inhibition by rapamycin in blocking Aβ42-growth effects was also 
studied. Rapamycin suppressed the Aβ growth effect, indicating that Aβ-
induced cell division is possibly mediated via mTOR signalling. Interestingly, the 
Aβ42-induced growth effect was observed only in Candida glabrata cells and 
not in Saccharomyces cerevisiae cells. Overall, the data has provided a greater 
understanding of the interplaying roles of the cell cycle and mTOR signalling in 
the Aβ42-induced growth in yeast cells.  
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Chapter 7 
Yeast Model for Intracellular 
Aβ42 Expression and 
Accumulation 
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7.1      Introduction: 
 
In the previous chapters, the effects of exogenously added Aβ (as a peptide 
and fusion protein) were studied in yeast. Oligomerizing Aβ42 peptide was 
significantly more toxic compared to the non-aggregating isoform Aβ42 (19:34) 
in yeast and also in neuronal cells. Localization analysis in yeast showed that 
both Aβ peptides bound the cell surface but were undetectable in the 
intracellular lumen. Oligomer Aβ42 showed increased affinity to the plasma 
membrane compared to non-aggregating Aβ42 (19:34) peptide and data 
suggested the plasma membrane H+ATPase as a possible target of oligomeric 
Aβ42 mediated cell death in yeast (Chapter 3). 
 
Although extracellular Aβ deposition and neuronal cell death are key 
pathological events in AD, growing evidence indicate that the clinical 
manifestations of the disease could be a collective contribution of numerous 
other pathological events associated with intraneuronal Aβ accumulation; 
reviewed in (LaFerla et al., 2007 ). Apart from uptake of secreted Aβ from the 
extracellular media, several reports indicate that Aβ can be generated 
intracellularly by APP processing in the trans-Golgi network (Xu et al., 1995), 
endoplasmic reticulum (ER), endosomal, lysosomal compartments (Kinoshita et 
al., 2003; Nixon et al., 2005; Yu et al., 2005) and mitochondrial membranes 
(Mizuguchi et al., 1992). Studies have reported accumulation of Aβ within 
neurons in post-mortem AD and transgenic mouse brains (Gouras et al., 2000; 
Nagele et al., 2002). Studies also indicate that the build-up of intracellular Aβ 
may be an early event in the pathogenesis of AD, preceding the formation of 
extracellular Aβ deposits (Gouras et al., 2000; Mori, 2002). It is thought that 
neurodegeneration and synaptic loss in AD could be the direct result of 
defective clearance mechanisms leading to intracellular Aβ accumulation and 
toxicity (Boland et al., 2008; Lee et al., 2010; Nixon, 2007). However, the 
contribution of various intracellular clearance pathways in the degradation of Aβ 
aggregates is not completely understood. In the following chapters, I have used 
yeast as a model to investigate the intracellular clearance of Aβ42 aggregates.  
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In chapter 3, I showed that Aβ42 was largely localised to the plasma 
membrane and was undetectable in the cytosolic lumen. Thus a model where, 
Aβ42 is expressed intracellularly would be more amenable for investigating 
clearance pathways. Yeast models expressing pathogenic proteins as green 
fluorescent protein (GFP) tagged fusion partners including α-synuclein (Cooper 
et al., 2006; Soper et al., 2008; Zabrocki et al., 2008; Zabrocki et al., 2005) have 
been engineered to reduce targeting for proteolysis in yeast cells and therefore 
enable real time monitoring of the protein of interest. Recently, a yeast model 
expressing GFP-Aβ42 was developed in Prof Macreadie‟s laboratory (Caine et 
al., 2007a). The expression of GFP-Aβ42 expression in yeast was shown to 
induce growth stress and heat shock response (Caine et al., 2007a). Also, GFP-
Aβ42 was found to localize into inclusion like structures compared to diffuse 
cytosolic expression of GFP in yeast. Overall, these findings suggest that GFP-
Aβ42 was misfolded and subsequently gets accumulated into amorphous 
inclusions inside the cell.  
 
In the following chapters, I have employed the GFP-Aβ42 expressing yeast 
model for investigating intracellular Aβ accumulation and degradation and 
evaluated the efficacy of agents that enhance clearance of intracellular Aβ 
aggregates. In the current chapter, a GFP-fusion Aβ42 (19:34) expression 
vector was generated and used to express the non-aggregating Aβ42 mutant in 
yeast. This chapter characterises intracellular expression and localisation of the 
mutant Aβ42 and native Aβ42 within yeast cells, prior to utilising these cells to 
investigate clearance pathways in subsequent chapters.  
 
7.2     Aim: 
 
Characterise localization and expression of GFP, GFP-Aβ42 and GFP-Aβ42 
(19:34) fusion proteins in yeast cells.  
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7.3      Materials and Methods: 
 
Wild type yeast cells (Saccharomyces cerevisiae, KVY55) transformed with 
p416 plasmids harbouring GFP/GFPAβ fusion protein construct and a URA 
selectable marker for growth in selective media (YNB+2% glucose –ura) was 
used in this work. GFP-Aβ42 (19:34) mutant was constructed from GFP-
Aβ42:p416 by site directed mutagenesis as described in Section 2.2.12 (the 
construct was made by Sonia Sankovich, CSIRO, Parkville). GFP levels and 
localization in GFP/GFPAβ expressing yeast grown in YNB+2% glucose (–ura) 
was analysed throughout the growth phase (early exponential till late log phase) 
by fluorescent microscopy as described in Section 2.2.16. Also the levels of 
GFP/GFPAβ protein in yeast cell lysates were analysed using immunoblotting 
with anti-GFP or anti-Aβ (WO2) as described in Section 2.2.17. The mRNA 
levels of GFP transcript were quantified in the GFP/GFPAβ expressing cells by 
real time q-PCR and comparative Ct analysis as described in Section 2.2.14. 
Cell viability of GFP/GFPAβ yeast transformants at different stages of growth 
was also determined using the Vi-Cell Cell viability analyser (Beckman Coulter).  
 
7.4       Results: 
7.4.1 Intracellular expression of GFP tagged Aβ42 fusion protein in 
yeast: 
Yeast is a widely used model for expression of neurotoxic proteins (Braun et 
al., 2010; Winderickx et al., 2008). Wild type yeast cells (Saccharomyces 
cerevisiae) constitutively expressing GFP-Aβ42 protein (Caine et al., 2007a) 
were utilized as a model for intracellular Aβ expression. Cells were transformed 
with a plasmid construct harbouring either the GFP or GFP-Aβ42 sequence with 
a uracil synthesis gene (URA3) (Figure 1A, B) for selective growth in media 
lacking uracil [YNB+2%glucose (-ura)], thus allowing for only stable 
transformants to be selected. To determine the localization of the fusion 
proteins within the cells, GFP and GFP-Aβ42 expressing yeast were studied by 
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fluorescent and immunoelectron microscopy. GFP expressing cells showed a 
diffuse green pattern of fluorescence compared to a punctate form of 
fluorescence in GFP-Aβ42 expressing cells (Figure 1C, D). The levels of 
fluorescence in GFP-Aβ42 expressing cells were also low compared to GFP 
alone. Immunoelectron microscopy using anti-GFP and anti-Aβ antibodies 
showed that GFP had a cytosolic distribution, whereas GFP-Aβ42 seemed to be 
localized into amorphous bodies (Figure 1E, F).  
This punctate fluorescence pattern and localization within inclusion like 
structures in yeast was reminiscent of an unfolded protein response in the cell 
(UPR) (Mori, 2009). GFP-Aβ42 expression also induced a heat shock response 
and growth stress (~5%) in the cell compared to GFP only (Caine et al., 2007a). 
Overall the data suggested that Aβ42 evoked a stress response in the cell, 
however it was unclear whether it was specific to the aggregating and toxic 
nature of Aβ42. To address this, a GFP tagged modified Aβ42 (19:34) isoform 
was generated for expression in yeast cells. 
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Figure 1: Expression of GFP-Aβ42 in yeast cells 
Sequence of the full length Aβ42 (A), Schematic diagram of the yeast 
centromere plasmid p416 harbouring the GFP–Aβ fusion protein gene (B). 
Fluorescent images of mid log phase yeast (w303-1a) cells grown in 
YNB+2%glucose (-ura) expressing GFP (C) or GFP-Aβ42 (D). GFP expressing 
cells show bright diffuse green fluorescence compared to punctate staining 
observed in GFP-Aβ42. Immunoelectron micrographs of yeast transformants 
expressing GFP (E) and GFP-Aβ42 (F) are shown here. Antibody to GFP was 
gold-labelled and probed against cells expressing GFP or GFP-Aβ42. Cells 
expressing GFP showed cytosolic localization as indicated by the black dots. 
However cells expressing GFP-Aβ42 showed localization in inclusion like 
structures. Note the labelling (black arrows) of amorphous structures (adapted 
from (Caine et al., 2007a).  
 
7.4.2 Generation of yeast cells expressing GFP-Aβ42 (19:34): 
 
Aβ42 peptide modified at positions F19S and L34P [Aβ42 (19:34)] has been  
shown to have reduced tendency to aggregate (Ahmed et al., 2010; Hughes et 
al., 1996; Luhrs et al., 2005; Wurth et al., 2002). In chapter 3, I showed that 
compared to native Aβ42 the Aβ42 (19:34) mutant remained largely monomeric, 
1μm 0.5μm
E F
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and did not form SDS stable oligomers (dimers, trimers and tetramers). 
Extracellular treatment in yeast and neuronal cells further showed that the non-
aggregating Aβ42 (19:34) mutant did not induce cell death compared to 
oligomeric Aβ42 (Section 3.4.2).  
Yeast cells expressing the GFP tagged non-aggregating Aβ42 (19:34) fusion 
protein was generated and its expression and localization pattern was 
compared to cells expressing GFP only or GFP-Aβ42. As described above, 
GFP-Aβ42 was found to localize into punctate like patterns (Figure. 2A) within 
the cell compared to the diffuse cytosolic localisation in cells expressing GFP 
only (Figure. 2C). Cells expressing GFP-Aβ42 (19:34) showed a similar diffuse 
pattern of expression to those expressing GFP only (compare Figure. 2B with 
2C). The GFP fluorescence patterns in the cells expressing the GFP/GFPAβ 
fusions suggested that GFP-Aβ42 was packaged and compartmentalized into 
inclusion bodies, whereas, GFP,  GFP-Aβ42 (19:34) was mainly localized in the 
cytoplasm.  
From the qualitative analysis of localisation it was noted that the 
fluorescence intensity was markedly less throughout the growth phase in cells 
expressing GFP-Aβ42 compared to those expressing GFP-Aβ42 (19:34) or 
GFP. To provide a more quantitative measure of expression and if it was altered 
through cell growth, the expression pattern and levels at early, intermediate and 
late stages of cell growth were assessed. 
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Figure 2: Localization of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) in yeast. 
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were 
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single 
GFP-Aβ42 (19:34) 
GFP-Aβ42
GFP
B
D
C
E
F
A
5µm
5µm
5µm
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yeast colony from stock agar plates was inoculated in 5ml YNB+2%glucose (-
ura) and incubated with shaking at 30ºC overnight. The overnight culture was 
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD 
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots 
at mid-late log phase (OD of 1-1.6) in selective minimal media 
(YNB+2%glucose, -ura) were collected and observed under the fluorescent and 
bright field microscope. Localization of GFPAβ42 (A, D), GFPAβ42 (19:34) (B, 
E) and GFP (C, F), expressed in wild-type yeast was investigated.  
 
 
7.4.3 Assessment of expression levels of GFP, GFP-Aβ42 and GFP- 
Aβ42 (19:34) over the yeast growth phase  
 
The expression levels of GFP/GFPAβ fusions in the cells were monitored 
throughout different growth phases. A single yeast colony of GFP/GFP-Aβ 
expressing yeast transformants from stock agar plates was inoculated in 5ml 
YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight. The 
overnight culture was resuspended in fresh YNB+2%glucose (-ura) media to an 
initial cell density (OD at 600nm) of 0.2 and incubated at 30°C. Following, 
sample aliquots throughout different growth phases starting from early 
exponential till mid-late log phase (cell density OD 600nm, 0.4-1.6) were 
collected for microscopy and immunoblotting analysis 
The percentage of green fluorescing cells was estimated in all cells from the 
starting point (initiation at cell density 0.2), through the early exponential phase 
(6-9 hours after initiation of the culture- cell density 0.4 and 0.7) till mid-late log 
growth phase of cells (10-12 hours after initiation; cell density 1 and 1.6) (Figure 
3). In the cells expressing GFP only, the percentage of fluorescent cells (~95%) 
remained stable throughout the growth phase. However, in cells expressing the 
GFP-Aβ42, only a maximum of ~15-20% of cells were fluorescent at the 
exponential phase and mid-late log phase (OD=1) of growth. In cells expressing 
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GFP-Aβ42 (19:34), ~70% cells were fluorescent in the exponential phase and 
mid-late log phase. A comparison of the percentage fluorescing cells between 
those cells expressing GFP-Aβ42 and those expressing GFP-Aβ42 (19:34), 
showed almost 50% less cells expressing GFP-Aβ42 (Figure 3). The 
percentage of fluorescing cells in GFP-Aβ42 expressing cells declined sharply 
during the mid-late log phase and was almost undetectable (less than 5%) at 
OD>1.6. However the percentage of GFP fluorescing cells were unchanged in 
GFP and GFP-Aβ42 (19:34) and remained at ~95% and ~70% respectively 
(Figure 3).  
As a more quantitative measure of the levels of these fusion proteins in the 
cells, extracts of the yeast transformants at different stages of the cell growth 
phase [early exponential phase (0.4) till mid-late log growth phase of cells (1.6)] 
was analysed by western immunoblotting with anti-Aβ and anti-GFP (Figure 4). 
Samples at the initiation point (0.2) were not collected for immunoblotting, due 
to lack of cell growth for protein extraction and analysis. Similar to the 
fluorescence quantification, the levels of GFP-Aβ42 (Figure 4A) was 
significantly lower than GFP-Aβ42 (19:34) (Figure 4B) and GFP (Figure 4C) 
throughout the growth phase (Figure D). Also GFP-Aβ42 protein levels sharply 
reduced and became undetectable at OD>1.6, compared to GFP and GFP-
Aβ42 (19:34) levels which were unchanged. Viability at different points of the 
growth phase was determined in all the transformants. No significant change in 
viability of the yeast GFP/Aβ transformants was observed throughout the cell 
cycle indicating that decreased levels of GFP-Aβ42 compared to GFP and GFP-
Aβ42 (19:34) was not due to cell death (Figure 4E).  
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Figure 3: GFP fluorescence levels in cells expressing GFP, GFP-Aβ42 and 
GFP-Aβ42 (19:34). 
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were 
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single 
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (-
ura) and incubated with shaking at 30ºC overnight. The overnight culture was 
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD 
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. The 
percentage of cells expressing green fluorescence in cells expressing GFP, 
GFPAβ42 and GFPAβ42 (19:34) fusion proteins were quantified at different 
phases of growth starting from early exponential phase (OD: 0.4) till late-log 
phase (OD: 1-1.6) as described in Section 2.2.16 (A). The percentage of 
fluorescing cells was significantly reduced in cell expressing GFP-Aβ42 (**, 
p<0.001), compared to those expressing GFP and GFP-Aβ42 (19:34) 
throughout the growth phase. The percentage of GFP fluorescence was 
significantly reduced in cell expressing GFP-Aβ42 (19:34) (**, p<0.001#, 
p<0.05), compared to those expressing GFP throughout the growth phase Data 
is expressed as mean ± SEM (n=4).  
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Figure 4: Expression levels of GFP-Aβ42, GFP-Aβ42 (19:34) and GFP proteins 
in yeast  
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were 
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single 
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (-
ura) and incubated with shaking at 30ºC overnight. The overnight culture was 
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD 
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots 
at different cell densities were collected for western blot analysis. Total protein 
extracts (50µg) from wild-type cells expressing GFPAβ42 (A), GFPAβ42 (19:34) 
(B) and GFP (C) throughout the growth phase (early exponential phase till mid 
log phase) were probed with anti-Aβ (WO2) or anti-GFP. Immunoreactive bands 
were quantified by densitometric analysis and expressed as arbitrary units (D). 
The protein levels of GFP-Aβ42 was significantly lower compared to GFP and 
GFP-Aβ42 (19:34) throughout the growth phase (**p<0.001). Cell viability of 
yeast transformants (GFP, GFP-Aβ42 and GFP-Aβ42 (19:34)) at different 
stages of growth in YNB+2%glucose (-ura) media at 30ºC was also measured 
(E). Data represented as mean ± SEM, n=3. No significant change in cell 
viability was observed among the different clones.    
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7.4.4 GFP transcription analysis using real time RT-PCR: 
To rule out the possibility that transcription levels of GFP-tagged Aβ genes 
were altered, GFP transcription was quantified by real time RT-PCR using 
comparative Ct method (Schmittgen and Livak, 2008). Equal number of yeast 
cells (~1-3 X 106 cells) expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) 
were collected at exponential growth phase (OD of 0.6). cDNA was synthesized 
from the frozen pellets  and used for the real time PCR amplification targeting 
the GFP transcript. The PCR products were analysed by 1.5% agarose gel 
electrophoresis and observed by UV transillumination. A ~90bp size band, 
representing GFP, was observed in all the transformants, but absent in 
untransformed and no-cell control (Figure 5A). This indicated the presence of 
the GFP mRNA transcripts in the yeast transformants. The levels of the 
transcripts were quantified from the Ct (threshold cycle) values. The Ct value 
represents the number of cycles required for the amplified PCR product (GFP) 
to reach the saturation threshold. The GFP mRNA levels were measured from 
the Ct values as described in Section 2.2.14 and were found to be similar in 
cells expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) (Figure 5B).  
In summary, I have characterised the localisation and expression of GFP, 
GFP-Aβ42 and Aβ42 (19:34) fusion proteins expressed in yeast. Compared to 
cells expressing GFP, or the non-aggregating GFP-Aβ42 (19:34), cells 
expressing GFP-Aβ42 showed punctate fluorescence staining. The expression 
levels of GFP-Aβ42 were markedly reduced, despite equal levels of transcript 
generated, indicating that transcription of the different GFP fusion proteins were 
not altered.   
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Figure 5: Transcription of GFP is not altered in yeast expressing GFP, GFP-
Aβ42 or GFP-Aβ42 (19:34).   
GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) expressing yeast cells (KVY55) were 
grown in selective YNB+2%glucose (-ura) media till exponential phase (OD 
0.6). Untransformed cells (KVY55) grown in YEPD media were also collected 
(OD 0.6). cDNA from the frozen pellets (~1-3 X 106 cells) was used for the real 
time PCR. The PCR products were analysed by 1.5% agarose gel 
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electrophoresis and observed under UV transillumination. Lanes (from left) are 
1) 100bp DNA ladder, 2) no cells control, 3) Untransformed cells, 4, 7) GFP, 5, 
8) GFP-Aβ42, 6, 9) GFP-Aβ42 (19:34) (A). A ~90bp size band, representing 
GFP, was observed in all the transformants, but absent in untransformed and 
no-cell control. The fold change in GFP transcription/106 cells using the 
comparative Ct method was measured as described previously (Schmittgen and 
Livak, 2008) (B). Levels of GFP transcript were similar in all cell lines. Data is 
expressed as mean ± SEM, n=3. 
 
7.5       Discussion: 
7.5.1 Yeast model for studying intracellular Aβ  
 
The budding yeast Saccharomyces cerevisiae has proven to be a valuable 
model organism for studying fundamental cellular processes and pathways 
involved in aggregation and toxicity of pathogenic proteins in neurodegenerative 
diseases (Bharadwaj et al., 2010; Braun et al., 2010; Winderickx et al., 2008). 
Yeast models have been extensively used for expression of misfolding proteins 
including α-synuclein (α-synucleinopathies) (Brandis et al., 2006; Cooper et al., 
2006; Flower et al., 2005; Franssens et al., 2009; Lee et al., 2008; Oien et al., 
2009; Outeiro and Lindquist, 2003; Sharma et al., 2006; Willingham et al., 2003; 
Zabrocki et al., 2005), Huntington protein (polyglutamine disorders) (Gokhale et 
al., 2005; Krobitsch and Lindquist, 2000; Meriin et al., 2002; Sokolov et al., 
2006), Tau (tauopathies) (Vandebroek et al., 2006; Vandebroek et al., 2005; 
Vanhelmont et al., 2010), TDP-43 (Frontotemporal dementia and Amyotrophic 
lateral sclerosis)(Armakola et al., 2010; Johnson et al., 2008; Kryndushkin et al., 
2011) and Aβ42 (Alzheimer‟s disease) (Bagriantsev and Liebman, 2006; Caine 
et al., 2007a; von der Haar et al., 2007). The Aβ expression model as 
developed in Prof. Ian Macreadie‟s laboratory by Caine and colleagues (2007) 
was the model of choice, since it was fused to green fluorescent protein (GFP) 
for much easier tractability as compared to the models developed by 
Bagriantsev and colleagues (2006) and von der Haar and colleagues (2007) 
who utilized Aβ fused to Sup35p prion proteins. 
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 Initial attempts at expressing native Aβ42 in yeast using a copper 
inducible system was unsuccessful (Caine et al., 2007a). This study showed 
that native expression of Aβ42 in yeast was undetectable, which was similar to 
findings from other attempts at generating yeast models of protein aggregates 
such as α-synuclein (Outeiro and Lindquist, 2003). It was suggested that using 
native expression, led to a rapid proteolysis of the protein of interest within the 
cell (Outeiro and Lindquist, 2003). Expression of native human proteins as GFP 
tagged fusions is known to reduce targeting for proteolysis in yeast cells and 
also enables real time monitoring of the protein of interest (Caine et al., 2007a; 
Outeiro and Lindquist, 2003). Thus, Caine and colleagues developed a yeast 
model expressing GFP-tagged fusion Aβ42 protein. The findings from this 
chapter have further characterised the localisation and expression of GFP-Aβ42 
in this model.   
 
The original study by Caine and colleagues showed that GFP-Aβ42 induced 
a heat shock response and a slight growth stress. It could be argued that this 
may alter cell growth or viability, or reduce expression of the labelled protein. 
However, the findings in Figure 4 show that cell viability is not altered by 
intracellular Aβ42 and that equal amount of transcript was generated in all cell 
lines. However, extracellular treatment of yeast cells with oligomeric Aβ42 
caused significant loss of viability and cell death [Chapter 3, (Bharadwaj et al., 
2008)]. It is notable that toxicity in wild type yeast cells was associated only with 
specific isoforms (oligomeric) and supraphysiological levels of Aβ42 treatment 
(micromolar). It is most likely that expression levels of GFP-Aβ42 intracellularly 
would therefore be too low to cause any significant toxicity. Further, the 
markedly reduced levels of GFP-Aβ42, compared to levels of the non-
aggregating, non-toxic GFP-Aβ42 (19:34) mutant and GFP alone, indicate that 
the cell can deal with the intracellular over-expression of Aβ42. The expression 
levels coupled with the previously reported heat shock response in the cell 
suggests that GFP-Aβ42 may be activating intracellular degradation pathways 
which may account for its decreased levels detected in the yeast cell. 
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Immunoelectron microscopy showed that GFP-Aβ42 is localized into 
vesicles reminiscent of autophagic bodies or endosome like structures ((Caine 
et al., 2007a), Figure 1). Reports showing that Aβ accumulates in 
vesicular/lysosomal structures in neurons of a variety of AD mouse models 
(Oddo et al., 2006; Wirths, 2001), human AD brains (Gouras et al., 2000; Nixon 
et al., 2005) and in neuronal cells treated with extracellular Aβ42 (Hu et al., 
2009) collectively supports the idea that GFP-Aβ42 may be accumulating in 
such vesicles in yeast.  
 
7.5.2 Altered localization of non aggregating Aβ42 (19:34) isoform 
in yeast 
 
Aβ42 is known to attain multiple isoforms in physiological conditions 
[reviewed in (Bharadwaj et al., 2009)]. The pathological basis of Aβ42 in AD is 
dependent on its ability to oligomerize and accumulate leading to cellular 
dysfunction. In addition to its intrinsic self associating nature, several 
environmental factors and binding partners can also affect Aβ aggregation and 
toxicity (Burdick et al., 1992; Holtzman, 2001; Stine et al., 2003). In chapter 3, 
synthetic derived Aβ42 was shown to form SDS stable low-n oligomers 
compared to monomeric Aβ42 (19:34) peptide. Although GFP-Aβ42 localized 
into punctate patterns within the cell indicated aggregation, oligomeric forms of 
GFP-Aβ42 were not observed by immunoblotting analysis. It is also suggested 
that identifying intracellular Aβ oligomers can be difficult due to their strong 
association with membranes (LaFerla et al., 2007 ).  
 
Therefore, expressing the non aggregating Aβ42 (19:34) as a GFP tagged 
fusion protein in yeast was beneficial in addressing whether the aggregating 
nature of Aβ affects the localization and expression levels of the GFP-Aβ fusion 
proteins in yeast. The modified form of Aβ42 (19:34) did not exhibit a punctate 
pattern like GFP-Aβ42, but rather had a cytoplasmic distribution similar to cells 
expressing GFP only. Recent findings also showed that expression of GFP-
Aβ42 (19:34) induced a markedly weak heat shock response compared to GFP-
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Aβ42 in yeast, as measured by β-galactosidase activity (Antony, 2008). Along 
with the aggregation/toxic properties of synthetically derived Aβ42 and Aβ42 
(19:34) peptides (Section 3.4.2), the distribution patterns of GFP-Aβ42 and 
GFP-Aβ42 (19:34) in yeast suggested that GFP-Aβ42 is misfolded/aggregated 
and is sequestered into vesicular structures (diagrammatic representation in 
Figure 6). The sequestering of GFP-Aβ42 into these vesicles may indicate a 
potential mechanism in yeast by which it could be targeted for degradation by 
the yeast vacuole. This is further investigated in chapters 7 and 8. 
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Figure 6: Schematic of GFP/GFPAβ fusion expression in yeast 
A diagrammatic representation of localization of GFP-Aβ42 (A), GFP- Aβ42 
(19:34) (B) and GFP (C) expression in yeast, GFP-Aβ42 protein is selectively 
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Aggregating/Misfolded 
GFP-Aβ42
GFP-Aβ42 (19:34)
B
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C
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sequestered into inclusions, whereas GFP-Aβ42 (19:34), a non aggregating 
Aβ42 isoform and GFP are localized in the cytosol. 
 
 
7.5.3 Reduced expression levels of GFP-Aβ42 in yeast 
 
Apart from the distinct localization patterns in the cells, the levels of GFP-
Aβ42 were markedly reduced throughout different stages of cell growth 
compared to GFP or GFP-Aβ42 (19:34) (Figure 4). Interestingly, the levels of 
GFP-Aβ42 were dramatically reduced and became almost undetectable during 
the mid-late log phase of growth, whereas GFP and GFP-Aβ42 (19:34) levels 
remained unchanged. Similar levels of GFP transcript in all three cell lines 
indicate transcription of the GFP fusion construct was not altered and therefore 
could not account for the marked reduction in percentage of cells expressing 
GFP-Aβ42. Further, cell viability was not significantly altered by expression of 
GFP-Aβ42 (Figure 4E).  
 
Overall the results from fluorescence quantification and immunoblotting 
analysis in GFP/GFPAβ transformants indicate that GFP-Aβ42 was degraded 
rapidly throughout the growth phase (exponential till late log phase) compared 
to GFP and GFP-Aβ42 (19:34) in yeast. The expression levels of GFP-Aβ42 
were consistently low compared to GFP and GFP-Aβ42 (19:34) during the 
exponential growth phase (OD 0.4-1.2), and further declined sharply during the 
mid-late log phase (>1.2) (Figure 3, 4). One possible explanation is that Aβ42 is 
degraded continuously during the growth phase, but during the late-log phase, 
there is an additional boost to the degradation possibly by activation of catabolic 
pathways. Notably the late-log phase indicates point of nutrient limitation and 
entry into starvation, where pathways like autophagy are stimulated. The results 
therefore indicate that Aβ42 can be degraded via distinct pathways in the cell 
depending on the different phases of growth. 
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7.6     Summary 
 
Overall this chapter has characterised a novel yeast model of 
intracellular Aβ42 accumulation, where Aβ42 was localised in a punctate 
pattern and expression was reduced over the growth phase of the cells. These 
findings provide evidence in support of Aβ42 being sequestered into 
cytoplasmic inclusion bodies/ vesicles which may be targeted for degradation. 
In the subsequent chapter, I report on the use of this model to investigate two 
intracellular clearance pathways, the ubiquitin-proteasome and the autophagy-
lysosome pathways and their contribution to the reduction of GFP-Aβ42 
expression observed in this model.  
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Chapter 8 
Clearance mechanisms of 
intracellular Aβ42 aggregates in 
Yeast  
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8.1      Introduction: 
 
Intraneuronal accumulation of beta amyloid (Aβ) protein in the brains of 
AD patients and transgenic mouse models has been widely reported previously 
(LaFerla et al., 1997; Nagele et al., 2002). Levels of Aβ rise substantially in 
endosomal-lysosomal compartments (Cataldo et al., 2004; Takahashi et al., 
2004) and cognitive deficits have been reported in AD models in which 
intracellular Aβ levels are elevated in the absence of plaque deposition 
(Koistinaho et al., 2001; LaFerla et al., 2007 ). Impaired clearance of Aβ from 
the CNS, rather than overproduction has been suggested to be the main 
contributor to accumulation of this peptide in the brains of sporadic AD patients 
(Bates et al., 2009; Mawuenyega et al., 2010). In addition to Aβ degrading 
enzymes, changes in efflux of Aβ from CNS into the periphery can influence 
cerebral Aβ accumulation and clearance. Another Aβ clearance mechanism is 
via the two main intracellular degradation/recycling pathways  
 
Firstly, the ubiquitin-proteasome system (UPS) which is responsible for 
the degradation of short lived peptides (Hochstrasser, 1996), and secondly, the 
autophagy-lysosome system which regulates longer lived proteins and 
organelles [reviewed in (Martinet et al., 2009)] are the two pathways which 
maintain protein homeostasis in cells. In AD, both autophagy-lysosome system 
and the UPS have been implicated to play important roles in regulating the 
levels of intracellular Aβ. Autophagy has been shown to be  an active pathway 
for turning over APP and generating the Aβ peptide (Nixon, 2007) and impaired 
clearance of autophagic vesicles are observed in AD mice models and AD brain 
(Nixon et al., 2005; Yu et al., 2005; Yu et al., 2004). Suggestions have been 
made that in AD, deficiences in autophagy and impaired clearance of 
autophagic vesicles could contribute to the accumulation of Aβ-containing 
autophagic vesicles within affected neurons (Nixon et al., 2005; Yu et al., 2005) 
(Boland et al., 2008). Apart from extensive involvement of autophagic 
processes in the AD brain, studies have also shown selective decrease of 
proteasomal activity in specific regions (Keck et al., 2003; Keller et al., 2000) 
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and accumulation of ubiquitin in plaques and tangles of AD brains (Mori et al., 
1987; Morishima-Kawashima et al., 1993; Perry et al., 1987; Tabaton et al., 
1991). Reports also suggest that Aβ oligomers can inhibit proteasomal function 
(Oh et al., 2005; Tseng et al., 2008). Although defective clearance by 
autophagy-lysosome and the ubiquitin-proteasome pathways are associated 
with increased Aβ accumulation in the brain, their exact roles and contributions 
of the various components involved in the degradation of Aβ aggregates inside 
the cell still remain unclear. 
 
In chapter 7, the GFP tagged Aβ expression system (Caine et al., 2007a) 
in yeast was utilized for studying intracellular Aβ accumulation. GFP-Aβ42 was 
found to be sequestered into amorphous inclusions, whereas GFP and GFP-
Aβ42 (19:34) showed diffuse cytosolic localization in the cell. Also compared to 
cells expressing GFP or GFP-Aβ42 (19:34), the levels of GFP-Aβ42 were 
markedly reduced throughout different stages of cell growth. Together with 
differences in distribution and levels of GFP fusion proteins, the results 
indicated that compared to non-aggregating GFP-Aβ42 (19:34) mutant, GFP-
Aβ42 aggregates are efficiently cleared from yeast. Also, the data supported the 
idea that GFP-Aβ42 is sequestered into cytoplasmic inclusion bodies/vesicles 
which may be targeted for degradation by autophagy or the proteasome in the 
cell.  
 
In this chapter, I describe the use of this yeast model in an attempt to 
understand the roles of autophagic vesicle (AV) transport, vacuolar protease 
activity and proteasomal chymotrypsin activity in clearance of GFP-Aβ42 
aggregates inside the cell. To achieve this objective, expression levels and 
distribution of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusion proteins were 
studied in mutants deficient in AV synthesis (atg8Δ), vacuolar proteases 
associated with autophagy (pep4Δ and cvt1Δ) and 26 proteasome subunits 
essential for chymotrypsin activity (pre1Δ and pre1-2Δ).  
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8.2     Aims: 
 
1.) Comparative analysis of the expression levels and localization of 
GFP/GFPAβ fusion proteins in wild type and AV synthesis mutant (atg8Δ) 
transformants. 
2.) Comparative analysis of the expression levels and localization of 
GFP/GFPAβ fusion proteins in wild type and vacuolar protease deficient 
mutants (pep4Δ and cvt1Δ) transformants. 
3.) Comparative analysis of the expression levels and localization of 
GFP/GFPAβ fusion proteins in wild type and proteasomal activity deficient 
mutants (pre1Δ and pre1-2Δ) transformants. 
 
8.3     Materials and Methods: 
 
GFP/GFPAβ fusion protein constructs were transformed into wild type, AV 
synthesis mutant (atg8Δ), vacuolar protease deficient mutants (pep4Δ and 
cvt1Δ) and proteasomal activity deficient mutants (pre1Δ and pre1-2Δ) yeast 
mutants cells. As described in Section 2.2.16 and Section 2.2.17, expression 
levels and localization of GFP/GFPAβ fusion proteins were studied by 
fluorescent microscopy and immunoblotting in all the yeast transformants.  
 
8.4     Results:  
 
In chapter 7, using a GFP tagged Aβ expressing yeast model, it was shown 
that compared to non-aggregating GFP-Aβ42 (19:34) mutant, levels of GFP-
Aβ42 were markedly reduced, suggesting clearance of Aβ aggregates. This 
was also supported by the punctate staining of GFP-Aβ42, compared to GFP-
Aβ42 (19:34) indicating sequestration of Aβ42 aggregates into cytoplasmic 
inclusion bodies/ vesicles, which may be targeted for degradation. This chapter 
reports on the contribution of autophagy and proteasomal activity in the 
degradation of GFP-Aβ42 in yeast. 
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8.4.1 Localization and expression levels of GFP/GFPAβ in 
autophagic vesicle (AV) synthesis mutant (atg8Δ) 
 
A pathway that has been implicated in clearing/ degrading intracellular 
aggregated proteins is autophagy. Autophagy is a catabolic process initiated by 
the formation of an autophagic vesicle (AV) which sequesters and transports 
the bulk of the cytoplasmic material for degradation in the lysosome (vacuole in 
yeast) by acid hydrolases. To determine the role of AV transport in GFP-Aβ42 
degradation in yeast, the distribution and expression levels of GFP/GFPAβ 
fusion proteins were determined in yeast cells deficient of a protein Atg8p 
(homolog of human LC3) essential for AV synthesis (atg8Δ). 
 
GFP, GFP-Aβ42 or the GFP-Aβ42 (19:34) transformants were generated 
in atg8Δ mutant cells and corresponding background wild type strain 
(Saccharomyces cerevisiae, KVY55). The distribution of GFP fluorescence in 
wild-type and atg8Δ cells expressing the GFP/GFPAβ fusion proteins was 
assessed. As described in chapter 7, in wild-type cells expressing GFP-Aβ42, 
fluorescence was found to localize into punctate like patterns (Figure. 1A) within 
the cell compared to diffuse cytosolic fluorescence in those expressing GFP 
only (Figure. 1C) or GFP-Aβ42 (19:34) (Figure. 1B). In atg8Δ mutant cells, the 
localization of GFP and GFP-Aβ42 (19:34) was diffuse and similar to that 
observed in wild type cells (compare Figure.1E, F with 1B, C). In atg8Δ cells 
expressing GFP-Aβ42, fluorescence was more diffuse and cytosolic compared 
to the punctate staining observed in wild-type cells expressing GFP-Aβ42 
(compare Figure. 1D with 1A) during the mid-late log phase (OD>1). The diffuse 
fluorescence in atg8Δ cells expressing GFP-Aβ42 suggested that the mutant 
had reduced ability to sequester the GFP-Aβ42 aggregates, possibly due to the 
lack of AV synthesis. Next, the expression levels of the GFP/GFPAβ fusion 
proteins in wild type and atg8Δ cells were determined.  
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Figure 1: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type and 
atg8Δ yeast transformants.  
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells 
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log 
phase (OD of 1-1.6) of growth in selective minimal media (YNB+2%glucose, -
ura) were observed under the fluorescent microscope. Localization of GFPAβ42 
(A, D), GFPAβ42 (19:34) (B, E) and GFP (C, F) in wild-type and atg8Δ cells 
respectively were investigated.  
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To determine if deficiency of AV synthesis in atg8Δ cells altered the 
levels of the fusion proteins, the percentage of green fluorescent cells were 
estimated for the transformant cell lines (Figure 2). A similar profile of 
percentage of GFP expressing cells to that shown in the previous chapter 
(Chapter 7, Figure 3) was observed for the wild-type transformant cells. Cells 
expressing GFP showed ~90% fluorescent cells throughout the growth phase 
compared to a maximum of only ~15-20% fluorescence (exponential to mid-late 
log phase) in cells expressing GFP-Aβ42. And, in cells expressing GFP-Aβ42 
(19:34), ~70% cells were fluorescent in the exponential phase and mid-late log 
phase. In atg8Δ cells expressing GFP and GFP-Aβ42 (19:34), the profile was 
similar to that seen in wild-type cells. However, compared to wild-type cells, a 
two-fold increase (up to ~40%) in fluorescent cells was observed from the early 
exponential growth phase in atg8Δ mutant cells expressing GFP-Aβ42 (Figure 
2). Also the levels were found to remain stable after mid-late log phase, even at 
cell density OD>1, whereas fluorescence was almost undetectable in wild-type 
cells at similar growth phase.  
 
To specifically determine the levels of these fusion proteins in the cells, 
extracts of the wild type (i) and atg8Δ (ii) yeast transformants at different time 
points in the growth phase was analysed by SDS-PAGE western blotting 
(Figure 3). Western immunoblotting of cell extracts for Aβ showed similar results 
to fluorescence data. No significant changes in the levels of GFP and GFP-
Aβ42 (19:34) was observed between wild type and atg8Δ cells (Figure 3B and 
C). It is noted that compared to cells expressing GFP-Aβ42, cells expressing 
GFP-Aβ42 (19:34) exhibit higher levels of the modified Aβ42. Compared to wild-
type cells, GFP-Aβ42 levels were increased in atg8Δ cells during mid-late log 
phase of growth (OD>0.6) (Figure. 3A). Also the GFP-Aβ42 levels remained 
unchanged in the atg8Δ even at OD>1.6, whereas it was markedly reduced at 
OD=1.2 and undetectable at OD=1.6 in the wild type (Figure 3A).  
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The overall differences in GFP-Aβ42 levels and distribution between 
wild-type and atg8Δ mutant yeast cells suggested that disruption of AV 
synthesis lead to increased accumulation of GFP-Aβ42 in the mutant compared 
to the wild type.  
 
 
Figure 2: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) 
expressing wild type and atg8Δ yeast transformants. 
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells 
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at different cell 
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densities were collected and observed under the fluorescent microscope. The 
percentage of cells expressing green fluorescence in wild type and atg8Δ cells 
expressing GFP, GFPAβ42 and GFPAβ42 (19:34) fusion proteins were 
quantified at different phases of growth starting from initiation (OD: 0.2) till late-
log phase (OD: 1-1.6) (A). The percentage of fluorescing cells was significantly 
reduced in wild type cells expressing GFP-Aβ42 (**, p<0.001), compared to 
those expressing GFP and GFP-Aβ42 (19:34) throughout the growth phase. 
The percentage of fluorescing cells was significantly higher in atg8Δ cells 
expressing GFP-Aβ42 (#, p<0.005) compared to wild type GFP-Aβ42. Data is 
expressed as mean ± SEM (n=4).  
 
Figure 3: Expression levels of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) proteins 
in wild type and atg8Δ yeast transformants. 
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells 
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal 
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YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at different cell 
densities were collected for immunoblotting analysis. Cell extracts (50µg) from 
wild-type (i) or atg8Δ mutant (ii) cells expressing GFPAβ42 (A), GFPAβ42 
(19:34) (B) and GFP (C) were probed using anti-Aβ (WO2) and anti-GFP 
antibodies.  
 
8.4.2 Localization and expression levels of GFP/GFPAβ in vacuolar 
protease mutants (pep4Δ and cvt1Δ) 
 
Vacuolar proteases are a family of acid hydrolases in yeast which operate 
as the key enzymes essential for degradation of cytoplasmic material 
transported to the vacuole (Klionsky and Emr, 2000). In yeast, pep4p ([homolog 
of human cathepsin D (Ammerer et al., 1986; Jones et al., 1982)], yscA) and 
cvt1p [(member of subtilisin family), yscB] are the main vacuolar 
endopeptidases (Teichert et al., 1989). To determine the contribution of 
vacuolar proteases in the degradation of GFP-Aβ42 in yeast, the distribution 
and expression levels of GFP/GFPAβ fusion proteins in mutant cells deficient of 
enzymes pep4p (pep4Δ) and cvt1p (cvt1Δ) was determined.  
GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) transformants were generated in 
pep4Δ, cvt1Δ mutant cells and corresponding background wild type strain 
(Saccharomyces cerevisiae, BY4743). The distribution of GFP fluorescence in 
wild-type, pep4Δ, and cvt1Δ cells expressing GFP/GFPAβ fusion proteins was 
assessed (Figure 4). The distribution of GFP fluorescence in wild-type cells 
expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) were similar to previous 
observations as described in chapter 7. In pep4Δ and cvt1Δ cells, the 
localization of GFP and GFP-Aβ42 (19:34) were diffuse and was similar to that 
in observed in wild type cells (compare Figure 4D-F and Figure 4G-I). In pep4Δ 
and cvt1Δ cells expressing GFP-Aβ42 the fluorescence was punctate similar to 
211 
 
wild type expressing GFP-Aβ42. However both pep4Δ and cvt1Δ cells 
expressing GFP-Aβ42 showed increased number of punctate staining 
compared to the wild type during the mid-late log phase (OD>2) (compare 
Figure 4A with 4B, C). This result suggested an increased accumulation of 
GFP-Aβ42 in pep4Δ and cvt1Δ compared to the wild type during starvation 
periods.  
 
 
Figure 4: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type, 
pep4Δ and cvt1Δ yeast transformants.  
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ and cvt1Δ cells 
(Saccharomyces cerevisiae, BY4743), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
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agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log 
phase (OD of 2-2.5) of growth in selective minimal media (YNB+2%glucose, -
ura) were observed under the fluorescent microscope. Localization of GFPAβ42 
(A-C), GFPAβ42 (19:34) (D-F) and GFP (G-I), in wild-type, pep4Δ, and cvt1Δ 
cells respectively were investigated.  
To determine if lack of the vacuolar proteases (pep4p and cvt1p) altered the 
levels of the fusion proteins, the percentage of green fluorescent cells were 
estimated for the transformant cell lines (Figure 5). A similar profile of 
percentage of fluorescing cells to that shown in Chapter 7 (See Figure. 3) was 
observed for the wild-type transformant cells. Also, the levels of GFP 
fluorescence in pep4Δ, cvt1Δ cells expressing GFP and GFP-Aβ42 (19:34) 
were similar to that of the wild type (Figure 5A, B). Comparing the wild type, the 
percent of fluorescing cells were increased in GFP-Aβ42 expressing cvt1Δ and 
pep4Δ cells during the mid-late log phase (OD 1.5-3). In pep4Δ-GFP-Aβ42 
cells, the percent of fluorescing cells were similar (~25%) to the wild type up to 
the mid-log phase (OD~1-1.5). However during the late log phase (>1.5), the 
decrease in percent fluorescing cells was significantly slow in pep4Δ cells 
compared to the wild type (~5% in wt compared to ~20% in pep4Δ) (Figure 5A). 
Interestingly, a similar trend was also observed in cvt1Δ-GFP-Aβ42 (~5% in wt 
compared to ~30% in cvt1Δ) (Figure 5B).  
Immunoblotting analysis for all transformant cell lines was also done (Figure 6). 
Similar to wild-type cells, the levels of GFP and GFP-Aβ42 (19:34) were 
unchanged throughout the growth phase in pep4Δ, cvt1Δ cells (Figure 6B, C). 
The GFP-Aβ42 protein levels were reduced markedly after OD>1.6 (late log 
phase) in the wild type cells. However in pep4Δ and cvt1Δ cells, the GFP-Aβ42 
protein levels do not reduce until OD 3.3. Unlike the atg8Δ mutant expressing 
GFP-Aβ42, the protein levels are not higher than the wild type during the early 
stages of growth (OD 0.4-1.6) (Figure 6A). Overall, the differences in GFP-Aβ42 
213 
 
levels and distribution between wild-type and the vacuolar protease mutants 
showed that, deficiency in acid hydrolases (pep4p, cvt1p) can result in 
increased accumulation of GFP-Aβ42, especially during the late log phase of 
growth (OD>1.6).  
0
20
40
60
80
100
120
0.2 0.7 1.1 2.4 3.3
wt_GFP-Aβ42
pep4Δ_GFP-Aβ42
wt_GFP-Aβ42 (19:34)
pep4Δ_GFP-Aβ42 (19:34)
wt_GFP
pep4Δ_GFP
Cell Density (OD, 600nm)
%
 c
e
ll
s
 e
x
p
re
s
s
in
g
 g
re
e
n
 f
lu
o
re
s
c
e
n
c
e
A
**
**
**
**
##
214 
 
 
Figure 5: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) 
expressing wild type, pep4Δ and cvt1Δ yeast transformants. 
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ and cvt1Δ cells 
(Saccharomyces cerevisiae, BY4743), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at different cell 
densities were collected and observed under the fluorescent microscope. The 
percentage of cells expressing green fluorescence in wild type compared 
individually to pep4Δ (A), cvt1Δ (B) cells expressing GFP, GFPAβ42 and 
GFPAβ42 (19:34) fusion proteins were quantified at different phases of growth 
starting from early exponential phase (OD: 0.2) till late-log phase (OD: 3.3) The 
percentage of fluorescing cells `is significantly reduced in wild type cells 
expressing GFP-Aβ42 (**, p<0.001), compared to those expressing GFP or 
GFP-Aβ42 (19:34) throughout the growth phase. The percentage of fluorescing 
0
20
40
60
80
100
120
0.2 0.7 1.1 2.4 3.3
wt_GFP-Aβ42
cvt1Δ_GFP-Aβ42
wt_GFP-Aβ42 (19:34)
cvt1Δ_GFP-Aβ42 (19:34)
wt_GFP
cvt1Δ_GFP
Cell Density (OD, 600nm)
%
 c
e
ll
s
 e
x
p
re
s
s
in
g
 g
re
e
n
 f
lu
o
re
s
c
e
n
c
e
B
**
**
**
**
#
#
215 
 
cells was similar in wild type, pep4Δ, and cvt1Δ cells expressing GFP and GFP-
Aβ42 (19:34). Comparing the wild type, % fluorescing cells was increased (#, 
p<0.05) in GFP-Aβ42 expressing cvt1Δ and pep4Δ cells during the mid-late log 
phase (OD 1.5-3). Data is expressed as mean ± SEM (n=4). 
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Figure 6: Expression levels of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusions 
in wild type pep4Δ, and cvt1Δ yeast transformants 
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ, and cvt1Δ 
cells (Saccharomyces cerevisiae, BY4743), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at different cell 
densities (OD 600nm, 0.4-3.3) were collected for immunoblotting analysis. Cell 
extracts (50µg) from wild-type (i), pep4Δ (ii), and cvt1Δ (iii) mutant cells 
expressing (A) GFPAβ42 (B), GFPAβ42 (19:34) and (C) GFP were probed 
using anti-Aβ (WO2) or anti-GFP antibodies. 
 
8.4.3 Localization and expression levels of GFP/GFPAβ in 
proteasomal mutants (pre1Δ and pre1-2Δ) 
 
The data  from Chapter 7 (see Figure 3) and current chapter (Figure 2 and 
5) in wild type yeast clearly shows that apart from the late log phase, GFP-Aβ42 
levels are significantly low throughout the exponential phase compared to wild-
type yeast expressing GFP and GFP-Aβ42 (19:34). This shows that levels of 
GFP-Aβ42 are tightly controlled during the entire growth phase (exponential 
phase till log phase). Under conditions of normal growth, the bulk of protein 
degradation occurs via the ubiquitin proteasomal system (UPS) (Hershko and 
Ciechanover, 1998). To determine the role of UPS activity in the degradation of 
GFP-Aβ42, the distribution and expression levels of GFP/GFPAβ fusion 
proteins were determined in yeast strains bearing mutations in genes coding for 
two proteolytic proteasome subunits responsible for chymotrypsin like activity: 
β4 (PRE1) and β5 (PRE2) (pre1Δ and pre1-2Δ) (Egner et al., 1995; Kragt et al., 
2005).  
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GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) transformants were generated in 
pre1Δ, pre1-2Δ cells and corresponding background wild type strain 
(Saccharomyces cerevisiae, Wcg4a). The distribution of GFP fluorescence in 
wild-type, pre1Δ and pre1-2Δ cells expressing GFP/GFPAβ fusion proteins was 
assessed (Figure 7). The distribution of GFP fluorescence in wild-type cells 
expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) were similar to previous 
observations in chapter 7. In pre1Δ and pre1-2Δ cells, the localization of GFP 
and GFP-Aβ42 (19:34) were diffuse and was similar to that in wild type 
(compare Figure 7D, E, F and Figure 7G, H, I). However, pre1Δ and pre1-2Δ 
cells expressing GFP-Aβ42 showed increased levels of punctate staining 
compared to wild type (Figure 7A-C). The increased punctuate fluorescence in 
pre1Δ and pre1-2Δ cells comparing wild type suggested an increased 
accumulation of GFP-Aβ42 within the cell. 
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Figure 7: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type, 
pre1Δ and pre1-2Δ.  
GFP/GFP-Aβ transformants were generated in wild type, pre1Δ and pre1-2Δ 
cells (Saccharomyces cerevisiae, Wcg4a), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log 
phase (OD of 2-2.5) of growth in selective minimal media (YNB+2%glucose, -
ura) were observed under the fluorescent microscope. Localization of GFPAβ42 
(A-C), GFPAβ42 (19:34) (D-F) and GFP (G-I), in wild type, pre1Δ and pre1-2Δ 
cells respectively were investigated.  
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The percentage of green fluorescent cells was estimated for the 
transformant cell lines (Figure 8). A similar profile of percentage of GFP 
expressing cells to that shown in the previous chapter (Chapter 7, Figure. 3) 
was observed for the wild-type transformant cells. The percent of fluorescing 
cells in pre1Δ and pre1-2Δ cells expressing GFP and GFP-Aβ42 (19:34) were 
similar to that of the wild type (Figure 8A, B). However, percent of fluorescing 
cells were ~2 fold higher throughout the growth phase (OD 0.7-3) in GFP-Aβ42 
expressing pre1Δ and pre1-2Δ cells compared to wild type (Figure 8A, B). Also, 
pre1-2Δ cells showed increased percent of fluorescing cells (~40%) compared 
to pre1Δ cells (~30%) during late log phase (OD 3.3), which was markedly 
higher than the wild type (~5%) at the same growth phase. 
 
Immunoblotting analysis for all transformant cell lines was also performed 
(Figure 9). Similar to wild-type cells, levels of GFP and GFP-Aβ42 (19:34) were 
unchanged throughout the growth phase in pre1Δ and pre1-2Δ cells (Figure 9B, 
C). However, GFP-Aβ42 levels in pre1Δ and pre1-2Δ were consistently high 
throughout the growth phase (OD 0.4-3.3) compared to the wild type (Figure 
9A). At the late-log phase of cells growth (OD 3.3), levels of GFP-Aβ42 were 
undetectable in wild-type cells (Figure 9A).  Similar to the fluorescence data, 
pre1-2Δ cells showed increased GFP-Aβ42 levels compared to pre1Δ cells 
during late log phase (OD 3.3), whereas undetectable in wild type. The data has 
shown that decreased chymotrypsin activity of the proteasome resulted in 
increased levels of GFP-Aβ42 in the cell throughout the growth phase of yeast 
(from exponential till the late log phase). 
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Figure 8: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) 
expressing wild type, pre1Δ and pre1-2Δ yeast transformants 
GFP/GFP-Aβ transformants were generated in wild type, pre1Δ and pre1-2Δ 
cells (Saccharomyces cerevisiae, Wcg4a), and stored on selective minimal 
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock 
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with 
shaking at 30ºC overnight. The overnight culture was resuspended in fresh 
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2. 
The culture was then incubated at 30ºC with shaking. Aliquots at different cell 
densities were collected and observed under the fluorescent microscope. The 
percentage of cells expressing green fluorescence in wild type compared 
individually to pre1Δ (A) and pre1-2Δ (B) cells expressing GFP, GFPAβ42 and 
GFPAβ42 (19:34) fusion proteins were quantified at different phases of growth 
starting from early exponential phase (OD: 0.2) till late-log phase (OD: 3.3) The 
percentage of GFP fluorescence is significantly reduced in wild type cells 
expressing GFP-Aβ42 (**, p<0.001), compared to those expressing GFP or 
GFP-Aβ42 (19:34) throughout the growth phase. The percentage of GFP 
fluorescence was similar in wild type, pre1Δ and pre1-2Δ cells expressing GFP 
and GFP-Aβ42 (19:34). Comparing the wild type GFP fluorescence was 
increased (##, p<0.05) in GFP-Aβ42 expressing pre1Δ and pre1-2Δ cells 
throughout the growth phase (OD 0.7-3). Data is expressed as mean ± SEM 
(n=4). 
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Figure 9: Expression levels of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusions 
in wild type, pre1Δ and pre1-2Δ yeast transformants 
GFP/GFP-Aβ transformants were generated in vacuolar protease deficient 
yeast mutants (Saccharomyces cerevisiae Wcg4a, pre1Δ and pre1-2Δ), and 
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single 
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (-
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ura) and incubated with shaking at 30ºC overnight. The overnight culture was 
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD 
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots 
at different cell densities (OD 600nm, 0.4-3.3) were collected for immunoblotting 
analysis. Cell extracts (50µg) from wild-type (i), pre1Δ (ii) and pre1-2Δ (iii) cells 
expressing (A) GFPAβ42 (B), GFPAβ42 (19:34) and (C) GFP were probed 
using anti-Aβ (WO2) or anti-GFP.  
 
 
8.5     Discussion: 
 
In chapter 7, the GFP tagged Aβ expressing system was utilized as a model 
for studying the intracellular accumulation of Aβ42. This system allowed the 
study of the various degradation pathways involved in the clearance of Aβ 
aggregates in the cell, without any loss of viability. Intracellular degradation 
pathways like autophagy and ubiquitin-proteasome have been comprehensively 
studied in yeast cells (Abeliovich and Klionsky, 2001; Hilt et al., 1996; Hilt and 
Wolf, 1996; Hochstrasser, 1995; Jentsch, 1992a, b; Nair and Klionsky, 2005; 
Yang and Klionsky, 2009). In addition, a variety of mutants deficient in specific 
processes of these pathways are available which can be used to dissect the 
mechanism and the various elements associated with Aβ42 trafficking and 
degradation inside the cell. 
 
8.5.1 Disruption of autophagic vesicle (AV) synthesis reduced 
GFP-Aβ42 trafficking and degradation 
 
The localization and expression of GFP-Aβ42 was determined in the mutant 
deficient of AV synthesis (atg8Δ). The Atg8p protein (and human homologue 
LC3) is essential for the formation of AV‟s that deliver intracellular components 
to the vacuole for degradation (Kabeya et al., 2000). Compared to the punctate 
inclusion pattern of localization in wild type GFP-Aβ42, the atg8Δ cells showed 
a more diffuse form of distribution. In addition the atg8Δ cells increased levels of 
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GFP-Aβ42 during late log phases of growth (Figure 1, 2, 3). Overall, the data 
suggested that the disruption of AV synthesis lead to a reduced ability to 
sequester the GFP-Aβ42 resulting in increased accumulation of GFP-Aβ42 in 
the mutant compared to the wild type.  
 
The function of Atg8p protein in yeast autophagy is well characterized. 
Atg8p undergoes conjugation to phosphatidylethanolamine forming the Atg8p-
PE complex. The Atg8p-PE complex plays an important role in the expansion of 
the autophagic membrane vesicle (phagophore) and in the formation of the 
autophagosome/AV (Huang et al., 2000; Xie et al., 2008). Atg8 gene expression 
is induced at least 10-fold in response to starvation (Gasch et al., 2000; Kirisako 
et al., 1999). In wild-type cells, GFP-Aβ42 is markedly reduced during late log 
phases of growth (Figure 3) which is a period of starvation in yeast. However 
compared to the wild type cells, the levels remain unchanged in the atg8Δ 
mutant throughout all stages of cell growth, most likely due to the inability to 
generate autophagosomes (AV), despite the initial signal by cell starvation to 
induce an autophagic response. Indeed, the atg8Δ mutants have been shown 
previously to have a low resistance to starvation conditions due to inability to 
form AV‟s and undergo autophagy (Xie et al., 2008). Interestingly, in wild-type 
cells only GFP-Aβ42 was reduced whereas GFP and GFP-Aβ42 (19:34) levels 
remained relatively stable during the late log phases. As GFP-Aβ42 (19:34) is 
unable to aggregate, these findings suggest that autophagy has a role in 
clearing Aβ42 aggregates and its up-regulation during the late stages of cells 
growth can enhance the clearance of these aggregates. 
 
The homolog of Atg8p in mammals belongs to a multigene family, consisting 
of GATE16 (GABA-A receptor-associated protein like protein), GABARAP 
(GABA-A receptor-associated protein), and LC3 (microtubule associated protein 
1) (Amar et al., 2006; Behrends et al., 2010; Hemelaar et al., 2003). Reports 
show co-localization of Aβ with LC3-II indicating that internalized Aβ can 
associate with autophagosomes (AV) (Hung et al., 2009). Also, a recent study 
showed that APP over-expressing mice with beclin1 (an autophagy related 
225 
 
protein, Atg6p in yeast) deficiency (APP+Becn1+/–) had reduced levels of LC3 
associated with intraneuronal accumulation of Aβ and AD like 
neurodegeneration and pathology (Pickford et al., 2008). These findings clearly 
showed that the disruption of neuronal autophagy can contribute to AD 
pathology. There are more than 30 autophagy-related (ATG) proteins identified 
so far in yeast. Analysis of yeast mutants deficient in ATG proteins can 
therefore help understanding the pathway of intracellular Aβ clearance and 
identify potential targets for intervention. A recent study has shown that cells 
deficient in Atg5p show increased levels of Aβ and altered metabolism (Tian et 
al., 2011). It is notable that Atg5p is a highly conserved protein which binds to 
Atg12p, and is involved in Atg8p lipidation and autophagosome (AV) synthesis 
(Mizushima et al., 1998; Mizushima et al., 2001).   
 
 
8.5.2 Vacuolar proteases mediate GFP-Aβ42 degradation during 
late log phase:  
 
Previous studies of AD brain revealed a marked up-regulation of 
lysosomal activity, including extensive involvement of various acid hydrolases 
and proteases such as cathepsins B and D with Aβ protein deposits (Cataldo et 
al., 1995; Cataldo et al., 1996; Dreyer et al., 1994; Evin et al., 1995; Nixon and 
Cataldo, 1993; Tagawa et al., 1991). Several lines of evidence indicate that 
autophagy in AD is predominantly a cause of defective lysosomal proteolysis 
(Nixon and Yang, 2011). In yeast, proteinases pep4p (yscA, homolog of 
cathepsin D) and cvt1p (yscB, member of subtilisin family) are the vital 
endopeptidases which are responsible for activation of most of the proteases 
which operate in the vacuolar (lysosomal) lumen under nutritional stress 
conditions and autophagy (Nair and Klionsky, 2005; Teichert et al., 1989).  
 
Unlike the atg8Δ mutant which showed diffuse fluorescence, GFP-Aβ42 
showed increased punctate fluorescence in the vacuolar protease deficient cells 
(pep4Δ and cvt1Δ). These findings suggest that although the GFP-Aβ42 can be 
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sequestered into AVs, the lack of vacuolar proteases prevent its degradation, 
leading to the accumulation of Aβ42 containing vesicles. This notion is 
supported by the findings that compared to wild-type cells, the pep4Δ and cvt1Δ 
mutants showed accumulation of GFP-Aβ42 levels during late log phase (Figure 
4, 5, 6), suggesting that degradation by the vacuole is impaired at these stages 
of growth. These findings are in line with others that show vacuolar hydrolase 
activity of pep4p and cvt1p are required for degradation of autophagic bodies 
(Xie et al., 2008) and are also associated with targeted degradation of misfolded 
proteins in the vacuole (Hong et al., 1996). A similar pattern of AV accumulation 
and neuritic dystrophy is also observed in the brain when lysosomal 
degradation is inhibited by deletion of cathepsins (pep4p in yeast) (Felbor et al., 
2002; Koike et al., 2000; Koike et al., 2005) or by lysosomal enzyme inhibitors 
(Bednarski et al., 1997; Boland et al., 2008; Ivy et al., 1989; Takeuchi and 
Takeuchi, 2001; Yang et al., 2008). Cathepsin mutations are also associated 
with lysosomal storage disorders coupled with severe neurodegeneration 
(Tyynela et al., 2000). Interestingly, compared to wild-type yeast, in the pep4Δ 
and cvt1Δ mutants the levels of GFP-Aβ42 expression during the active growth 
phase (OD 0.2-1.1, Figure 5) were unaltered. These results indicate that the 
proteases pep4p and cvt1p are not involved in actively degrading GFP-Aβ42 
during the active growth phase of yeast. Unlike pep4Δ and cvt1Δ, the levels of 
GFP-Aβ42 were increased during the active growth phase in atg8Δ mutant 
compared to the wild type. This indicates that low levels of autophagy can 
operate in the cell during the active growing stage. Atg8p is also known to be 
involved in the formation of vesicles required for the cytoplasm to vacuole (CVT) 
pathway which operates constitutively under growing conditions (Kirisako et al., 
2000; Nair and Klionsky, 2005). Therefore this result suggests that Aβ42 
degradation maybe targeted via the CVT pathway in addition to 
macroautophagy as both pathways involve Atg8p.  
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8.5.3 Decreased proteasomal activity increases GFP-Aβ42 
accumulation: 
 
Overall data from the GFP-Aβ42 expression in autophagosome/AV 
synthesis deficient (atg8Δ) cells and vacuolar protease deficient (pep4Δ, cvt1Δ) 
cells suggests that apart from catabolic mechanisms like autophagy operating 
during starvation, degradation of GFP-Aβ42 can also occur constitutively during 
the growth phase. Another pathway that can be active during cell growth and 
can actively degrade proteins is the ubiquitin-proteasome pathway. Apart from 
short lived proteins, the 26S proteasome is also responsible for degradation of 
damaged, misfolded proteins (Cohen et al., 2008; Hilt and Wolf, 1996; 
Hochstrasser, 1996; Loayza and Michaelis, 1998; Werner et al., 1996). Studies 
also reveal interactions between UPS and autophagy suggesting a coordinated 
and complementary relationship between these degradation systems which is 
critical during periods of cellular stress (Nedelsky et al., 2008).  
 
The expression of GFP/GFPAβ was studied in yeast strains (pre1Δ and 
pre1-2Δ) bearing mutations in genes coding for two proteolytic proteasome 
subunits responsible for chymotrypsin like activity: β4 (PRE1) and β5 (PRE2) 
(Egner et al., 1995; Kragt et al., 2005). The pre1-2Δ mutant has been shown to 
have lower chymotrypsin activity than pre1Δ (Heinemeyer et al., 1991). 
Compared to wild-type cells, GFP-Aβ42 accumulated throughout the growth 
phases in pre1Δ and pre1-2Δ mutant cells (Figure 7, 8 and 9). This result 
indicates that in yeast, these proteolytic proteasomal subunits can degrade 
Aβ42. At the later stages of cell growth (OD3.3) GFP-Aβ42 expression was 
undetectable in wild-type yeast but also reduced in pre1Δ and pre1-2Δ mutant 
cells. These results indicate that at later stages of cell growth, autophagy is the 
prominent pathway that is responsible for the reduction in Aβ42 levels. 
Differences in GFP-Aβ42 degradation in pre1Δ and pre1-2Δ cells were apparent 
only during the late log phase (OD 3.3) (Figure 8, 9). This may suggest that 
autophagy maybe compensating for the differences in chymotrypsin activity 
between pre1Δ and pre1-2Δ during the growth phase.  
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Herein this chapter, I showed that levels of Aβ42 can be regulated by both 
autophagy and the proteasome pathways in the cell. Since Aβ42 has a strong 
tendency to self-aggregate, it is likely that a variety of GFP-Aβ42 isoforms (low-
n oligomer to aggregates) maybe be present in the cell. It is possible that 
different GFP-Aβ42 forms are degraded differently by autophagy and the 
proteasome in the cell as it is widely accepted that the proteasome and 
autophagy have distinct differences in substrates for degradation (Rubinsztein, 
2007). It is possible that smaller misfolded oligomeric forms of GFP-Aβ42 are 
degraded by the proteasome and the larger aggregated forms are degraded by 
autophagy. This might also explain the different patterns of GFP-Aβ42 
expression levels in autophagy-lysosomal pathway and ubiquitin-proteasome 
deficient mutants. 
 
8.6    Summary 
 
In this chapter the GFP-Aβ expressing yeast model was used for 
characterizing the role of important pathways involved in the intracellular 
degradation of Aβ42 aggregates. Mutants deficient in vesicular transport of 
autophagic vesicles (atg8Δ), acid hydrolases involved in degradation in the 
vacuole (pep4Δ, cvt1Δ) and proteasomal activity (pre1Δ and pre1-2Δ) have 
provided insight into some of the pathways involved in the clearance of Aβ42 
aggregates inside the cell. Modulation of these cellular degradation pathways to 
enhance clearance of protein aggregates is gaining interest as a therapeutic 
strategy in many neurodegenerative diseases particularly AD where the majority 
of cases are defective in clearing A. Similar to other yeast models for studying 
protein aggregates such as huntington poly Q aggregates (Sokolov et al., 2006) 
or α-synculein aggregates (Zabrocki et al., 2005) the GFP-Aβ42 yeast model 
can also be used to identify/screen agents that can enhance Aβ42 intracellular 
clearance. In the next chapter, the use of this yeast model to determine the 
ability of known autophagy enhancer rapamycin in GFP-Aβ clearance is 
presented. In addition, the molecular action of the AD drug latrepirdine in 
enhancing autophagy and promoting GFP-Aβ clearance has been assessed. 
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The Role of Latrepirdine in 
Enhancing Aβ42 Clearance   
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9.1     Introduction: 
 
In chapter 8, the role of the intracellular degradation/clearance pathways 
(autophagy-lysosome and ubiquitin-proteasome) on distribution and levels of 
GFP-Aβ42 in yeast was studied. The expression levels and distribution of 
GFP/GFPAβ fusion proteins were analysed in yeast cells deficient in AV 
synthesis (atg8Δ), vacuolar proteases (pep4Δ and cvt1Δ) or proteasomal 
activity (pre1Δ and pre1-2Δ). Overall, the data showed that GFP-Aβ42 
accumulated in yeast mutant cells that lacked autophagy or proteasomal 
activity, indicating that disruption of these intracellular degradation pathways 
impaired the clearance of GFP-Aβ42 in the cell.  
 
Modulating cellular degradation pathways to enhance clearance of 
protein aggregates is gaining interest as a therapeutic strategy in many 
neurodegenerative diseases (Rubinsztein et al., 2007). However, stimulating 
proteasomal activity as a therapeutic approach can have serious undesirable 
effects because many key short-lived intracellular regulators, which are 
essential for the normal functioning of the cell, are also degraded. Therefore up-
regulating autophagy is considered to be more safer and tractable alternative as 
its substrates are generally long lived proteins and are not believed to be 
selectively degraded (Rubinsztein, 2006). Enhancing autophagy has been 
suggested as a treatment strategy for Huntington‟s Disease (HD) (Ravikumar et 
al., 2004; Sarkar et al., 2007b; Williams et al., 2008) and α-synucleinopathies 
such as Dementia with Lewy Bodies (DLB; (Crews et al., 2010)). Currently the 
commonly used pharmacological agent for up-regulating autophagy in neurons 
is rapamycin (Rubinsztein et al., 2007; Williams et al., 2008). This agent is 
known to activate autophagy by inhibiting mTOR and has been shown to 
enhance clearance of Huntington protein and α-synuclein aggregates in various 
cell and animal models (Crews et al., 2010; Ravikumar et al., 2004). It has also 
been shown to protect SH-SY5Y cells from Aβ42 toxicity (Hung et al., 2009), 
and recently been shown to improve cognition and reduce cerebral amyloid load 
in a mouse model of AD (Spilman et al., 2010). A recent study has also shown 
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that a small molecule enhancer of rapamycin (SMER28) decreases levels of Aβ 
via Atg5 dependent autophagy in neuronal cells (Tian et al., 2011). 
 
Another agent which has received considerable attention recently as a 
result of successful phase II clinical trials for HD (Kieburtz et al., 2010) and AD 
(Doody et al., 2008) is latrepridine (Dimebon, dimebolin). Like rapamycin, 
latrepridine also shows neuroprotective activity (Bachurin et al., 2001; 
Lermontova et al., 2001; Wu et al., 2008; Zhang et al., 2010b).  A study of 
synucleinopathy in a mouse model has found that latrepirdine reduced levels of 
-synuclein protein deposits and associated neurodegeneration, suggesting 
enhanced clearance of protein deposits (Bachurin et al., 2009). It has also been 
shown to modulate Aβ secretion and metabolism in neuronal cells and promote 
the secretion of Aβ42 into the interstitial fluid of AD mice (Steele et al., 2009). 
Recent studies have also reported latrepirdine‟s cognitive enhancing properties 
in wild-type and AD transgenic mice, although the mechanism of action 
responsible for improving memory functions is unclear (Giorgetti et al., 2010; 
Vignisse et al., 2011). It is conceivable that latrepirdine may have multiple 
targets that may account for its neuroprotective functions; however the studies 
from Bachurin et al., (2009) and Steele et al., (2009) in particular, suggest a role 
for latrepirdine in the removal of protein aggregates or preventing the formation 
through enhancing clearance. This may represent an underlying mechanism for 
latrepirdine‟s benefits in neurodegenerative disease characterised by 
accumulation of misfolded or aggregated proteins. In this chapter, I employed 
the GFP-Aβ42 expressing yeast model to investigate whether enhancing 
autophagy can reduce levels of Aβ aggregates. I investigated whether 
latrepirdine (DimebonTM) upregulates autophagy similar to that observed for 
established activators rapamycin or nitrogen starvation. Latrepirdine‟s ability to 
alter GFP-Aβ42 levels and protect against oligomer Aβ toxicity in the yeast 
model was also assessed.   
 
The clearance of Aβ42 from the periphery is thought to play an important 
role in preventing the accumulation of Aβ in the brain (see introduction Section 
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1.9.1). Our laboratory has developed an in vivo model in which the clearance of 
peripherally injected human Aβ42 is followed over a period of time (Hone et al., 
2003; Sharman et al., 2010). We have used this model to show APOE genotype 
specific effects on the peripheral clearance of Aβ42, in which the presence of 
APOEε4 results in impaired clearance from the blood and the major peripheral 
organ to degrade Aβ, the liver (Sharman et al., 2010). Using this model, the 
ability of latrepirdine to enhance clearance of Aβ42, in the presence of APOE ε4 
was also determined.  
 
9.2    Aims: 
 
1.) Assess the levels of GFP-Aβ42 in wild-type and autophagy deficient (atg8Δ) 
mutant yeast cells following treatment with rapamycin.  
2.) (i) Determine if latrepirdine can induce autophagy by evaluating vacuolar 
uptake of FM4-64 dye, Pho8 activity and Atg8p localization in latrepirdine 
treated wild type and atg8Δ yeast cells and (ii) compare activity with those 
observed for the known activators of autophagy in yeast, nitrogen starvation 
and rapamycin treatment. 
3.) Assess the cellular distribution and levels of GFP-Aβ42 in wild-type and 
autophagy deficient (atg8Δ) mutant yeast cells following activation of autophagy 
via latrepirdine. 
4.) Determine if enhancing autophagy can protect yeast cells from oligomer 
Aβ42 induced toxicity.  
5.) Determine if latrepirdine can enhance the peripheral clearance of Aβ42, in 
vivo, in the presence of APOE ε4.  
 
9.3     Materials and Methods: 
 
Non transformant or GFP-Aβ42/ GFP-Aβ42 (19:34) expressing (wild type 
and atg8Δ) yeast cells treated with rapamycin (0.1-0.2μM), latrepirdine (1-5μM) 
or incubated in nitrogen depleted media were analysed by anti-Aβ (WO2) 
immunoblotting and assays for measuring autophagy as described in Section 
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2.2.18. Aβ42 mediated loss of cell viability in yeast (Candida glabrata) cells 
following pre-treatment with latrepirdine, rapamycin or nitrogen starvation was 
measured by colony count assay as described in Section 2.2.4.3.  
 
APOE KO mice were injected with Aβ42 (20µg) +ApoE4 lipid emulsions 
in the absence or presence of latrepirdine (3.5mg/kg). Following injections, the 
animals were sacrificed at different time points (2.5, 5 and 15 min) and the 
levels of Aβ42 in the blood plasma and liver tissues were determined by 
immunoblotting analysis as described in Section 2.2.19. The peripheral 
clearance experiments in mice were performed by Dr Ian Martins, Kevin Taddei, 
Mike Morici and Linda Wijaya from our laboratory.  
 
9.4       Results: 
9.4.1 Rapamycin treatment in GFP-Aβ expressing wild type and 
atg8Δ yeast cells 
To determine if activation of autophagy would reduce levels of 
intracellular Aβ42 in yeast, actively growing (OD 0.7) wild type and autophagy 
deficient mutant (atg8Δ) cells expressing GFP-Aβ42 and wild type cells 
expressing GFP-Aβ42 (19:34) were treated with rapamycin. Rapamycin inhibits 
mTOR signalling and activates autophagy by binding to FK-binding protein 12 
(FKBP12) and preventing the complex formation with mTORC1. It is also a 
widely used compound for enhancing autophagy in yeast cells (Klionsky, 2010; 
Nair and Klionsky, 2005). Following rapamycin treatment for 1h at 30°C, cells 
were collected for fluorescence quantification, Aβ immunoblotting and cell 
viability.  
The GFP fluorescence images of untreated and rapamycin treated 
(0.2μM) wt-GFP-Aβ42, atg8Δ-GFP-Aβ42 and wt-GFP-Aβ42 (19:34) expressing 
cells are shown in Figure 1A-F.The distribution of the GFP fusion proteins in 
wild-type and atg8Δ cells are similar to that described in chapter 8 (Section 
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8.4.1). Rapamycin treatment did not appear to alter the distribution of GFP 
fluorescence but instead in wild-type cells expressing GFP-Aβ42, appeared to 
reduce the amount of punctate/ diffuse fluorescence.  To provide a quantitative 
assessment, the percentage of green fluorescent cells was estimated following 
treatment (Figure 1G). Compared to vehicle, rapamycin treatment (0.1 and 
0.2μM) resulted in significant reduction in the percentage of cells expressing 
GFP.  However, wild-type cells expressing GFP-Aβ42 were more sensitive to 
rapamycin where treatment resulted in an 80-95% decrease in Aβ42 levels. 
Rapamycin treatment of atg8Δ mutant yeast, resulted in a 55-80% decrease in 
fluorescence levels, whilst treatment of wild type cells expressing non 
aggregating GFP-Aβ42 (19:34) resulted in a 40-75% decline (Figure 1G).  
As a more quantitative measure of levels of the GFP-Aβ proteins after 
rapamycin treatment, aliquots of cells were collected for Aβ immunoblotting 
analysis (Figure 2). Compared to vehicle treatment, rapamycin treatment (0.1, 
0.2µM) resulted in a significant reduction in Aβ42 levels in all cell lines (Figure 
2A, B). In addition, to enhancing autophagy, rapamycin is a potent inhibitor of 
mTOR which is an important pathway for cell growth and protein synthesis. To 
rule out the possibility that the reduction in GFP-Aβ42 in wild-type and mutant 
cells was due to impaired cell growth, percentage cell viability was estimated 
following treatment. The results (Figure 2C) show that rapamycin treatment did 
not  alter cell viability indicating that  the decrease in  Aβ levels following 
rapamycin treatment was not due to a reduction in the percentage of viable cells 
(Figure 2C). However, it cannot be ruled out that the non-specific effects of 
rapamycin on protein synthesis contributed to the reduction in GFP-Aβ42 levels 
in treated wild-type and atg8Δ cells.  
The reduction of Aβ42 levels was more prominent in wild-type yeast cells 
expressing GFP-Aβ42, compared to mutant cells expressing GFP-Aβ42 or wild-
type cells expressing GFP-Aβ42 (19:34). Wild-type cells expressing GFP-Aβ42 
were more sensitive to rapamycin where treatment resulted in an 80-95% 
decrease in Aβ42 levels. Rapamycin treatment of atg8Δ mutant yeast, resulted 
in a 65-80% decrease in Aβ42 levels, whilst treatment of wild type cells 
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expressing non- aggregating GFP-Aβ42 (19:34) resulted in a 40-80% decline in 
GFP-Aβ42 levels (Figure 2B). These results indicate that although rapamycin 
led to non-specific background effects in yeast, its ability to induce autophagy 
resulted in a reduction in intracellular GFP-Aβ42. I next investigated if similar to 
rapamycin; latrepirdine induced autophagy and reduced the intracellular 
accumulation of GFP-Aβ42 aggregates. 
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Figure 1: Rapamycin treatment in GFP-Aβ42 and GFP-Aβ42 (19:34) 
expressing wild type and atg8Δ cells: percentage of fluorescing cells  
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were 
grown overnight in 5ml YNB+2%glucose (-ura) media. Cells were resuspended 
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After 
incubation at 30ºC, at OD of 0.7, the cells were treated with rapamycin (0, 0.1 
and 0.2μM) for 1h. Following treatment the cells were collected for microscopic 
analysis. GFP fluorescence images of untreated and rapamycin treated (0.2μM) 
wt-GFP-Aβ42 (A, D), atg8Δ-GFP-Aβ42 (B, E) and wt-GFP-Aβ42 (19:34) (C, F) 
expressing cells are shown here. The percentage of cells expressing green 
fluorescence following treatment was estimated as described in the Section 
2.2.16 (G).  Compared to untreated control, the percentage of cells expressing 
green fluorescence were significantly reduced in all cell lines treated with 
rapamycin (#, p<0.01). Compared to wild-type cells expressing GFP-Aβ42 
(19:34) or atg8Δ mutant cells expressing GFP-Aβ42, the fluorescence levels 
were significantly reduced in wild-type cells expressing GFP-Aβ42 (*, p<0.01 at 
0.1 and 0.2µM rapamycin treatment). Data is represented as mean ± SEM 
(n=3). 
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Figure 2: Rapamycin treatment in GFP-Aβ42 and GFP-Aβ42 (19:34) 
expressing wild type and atg8Δ cells: Levels of GFP-Aβ fusion proteins 
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were 
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended 
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After 
incubation at 30ºC, at OD of 0.7, the cells were treated with rapamycin (0, 0.1 
and 0.2μM) for 1h. Following treatment the cells were collected for 
immunoblotting and viability analysis. Cell extracts (100µg) from untreated and 
rapamycin treated (0.1μM or 0.2μM) wild-type and atg8Δ mutant cells 
expressing GFP-Aβ42 or wild-type cells expressing GFP-Aβ42 (19:34) were 
prepared and probed with anti-Aβ (WO2) (A). Expression levels of Aβ42 
(immunoreactive bands) were quantified and expressed as a percentage of 
untreated control and data represented as mean ± SEM (n=3) (B). Compared to 
untreated control, levels of Aβ42 were significantly reduced in all cell lines 
treated with rapamycin (#, p<0.01). Compared to wild-type cells expressing 
GFP-Aβ42 (19:34) or atg8Δ mutant cells expressing GFP-Aβ42, Aβ42 levels 
were significantly reduced in wild-type cells expressing GFP-Aβ42 (*, p<0.05 **, 
p<0.01 at 0.1 and 0.2µM rapamycin treatment). Cell viability was estimated in 
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all untreated and treated cell lines and expressed as a percentage of untreated 
control (C). Rapamycin treatment did not significantly alter the viability of cells.  
 
9.4.2 Autophagy in nitrogen starved, rapamycin or latrepirdine 
treated wild type and atg8Δ yeast cells 
Latrepirdine‟s ability to enhance autophagy was compared to known 
activators of autophagy in yeast. Incubating cells in growth media depleted of 
any form of nitrogen source or treating with rapamycin are well known methods 
of inducing autophagy in yeast (Cheong and Klionsky, 2008). Exponentially 
growing wild-type and atg8Δ mutant cells (OD 0.7) were either nitrogen starved, 
treated with various doses of latrepirdine or 0.2M rapamycin for 6h. Autophagy 
was then monitored by following the bulk transport of cytosolic material for 
degradation in the vacuole using a vacuolar specific lipophilic dye FM 4-64 
(Journo et al., 2008) and by measuring increased vacuolar alkaline 
phosphatase (Pho8) activity in cell extracts using the fluorimetric α-naphthyl 
phosphate assay (Noda and Klionsky, 2008).  
Cells that either underwent nitrogen starvation or treated with rapamycin 
(0.2μM) or latrepirdine (2.5μM) were stained with FM 4-64 (Figure 3). Activation 
of autophagy was indicated by intravacuolar staining and multivesicular bodies 
as shown in wild-type cells treated with rapamycin or nitrogen starved (Figure 
3B, C) indicating transport of cytosolic material for degradation. However, in the 
absence of autophagy in either untreated wild-type cells or atg8Δ mutant cells, 
staining of the vacuole perimeter was observed (Figure. 3A, I-L). The 
percentage of cells showing intravacuolar staining was estimated and shown in 
Figure 3Q. As expected, nitrogen starvation and rapamycin treatment resulted 
in almost 90% of cells showing intravacuolar staining, indicating strong 
activation of autophagy. Although latrepirdine treatment also showed 
significantly increased intravacuolar staining (up to ~40% cells, Figure 3D, Q, 
p<0.01), it was ~2 fold less than nitrogen starvation and rapamycin treatment. 
As expected nitrogen starvation, rapamycin or latrepirdine treatment of atg8Δ 
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mutant cells did not result in significant intravacuolar staining, consistent with 
the inability of these cells to undergo autophagy.  
Similar results were obtained when vacuolar alkaline phosphatase 
(Pho8) activity was assessed. Compared to untreated wild-type cells, nitrogen 
starvation and rapamycin treatment resulted in a 4-5 fold increase in alkaline 
phosphatase activity (Figure. 4A). Treatment of cells with latrepirdine also 
resulted in an increase in alkaline phosphatase activity (Figure. 4B). However, 
Latrepirdine was less potent than either rapamycin or nitrogen starvation (eg. 
activity for nitrogen starvation = 4.5 U/g, highest activity for latrepirdine =1.7 
U/g). Treatment of atg8Δ mutant cells did not result in any increase in vacuolar 
phosphatase activity. To investigate a more specific autophagic marker, I 
studied the localization of Atg8p, an essential autophagic protein involved in 
autophagosome formation which is up-regulated and transported to vacuole 
during autophagy (Xie et al., 2008). 
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Figure 3: N-starvation, rapamycin and latrepirdine treatment induces vacuolar 
uptake of FM 4-64 dye.  
Wild type and atg8Δ yeast were grown overnight in 5mL YEPD media. Cells 
were resuspended in fresh YEPD to a cell density (OD at 600nm) of 0.2-0.3. 
After incubation at 30ºC, at OD of 0.7, the cells were washed in sterile water 
and resuspended in minimal media (YNB complete) containing rapamycin 
(0.2µM) or latrepirdine (ltp) (1µM, 2.5µM) or in YNB (-N) media for 6h. Following 
treatment cells were stained with FM 4-64 as described in the material and 
methods. FM 4-64 staining was observed by fluorescence microscopy in wild 
type (A-H) and atg8Δ (I-P) cells. The number of cells showing intravacuolar 
staining and multivesicular morphology were counted as percentage of total cell 
population (Q). Untreated cells showed minimal (<10%) of intravacuolar or 
multivesicular staining. Significant increase in intravacuolar or multivesicular 
staining was observed in wild-type cells compared to atg8Δ mutant cells that 
underwent N-starvation, rapamycin treatment (0.2μM) or latrepirdine treatment 
(1µM, 2.5µM) (**, p<0.01). Data represents mean ±SEM (n=4). 
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Figure 4: N-starvation, rapamycin and latrepirdine treatment increases vacuolar 
Alkaline Phosphate (Pho8) activity.  
Wild type and atg8Δ yeast were grown overnight in 5mL YEPD media. Cells 
were resuspended in fresh YEPD to a cell density (OD at 600nm) of 0.2-0.3. 
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After incubation at 30ºC, at OD of 0.7, the cells were washed in sterile water 
and resuspended in minimal media (YNB complete) containing rapamycin 
(0.2µM) or latrepirdine (0.25µM, 0.5µM, 1µM, 2.5µM and 5µM) or in YNB (-N) 
media for 6h. Vacuolar alkaline phosphatase activity was measured in cell 
extracts and expressed as U/μg of total protein in the cell extract (A). Alkaline 
phosphatase activity was significantly increased (**, p< 0.01, n=3) in wild type 
compared to atg8Δ cells that underwent N-starvation or treatment with 0.2μM 
rapamycin.  Cells treated with latrepirdine exhibited ~4 fold lesser activity than 
those that underwent N-starvation or rapamycin treatment and thus activities 
were represented on separate graphs (B). Activity was significantly increased 
dose dependently in wild type compared to atg8Δ cells treated with latrepirdine 
(**, p<0.01, n=3). atg8Δ mutant cells that underwent latrepirdine treatment 
showed similar levels of activity as untreated wild-type cells in accordance with 
the inability of this cell line to undergo autophagy. Data is represented as mean 
± SEM (n=4). 
 
 
A GFP-Atg8p expressing yeast was used to examine the transport of Atg8p to 
the vacuole (Yen et al., 2007). atg8Δ cells were transformed with GFP-Atg8p 
plasmid (pRS306). Starting at OD 0.2 yeast culture (wt, atg8Δ) was cultured 
until exponential phase (OD 0.7) and then treated with rapamycin (0.2µM) 
(Figure 5B, F), nitrogen starved (Figure 5C, G) or latrepirdine (2.5µM) (Figure 
5D, H) for 6h. Following treatment, the cells were observed by fluorescent 
microscopy. With activation of autophagy, the GFP-Atg8p is transported to the 
vacuole for degradation. While the Atg8p is recycled, the GFP moiety remained 
intact in the vacuole showing diffuse green fluorescence which was used to 
monitor autophagic flux (Kim et al., 2001a). Compared to vehicle treated cells, 
rapamycin, nitrogen starvation and latrepirdine treated cells showed significant 
increase in cells with diffuse GFP fluorescence. With 2.5µM latrepirdine 
treatment ~25% of the cell population exhibited diffuse GFP fluorescence 
compared to ~90% with nitrogen starvation or rapamycin treatment (Figure 5I), 
indicating activation of autophagy. Overall, employment of three different 
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markers of the autophagy-vacuolar pathway indicates that although not a very 
strong inducer of autophagy compared to nitrogen starvation or rapamycin, 
latrepirdine induces autophagic like characteristics in yeast. Next I determined if 
similar to rapamycin, latrepirdine enhanced autophagy contributes to a 
reduction in GFP-Aβ42 levels.  
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Figure 5: N-starvation, rapamycin and latrepirdine treatment enhances 
transport of GFP-Atg8p to the vacuole.  
atg8Δ cells were transformed with GFP-Atg8p plasmid with URA selectable 
marker. The transformants were stored on YNB+2%glucose (-ura) agar plates 
at 4ºC. A single yeast colony from stock agar plates was inoculated in 5mL 
YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight. The 
overnight culture was resuspended in fresh YNB+2%glucose (-ura) media to a 
cell density (OD at 600nm) of 0.2. At cell density of 0.7, the cells were treated 
with rapamycin (0.2µM) (B, F), Nitrogen starved (C, G) or latrepirdine (2.5µM) 
(D, H) for ~6h till OD 0.8. Following treatment, the cells were observed by 
fluorescent microscopy. The number of cells showing diffuse green 
fluorescence was counted as a percentage in the total cell population (I) as 
described in the materials and methods. Data is represented as mean ± SEM 
(n=4). Rapamycin (0.2µM), Nitrogen starved or latrepirdine treatment (2.5µM) 
significantly increased the levels of diffuse GFP fluorescence (**, p<0.01, n=3) 
indicating the increased transport of GFP-Atg8p to the vacuole.  
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9.4.3 Latrepirdine treatment in GFP-Aβ expressing wild type and 
atg8Δ yeast cells  
To determine if activation of autophagy by latrepirdine reduced GFP-
Aβ42 levels, wild type and autophagy deficient mutant (atg8Δ) cells expressing 
GFP-Aβ42 and wild type yeast expressing GFP-Aβ42 (19:34) were treated with 
latrepirdine. Exponentially growing yeast cells (OD 0.7) were treated with 
different concentrations of latrepirdine ranging from 1-5µM. After incubating at 
30°C till OD 0.8 for ~4-5h, aliquots were collected for fluorescence 
quantification, Aβ immunoblotting and cell viability.  
GFP fluorescence images of untreated and latrepirdine treated (5μM) wt-
GFP-Aβ42, atg8Δ-GFP-Aβ42 and wt-GFP-Aβ42 (19:34) expressing cells are 
shown in Figure 6A-F. The distribution of the GFP fusion proteins in wild-type 
and atg8Δ cells are similar to that described in chapter 8 (Section 8.4.1). 
Latrepirdine treatment did not appear to alter the distribution of GFP 
fluorescence but instead in wild-type cells expressing GFP-Aβ42, appeared to 
reduce the amount of punctate/ diffuse fluorescence. To provide a quantitative 
assessment, the percentage of green fluorescent cells were estimated following 
treatment (Figure 6G). Compared to vehicle, latrepirdine treatment resulted in a 
significant reduction in percent of green fluorescent cells in wild type expressing 
GFP-Aβ42 (Figure 6G). A decrease of ~10% with 1µM up to ~40-50% with 2.5-
5µM was observed with latrepirdine treatment in wild type expressing GFP-
Aβ42 (Figure 6G). However, latrepirdine treatment did not significantly alter the 
percentage of fluorescence wild-type yeast cells expressing GFP-Aβ42 (19:34) 
or atg8Δ mutant cells expressing GFP-Aβ42 (Figure 6G). 
As a more quantitative measure of the levels of the GFP-Aβ proteins 
after latrepirdine treatment, aliquots of cells were collected for Aβ 
immunoblotting analysis (Figure 7). Compared to vehicle, latrepirdine treatment 
resulted in a significant reduction in GFP-Aβ42 protein levels in wild-type cells 
as measured by densitometric analysis of the Aβ immunoreactive bands (Figure 
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7A and B). A decrease of ~20% with 2.5µM up to ~40% with 5µM was observed 
with latrepirdine treatment in wild type expressing GFP-Aβ42 (Figure 7B). 
However, latrepirdine treatment did not significantly alter the Aβ levels of wild-
type yeast cells expressing GFP-Aβ42 (19:34) or atg8Δ mutant cells expressing 
GFP-Aβ42 (Figure 7A and B). In addition, latrepirdine treatment did not alter cell 
viability (Figure 7C).  
Overall, the data indicated that latrepirdine can reduce the levels of GFP-
Aβ42 in wild type cells expressing GFP-Aβ42. Unlike rapamycin, latrepirdine 
treatment reduced Aβ levels only in the wild type GFP-Aβ42 expressing cells 
and not in atg8Δ GFP-Aβ42 and wild type -GFP-Aβ42 (19:34) cells (compare 
Figure 6, 7 with 1, 2). Both rapamycin and latrepirdine have shown 
neuroprotective functions against Aβ toxicity in neurons. I further determined 
whether rapamycin and latrepirdine pre-treatment enhanced survival against Aβ 
toxicity in wild type and atg8Δ cells. 
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Figure 6: Latrepirdine treatment in GFP-Aβ42 and GFP-Aβ42 (19:34) 
expressing wild type and atg8Δ cells: percentage of fluorescing cells 
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were 
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended 
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After 
incubation at 30ºC, at OD of 0.7, the cells were treated with latrepirdine (0, 1, 
2.5, 5μM) for 6h. Following treatment the cells were collected for microscopic 
analysis. GFP fluorescence images of untreated and latrepirdine treated (5μM) 
wt-GFP-Aβ42 (A, D), atg8Δ-GFP-Aβ42 (B, E) and wt-GFP-Aβ42 (19:34) (C, F) 
expressing cells are shown here. The percentage of cells expressing green 
fluorescence following treatment was quantified as described in the materials 
and methods (G). Compared to untreated cells, latrepirdine treatment resulted 
in significant reduction in fluorescence levels in the wild type-GFP-Aβ42 
(*p<0.05). However no significant change in fluorescence levels was observed 
in wild type expressing GFP-Aβ42 (19:34) and atg8Δ expressing GFP-Aβ42. 
Data is represented as mean ± SEM (n=3). 
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Figure 7: Latrepirdine treatment in GFP-Aβ42 and GFP-Aβ42 (19:34) 
expressing wild type and atg8Δ cells: Levels of GFP-Aβ fusion proteins 
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were 
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended 
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After 
incubation at 30ºC, at OD of 0.7, the cells were treated with latrepirdine (0, 1, 
2.5, 5μM) for 6h. Following treatment the cells were collected for 
immunoblotting and viability analysis. Cell extracts (50µg) from untreated and 
latrepirdine treated (1-5μM) wild-type and atg8Δ mutant cells expressing GFP-
Aβ42 or wild-type cells expressing GFP-Aβ42 (19:34) were prepared and 
immunoblotted with WO2 (A) Expression levels of Aβ42 (immunoreactive 
bands) were quantified and expressed as a percentage of untreated control (C) 
and data represented as mean ± SEM (n=3). Compared to untreated cells, 
latrepirdine treatment resulted in significant reduction in Aβ levels wild type-
GFP-Aβ42 (*p<0.05, **p<0.01). However no significant change in fluorescence 
levels was observed in wild type expressing GFP-Aβ42 (19:34) and atg8Δ 
expressing GFP-Aβ42. Cell viability was estimated in all untreated and treated 
cell lines and expressed as a percentage of untreated control. Latrepirdine 
treatment did not significantly alter the viability of cells.  
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9.4.4 Aβ42 toxicity in yeast cells pre-treated with rapamycin, 
nitrogen starvation or latrepirdine 
Both rapamycin and latrepirdine have been shown to protect cerebellar 
neuron cultures against Aβ induced toxicity, modulate Ca+ channels (Bachurin 
et al., 2001; Lermontova et al., 2001; Wu et al., 2008) and enhance 
mitochondrial function in the absence or presence of cell stresses (Zhang et al., 
2010b). Thus, I next determined whether enhancing autophagy by rapamycin, 
latrepirdine or nitrogen starvation can reduce Aβ42 mediated toxicity in yeast.   
Exponentially growing Saccharomyces cerevisiae (KVY55) wild type cells 
(OD 0.7) were incubated with rapamycin (0.2μM), latrepirdine (1-5μM) or 
nitrogen depleted media for 6h. After treatment, cells were treated with oligomer 
Aβ42 (2μM) for 20h. Cell viability was measured by viable colony count and 
represented as percent of untreated (Figure 8). Aβ42 (2µM) treatment caused 
significant cell death (~80%) in vehicle treated wild type cells. However in 
nitrogen starved or rapamycin pre-treated wild type cells, Aβ42 caused only 
~30-40% cell death.  Similarly with latrepirdine pre-treatment (2.5 and 5µM) of 
wild type cells, Aβ42 caused only 40-50% cell death. The data showed that 
rapamycin, latrepirdine or nitrogen starvation pre-treatment reduced Aβ42 
mediated toxicity in wild type yeast (Figure 8A). 
 
To determine whether activation of autophagy induced protection against 
Aβ42, autophagy deficient (atg8Δ) cells pre-treated with rapamycin (0.2μM), 
latrepirdine (1-5μM) or nitrogen starved were treated with Aβ42 similar to the 
wild type cells. Interestingly, atg8Δ cells showed increased cell viability 
compared to wild type cells with Aβ42 treatment (see Figure 8B, A). Treatment 
of cells with 2μM Aβ42 caused cell death of only ~40% (~60% survival) in the 
atg8Δ cells compared to ~80% (~20% survival) in the wild type. However unlike 
wild type, the cell survival did not increase in atg8Δ cells pre-treated with 
rapamycin (0.2μM), latrepirdine (1-5μM) or nitrogen starved following Aβ42 
treatment. This showed that rapamycin, latrepirdine or nitrogen starvation did 
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not affect Aβ42 mediated toxicity in atg8Δ cells (Figure 8B). 
 
Overall the data showed that pre-treatment with known activators of 
autophagy, rapamycin and nitrogen starvation enhanced survival against Aβ42 
toxicity. In a similar fashion, latrepirdine pre-treatment also enhanced survival 
against Aβ42 toxicity. The increase in cell survival with rapamycin, nitrogen 
starvation or latrepirdine pre-treatment was evident only in wild type cells and 
was absent in the autophagy deficient mutant (atg8Δ). This result indicated that 
stimulation of autophagy in wild type cells increased its resistance against Aβ42 
toxicity, whereas due to the lack of autophagy atg8Δ cells did not show any 
increase in cell survival with rapamycin, nitrogen starvation or latrepirdine. 
Supporting this data is the previous observations where atg8Δ cells did not 
show any increase in autophagy with rapamycin, nitrogen starvation or 
latrepirdine treatment (Figure 3, 4 and 5). Interestingly, the atg8Δ cells 
displayed an increased resistance to Aβ42 toxicity (Figure 8). Whether this 
phenomenon is associated with a deficiency in autophagy in the mutant or due 
to a secondary effect of Atg8 gene deletion remains to be determined. 
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Figure 8: Oligomer Aβ42 toxicity in wild type and atg8Δ cells pre-treated with 
rapamycin, nitrogen starvation or latrepirdine  
Exponentially growing Saccharomyces cerevisiae (KVY55) wild type were 
incubated with rapamycin (0.2μM), nitrogen depleted media or increasing 
concentrations of latrepirdine (1-5μM) for 6h. After treatment, cells were treated 
with oligomer Aβ42 (2μM) for 20h. Cell viability was measured by viable colony 
count and represented as percent of untreated (A). Aβ42 treatment caused 
significant loss of viability in vehicle treated cells (#, p<0.001). However cell 
viability following Aβ42 treatment was significantly higher in nitrogen starved, 
rapamycin treated or latrepirdine (2.5 and 5μM) treated wild type cells 
compared to vehicle treated (*, p<0.05 **, p<0.01). Similarly, exponentially 
growing Saccharomyces cerevisiae (KVY55) atg8Δ cells were incubated with 
rapamycin (0.2μM), nitrogen depleted media or increasing concentrations of 
latrepirdine (1-5μM) for 6h. After treatment, cells were treated with oligomer 
Aβ42 (2μM) for 20h. Viability was represented as percent of untreated (B). 
Aβ42 treatment caused significant loss of viability in vehicle treated cells (#, 
p<0.001). No significant change in cell viability following Aβ42 treatment was 
observed in nitrogen starved, rapamycin treated or latrepirdine (2.5 and 5μM) 
treated atg8Δ cells compared to vehicle treated. All data expressed as mean± 
SEM (n=5). 
9.4.5 Latrepirdine enhanced the peripheral clearance of Aβ42 in 
vivo.   
 
A recent study has shown that latrepirdine stimulates secretion of Aβ in cell 
culture and also into the interstitial fluid of AD mouse brains (Steele et al., 
2009), suggesting that latrepirdine may promote the secretion/efflux from 
neuronal cells/brain. The efflux of Aβ42 from the CNS into the periphery and 
subsequent clearance/degradation by peripheral tissues is thought to be an 
important mechanism to regulate Aβ levels within the brain (basis of the 
peripheral sink hypothesis: see introduction section 1.9.1). Using an in vivo 
model developed by our laboratory to assess the clearance of Aβ42 in the 
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periphery, latrepirdine‟s ability to enhance clearance was evaluated.  
 
The clearance of peripherally injected human Aβ42 in plasma and 
subsequent degradation by peripheral organs was assessed as described in 
Section 2.2.19. Our laboratory has demonstrated that Aβ is rapidly removed 
from the plasma by the liver and kidney and the rate of its clearance is affected 
by ApoE in C57BL/6J and APOE knockout mice (Hone et al., 2003). Recently 
our laboratory showed that peripheral clearance of Aβ42 was impaired by the 
presence of ApoE4 (Sharman et al., 2010). This was shown in mice expressing 
human APOE ε4 (APOE ε4 targeted replacement (TR) mice) and also in APOE 
knockout mice injected with Aβ42 and lipidated ApoE4. To determine whether 
latrepirdine can promote clearance of Aβ42 in the periphery in the presence of 
ApoE4, APOE knockout mice were injected via the lateral tail vein with Aβ42 
(20µg) + lipidated ApoE4 in the absence or presence of latrepirdine. Mice were 
sacrificed at 2.5, 5 and 15 mins and blood plasma and liver tissues were 
collected. The levels of Aβ42 in blood plasma and liver were determined by 
immunoblotting analysis (Figure 9).  
 
 Aβ42 levels were significantly decreased in the plasma of mice injected with 
Aβ42+latrepirdine compared to Aβ42+saline at 2.5 and 5 minute time points 
(Figure 9A, B). At 2.5-5 minutes, the plasma Aβ42 levels were 50-65% less with 
latrepirdine injections compared to saline (Figure 9B). At 15 minutes, a trend 
towards a reduction in Aβ42 levels was observed between the two groups but 
this was not statistically significant. To further determine whether the reduced 
levels of Aβ42 in the plasma were associated with increased uptake in the liver, 
total protein extracts from the liver tissue homogenates were analysed by Aβ 
immunoblotting at similar time points (Figure 9A, C). A significant increase in 
the levels of Aβ42 was observed in the liver homogenates of Aβ42+latrepirdine 
injected mice compared to that of Aβ42+saline (Figure 9C). The increase in 
Aβ42 levels was significant only at the initial time point of 2.5 minutes. However 
no significant increase was observed at 5 and 15 minutes. Overall the data 
showed that in the presence of ApoE4, compared to saline, latrepirdine reduced 
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the levels of intravenously injected Aβ42 in the plasma. This reduction in blood 
plasma corresponded with an accumulation in Aβ42 in the liver at an early time 
point, possibly indicating that latrepirdine mediates the rapid transport of Aβ42 
from the plasma to the liver.  
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Figure 9: Peripheral Aβ42 Clearance in APOE KO mice administered ApoEε4 
and Aβ42 in the presence or absence of latrepirdine.  
Saline (S) or latrepirdine (L; 3.5mg/Kg) was co-incubated with Aβ42 (20μg) for 
3h prior to combining with ApoEε4 lipid emulsion and injecting into the tail vein 
of APOE KO mice. Mice were sacrificed at 2.5, 5 and 15 min after injection and 
Aβ clearance assessed by immunoblotting plasma and liver homogenates (A). 
In the presence of latrepirdine, more Aβ is cleared from the plasma (B), 
particularly at 2.5 and 5 min, with a corresponding increased uptake by the liver 
at 2.5 min (C). Data represents means ±SEM, n=4 in saline (S) group, n=5 in 
latrepirdine (L) group. Plasma Aβ levels are significantly reduced in mice 
injected with latrepirdine+Aβ42 compared to saline + Aβ42 injected ones (*, 
p<0.05; ** p<0.01). Liver Aβ levels was significantly increased in mice injected 
with latrepirdine+Aβ42 compared to saline + Aβ42 injected ones (#, p<0.05).  
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9.5     Discussion: 
 
The ubiquitin-proteasome and autophagy-lysosome pathways are the main 
intracellular degradation pathways for protein and organelle clearance in 
eukaryotic cells. Dysfunction of these pathways resulting in the accumulation of 
aggregate prone and toxic proteins in cells contributes to the pathology of 
several neurodegenerative diseases including AD. Modulating these cellular 
degradation pathways to enhance clearance of protein aggregates is gaining 
interest as a therapeutic strategy. In chapter 8, I showed that the proteasome 
had a greater contribution to reducing intracellular Aβ42 levels in yeast than 
autophagy, particularly at early stages of cell growth. However, at late log phase 
of cell growth, autophagy was the major contributor to reducing Aβ42 as cells 
enter a nutrient starvation stage. It is suggested that enhancing the autophagy-
lysosome pathway is a more favourable target to promote clearance of protein 
aggregates compared to the ubiquitin-proteasome system (Rubinsztein, 2006). 
One reason is the substrate limitations for proteasome mediated degradation. 
The proteasome degrades proteins that are ubiquitin tagged and only unfolded 
proteins which can enter the proteasomal core. By contrast, autophagy has the 
capacity to degrade folded proteins, large aggregates and even entire 
organelles. Upregulating autophagy is also considered to be safer and a more 
attractive alternative compared to enhancing the proteasomal activity as 
discussed previously in the introduction to this chapter (Section 9.1). Studies 
from a variety of models have shown that up-regulation of autophagy; both 
pharmacologically and physiologically can promote clearance of protein 
aggregates and attenuate neurodegeneration (Berger et al., 2006; Mizushima et 
al., 2008; Ravikumar et al., 2004; Sarkar et al., 2007b; Williams et al., 2008). 
 
In chapters 7 and 8, the GFP-Aβ expressing yeast model was used to 
investigate intracellular Aβ accumulation and degradation pathways involved in 
clearance of Aβ. Disruption of both ubiquitin-proteasome and autophagy-
lysosome pathway resulted in increased accumulation of GFP-Aβ42 compared 
to the wild type in the yeast cell. The use of this model to determine the effect of 
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rapamycin, a known activator of autophagy, in the clearance of GFP-Aβ42 in 
yeast cells has been presented here. Further, the ability of latrepirdine in 
activating autophagy, promoting clearance of GFP-Aβ42 and protecting cells 
from Aβ42 toxicity provides a novel mechanism of action for this promising drug 
for AD. 
 
9.5.1 Rapamycin reduced intracellular GFP-Aβ42 levels in yeast  
 
The typical pathway for modulating autophagy is via mTOR, a protein kinase 
that is central to nutrient-sensing signal transduction, regulation of translation 
and cell-cycle progression (Klionsky et al., 2005; Noda and Klionsky, 2008). 
mTOR can be inhibited by rapamycin and related molecules, which belongs to a 
family of lipophilic macrolide antibiotics that form a complex with the 
immunophilin FK506-binding protein 12 (FKBP12), which then binds to and 
inactivates mTOR, leading to an up-regulation of autophagy. Inhibition of mTOR 
by rapamycin has been widely reported to enhance clearance of aggregate-
prone proteins (Berger et al., 2006; Ravikumar et al., 2004; Sarkar and 
Rubinsztein, 2008). In mammalian AD models, rapamycin induced activation of 
autophagy have been shown to be neuroprotective and confer cognitive 
benefits (Hung et al., 2009; Spilman et al., 2010).  
 
Rapamycin treatment of GFP-Aβ42 expressing wild-type cells resulted in a 
reduction in GFP-Aβ42 levels (Figure 1). It is noted that rapamycin also led to a 
reduction in levels of GFP-Aβ42 expressed in atg8Δ mutant cells and the levels 
of the GFP-Aβ42 (19:34) expressed in wild-type cells. This may be due to 
rapamycin‟s action as a potent inhibitor of mTOR signalling, which is an 
important pathway for growth and cell cycle progression. Also rapamycin has 
been demonstrated to attenuate cell growth and inhibit protein synthesis in 
many cell lines (Hay and Sonenberg, 2004; Heitman et al., 1991). Results 
presented in Figure 1C show that cell viability was not significantly altered, 
however inhibition of protein synthesis cannot be ruled out which may have 
contributed to the decreased Aβ levels in  atg8Δ cells. Moreover, 
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macroautophagy is largely a non-specific process which sequesters bulk 
cytoplasmic material for degradation in the vacuole (Nair and Klionsky, 2005) 
and thus, apart from aggregate proteins, soluble cytosolic proteins and 
organelles are also degraded which may account for the reduction in levels of 
the non-aggregated GFP-Aβ42 (19:34). Nevertheless, it was shown that 
rapamycin mediated reduction in intracellular Aβ42 levels were more 
pronounced in the wild type cells expressing GFP-Aβ42 (Figure 1) compared to 
those expressing GFP-Aβ42 (19:34) and atg8Δ mutant cells expressing GFP-
Aβ42. The results suggest that rapamycin enhanced autophagy contributes to 
the removal of aggregated forms of Aβ. However, as is seen by the reduction in 
Aβ levels in cells that are unable to undergo autophagy, other non-autophagy 
related effects must be taken into consideration.  
 
Its effects on mTOR signalling cell growth, proliferation and protein synthesis 
(Hay and Sonenberg, 2004) and its known immunosuppressant effects 
(Abraham, 1998) indicates that rapamycin can have multiple cellular targets, 
some undesirable. Synthetic small molecule derivatives of rapamycin have 
been shown to have benefits at reducing toxicity induced by Huntington protein 
aggregates whist minimising its adverse effects (Floto et al., 2007; Ravikumar et 
al., 2004). A recent study has also shown that small molecule enhancer of 
rapamycin (SMER28) decreased levels of Aβ and APP-CTF via Atg5 dependent 
autophagy in neuronal cells (Tian et al., 2011). Further, derivatives of known 
agents shown to have benefits in AD models, such as resveratrol, have been 
developed and shown to modulate mTOR signalling and facilitate autophagy 
and Aβ clearance (Vingtdeux et al., 2010).  
 
Autophagy can also be induced by an mTOR-independent route by 
physiological stress, such as starvation or by 1) lowering myo-inositol-1,4,5-
triphosphate (IP3) levels (lithium, sodium valproate and carbamezapine) 2) L-
type Ca2+ channel antagonists (e.g. verapamil), 3) calpain inhibitors (e.g. 
calpastatin and calpeptin) and 4) Gsα inhibitors (such as NF449) (Zhang et al., 
2007) (Fornai et al., 2008; Sarkar et al., 2005). Trehalose, an mTOR 
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independent autophagy activator has also shown to enhance clearance of 
protein aggregates in HD and PD models (Sarkar et al., 2007a). As discussed 
below, the results presented in this chapter provide evidence in support of 
latrepirdine‟s ability to induce autophagy and reduce intracellular Aβ levels, 
without exhibiting the non-autophagy related effects observed for rapamycin. 
 
9.5.2 Latrepirdine induced autophagy and reduced intracellular 
levels of GFP-Aβ42  
 
Latrepirdine (Dimebon™; dimebolin) is a neuroactive compound with 
antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors 
(Wu et al., 2008). Latrepirdine is another small molecule that appears to 
mediate a number of activities associated with receptor inhibition (Grigorev et 
al., 2003), enhancing cognitive function (Lermontova et al., 2000), promoting 
neuronal survival (Bachurin et al., 2001; Zhang et al., 2010b), intracellular Ca+2 
stabilisation (Lermontova et al., 2001), Aβ secretion and metabolism (Steele et 
al., 2009) and clearance of α-synuclein protein aggregates (Wu et al., 2008; 
Yamashita et al., 2009). Some recent studies have also reported latrepirdine‟s 
cognitive enhancing properties (Giorgetti et al., 2010; Vignisse et al., 2011). In 
the current study an additional function for latrepirdine in enhancing autophagy 
was demonstrated. Latrepirdine was shown to induce autophagy by three 
independent methods, including morphological detection of autophagic bodies 
using FM 4-64 staining, measuring the autophagic flux by determining Pho8 
enzyme activity and by monitoring the vesicle delivery into the vacuole using a 
GFP-Atg8p expressing yeast (Figure 2, 3 and 4).    
 
The FM 4-64 dye belongs to a group of cationic amphiphilic styryl dyes that 
fluoresce in the presence of a hydrophobic environment (Betz et al., 1992). 
Under normal conditions the FM 4-64 dye is associated with the biological 
membrane and with longer incubations they are internalized and concentrate 
onto the vacuolar membranes. During starvation conditions, autophagic bodies 
accumulate in the cell and are transported into the vacuole for degradation. 
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When the breakdown of the autophagic bodies in the vacuole is inhibited by 
protease inhibitor (PMSF), intravacuolar bodies are observed accumulating in 
the vacuole marked by intense FM 4-64 staining inside the vacuole (Takeshige 
et al., 1992). Known activators of autophagy like nitrogen starvation and 
rapamycin induced accumulation of autophagic bodies associated with strong 
intravacuolar staining of FM 4-64 in yeast (Figure 2B, C). Latrepirdine treatment 
induced a similar phenotype in yeast indicating an increased accumulation of 
autophagic bodies in the vacuole (Figure 2D). Latrepirdine treatment (1-2.5µM) 
induced intravacuolar FM 4-64 uptake in approximately 40% of cells compared 
to ~90% in N-starved and rapamycin treated. However in the atg8Δ cells, where 
autophagy is impaired, such morphology was absent with nitrogen starvation, 
rapamycin and latrepirdine treatment (Figure 2I-L).   
 
Measurement of the activity of autophagy is referred to as autophagic flux. 
The Pho8 assay is a commonly used quantitative monitoring system of yeast 
autophagic flow based on the measurement of the enzyme activity during 
stimulation of autophagy (Noda and Klionsky, 2008). PHO8 is the gene 
encoding the sole vacuolar alkaline phosphatase in yeast. It is a type II 
transmembrane protein containing an N-terminal cytosolic tail with the active 
site and the C-terminus are located within the vacuolar lumen (Klionsky and 
Emr, 1989). During autophagy, the C terminal pro-peptide is cleaved off by 
vacuolar proteases resulting in the generation of the active form. Pho8 activity 
was measured using a specific substrate (α-naphthyl phosphate) using a 
fluorimetric assay. Latrepirdine increased the Pho8 activity in a dose dependent 
fashion at concentrations (0.25-5µM) (Figure 3). Similar to the FM 4-64 staining, 
latrepirdine treatment stimulation of Pho8 activity was markedly less than 
nitrogen starvation and rapamycin treatment. No increase in activity with 
latrepirdine, nitrogen starvation or rapamycin treatment was observed in atg8Δ 
cells, indicating that AV synthesis and Atg8p were essential for latrepirdine 
induced alkaline phosphatase activity. 
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The Atg8p molecule is an ubiquitin-like protein which conjugates to 
phosphatidylethanolamine (PE) and associates with the autophagosome/AV 
membrane during autophagy (Huang et al., 2000; Xie et al., 2008). After 
delivery to the vacuole, the Atg8p–PE complex is cleaved from the outer 
surface of the sequestering vesicle, but the GFP tag (in the GFP-Atg8p 
transformant) located on the inside of the vesicle remains trapped and was 
used as a functional marker for monitoring delivery of vesicles to the vacuole 
(Kim et al., 2001a). The released GFP moiety remains relatively stable from 
vacuolar hydrolysis, whereas Atg8p is rapidly degraded. Nitrogen starvation and 
rapamycin treatment induced a vacuolar GFP fluorescence phenotype in ~90% 
of cells, whereas latrepirdine treatment (2.5µM) induced a similar phenotype in 
~25% (Figure 4).  
 
Although not as efficient as rapamycin or N-starvation, latrepirdine promoted 
uptake of the vacuole stain FM 4-64, increased activity of the vacuolar alkaline 
phosphatase and up-regulation of GFP-Atg8p. Overall the data indicated that 
latrepirdine can promote autophagy in yeast cells. The lack of activation of 
autophagy in cells deficient in Atg8p may suggest that latrepirdine mediated 
autophagy in yeast was Atg8 dependent. However the exact mechanism of 
action is unclear.  The concentrations needed to induce autophagy for 
latrepirdine in yeast is around 1-5µM, which is approximately 5-50 times (by 
molarity) more than rapamycin (0.1-0.2µM). This probably suggests that 
latrepirdine may be a weak inhibitor of TOR, targeting a downstream signalling 
molecule of mTOR pathway or even mTOR independent. Isolating yeast 
mutants resistant to latrepirdine stimulated autophagy can assist in the 
identification of the potential mechanism of latrepirdine induced autophagy. In 
addition, analysis of other mutants lacking particular genes in the autophagic 
pathway, such as Atg1 (protein kinase required for vesicle formation) or Atg5 
(formation and transport of autophagosome) may provide further insight into 
potential targets for latrepirdine in the autophagic-vacuolar pathway in yeast. 
 
Latrepirdine significantly reduced GFP-Aβ42 levels expressed in wild-type 
266 
 
yeast cells but not in atg8Δ mutant cells, indicating the involvement of 
autophagic-vacuolar pathways. Similar to the activity observed in the 
autophagic assays, latrepirdine mediated decrease in GFP-Aβ42 levels in yeast 
was significantly lower compared to rapamycin treatment [40% decrease with 
5µM latrepirdine compared to ~95% with 0.2µM rapamycin (compare Figure 5 
and 1)]. The decreased ability of latrepirdine to stimulate autophagy compared 
to rapamycin may account for this. Assessing GFP-Aβ42 clearance in yeast 
cells deficient in essential components involved in the initiation of the pathway 
(through inhibition of mTOR), autophagosome formation and transport or 
autophagosome-vacuolar fusion, will provide further insight into possible targets 
for latrepirdine. Once identified this would require further validation in 
mammalian neuronal cells.  
 
9.5.3 Activation of autophagy protects yeast cells from Aβ42 
toxicity 
 
Activation of autophagy has been shown to be protective against a variety of 
stresses to cells (Levine and Kroemer, 2008; Mizushima et al., 2008). The pro-
survival function of autophagy has been demonstrated in cells and animal 
models during nutrient and growth factor deprivation, endoplasmic reticulum 
stress, development, microbial infection, and diseases characterized by the 
accumulation and toxicity of protein aggregates (Lum et al., 2005; Yorimitsu and 
Klionsky, 2007). 
 
Stimulation of autophagy by rapamycin and latrepirdine was shown to 
reduce the levels of GFP-Aβ42 aggregates in yeast cells (Section 9.5.1 and 
9.5.2). Therefore, I further determined whether activation of autophagy reduced 
toxicity of oligomeric Aβ42 using the colony count viability assay in yeast 
(Bharadwaj et al., 2008). Wild type and autophagy deficient atg8Δ cells were 
pre-treated with rapamycin, latrepirdine or nitrogen starved followed by oligomer 
Aβ42 treatment (Figure 8). The data showed that activation of autophagy by 
rapamycin, latrepirdine and nitrogen starvation enhanced survival against Aβ42 
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toxicity. The increase in cell survival was evident only in wild type cells and was 
absent in the atg8Δ cells. This result indicated that stimulation of autophagy in 
wild type cells increased its resistance against Aβ42 toxicity, whereas due to the 
lack of autophagy atg8Δ cells did not show any increase in cell survival. The 
observations that atg8Δ cells do not respond to rapamycin, nitrogen starvation 
or latrepirdine treatment (Figure 3, 4 and 5) further supported the notion that 
activation of autophagy enhanced survival against oligomer Aβ42 toxicity. 
 
 Interestingly, under normal conditions (without any pre-treatment) atg8Δ 
cells displayed an increased resistance to Aβ42 toxicity compared to the wild 
type (compare Figure 8A with 8B). Ideally, the atg8Δ mutant would have 
expected to be more susceptible to oligomeric Aβ42 treatment due to its inability 
to undergo autophagy. However in the yeast Aβ42 toxicity assay, atg8Δ cells 
showed almost ~2 fold increase in cell survival comparing the wild type. Studies 
indicate that autophagic related (ATG) genes can act both in cellular protection 
and also in cell death (Levine and Kroemer, 2008; Mizushima et al., 2008). 
Notably, many examples of ATG-gene dependent death occur in mammalian 
cells (Levine and Yuan, 2005; Pattingre et al., 2005). Whether Aβ42 mediated 
cell death in yeast is associated with Atg8 gene expression in cells is yet to be 
determined. Another likely possibility is that the knock-out of Atg8 gene in yeast 
may be associated with effects beyond autophagy which may contribute to this 
phenomenon. It is therefore unclear whether the increased resistance of atg8Δ 
cells to oligomer Aβ42 toxicity is autophagy dependent or a result of a 
secondary effect of Atg8 gene deletion. Investigation of oligomer Aβ42 toxicity 
in other ATG gene knock out mutants including Atg1, Atg5, Atg8, and Atg9 can 
provide a better insight into this effect. 
 
9.5.4 Latrepirdine promotes peripheral clearance of Aβ42 in the 
presence of ApoE4  
 
In addition to intracellular degradation pathways like autophagy, one of 
the important mechanisms of action with respect to clearance of Aβ from the 
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brain is the “peripheral sink” hypothesis (DeMattos et al., 2001). The main basis 
of this hypothesis is that Aβ is transported out of the brain, into the periphery 
where proteins in the circulation can sequester Aβ and deliver it to peripheral 
tissues like liver and kidney for clearance. Plasma Aβ levels in the periphery are 
typically low (Gandy et al., 2001), indicating that metabolic process facilitates 
rapid clearance of this protein in the periphery. Earlier studies (DeMattos et al., 
2001; DeMattos et al., 2002) have shown that Aβ can be cleared to the plasma 
from the brain by the use of anti-Aβ antibodies. In addition, work by Matsuoka et 
al. (Matsuoka et al., 2003) has showed that peripheral treatment with an agent 
having a high affinity for Aβ reduced brain levels of Aβ.  
 
 
While the yeast studies clearly provide valuable insight into the 
mechanism of action of latrepirdine in clearing A its clinical significance 
requires an in vivo model. Latrepirdine was therefore assessed for its ability to 
promote Aβ42 clearance in the periphery using APOE knockout mice injected 
with Aβ42+ lipidated ApoE4 (Figure 9). Substantial differences in the expression 
levels of total plasma ApoE has been observed in different APOE (ε2, ε3, and 
ε4) knock-in mice (APOE-targeted replacement (TR) mice) (Knouff et al., 1999; 
Sullivan et al., 1998). Therefore, to control for the differeing levels of plasma 
ApoE across genotypes, the peripheral clearance of Aβ42 was evaluated in the 
APOE knockout mouse model utilizing lipidated recombinant ApoE isoforms 
(Sharman et al., 2010). Regardless of the model used (APOE-TR mice or 
APOE KO mice +lipidated ApoE4), Sharman and colleagues showed that the 
presence of ApoE4 impaired the peripheral clearance of injected human Aβ42. 
The results presented in this chapter show that latrepirdine, compared to the 
saline control, can markedly improve the clearance of Aβ42 from the blood 
plasma and promote uptake by the liver, (Figure 9), in the presence of ApoE4. 
The reasons for these marked effects of latrepirdine on the peripheral clearance 
of Aβ42 are unclear. A possible explanation is that latrepirdine interacts with 
Aβ42; either preventing its further aggregation (thus promoting more effective 
clearance of Aβ monomers) or this interaction may promote its uptake (possibly 
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receptor mediated) and clearance/degradation by the liver. Steele et al., (2009) 
study reported increased Aβ levels in ISF of mice treated with latrepirdine. It is 
conceivable that as part of latrepirdine‟s overall effect, it enhances clearance of 
Aβ from the ISF and the CNS into the periphery where it is rapidly cleared.  
 
The findings presented in this chapter have provided initial evidence for a 
novel mechanism of action for latrepirdine in promoting the clearance of Aβ, in 
vivo. Further investigation into whether latrepirdine could modulate the 
aggregation and degradation of Aβ in mammalian in vitro and in vivo systems 
would be required. 
 
 
9.6    Summary 
 
Overall the data presented in this chapter has established the use of the 
yeast model for screening compounds which can reduce intracellular 
accumulation of Aβ, by possibly enhancing its clearance. A novel mechanism of 
action has also been identified for the AD drug latrepirdine. Latrepirdine was 
shown to enhance autophagy and promote Aβ clearance in cells. Although 
latrepirdine has shown mixed results in AD clinical trials, more recent studies 
are reporting its cognitive benefits in animal models. The ability of latrepirdine to 
stimulate autophagy in the yeast model can be used to develop analogues with 
increased potency and lesser toxicity. While rapamycin is the most widely used 
autophagy stimulating drug, growing evidence has emphasized the need for 
more specific and potent agents/small molecules to replace this first generation 
autophagy promoting drug. The identification of novel compounds which can 
specifically inhibit particular elements of autophagy combined with genetic 
screens can be resourceful to understand the pathways and the proteins 
involved with the clearance of intracellular aggregates. Besides its ability to 
modulate autophagy, in vivo studies showed that latrepirdine can promote 
peripheral Aβ42 clearance and also increase uptake into liver. In general, the 
data presented in this chapter have suggested that latrepirdine may operate by 
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multiple mechanisms to promote Aβ clearance thereby reducing its 
accumulation and toxicity. How and which of these effects relate to drug-related 
changes in cognition and behaviour will need to be elucidated in order to 
selectively modify this promising drug candidate and thus develop more potent 
related molecules that are tailored to effectively treat AD. 
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Chapter 10 
Conclusions and Future 
Directions 
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General Discussion: Cellular models are essential for studying the 
underlying pathology of a disease and designing novel techniques for drug 
discovery. Yeast has been used as a model for several neurological disorders 
characterized by protein misfolding and aggregation: reviewed in [(Braun et al., 
2010; Winderickx et al., 2008)]. In addition to its conserved nature, yeast cells 
are robust and have better tractability and reduced complexity compared to 
other mammalian cells which makes it a resourceful model for studying disease 
pathways and drug mechanisms. The work presented in my thesis has primarily 
focussed on establishing yeast models for investigating the toxicity and 
intracellular clearance pathways of beta amyloid (Aβ), a peptide central to the 
pathogenesis of Alzheimer‟s disease (AD). In this thesis, I have also 
demonstrated the use of the yeast model in investigating novel agents which 
can attenuate Aβ toxicity or enhance its clearance.  
 
10.1 Oligomer Aβ Toxicity 
10.1.1 Membrane associated toxicity of Oligomeric Aβ42  
 
AD is characterized by extensive neuronal loss associated with senile 
amyloid plaques in the brain. There is considerable evidence to clearly indicate 
that the soluble oligomeric forms of Aβ protein are the main toxic species which 
are responsible for the pathology of the disease. Aβ is an intramembrane 
cleavage product of APP and is largely secreted into the extracellular lumen. It 
can therefore have a major impact on neuronal functions and viability by 
interacting with cell surface membranes (Talaga and Quere, 2002; Verdier and 
Penke, 2004; Verdier et al., 2004). Due to its hydrophobic nature, Aβ has an 
inherent ability to associate with biological membranes. The ability to interact 
with membranes is therefore an important feature of oligomer Aβ mediated 
toxicity to cells.  
 
In earlier work I had demonstrated that  Aβ was shown to be toxic to yeast 
cells (Bharadwaj et al., 2008). I now show in chapter 3 of this thesis the 
significance of Aβ42 binding to the plasma membrane in causing cell death in 
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yeast. The uptake of the Aβ42 peptide by yeast and its localisation indicated 
that oligomeric Aβ42 mediated cell death was associated with binding to the 
plasma membrane. Taken together with previous reports in neuronal cells 
(Ciccotosto et al., 2004; Hung et al., 2008), the data supports the notion that 
reduced binding to the plasma membrane is associated with decreased toxicity. 
  
In yeast, oligomeric Aβ42 was shown to alter the activity of the plasma 
membrane proton pump H+ATPase (Section 3.4.5, Chapter 3), a functional 
homolog of the mammalian Na+/K+ ATPase. This data is consistent with 
previous reports from a non-yeast model which showed decreased Na+/K+ 
ATPase and Cl--ATPase activity in plasma membranes isolated from Aβ42 
peptide treated hippocampal cells (Bores et al., 1998; Mark et al., 1995; Xiao et 
al., 2002). This may be one mechanism by which oligomeric Aβ42 can impact 
cellular homeostasis and cause cell death. Further investigation is required to 
determine how oligomer Aβ42 inhibits the H+ATPase and whether modulating 
the activity of H+ATPase can rescue Aβ mediated cell death.  
 
10.1.2    Suppression of Aβ42 Oligomerization prevented Toxicity  
 
Preventing the formation or disrupting the specific toxic oligomer structures 
to reduce Aβ caused neuronal dysfunction in the brain has been proposed as a 
therapeutic strategy in AD (Klein, 2007; Kruzel et al., 2001). In my study, the 
effect of dairy peptides on Aβ oligomerization and toxicity was determined using 
the yeast model. Dairy peptides lowered the net β-sheet content and more 
specifically the anti-parallel β-sheet content in Aβ42 thereby inhibiting 
oligomerization. Studies indicating the essential role of anti-parallel β-sheets in 
the formation of Aβ oligomers further supported this data (Cerf et al., 2009). The 
concomitant reduction in the toxicity of the Aβ42 peptides with reduced 
oligomerization was clearly evident in both yeast and neuronal cells. The 
pattern of loss of high mass oligomers (Figure 5, Chapter 4) of Aβ42 and 
associated toxicity was very similar to that seen in the presence of curcumin 
(Yang et al., 2005). It appears that the high mass oligomers represent the main 
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toxic species involved in cell death. However, their exact structural nature is 
unclear and needs further investigation. Overall, a positive correlation between 
suppression of β-sheet content and oligomerization by dairy peptides (Figures 
2-5, Chapter 4) and protection against Aβ42-mediated toxicity to both yeast and 
neuronal cells (Figure 6, Chapter 4) was observed. The results presented in this 
chapter 4 established the application of the yeast model for screening 
compounds which can affect Aβ oligomerization and toxicity. Comparing 
neuronal cell cultures, the use of yeast cells for screening such compounds can 
be cost effective and is more amenable to developing a rapid in vitro screening 
tool for agents targeting oligomeric Aβ mediated toxicity.  
 
10.1.3     MBP-Aβ42 fusion protein: A model for oligomeric Aβ  
 
The majority of the assays used for identifying compounds which bind Aβ or 
target oligomerization and toxicity are based on using synthetic Aβ preparations 
[derived from solid phase peptide synthesis (SPSS)]. As discussed in Chapter 
5, the preparation of oligomeric Aβ peptide solutions from synthetic Aβ is 
expensive and can be unsuitable for large scale studies. As a result, an 
increasing number of studies are adopting methods for recombinant production 
of Aβ (Dobeli et al., 1995; Hortschansky et al., 2005; Lee et al., 2005; Li et al., 
2009; Luhrs et al., 2005; Sharpe et al., 2005; Subramanian and Shree, 2007; 
Walsh et al., 2009; Wiesehan et al., 2007). The maltose binding protein tagged 
Aβ42 (MBP-Aβ42) fusion protein reported by Caine et al. (2007) is a 
recombinant protein which can be stably produced in large quantities, purified 
easily using affinity columns and also showed properties (binding to Cu and Zn) 
similar to Aβ peptide (Caine et al., 2007b). The work presented in this thesis 
investigated the structural properties and toxicity of MBP-Aβ fusion proteins in 
yeast and neuronal cells (Caine et al., 2011). 
 
Overall the data provided clear evidence that MBP-Aβ42 formed oligomers 
in solution and was more toxic compared to the truncated MBP-Aβ16 (Chapter 
5). However compared with the Aβ42 peptide, the MBP-Aβ42 fusion protein 
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showed reduced ability to form higher oligomeric structures (greater than 
hexamer) and also fibrillar forms. Consequently, the MBP-Aβ42 also showed 
decreased toxicity compared to Aβ42 peptide in yeast  and neuronal cells 
[Chapter 3, (Bharadwaj et al., 2008)]. The reduced toxicity of the MBP-Aβ42 
solutions could be attributed to the absence of higher oligomeric structures 
which are observed with Aβ42. The data supported the notion that oligomer 
Aβ42 mediated cell death is caused collectively by an array of soluble 
oligomeric Aβ species with neurotoxic properties (Haass and Selkoe, 2007). 
Further investigation using stable cross-linking analysis of the different MBP-
Aβ42 species may provide greater insight into the individual contributions of the 
different isoforms to toxicity and cell death.   
 
Although MBP-Aβ42 may not be a naturally occurring form, it can have 
multiple applications based on its structural and toxic properties demonstrated 
in this thesis. Due to its relatively cheap manufacturing costs and high stability, 
it is a well suited model for large unbiased screening methods for structural 
elucidation and physicochemical studies for identifying Aβ binding ligands and 
compounds which can affect Aβ oligomerization. Moreover, it provides the 
opportunity for developing assays for identifying potential inhibitors of Aβ 
peptide toxicity in yeast.  
 
10.1.4    Cell cycle dependent effects of Aβ  
 
In addition to its toxic effects, reports have also demonstrated neurotrophic 
properties of Aβ peptides (Chan et al., 1999; Koo et al., 1993; Luo et al., 1996a; 
Whitson et al., 1989; Yankner et al., 1990). Studies indicate that the 
neurotrophic effects of Aβ reflect its role in neuronal development. But why a 
certain population of neurons become susceptible to Aβ42 mediated 
neurodegeneration in the AD brain is uncertain. Data presented in this thesis 
provides evidence that Aβ42 mediated toxicity or growth effects is dependent on 
the cell cycle which may explain the selective vulnerability of neurons in AD. 
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The results showed that Aβ42 can promote proliferation only in cells that are 
in the stationary phase and induce cell death in exponentially growing cells 
(Chapter 6). The Aβ-induced growth and toxic effects within different cell cycles 
in yeast is comparable to the initial report showing that Aβ can enhance survival 
in freshly plated undifferentiated hippocampal cells (Yankner et al., 1990), but 
toxic in aged differentiated cultures. Studies showing Aβ42 mediated cell death 
in neurons expressing particular cell cycle-related elements (Giovanni et al., 
1999; Liu et al., 2004), and in G1 cell cycle stage (Simakova and Arispe, 2007) 
further supported the notion that Aβ42 mediated toxicity or growth is dependent 
on the cell cycle. mTOR is one important eukaryotic cell signalling pathway 
associated with Aβ induced growth effects. It was shown that rapamycin; an 
mTOR inhibitor, suppressed Aβ42-induced cell division in stationary phase 
yeast cells. This data supported the previous reports showing that mTOR 
inhibitors block Aβ42 induced neuronal cell cycle events (Bhaskar et al., 2009; 
Frasca et al., 2004; Malik et al., 2008; Varvel et al., 2008; Wu et al., 2000).  
 
However, the exact role of mTOR signalling in AD is contentious as some 
studies have shown increased levels of p-mTOR in the AD brain (Chang et al., 
2002; Li et al., 2005; Li et al., 2004), whereas a significant decrease in p-mTOR 
levels has also been reported (Lafay-Chebassier et al., 2005). A recent study 
showed that long-term inhibition of mTOR by rapamycin reduced Aβ levels in 
the brain and prevented AD-like cognitive deficits (Spilman et al., 2010). In 
contrast, another recent study showed correlation between the inhibition of 
mTOR signalling and Aβ induced impairment of synaptic plasticity (Ma et al., 
2010b). It is evident that Aβ42 and mTOR are closely associated in AD 
pathology and can regulate each other. However, further investigation is 
required to determine the exact role of mTOR signalling and its association with 
Aβ42 mediated neurodegeneration in AD.   
 
Data presented in this work has suggested a significant role of Aβ42 in 
mediating both growth and toxicity which can be associated with essential 
signalling pathways in the cell like mTOR. The strong association of Aβ42 on 
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the yeast plasma membrane (Section 3.4.4) suggests that the peptide mediated 
effects could be a result of its interaction with cell surface receptors. The 
reduced toxicity in stationary phase cells compared to the actively growing cells 
and the levels required for Aβ42 induced toxicity (micromolar) and cell 
proliferation (nanomolar) suggests that diverse receptors or their varied 
expression levels depending on the cell cycle may influence the Aβ42 mediated 
effects (Section 6.5.1). Interestingly, Aβ42 induced growth effect was observed 
only in Candida glabrata and was absent in Saccharomyces cerevisiae cells 
(Section 4.4.4). This observation is particular intriguing and further investigation 
of other fungal species using mutational analysis would provide a greater 
understanding of the pathways and receptor molecules involved in Aβ mediated 
proliferation and cell cycle events.  
 
10.2 Intracellular Aβ42 Accumulation 
10.2.1 Aβ clearance pathways in the cell 
 
Data presented in chapters 7 and 8 of this thesis employ a GFP tagged Aβ 
expressing yeast model (Caine et al., 2007a) for investigating intracellular 
clearance pathways involved in the degradation of Aβ42. Further in chapter 9, 
enhancing autophagy to promote clearance of intracellular Aβ42 was 
investigated. 
 
GFP-Aβ42 was found localized into vesicles reminiscent of autophagic 
bodies or endosome like structures [(Caine et al., 2007a), Chapter 7]. Reports 
showing that Aβ accumulates in vesicular/lysosomal structures in neurons of a 
variety of AD mouse models (Oddo et al., 2006; Wirths, 2001), human AD 
brains (Gouras et al., 2000; Nixon et al., 2005) and in neuronal cells treated with 
extracellular Aβ42 (Hu et al., 2009) supports the idea that GFP-Aβ42 may 
accumulate in such vesicles. The reduced levels and the punctate staining of 
GFP-Aβ42 observed in yeast indicated that Aβ42 is sequestered into these 
vesicles and targeted for degradation (Chapter 7). The results suggested that 
expression of GFP-Aβ42 in the cell elicited a degradative response and that it 
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can be cleared via distinct pathways. Autophagy-lysosome and ubiquitin 
proteasome system (UPS) are the main protein degradative mechanisms in 
cells. Data presented in Chapter 8 provided evidence for Aβ clearance by both 
the UPS and autophagic pathways.  
 
 
10.2.2     Lack of autophagic vesicle synthesis, vacuolar hydrolases 
and proteasomal activity elevates intracellular Aβ42 
accumulation 
 
The morphology of neurons and the plasticity of synapses impose unique 
challenges on the cellular machinery for both protein synthesis and degradation 
(Steward and Schuman, 2003). Therefore post-mitotic differentiated neurons in 
the adult brain are highly vulnerable to accumulation of protein aggregates 
which is a main feature in several neurodegenerative diseases including AD. 
Hence disruption of protein homeostasis or imbalance in synthesis/clearance 
can be a major contributing factor of neuronal dysfunction.   
 
It was shown that disruption of autophagy (atg8Δ) or vacuolar hydrolase 
(pep4Δ, cvt1Δ) activity elevated total GFP-Aβ42 levels and accumulation of 
GFP-Aβ42 containing vesicles in the yeast cell especially during the starvation 
periods of growth (Chapter 8). Baseline levels of autophagy during the active 
growth phase also contributed to the clearance of GFP-Aβ42 in yeast. The 
accumulation of Aβ has been reported in the absence of other autophagy genes 
such as Atg5p, Beclin1 and Ulk1 (Pickford et al., 2008; Tian et al., 2011). 
Accumulation of autophagic vesicles with loss of cathepsins (hydrolases) has 
also been previously reported. (Felbor et al., 2002; Koike et al., 2000; Koike et 
al., 2005). Besides autophagy, the UPS also showed a significant contribution 
towards the degradation of GFP-Aβ42 especially during the active growth 
phase. Interestingly, autophagy was shown to partially compensate for Aβ 
clearance during the growth phase in the proteasomal mutant (pre1-2Δ) lacking 
chymotrypsin activity (Chapter 8). This indicates that Aβ accumulation in AD 
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brain may be a collective contribution of aberrant degradation mechanisms. The 
findings presented in the work showed that both autophagy and the proteasome 
are actively involved in regulating the levels of Aβ42 aggregates and disruption 
of these functions leads to increased Aβ42 accumulation in the cell. The study 
of these pathways in yeast as presented in this thesis has provided evidence for 
the use of this in vitro model to screen compounds which can reduce 
intracellular accumulation of Aβ. 
 
10.2.3    Stimulating Autophagy and a novel mechanism of action for 
Latrepirdine in Enhancing Aβ42 Clearance   
 
Although less potent compared to the known autophagy activator rapamycin, 
the findings presented in this thesis have provided, for the first time, a novel 
mechanism of action for latrepirdine on enhancing autophagy and promoting the 
clearance of GFP-Aβ42 in yeast cells. Notably, rapamycin mediated reduction 
of GFP-Aβ42 levels was associated with pleotropic effects including inhibition of 
protein synthesis in cells (Heitman et al., 1991). In contrast, latrepirdine did not 
show such effects and was found to be dependent on the activity of the Atg8 
gene, which is essential in the formation of autophagosomes which is a critical 
step prior to the fusion with the vacuole to release its contents for degradation. 
The ability of latrepirdine to stimulate autophagy in yeast model can be used to 
develop analogues with increased potency and lesser toxicity. Besides its ability 
to modulate autophagy, in vivo studies showed that latrepirdine can promote 
peripheral Aβ42 clearance and also increase its uptake into liver. Overall the 
data showed that latrepirdine may operate via multiple mechanisms both 
indirectly (via stimulation of intracellular degradation pathways) and directly 
(transport and clearance in the periphery) to promote Aβ clearance. It is also 
possible that latrepirdine modulates Aβ structure and aggregation to promote 
these effects. Further investigation is required to determine how these 
mechanisms explain the overall effects of latrepirdine on cognitive and memory 
function.  
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10.3 Future Directions 
 
The work presented in this thesis has provided evidence for the use of yeast 
in studying pathological mechanisms underlying Aβ toxicity and clearance and 
its utilization as a model to screen novel agents which can attenuate toxicity or 
enhance Aβ clearance. One direction for future research is to identify pathways 
and putative receptors involved in Aβ42 mediated cell proliferation in yeast 
cells. The Aβ growth effect can be systematically designed to be tested in a 
wide range of selected yeast species with diverse genomic backgrounds to 
determine the various pathways and associated receptor protein complexes 
involved with this action of A. Another important course for future research is 
to establish a mutation screen in yeast for dissecting the various autophagic 
genes involved in degradation of intracellular Aβ42. More than 30 ATG 
(autophagy related) genes have been identified in yeast. Expression of GFP-
Aβ42 in each of the 30 ATG gene deletion mutants followed by quantitative Aβ 
immunoblotting assays and localization analysis can be done to identify the 
mechanism and the genes directly involved in the degradation process of Aβ 
aggregates. A similar screen can be used for identifying the mechanism of 
latrepirdine induced autophagy and Aβ clearance. It will also be useful to 
determine the global effects of latrepirdine in cells using DNA microarray 
analysis to assess the possible influence of other non-autophagic genes and 
regulatory proteins in the modulation of degradation pathways. However, it is 
important to demonstrate that the findings in yeast are replicated in neuronal 
cells.          
  
10.4 Conclusion 
 
This study has established and broadened the application of yeast models 
for investigating toxicity and intracellular clearance mechanisms of Aβ. Using 
the yeast model for oligomer Aβ toxicity, this work has identified protective 
functions for dairy derived peptides and established recombinant MBP-Aβ 
fusion proteins as a model for studying Aβ oligomers. Furthermore using the 
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GFP-Aβ expressing yeast, the degradation pathways involved in clearance of 
Aβ aggregates was investigated and a novel mechanism identified for a drug 
currently in clinical trials, latrepirdine, in enhancing autophagy and promoting 
clearance of intracellular Aβ.  
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